10/560723

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification[7]: C12Q 1/68

(21) International Application Number:
PCT/IB2004/002394

(22) International Filing Date: 25 June 2004 (25.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/482,595 26 June 2003 (26.06.2003) US

(71) Applicant (for all designated States except US): EXON-HIT THERAPEUTICS SA [FR/FR]; 26, rue Brunel, F-75017 Paris (FR).

(72) Inventors; and
(75) Inventors/Applicants (for US only): EINSTEIN, Richard [US/US]; 12421 Galesville Dr., Gaithersburg, MD 20878 (US). MCGOWAN, Kevin, M. [US/US]; 15132 Winesap Drive, N. Potomac, MD 20878 (US). PANDO, Matthew, P. [US/US]; 2004 N. Cleveland Street, Arlington, VA 22201 (US).

(74) Agents: BECKER, Philippe et al.; Becker & Associés, 35 rue des Mathurins, F-75008 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— of inventorship (Rule 4.17(iv)) for US only

Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROSTATE SPECIFIC GENES AND THE USE THEREOF AS TARGETS FOR PROSTATE CANCER THERAPY AND DIAGNOSIS

(57) Abstract: Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.

PROSTATE SPECIFIC GENES AND THE USE THEREOF AS TARGETS FOR PROSTATE CANCER THERAPY AND DIAGNOSIS

FIELD OF THE INVENTION

5   The present invention relates to the identification of DNA sequences that correspond to alternatively spliced events in genes expressed on the surface of prostate cancer cells. These genes or their corresponding proteins are to be targeted for the treatment, prevention and/or diagnosis of cancers wherein these genes are differentially regulated and/or spliced,

10   particularly in prostate cancer.

BACKGROUND OF THE INVENTION

        Genetic detection of human disease states is a rapidly developing field (Taparowsky et al., 1982; Slamon et al., 1989; Sidransky et al., 1992; Miki et al., 1994; Dong et al., 1995;

15   Morahan et al., 1996; Lifton, 1996; Barinaga, 1996). However, some problems exist with this approach. A number of known genetic lesions merely predispose an individual to the development of specific disease states. Individuals carrying the genetic lesion may not develop the disease state, while other individuals may develop the disease state without possessing a particular genetic lesion. In human cancers, genetic defects may potentially occur in a large

20   number of known tumor suppresser genes and proto-oncogenes.

        Genetic detection of cancer has a long history. Some of the earliest genetic lesions shown to predispose to cancer were transforming point mutations in the ras oncogenes (Taparowsky et al., 1982). Transforming ras point mutations may be detected in the stool of individuals with benign and malignant colorectal tumors (Sidransky et al., 1992). However,

25   only 50% of such tumors contained a ras mutation (Sidransky et al., 1992). Similar results have been obtained with amplification of HER-2/neu in breast and prostate cancer (Slamon et al., 1989), deletion and mutation of p53 in bladder cancer (Sidransky et al., 1991), deletion of DCC in colorectal cancer (Fearon et al., 1990) and mutation of BRCA1 in breast and prostate cancer (Miki et al., 1994).

30   None of these genetic lesions are capable of predicting a majority of individuals with cancer and most require direct sampling of a suspected tumor, and make screening difficult. Further, none of the markers described above are capable of distinguishing between metastatic

and non-metastatic forms of cancer. In effective management of cancer patients, identification of those individuals whose tumors have already metastasized or are likely to metastasize is critical. Because metastatic cancer kills 560,000 people in the U.S. each year (ACS home page), identification of markers for metastatic prostate cancer would be an important advance.

5   A particular problem in cancer detection and diagnosis occurs with prostate cancer. Carcinoma of the prostate is the most frequently diagnosed cancer among men in the United States (Veltri et al., 1996). Prostate cancer was diagnosed in approximately 189,500 men in 1998 and about 40,000 men succumbed to the malignancy (Landis et al, 1998). Although relatively few prostate tumors progress to clinical significance during the lifetime of the

10   patient, those which are progressive in nature are likely to have metastasized by the time of detection. Survival rates for individuals with metastatic prostate cancer are quite low. Between these extremes are patients with prostate tumors that will metastasize but have not yet done so, for whom surgical prostate removal is curative. Determination of which group a patient falls within is critical in determining optimal treatment and patient survival.

15   The FDA approval of the serum prostate specific antigen (PSA) test in 1984 changed the way that prostate disease was managed (Allhoff et al., 1989; Cooner et al., 1990; Jacobson et al, 1995; Orozco et al., 1998). PSA is widely used as a serum biomarker to detect and monitor therapeutic response in prostate cancer patients (Badalament et al., 1996; O'Dowd et al., 1997). Several modifications in PSA assays (Partin and Oesterling, 1994; Babian et al.,

20   1996; Zlotta et al, 1997) have resulted in earlier diagnoses and improved treatment.

Although PSA has been widely used as a clinical marker of prostate cancer since 1988 (Partin and Oesterling, 1994), screening programs utilizing PSA alone or in combination with digital rectal examination (DRE) have not been successful in improving the survival rate for men with prostate cancer (Partin and Oesterling, 1994). Although PSA is specific to prostate

25   tissue, it is produced by normal and benign as well as malignant prostatic epithelium, resulting in a high false-positive rate for prostate cancer detection (Partin and Oesterling, 1994).

While an effective indicator of prostate cancer when serum levels are relatively high, PSA serum levels are more ambiguous indicators of prostate cancer when only modestly elevated, for example when levels are between 2-10 ng/ml. At these modest elevations, serum

30   PSA may have originated from non-cancerous disease states such as BPH (benign prostatic hyperplasia), prostatitis or physical trauma (McCormack et al, 1995). Although application of

3

the lower 2.0 ng/ml cancer detection cutoff concentration of serum PSA has increased the

diagnosis of prostate cancer, especially in younger men with nonpalpable early stage tumors

(Stage Tlc) (Soh et al., 1997; Carter and Coffey, 1997; Harris et al., 1997; Orozco et al., 1998),

the specificity of the PSA assay for prostate cancer detection at low serum PSA levels remains

5   a problem.

Several investigators have sought to improve upon the specificity of serologic detection

of prostate cancer by examining a variety of other biomarkers besides serum PSA

concentration (Ralph and Veltri, 1997). One of the most heavily investigated of these other

biomarkers is the ratio of free versus total PSA (f/t PSA) in a patient's blood. Most PSA in

10   serum is in a molecular form that is bound to other proteins such as alpha1-antichymotrypsin

(ACT) or alpha2-macroglobulin (Christensson et al, 1993; Stenman et al., 1991; Lilja et al.,

1991). Free PSA is not bound to other proteins. The ratio of free to total PSA (f/tPSA) is

usually significantly higher in patients with BPH compared to those with organ confined

prostate cancer (Marley et al., 1996; Oesterling et al., 1995; Pettersson et al., 1995). When an

15   appropriate cutoff is determined for the f/tPSA assay, the f/tPSA assay can help distinguish

patients with BPH from those with prostate cancer in cases in which serum PSA levels are

only modestly elevated (Marley et al., 1996; Partin and Oesterling, 1996). Unfortunately, while

f/tPSA may improve on the detection of prostate cancer, information in the f/tPSA ratio is

insufficient to improve the sensitivity and specificity of serologic detection of prostate cancer

20   to desirable levels.

Other markers that have been used for prostate cancer detection include prostatic acid

phosphatase (PAP) and prostate secreted protein (PSP). PAP is secreted by prostate cells under

hormonal control (Brawn et al., 1996). It has less specificity and sensitivity than does PSA. As

a result, it is used much less now, although PAP may still have some applications for

25   monitoring metastatic patients that have failed primary treatments. In general, PSP is a more

sensitive biomarker than PAP, but is not as sensitive as PSA (Huang et al., 1993). Like PSA,

PSP levels are frequently elevated in patients with BPH as well as those with prostate cancer.

Another serum marker associated with prostate disease is prostate specific membrane

antigen (PSMA) (Horoszewicz et al., 1987; Carter and Coffey, 1996; Murphy et al., 1996).

30   PSMA is a Type II cell membrane protein and has been identified as Folic Acid Hydrolase

(FAH) (Carter and Coffey, 1996). Antibodies against PSMA react with both normal prostate

4

tissue and prostate cancer tissue (Horoszewicz et al., 1987). Murphy et al. (1995) used ELISA to detect serum PSMA in advanced prostate cancer. As a serum test, PSMA levels are a relatively poor indicator of prostate cancer. However, PSMA may have utility in certain circumstances. PSMA is expressed in metastatic prostate tumor capillary beds (Silver et al.,

5   1997) and is reported to be more abundant in the blood of metastatic cancer patients (Murphy et al., 1996). PSMA messenger RNA (mRNA) is down-regulated 8-10 fold in the LNCaP prostate cancer cell line after exposure to 5-alpha-dihydroxytestosterone (DHT) (Israeli et al., 1994).

        Two relatively new potential biomarkers for prostate cancer are human kallekrein 2

10   (HK2) (Piironen et al., 1996) and prostate specific transglutaminase (pTGase) (Dubbink et al., 1996). HK2 is a member of the kallekrein family that is secreted by the prostate gland (Piironen et al., 1996). Prostate specific transglutaminase is a calcium-dependent enzyme expressed in prostate cells that catalyzes post-translational cross-linking of proteins (Dubbink et al., 1996). In theory, serum concentrations of HK2 or pTGase may be of utility in prostate

15   cancer detection or diagnosis, but the usefulness of these markers is still being evaluated.

        Interleukin 8 (IL-8) has also been reported as a marker for prostate cancer. (Veltri et al., 1999). Serum IL-8 concentrations were reported to be correlated with increasing stage of prostate cancer and to be capable of differentiating BPH from malignant prostate tumors. (Id.) The wide-scale applicability of this marker for prostate cancer detection and diagnosis is still

20   under investigation.

        In addition to these protein markers for prostate cancer, several genetic changes have been reported to be associated with prostate cancer, including: allelic loss (Bova, et al., 1993; Macoska et al., 1994; Carter et al., 1990); DNA hypermethylation (Isaacs et al., 1994); point mutations or deletions of the retinoblastoma (Rb), p53 and KAI1 genes (Bookstein et al.,

25   1990a; Bookstein et al., 1990b; Isaacs et al., 1991; Dong et al., 1995); and aneuploidy and aneusomy of chromosomes detected by fluorescence in situ hybridization (FISH) (Macoska et al., 1994; Visakorpi et al., 1994; Takahashi et al., 1994; Alcaraz et al., 1994). None of these have been reported to exhibit sufficient sensitivity and specificity to be useful as general screening tools for asymptomatic prostate cancer.

30   In current clinical practice, the serum PSA assay and digital rectal exam (DRE) is used to indicate which patients should have a prostate biopsy (Lithrup et al., 1994; Orozco et al.,

1998). Histological examination of the biopsied tissue is used to make the diagnosis of prostate cancer. Based upon the 189,500 cases of diagnosed prostate cancer in 1998 (Landis, 1998) and a known cancer detection rate of about 35% (Parker et al., 1996), it is estimated that in 1998 over one-half million prostate biopsies were performed in the United States (Orozco et

5   al., 1998; Veltri et al., 1998). Clearly, there would be much benefit derived from a serological test that was sensitive enough to detect small and early stage prostate tumors that also had sufficient specificity to exclude a greater portion of patients with noncancerous or clinically insignificant conditions.

There remain deficiencies in the prior art with respect to the identification of the genes

10 linked with the progression of prostate cancer and the development of diagnostic methods to monitor disease progression. Likewise, the identification of genes, which are differentially expressed in prostate cancer, would be of considerable importance in the development of a rapid, inexpensive method to diagnose cancer. Although a few prostate specific genes have been cloned (PSA, PSMA, HK2, pTGase, etc.), these are typically not upregulated in prostate

15 cancer. The identification of a novel, prostate specific gene that is differentially expressed in prostate cancer, compared to non-malignant prostate tissue, would represent a major, unexpected advance for the diagnosis, prognosis and treatment of prostate cancer.

The use of therapeutic antibodies for treatment of cancers that target surface proteins is known. Examples thereof include RITUXAN® that targets CD20 on B cell lymphoma,

20 Campath® that targets a surface antigen CD52 expressed by chronic lymphocytic leukemia, Herceptin® that targets erbB2 on breast and other cancers and Mybtara that targets CD33 surface antigen expressed on leukemia cells. However, to date, a monoclonal antibody for treatment of prostate cancer has not been approved for therapeutic use.

25   **SUMMARY OF THE INVENTION**

The present invention relates to the identification of novel nucleic acid and amino acid sequences that are characteristic of prostate cancer cell or tissue, and which represent targets for therapy or diagnosis of such a condition in a subject.

The invention more specifically discloses 159 specific, isolated nucleic acid molecules

30 that encode novel expression sequences. Of these, 122 are expressed sequence tags that are differentially spliced and correspond to SEQ ID NOS 1-65, 74, 80, 85, 102-134, 136, 141, 146,

6

150-165, 167, 168. In addition, 42 specific isoforms of known genes have been identified corresponding to SEQ ID NOS. 67-72, 75-77, 81-83, 86-90, 92, 93, 95-98, 100, 101, 137-139, 143, 144, 147-149, 169-173, 175, 177, 179, and 181. These novel sequences were found to be differentially expressed between normal prostate and prostate cancer. The expressed sequence tag represent novel exons that are alternatively spliced in prostate cancer, and as such, directly identify distinct isoforms. These sequences and molecules represent targets and valuable information to develop methods and materials for the detection, diagnosis, and treatment of prostate cancer.

It is an object of the invention to provide methods and materials for treatment and diagnosis of prostate cancer.

It is a more specific object of the invention to identify novel exons (novel splice variants) that are expressed by prostate cancer tissue which are potential gene targets for treatment and diagnosis of prostate cancer.

It is a specific object of the invention to develop novel therapies for treatment of prostate cancer involving the administration or use of anti-sense oligonucleotides corresponding to novel gene targets that are specifically expressed by the prostate cancer.

It is another specific object of the invention to identify exons and the corresponding protein domain encoded by those exons specifically upregulated in prostate cancer cells.

It is another specific object of the invention to produce ligands that bind antigens encoded by the exons, expressed as a protein domain by certain prostate cancers, including, but not limited to, monoclonal antibodies.

It is another specific object of the invention to provide novel therapeutic regimens for the treatment of prostate cancer that involve the administration or use of antigens expressed by certain prostate cancers, alone or in combination with adjuvants that elicit an antigen-specific cytotoxic T-cell lymphocyte response against cancer cells that express such antigen.

It is another object of the invention to provide novel therapeutic regimens for the treatment of prostate cancer that involve the administration or use of ligands, especially monoclonal antibodies that specifically bind novel antigens that are expressed by certain prostate cancers.

7

It is an other object of this invention to provide pharmaceutical compositions comprising a ligand or antigen as defined above, in combination with a pharmaceutically acceptable carrier or excipient and/or an adjuvant.

It is another object of the invention to provide a novel method for diagnosis of prostate
5   cancer by using ligands, e.g., monoclonal antibodies, which specifically bind to antigens that are specifically expressed by certain prostate cancers, in order to detect whether a subject has or is at increased risk of developing prostate cancer.

It is another object of the invention to provide a novel method of detecting persons having, or at increased risk of developing prostate cancer by use of labeled DNAs that
10 hybridize to novel gene targets expressed by certain prostate cancers.

It is yet another object of the invention to provide diagnostic test kits for the detection of persons having or at increased risk of developing prostate cancer that comprise a ligand, e.g., monoclonal antibody that specifically binds to an antigen expressed by prostate cancer cells, and a detectable label, e.g. indicator enzymes, a radiolabels, fluorophores, or
15 paramagnetic particles.

It is another object of the invention to provide diagnostic kits for detection of persons having or at risk of developing prostate cancer that comprise DNA primers or probes specific for novel gene targets specifically expressed by prostate cancer cells, and a detectable label, e.g. indicator enzymes, a radiolabels, fluorophores, or paramagnetic particles.

20 It is another object of this invention to provide methods for selecting, identifying, screening, characterizing or optimizing biologically active compounds, comprising a determination of whether a candidate compound binds, preferably selectively, an antigen or a polynucleotide as disclosed in the present application. Such compounds represent drug candidates or leads for treating cancer diseases, particularly prostate cancer.

25 It is another object of the invention to identify genes that are expressed in altered forms in prostate cancer cells. These forms represent splice variants of the gene, where the DATAS™ fragment either 1) indicates the splice event occurring within the gene, or 2) points to a gene that is actively spliced to produce different gene products. These different splice variants or isoforms can be targets for therapeutic intervention.

30

LEGEND TO THE FIGURES

Figure 1 : Expression of Sequence ID: No. 92 in normal human tissue. Primers were designed to detect the DATAS clone sequence and RT-PCR analysis was performed for 30 cycles. Lane 1, Prostate; lane 2, Heart; lane 3, Lung; lane 4, Kidney; lane 5, Liver; lane 6, Brain; lane 7, Placenta; lane 8, Sk. Muscle; lane 9, Pancreas; lane 10, Spleen; lane 11, Thymus; lane 12, Testis; lane 13, Ovary; lane 14, Sm. Intestine; lane 15, Colon; lane 16 Leukocyte.

Figure 2 : Expression of clone (SEQ ID NO 92) in normal and tumor prostate samples. Primers were designed to detect the DATAS clone and RT-PCR analysis was performed for 40 cycles. Individual RNA samples (normal and tumor) were tested both as pooled and as individual samples. The pooled RNA samples were used to produce cDNA using either an oligo dT approach (dT) or through a random primer protocol (RP). Individual patient cDNA samples (lanes 9-12) were prepared through the random primed protocol. Lane 1, prostate tumor pool 1 (RP cDNA); lane 2, normal prostate pool 1 (RP cDNA); lane 3, prostate tumor pool 2 (RP cDNA); lane 4, normal prostate pool 2 (RP cDNA); lane 5, prostate tumor pool 1 (dT cDNA); lane 6, normal prostate pool 1 (dT cDNA); lane 7, normal prostate pool 2 (dT cDNA); lane 8, NTC; lane 9, Patient 1 (OHK); lane 10, Patient 2 (T523); lane 11, Patient 3 (82B) ; lane 12, Patient 4 (4BK).

Figure 3 : Alignment of the different isoforms isolated from structural analysis of clone (DATAS clone number). The sequences isolated from the DATAS derived events were mapped using Blat against the Human genome to annotate the gene and determine the each unique splicing event. Five events are mapped with AK092666, an EST that closely resembles the five events.

Figure 4 : Western blot analysis for the expression of STEAP2 isoforms. Protein extracts from prostate cancer cell lines were separated on SDS_PAGE gels and transferred to nitrocellulose, and probed with an antibody raised against a peptide sequence present in the N-terminal portion of the wild type STEAP2 protein. Five different cell lines were analyzed: lane 1) LNCaP; 2) 22Rv1 3) MDA-PCa2b; 4) PC3; 5) DU145. The blot was developed using standard chemiluminescence reagents.

DETAILED DESCRIPTION OF THE INVENTION

DATAS (Different Analysis of Transcripts with Alternative Splicing) analyzes structural differences between expressed genes and provides systematic access to alterations in RNA splicing (disclosed in U.S. Patent No.6,251,590, the disclosure of which is incorporated by reference in its entirety). Having access to these spliced sequences, which are critical for cellular homeostasis, represents a useful advance in functional genomics.

The DATAS Technology generates two libraries when comparing two samples, such as normal vs. tumor tissue. Each library specifically contains clones of sequences that are present and more highly expressed in one sample. For example, library A will contain sequences that are present in genes in the normal samples but absent in the tumor samples. These sequences are identified as being removed or spliced out from the genes in the tumor samples. In contrast, library B will contain sequences that are present only in the tumor samples and not present in the normal samples. These represent exons/introns that are alternatively spliced into genes expressed *only* in the tumor samples.

The present invention is based in part on the identification of exons that are isolated using DATAS and then determined to be differentially regulated or expressed in prostate tumor samples. Specifically, 122 expressed sequence tags were identified through DATAS and confirmed to be differentially expressed between normal prostate tissue and prostate tumor tissue. These DATAS fragments (DF) are small sections of genes that are selected for inclusion or exclusion in one sample but not the other. These small sections are part of the expressed gene transcript, and can consist of sequences derived from several different regions of the gene, including, but not limited to, portions of single exons, several exons, sequence from introns, and sequences from exons and introns. This alternative usage of exons in different biological samples produces different gene products from the same gene through a process well known in the art as alternative RNA splicing. In particular, 37 alternatively spliced isoforms have been identified from the DATAS fragment sequences, and produce alternate gene products that fit all the descriptions of targets and gene products below.

10

Alternatively spliced mRNA's produced from the same gene contain different ribonucleotide sequence, and therefore translate into proteins with different amino acid sequences. Nucleic acid sequences that are alternatively spliced into or out of the gene products can be inserted or deleted in frame or out of frame from the original gene sequence. This leads to the translation

5   of different proteins from each variant. Differences can include simple sequence deletions, or novel sequence information inserted into the gene product. Sequences inserted out of frame can lead to the production of an early stop codon and produce a truncated form of the protein. Alternatively, in-frame insertions of nucleic acid may cause an additional protein domain to be expressed from the mRNA. The end stage target is a novel protein containing either a novel

10   epitope or function. Many variations of known genes have been identified and produce protein variants that can be agonistic or antagonistic with the original biological activity of the protein.

DATAS fragments thus identify genes and proteins which are subject to differential regulation and alternative splicing(s) in prostate cancer cells. DATAS fragments thus allow the definition

15   of target molecules suitable for diagnosis or therapy of prostate cancers, which target molecules comprise all or a portion of genes or RNAs comprising the sequence of a DATAS fragment, or of genes or RNA from which the sequence of a DATAS fragment derives, as well as corresponding polypeptides or proteins, and variants thereof.

A first type of target molecule is a target nucleic acid molecule comprising the sequence of a

20   full gene or RNA molecule comprising the sequence of a DATAS fragment as disclosed in the present application. Indeed, since DATAS identifies genetic deregulations associated with prostate tumor, the whole gene or RNA sequence from which said DATAS fragment derives can be used as a target of therapeutic intervention or diagnosis.

Similarly, another type of target molecule is a target polypeptide molecule comprising the

25   sequence of a full-length protein comprising the amino acid sequence encoded by a DATAS fragment as disclosed in the present application.

A further type of target molecule is a target nucleic acid molecule comprising a fragment of a gene or RNA as disclosed above. Indeed, since DATAS identifies genes and RNAs that are altered in prostate tumor cells, portions of such genes or RNAs, including portions that do not

30   comprise the sequence of a DATAS fragment, can be used as a target for therapeutic intervention or diagnosis. Examples of such portions include : DATAS fragments, portions

thereof, alternative exons or introns of said gene or RNA, exon-exon, exon-intron or intron-intron junction sequences generated by splicing(s) in said RNA, etc. Particular portions comprise a sequence encoding a extra-cellular domain of a polypeptide.

Similarly, another type of target molecule is a fragment of a protein comprising the amino acid

5   sequence encoded by a DATAS fragment as disclosed in the present application. Such fragments may comprise or not the DATAS sequence, and may comprise newly generated amino acid sequence resulting, for instance, from a frame shift, a novel exon-exon or exon-intron junction, the creation of new stop codon, etc.

10   These target molecules (including genes, fragments, proteins and their variants) can serve as diagnostic agents and as targets for the development of therapeutics. For example, these therapeutics may modulate biological processes associated with prostate tumor viability. Agents may also be identified that are associated with the induction of apoptosis (cell death) in prostate tumor cells. Other agents can also be developed, such as monoclonal antibodies, that

15   bind to the protein or its variant and alter the biological processes important for cell growth. Alternatively, antibodies can deliver a toxin which can inhibit cell growth and lead to cell death.

     Specifically, the invention provides sequences that are expressed in a variant protein

20   and are prostate tumor specific or prostate specific. These sequences are portions of genes identified to be in the plasma membrane of the cell through bioinformatic analysis, and the specific sequences of the invention are expressed on the extracellular region of the protein, so that the sequences may be useful in the preparation of prostate tumor vaccines, including prophylatic and therapeutic vaccines.

25   Based thereon, it is anticipated that the disclosed genes that are associated with the differentially expressed sequences and the corresponding variant proteins should be suitable targets for prostate cancer therapy, prevention or diagnosis, e.g. for the development of antibodies, small molecular inhibitors, anti-sense therapeutics, and ribozymes. The potential therapies are described in greater detail below.

30   Such therapies will include the synthesis of oligonucleotides having sequences in the antisense orientation relative to the subject nucleic acids which appear to be up-regulated in

prostate cancer. Suitable therapeutic antisense oligonucleotides will typically vary in length from two to several hundred nucleotides in length, more typically about 50-70 nucleotides in length or shorter. These antisense oligonucleotides may be administered as naked nucleic acids or in protected forms, e.g., encapsulated in liposomes. The use of liposomal or other

5   protected forms may be advantageous as it may enhance *in vivo* stability and thus facilitate delivery to target sites, i.e., prostate tumor cells.

Also, the subject novel genes may be used to design novel ribozymes that target the cleavage of the corresponding mRNAs in prostate tumor cells. Similarly, these ribozymes may be administered in free (naked) form or by the use of delivery systems that enhance stability

10   and/or targeting, e.g., liposomes.

Also, the present invention embraces the administration of use of nucleic acids that hybridize to the novel nucleic acid targets identified *infra*, attached to therapeutic effector moieties, e.g., radiolabels, (e.g., ^{90}Y, ^{131}I) cytotoxins, cytotoxic enzymes, and the like in order to selectively target and kill cells that express these nucleic acids, i.e., prostate tumor cells.

15   Also, the present invention embraces the treatment and/or diagnosis of prostate cancer by targeting altered genes or the corresponding altered protein particularly splice variants that are expressed in altered form in prostate tumor cells. These methods will provide for the selective detection of cells and/or eradication of cells that express such altered forms thereby minimizing adverse effects to normal cells.

20   Still further, the present invention encompasses non-nucleic acid based therapies. For example, the invention encompasses the use of a DNA containing one of the novel cDNAs corresponding to novel antigen identified herein. It is anticipated that the antigens so encoded may be used as therapeutic or prophylactic anti-tumor vaccines. For example, a particular contemplated application of these antigens involves their administration with adjuvants that

25   induce a cytotoxic T lymphocyte response.

Administration of the subject novel antigens in combination with an adjuvant may result in a humoral immune response against such antigens, thereby delaying or preventing the development of prostate cancer.

These embodiments of the invention will comprise administration of one or more of

30   the subject novel prostate cancer antigens, ideally in combination with an adjuvant, e.g., PROVAX™ (as disclosed U.S. Patents Nos. 5,709,860, 5,695,770, and 5,585,103, which

13

comprises a microfluidized adjuvant containing Squalene, Tween and Pluronic), ISCOM'S®, DETOX®, SAF, Freund's adjuvant, Alum®, Saponin®, among others. This composition will be administered in an amount sufficient to be therapeutically or prophylactically effective, e.g. on the order of 50 to 20,000 mg/kg body weight, 100 to 5000 mg/kg body weight.

5   Yet another embodiment of the invention will comprise the preparation of monoclonal antibodies against the antigens encoded by the novel genes containing the nucleic acid sequences disclosed infra. Such monoclonal antibodies may be produced by conventional methods and include human monoclonal antibodies, humanized monoclonal antibodies, chimeric monoclonal antibodies, single chain antibodies, e.g., scFv's and antigen-binding

10   antibody fragments such as Fab and Fab' fragments. Methods for the preparation of monoclonal antibodies are known in the art. In general, preparation of monoclonal antibodies will comprise immunization of an appropriate (non-homologous) host with the subject prostate cancer antigens, isolation of immune cells therefrom, use of such immune cells to isolate monoclonal antibodies and screening for monoclonal antibodies that specifically bind to either

15   of such antigens. Antibody fragments may be prepared by known methods, e.g., enzymatic change of monoclonal antibodies.

These monoclonal antibodies and fragments will be useful for passive anti-tumor immunotherapy, or may be attached to therapeutic effector moieties, e.g., radiolabels, cytotoxins, therapeutic enzymes, agents that induce apoptosis, and the like in order to provide

20   for targeted cytotoxicity, i.e., killing of human prostate tumor cells. Given the fact that the subject genes are apparently not significantly expressed by many normal tissues this should not result in significant adverse side effects (toxicity to non-target tissues).

In one embodiment, of the present invention such antibodies or fragments will be administered in labeled or unlabeled form, alone or in conjunction with other therapeutics,

25   e.g., chemotherapeutics such as cisplatin, methotrexate, adriamycin, and the like suitable for prostate cancer therapy. The administered composition will also typically include a pharmaceutically acceptable carrier, and optionally adjuvants, stabilizers, etc., used in antibody compositions for therapeutic use.

Preferably, the subject monoclonal antibodies will bind the target antigens with high

30   affinity, e.g., possess a binding affinity (Kd) on the order of 10^{-6} to 10^{-12} M.

14

As noted, the present invention also embraces diagnostic applications that provide for detection of the expression of prostate specific splice variants disclosed herein. This will comprise detecting the expression of one or more of these genes at the RNA level and/or at the protein level.

5   For nucleic acids, expression of the subject genes will be detected by known nucleic acid detection methods, e.g., Northern blot hybridization, strand displacement amplification (SDA), catalytic hybridization amplification (CHA), and other known nucleic acid detection methods. Preferably, a cDNA library will be made from prostate cells obtained from a subject to be tested for prostate cancer by PCR using primers corresponding to the novel isoforms

10   disclosed in this application.

The presence or absence of prostate cancer can be determined based on whether PCR products are obtained, and the level of expression. The levels of expression of such PCR product may be quantified in order to determine the prognosis of a particular prostate cancer patient (as the levels of expression of the PCR product often will increase or decrease

15   significantly as the disease progresses.) This may provide a method for monitoring the status of a prostate cancer patient.

Alternatively, the status of a subject to be tested for prostate cancer may be evaluated by testing biological fluids, e.g., blood, urine, lymph, and the like with an antibody or antibodies or fragment that specifically binds to the novel prostate tumor antigens disclosed

20   herein.

Methods for using antibodies to detect antigen expression are well known and include ELISA, competitive binding assays, and the like. In general, such assays use an antibody or antibody fragment that specifically binds the target antigen directly or indirectly bound to a label that provides for detection, e.g. indicator enzymes, a radiolabels, fluorophores, or

25   paramagnetic particles.

Patients which test positive for the enhanced presence of the antigen on prostate cells will be diagnosed as having or being at increased risk of developing prostate cancer. Additionally, the levels of antigen expression may be useful in determining patient status, i.e., how far disease has advanced (stage of prostate cancer).

30   As noted, the present invention provides novel splice variants that encode antigens that correlate to human prostate cancer. The present invention also embraces variants thereof. As

used herein "variants" means sequences that are at least about 75% identical thereto, more preferably at least about 85% identical, and most preferably at least 90% identical and still more preferably at least about 95-99% identified when these DNA sequences are compared to a nucleic acid sequence encoding the subject DNAs or a fragment thereof having a size of at

5   least about 50 nucleotides. This includes allelic and splice variants of the subject genes. The present invention also encompasses nucleic acid sequences that hybridize to the subject splice variants under high, moderate or low stringency conditions e.g., as described infra.

Also, the present invention provides for primer pairs that result in the amplification of DNAs encoding the subject novel genes or a portion thereof in an mRNA library obtained

10   from a desired cell source, typically human prostate cell or tissue sample. Typically, such primers will be on the order of 12 to 50 nucleotides in length, and will be constructed such that they provide for amplification of the entire or most of the target gene.

Also, the invention embraces the antigens encoded by the subject DNAs or fragments thereof that bind to or elicits antibodies specific to the full-length antigens. Typically, such

15   fragments will be at least 10 amino acids in length, more typically at least 25 amino acids in length.

As noted, the subject DNA fragments are expressed in a majority of prostate tumor samples tested. The invention further contemplates the identification of other cancers that express such genes and the use thereof to detect and treat such cancers. For example, the

20   subject DNA fragments or variants thereof may be expressed on other cancers, e.g., breast, ovary, pancreas, lung or prostate cancers. Essentially, the present invention embraces the detection of any cancer wherein the expression of the subject novel genes or variants thereof correlate to a cancer or an increased likelihood of cancer. To facilitate under-study of the invention, the following definitions are provided.

25   "Isolated tumor antigen or tumor protein" refers to any protein that is not in its normal cellular environment. This includes by way of example compositions comprising recombinant proteins encoded by the genes disclosed infra, pharmaceutical compositions comprising such purified proteins, diagnostic compositions comprising such purified proteins, and isolated protein compositions comprising such proteins. In preferred embodiments, an isolated prostate

30   tumor protein according to the invention will comprise a substantially pure protein, in that it is substantially free of other proteins, preferably that is at least 90% pure, that comprises the

16

amino acid sequence contained herein or natural homologues or mutants having essentially the same sequence. A naturally occurring mutant might be found, for instance, in tumor cells expressing a gene encoding a mutated protein according to the invention.

"Native tumor antigen or tumor protein" refers to a protein that is a non-human primate
5   homologue of the protein having the amino acid sequence contained infra.

"Isolated prostate tumor gene or nucleic acid sequence" refers to a nucleic acid molecule that encodes a tumor antigen according to the invention which is not in its normal human cellular environment, e.g., is not comprised in the human or non-human primate chromosomal DNA. This includes by way of example vectors that comprise a gene according
10   to the invention, a probe that comprises a gene according to the invention, and a nucleic acid sequence directly or indirectly attached to a detectable moiety, e.g. a fluorescent or radioactive label, or a DNA fusion that comprises a nucleic acid molecule encoding a gene according to the invention fused at its 5' or 3' end to a different DNA, e.g. a promoter or a DNA encoding a detectable marker or effector moiety. Also included are natural homologues or mutants having
15   substantially the same sequence. Naturally occurring homologies that are degenerate would encode the same protein including nucleotide differences that do not change the corresponding amino acid sequence. Naturally occurring mutants might be found in tumor cells, wherein such nucleotide differences may result in a mutant tumor antigen. Naturally occurring homologues containing conservative substitutions are also encompassed.

20   "Variant of prostate tumor antigen or tumor protein" refers to a protein possessing an amino acid sequence that possess at least 90% sequence identity, more preferably at least 91% sequence identity, even more preferably at least 92% sequence identity, still more preferably at least 93% sequence identity, still more preferably at least 94% sequence identity, even more preferably at least 95% sequence identity, still more preferably at least 96% sequence identity,
25   even more preferably at least 97% sequence identity, still more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity, to the corresponding native tumor antigen wherein sequence identity is as defined infra. Preferably, this variant will possess at least one biological property in common with the native protein.

"Variant of prostate tumor gene or nucleic acid molecule or sequence" refers to a
30   nucleic acid sequence that possesses at least 90% sequence identity, more preferably at least 91%, more preferably at least 92%, even more preferably at least 93%, still more preferably at

least 94%, even more preferably at least 95%, still more preferably at least 96%, even more preferably at least 97%, even more preferably at least 98% sequence identity, and most preferably at least 99% sequence identity, to the corresponding native human nucleic acid sequence, wherein "sequence identity" is as defined infra.

5   "Fragment of prostate antigen encoding nucleic acid molecule or sequence" refers to a nucleic acid sequence corresponding to a portion of the native human gene wherein said portion is at least about 50 nucleotides in length, or 100, more preferably at least 150 nucleotides in length.

          "Antigenic fragments of prostate tumor antigen" refer to polypeptides corresponding to
10   a fragment of a prostate protein or a variant or homologue thereof that when used itself or attached to an immunogenic carrier elicits antibodies that specifically bind the protein. Typically such antigenic fragments will be at least 8-15 amino acids in length, and may be much longer.

          Sequence identity or percent identity is intended to mean the percentage of the same
15   residues shared between two sequences, referenced to human protein A or protein B or gene A or gene B, when the two sequences are aligned using the Clustal method [Higgins et al, Cabios 8:189-191 (1992)] of multiple sequence alignment in the Lasergene biocomputing software (DNASTAR, INC, Madison, WI), or alignment programs available from the Genetics Computer Group (GCG Wisconsin package, Accelrys, San Diego, CA). In this method,
20   multiple alignments are carried out in a progressive manner, in which larger and larger alignment groups are assembled using similarity scores calculated from a series of pairwise alignments. Optimal sequence alignments are obtained by finding the maximum alignment score, which is the average of all scores between the separate residues in the alignment, determined from a residue weight table representing the probability of a given amino acid
25   change occurring in two related proteins over a given evolutionary interval. Penalties for opening and lengthening gaps in the alignment contribute to the score. The default parameters used with this program are as follows: gap penalty for multiple alignment=10; gap length penalty for multiple alignment=10; k-tuple value in pairwise alignment=1; gap penalty in pairwise alignment=3; window value in pairwise alignment=5; diagonals saved in pairwise
30   alignment=5. The residue weight table used for the alignment program is PAM250

18

[Dayhoffet al., in Atlas of Protein Sequence and Structure, Dayhoff, Ed., NDRF, Washington, Vol. 5, suppl. 3, p. 345, (1978)].

Percent conservation is calculated from the above alignment by adding the percentage of identical residues to the percentage of positions at which the two residues represent a
5   conservative substitution (defined as having a log odds value of greater than or equal to 0.3 in the PAM250 residue weight table). Conservation is referenced to human Gene A or gene B when determining percent conservation with non-human Gene A or gene B, e.g. mgene A or gene B, when determining percent conservation. Conservative amino acid changes satisfying this requirement include: R-K; E-D, Y-F, L-M; V-I, Q-H.
10

Polypeptide Fragments

The invention provides polypeptide fragments of the disclosed proteins. Polypeptide fragments of the invention can comprise at least 8, more preferably at least 25, still more preferably at least 50 amino acid residues of the protein or an analogue thereof. More
15   particularly such fragment will comprise at least 75, 100, 125, 150, 175, 200, 225, 250, 275 residues of the polypeptide encoded by the corresponding gene. Even more preferably, the protein fragment will comprise the majority of the native protein, e.g. about 100 contiguous residues of the native protein.

20   *Biologically Active Variants*

The invention also encompasses mutants of the novel prostate proteins disclosed infra which comprise an amino acid sequence that is at least 80%, more preferably 90%, still more preferably 95-99% similar to the native protein.

Guidance in determining which amino acid residues can be substituted, inserted, or
25   deleted without abolishing biological or immunological activity can be found using computer programs well known in the art, such as DNASTAR or software from the Genectics Computer Group (GCG). Preferably, amino acid changes in protein variants are conservative amino acid changes, *i.e.*, substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of a family of amino acids which are related in
30   their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine,

leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids.

5   A subset of mutants, called muteins, is a group of polypeptides in which neutral amino acids, such as serines, are substituted for cysteine residues which do not participate in disulfide bonds. These mutants may be stable over a broader temperature range than native secreted proteins. See Mark *et al.*, U.S. Patent 4,959,314.

It is reasonable to expect that an isolated replacement of a leucine with an isoleucine or

10   valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the biological properties of the resulting secreted protein or polypeptide variant.

Protein variants include glycosylated forms, aggregative conjugates with other molecules, and covalent conjugates with unrelated chemical moieties. Also, protein variants

15   also include allelic variants, species variants, and muteins. Truncations or deletions of regions which do not affect the differential expression of the gene are also variants. Covalent variants can be prepared by linking functionalities to groups which are found in the amino acid chain or at the N- or C-terminal residue, as is known in the art.

It will be recognized in the art that some amino acid sequence of the prostate proteins

20   of the invention can be varied without significant effect on the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there are critical areas on the protein which determine activity. In general, it is possible to replace residues that form the tertiary structure, provided that residues performing a similar function are used. In other instances, the type of residue may be completely unimportant if the

25   alteration occurs at a non-critical region of the protein. The replacement of amino acids can also change the selectivity of binding to cell surface receptors. Ostade et al., *Nature* 361:266-268 (1993) describes certain mutations resulting in selective binding of TNF-alpha to only one of the two known types of TNF receptors. Thus, the polypeptides of the present invention may include one or more amino acid substitutions, deletions or additions, either from natural

30   mutations or human manipulation.

20

The invention further includes variations of the prostate proteins disclosed infra which show comparable expression patterns or which include antigenic regions. Such mutants include deletions, insertions, inversions, repeats, and site substitutions. Guidance concerning which amino acid changes are likely to be phenotypically silent can be found in Bowie, J.U., et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

Of particular interest are substitutions of charged amino acids with another charged amino acid and with neutral or negatively charged amino acids. The latter results in proteins with reduced positive charge to improve the characteristics of the disclosed protein. The prevention of aggregation is highly desirable. Aggregation of proteins not only results in a loss of activity but can also be problematic when preparing pharmaceutical formulations, because they can be immunogenic. (Pinckard et al., *Clin. Exp. Immunol.* 2:331-340 (1967); Robbins et al., *Diabetes* 36:838-845 (1987); Cleland et al., *Crit. Rev. Therapeutic Drug Carrier Systems* 10:307-377 (1993)).

Amino acids in the polypeptides of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244: 1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as binding to a natural or synthetic binding partner. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., *J Mol. Biol.* 224:899-904 (1992) and de Vos et al. *Science* 255: 306-312 (1992)).

As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein. Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the number of substitutions for any given polypeptide will not be more than 50, 40, 30, 25, 20, 15, 10, 5 or 3.

Fusion Proteins

Fusion proteins comprising proteins or polypeptide fragments of the subject prostate tumor antigen can also be constructed. Fusion proteins are useful for generating antibodies against amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with a protein of the invention or which interfere with its biological function. Physical methods, such as protein affinity chromatography, or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can also be used for this purpose. Such methods are well known in the art and can also be used as drug screens. Fusion proteins comprising a signal sequence and/or a transmembrane domain of a protein according to the invention or a fragment thereof can be used to target other protein domains to cellular locations in which the domains are not normally found, such as bound to a cellular membrane or secreted extracellularly.

A fusion protein comprises two protein segments fused together by means of a peptide bond. As noted, these fragments may range in size from about 8 amino acids up to the full length of the protein.

The second protein segment can be a full-length protein or a polypeptide fragment. Proteins commonly used in fusion protein construction include ß-galactosidase, ß-glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags can be used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP 16 protein fusions.

These fusions can be made, for example, by covalently linking two protein segments or by standard procedures in the art of molecular biology. Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises a coding sequence encoding a possible antigen according to the invention or a fragment thereof in proper reading frame with a nucleotide encoding the second protein segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion

22

proteins are available from companies that supply research labs with tools for experiments, including, for example, Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), Clontech (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal,

5   Canada; 1-888-DNA-KITS).

Proteins, fusion proteins, or polypeptides of the invention can be produced by recombinant DNA methods. For production of recombinant proteins, fusion proteins, or polypeptides, a sequence encoding the protein can be expressed in prokaryotic or eukaryotic host cells using expression systems known in the art. These expression systems include

10   bacterial, yeast, insect, and mammalian cells.

The resulting expressed protein can then be purified from the culture medium or from extracts of the cultured cells using purification procedures known in the art. For example, for proteins fully secreted into the culture medium, cell-free medium can be diluted with sodium acetate and contacted with a cation exchange resin, followed by hydrophobic interaction

15   chromatography. Using this method, the desired protein or polypeptide is typically greater than 95% pure. Further purification can be undertaken, using, for example, any of the techniques listed above.

It may be necessary to modify a protein produced in yeast or bacteria, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain a functional

20   protein. Such covalent attachments can be made using known chemical or enzymatic methods.

A protein or polypeptide of the invention can also be expressed in cultured host cells in a form which will facilitate purification. For example, a protein or polypeptide can be expressed as a fusion protein comprising, for example, maltose binding protein, glutathione-S-transferase, or thioredoxin, and purified using a commercially available kit. Kits for

25   expression and purification of such fusion proteins are available from companies such as New England BioLabs, Pharmacia, and Invitrogen. Proteins, fusion proteins, or polypeptides can also be tagged with an epitope, such as a "Flag" epitope (Kodak), and purified using an antibody which specifically binds to that epitope.

The coding sequence of the protein variants identified through the sequences disclosed

30   herein can also be used to construct transgenic animals, such as mice, rats, guinea pigs, cows, goats, pigs, or sheep. Female transgenic animals can then produce proteins, polypeptides, or

23

fusion proteins of the invention in their milk. Methods for constructing such animals are known and widely used in the art.

Alternatively, synthetic chemical methods, such as solid phase peptide synthesis, can be used to synthesize a secreted protein or polypeptide. General means for the production of peptides, analogs or derivatives are outlined in Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins -- A Survey of Recent Developments, B. Weinstein, ed. (1983). Substitution of D-amino acids for the normal L-stereoisomer can be carried out to increase the half-life of the molecule.

Typically, homologous polynucleotide sequences can be confirmed by hybridization under stringent conditions, as is known in the art. For example, using the following wash conditions: 2 x SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2 x SSC, 0.1% SDS, 50 °C once, 30 minutes; then 2 x SSC, room temperature twice, 10 minutes each, homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

The invention also provides polynucleotide probes which can be used to detect complementary nucleotide sequences, for example, in hybridization protocols such as Northern or Southern blotting or *in situ* hybridizations. Polynucleotide probes of the invention comprise at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, or 40 or more contiguous nucleotides of the nucleic acid sequences provided herein. Polynucleotide probes of the invention can comprise a detectable label, such as a radioisotopic, fluorescent, enzymatic, or chemiluminescent label.

Isolated genes corresponding to the cDNA sequences disclosed herein are also provided. Standard molecular biology methods can be used to isolate the corresponding genes using the cDNA sequences provided herein. These methods include preparation of probes or primers from the nucleotide sequence disclosed herein for use in identifying or amplifying the genes from mammalian, including human, genomic libraries or other sources of human genomic DNA.

Polynucleotide molecules of the invention can also be used as primers to obtain additional copies of the polynucleotides, using polynucleotide amplification methods. Polynucleotide molecules can be propagated in vectors and cell lines using techniques well

known in the art. Polynucleotide molecules can be on linear or circular molecules. They can be on autonomously replicating molecules or on molecules without replication sequences. They can be regulated by their own or by other regulatory sequences, as is known in the art.

5   *Polynucleotide Constructs*

Polynucleotide molecules comprising the coding sequences of the gene variants identified through the sequences disclosed herein can be used in a polynucleotide construct, such as a DNA or RNA construct. Polynucleotide molecules of the invention can be used, for example, in an expression construct to express all or a portion of a protein, variant, fusion

10   protein, or single-chain antibody in a host cell. An expression construct comprises a promoter which is functional in a chosen host cell. The skilled artisan can readily select an appropriate promoter from the large number of cell type-specific promoters known and used in the art. The expression construct can also contain a transcription terminator which is functional in the host cell. The expression construct comprises a polynucleotide segment which encodes all or a

15   portion of the desired protein. The polynucleotide segment is located downstream from the promoter. Transcription of the polynucleotide segment initiates at the promoter. The expression construct can be linear or circular and can contain sequences, if desired, for autonomous replication.

Also included are polynucleotide molecules comprising the promoter and UTR

20   sequences of the subject novel genes, operably linked to the associated protein coding sequence and/or other sequences encoding a detectable or selectable marker. Such promoter and/or UTR-based constructs are useful for studying the transcriptional and translational regulation of protein expression, and for identifying activating and/or inhibitory regulatory proteins.

25

Host Cells

An expression construct can be introduced into a host cell. The host cell comprising the expression construct can be any suitable prokaryotic or eukaryotic cell. Expression systems in bacteria include those described in Chang *et al.*, *Nature* 275:615 (1978); Goeddel *et*

30   *al.*, *Nature* 281: 544 (1979); Goeddel *et al.*, *Nucleic Acids Res.* 8:4057 (1980); EP 36,776;

U.S. 4,551,433; deBoer *et al., Proc. Natl. Acad Sci. USA* 80: 21-25 (1983); and Siebenlist *et al., Cell* 20: 269 (1980).

Expression systems in yeast include those described in Hinnnen *et al., Proc. Natl. Acad. Sci. USA* 75: 1929 (1978); Ito *et al., J Bacteriol* 153: 163 (1983); Kurtz *et al., Mol. Cell. Biol.* 6: 142 (1986); Kunze *et al., J Basic Microbiol.* 25: 141 (1985); Gleeson *et al., J. Gen. Microbiol.* 132: 3459 (1986), Roggenkamp *et al., Mol. Gen. Genet.* 202: 302 (1986)); Das *et al.,* J Bacteriol. 158: 1165 (1984); De Louvencourt *et al., J Bacteriol.* 154:737 (1983), Van den Berg *et al., Bio/Technology* 8: 135 (1990); Kunze et al., *J. Basic Microbiol.* 25: 141 (1985); Cregg *et al., Mol. Cell. Biol.* 5: 3376 (1985); U.S. 4,837,148; U.S. 4,929,555; Beach and Nurse, *Nature* 300: 706 (1981); Davidow *et al., Curr. Genet.* 10: 380 (1985); Gaillardin *et al., Curr. Genet.* 10: 49 (1985); Ballance *et al., Biochem. Biophys. Res. Commun.* 112: 284-289 (1983); Tilburn *et al., Gene* 26: 205-22 (1983); Yelton *et al., Proc. Natl. Acad, Sci. USA* 81: 1470-1474 (1984); Kelly and Hynes, *EMBO J.* 4: 475479 (1985); EP 244,234; and WO 91/00357.

Expression of heterologous genes in insects can be accomplished as described in U.S. 4,745,051; Friesen *et al.* (1986) "The Regulation of Baculovirus Gene Expression" in: THE MOLECULAR BIOLOGY OF BACULOVIRUSES (W. Doerfler, ed.); EP 127,839; EP 155,476; Vlak *et al., J. Gen. Virol.* 69: 765-776 (1988); Miller *et al., Ann. Rev. Microbiol.* 42: 177 (1988); Carbonell *et al., Gene* 73: 409 (1988); Maeda *et al., Nature* 315: 592-594 (1985); Lebacq-Verheyden *et al., Mol. Cell Biol.* 8: 3129 (1988); Smith *et al., Proc. Natl. Acad. Sci. USA* 82: 8404 (1985); Miyajima *et al., Gene* 58: 273 (1987); and Martin *et al., DNA* 7:99 (1988). Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts are described in Luckow *et al., Bio/Technology* (1988) 6: 47-55, Miller *et al.,* in GENETIC ENGINEERING (Setlow, J.K. *et al.* eds.), Vol. 8, pp. 277-279 (Plenum Publishing, 1986); and Maeda *et al., Nature,* 315: 592-594 (1985).

Mammalian expression can be accomplished as described in Dijkema *et al., EMBO J.* 4: 761(1985); *Gormanetal., Proc. Natl. Acad. Sci. USA* 79: 6777 (1982b); Boshart *et al., Cell* 41: 521 (1985); *and U.S.* 4,399,216. Other features of mammalian expression can be facilitated as described in Ham and Wallace, *Meth Enz.* 58: 44 (1979);

Expression constructs can be introduced into host cells using any technique known in the art. These techniques include transferrin-polycation-mediated DNA transfer, transfection

26

with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun," and calcium phosphate-mediated transfection.

5   The invention can also include hybrid and modified forms thereof including fusion proteins, fragments and hybrid and modified forms in which certain amino acids have been deleted or replaced, modifications such as where one or more amino acids have been changed to a modified amino acid or unusual amino acid.

        Also included within the meaning of substantially homologous is any human or non-human primate protein which may be isolated by virtue of cross-reactivity with antibodies to
10   proteins encoded by a gene described herein or whose encoding nucleotide sequences including genomic DNA, mRNA or cDNA may be isolated through hybridization with the complementary sequence of genomic or subgenomic nucleotide sequences or cDNA of a gene herein or fragments thereof. It will also be appreciated by one skilled in the art that degenerate DNA sequences can encode a tumor protein according to the invention and these are also
15   intended to be included within the present invention as are allelic variants of the subject genes.

        Preferred is a prostate protein according to the invention prepared by recombinant DNA technology. By "pure form" or "purified form" or "substantially purified form" it is meant that a protein composition is substantially free of other proteins which are not the desired protein.

20   The present invention also includes therapeutic or pharmaceutical compositions comprising a protein according to the invention in an effective amount for treating patients with disease, and a method comprising administering a therapeutically effective amount of the protein. These compositions and methods are useful for treating cancers associated with the subject proteins, e.g. prostate cancer. One skilled in the art can readily use a variety of assays
25   known in the art to determine whether the protein would be useful in promoting survival or functioning in a particular cell type.

        Anti-Prostate Antigen Antibodies

        As noted, the invention includes the preparation and use of anti-prostate antigen antibodies and fragments for use as diagnostics and therapeutics. These antibodies may be
30   polyclonal or monoclonal. Polyclonal antibodies can be prepared by immunizing rabbits or other animals by injecting antigen followed by subsequent boosts at appropriate intervals. The

27

animals are bled and sera assayed against purified protein usually by ELISA or by bioassay based upon the ability to block the action of the corresponding gene. When using avian species, e.g., chicken, turkey and the like, the antibody can be isolated from the yolk of the egg. Monoclonal antibodies can be prepared after the method of Milstein and Kohler by

5   fusing splenocytes from immunized mice with continuously replicating tumor cells such as myeloma or lymphoma cells. [Milstein and Kohler, *Nature 256*:495-497 (1975); Gulfre and Milstein, *Methods in Enzymology: Immunochemical Techniques 73*:1-46, Langone and Banatis eds., Academic Press, (1981) which are incorporated by reference]. The hybridoma cells so formed are then cloned by limiting dilution methods and supernates assayed for antibody

10   production by ELISA, RIA or bioassay.

The unique ability of antibodies to recognize and specifically bind to target proteins provides an approach for treating an overexpression of the protein. Thus, another aspect of the present invention provides for a method for preventing or treating diseases involving overexpression of the protein by treatment of a patient with specific antibodies to the protein.

15   Specific antibodies, either polyclonal or monoclonal, to the protein can be produced by any suitable method known in the art as discussed above. For example, by recombinant methods, preferably in eukaryotic cells murine or human monoclonal antibodies can be produced by hybridoma technology or, alternatively, the protein, or an immunologically active fragment thereof, or an anti-idiotypic antibody, or fragment thereof can be administered to an

20   animal to elicit the production of antibodies capable of recognizing and binding to the protein. Such antibodies can be from any class of antibodies including, but not limited to IgG, IgA, IgM, IgD, and IgE or in the case of avian species, IgY and from any subclass of antibodies.

The availability of isolated protein allows for the identification of small molecules and low molecular weight compounds that inhibit the binding of protein to binding partners,

25   through routine application of high-throughput screening methods (HTS). HTS methods generally refer to technologies that permit the rapid assaying of lead compounds for therapeutic potential. HTS techniques employ robotic handling of test materials, detection of positive signals, and interpretation of data. Lead compounds may be identified via the incorporation of radioactivity or through optical assays that rely on absorbance, fluorescence or

30   luminescence as read-outs. [Gonzalez, J.E. *et al., Curr. Opin. Biotech.* 9:624-63 1 (1998)].

28

Model systems are available that can be adapted for use in high throughput screening for compounds that inhibit the interaction of protein with its ligand, for example by competing with protein for ligand binding. Sarubbi *et al., Anal. Biochem. 237*:70-75 (1996) describe cell-free, non-isotopic assays for discovering molecules that compete with natural ligands for binding to the active site of IL-1 receptor. Martens, C. *et al., Anal. Biochem. 273*:20-31 (1999) describe a generic particle-based nonradioactive method in which a labeled ligand binds to its receptor immobilized on a particle; label on the particle decreases in the presence of a molecule that competes with the labeled ligand for receptor binding.

Antibody Preparation

10   (i) Starting Materials and Methods

Immunoglobulins (Ig) and certain variants thereof are known and many have been prepared in recombinant cell culture. For example, see U.S. Pat. No. 4,745,055; EP 256,654; EP 120,694; EP 125,023; EP 255,694; EP 266,663; WO 30 88/03559; Faulkner et al., Nature, 298: 286 (1982); Morrison, J. Immun., 123: 793 (1979); Koehler et al., Proc. Natl. Acad. Sci. USA, 77: 2197 (1980); Raso et al., Cancer Res., 41: 2073 (1981); Morrison et al., Ann. Rev. Immunol., 2: 239 (1984); Morrison, Science, 229: 1202 (1985); and Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851 (1984). Reassorted immunoglobulin chains are also known. See, for example, U.S. Pat. No. 4,444,878; WO 88/03565; and EP 68,763 and references cited therein. The immunoglobulin moiety in the chimeras of the present invention may be obtained from IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA, IgE, IgD, or IgM, but preferably from IgG-1 or IgG-3.

(ii) Polyclonal Antibodies

Polyclonal antibodies to the subject prostate antigens are generally raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the antigen and an adjuvant. It may be useful to conjugate the antigen or a fragment containing the target amino acid sequence to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues),

glutaraldehyde or succinic anhydride.

Animals are immunized against the polypeptide or fragment, immunogenic conjugates, or derivatives by combining about 1 mg or 1 .µg of the peptide or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution 5 intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer to the antigen or a fragment thereof. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same polypeptide or 10 fragment thereof, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response.

(iii) Monoclonal Antibodies

15   Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.

20   For example, monoclonal antibodies using for practicing this invention may be made using the hybridoma method first described by Kohler and Milstein, Nature, 256: 495 (1975), or may be made by recombinant DNA methods (Cabilly et al., supra).

In the hybridoma method, a mouse or other appropriate host animal, such as a hamster, is immunized as hereinabove described to elicit lymphocytes that produce or are capable of 25 producing antibodies that will specifically bind to the antigen or fragment thereof used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 [Academic Press, 1986]).

The hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells. For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for

5   the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. Among these, preferred myeloma cell lines are murine myeloma lines,

10   such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, Calif. USA, and SP-2 cells available from the American Type Culture Collection, Rockville, Md. USA.

Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the prostate antigen. Preferably, the binding specificity

15   of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107: 220 (1980).

20   After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods (Goding, supra). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium. In addition, the hybridoma cells may be grown in vivo as ascites tumors in an animal.

25   The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies of the invention is readily isolated and

30   sequenced using conventional procedures (e.g., by using oligonucleotide probes that are

capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or

5   myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al., Curr. Opinion in Immunol., 5: 256-262 (1993) and Pluckthun, Immunol. Revs., 130: 151-188 (1992).

The DNA also may be modified, for example, by substituting the coding sequence for human

10   heavy- and light-chain constant domains in place of the homologous murine sequences (Morrison, et al., Proc. Natl. Acad. Sci. USA, 81: 6851 [1984]), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. In that manner, "chimeric" or "hybrid" antibodies are prepared that have the binding specificity of an anti-prostate antigen monoclonal antibody herein.

15   Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody of the invention, or they are substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for prostate antigen according to the invention and another antigen-combining site having specificity for a different

20   antigen.

Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and

25   methyl-4-mercaptobutyrimidate.

(iv) Humanized Antibodies

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be

30

32

essentially performed following the method of Winter and co-workers (Jones et al., Nature 321, 522-525 [1986]; Riechmann et al., Nature 332, 323-327 [1988]; Verhoeyen et al., Science 239, 1534-1536 [1988]), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric

5   antibodies (Cabilly et al., supra), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

10   The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized

15   antibody (Sims et al., J. Immunol., 151: 2296 [1993]; Chothia and Lesk, J. Mol. Biol., 196: 901 [1987]). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89: 4285 [1992]; Presta et al., J. Immnol., 151: 2623 [1993]).

20   It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly

25   available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its

30   antigen. In this way, FR residues can be selected and combined from the consensus and import sequences so that the desired antibody characteristic, such as increased affinity for the target

33

antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.

(v) Human Antibodies

Human monoclonal antibodies can be made by the hybridoma method. Human
5   myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described, for example, by Kozbor, J. Immunol. 133, 3001 (1984); Brodeur, et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86-95 (1991).
10   It is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_H) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production.
15   Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90: 2551 (1993); Jakobovits et al., Nature, 362: 255-258 (1993); Bruggermann et al., Year in Immuno., 7: 33 (1993).

Alternatively, the phage display technology (McCafferty et al., Nature, 348: 552-553
20   [1990]) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from non-immunized donors. According to this technique, antibody V domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous
25   particle contains a single-stranded DNA copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties. Thus, the phage mimics some of the properties of the B-cell. Phage display can be performed in a variety of formats; for their review see, e.g., Johnson and Chiswell, Curr. Op. Struct. Biol., 3: 564-571 (1993). Several sources of V-gene segments can
30   be used for phage display. Clackson et al., Nature, 352: 624-628 (1991) isolated a diverse array

of anti-oxazolone antibodies from a small random combinatorial library of V genes derived from the spleens of immunized mice. A repertoire of V genes from non-immunized human donors can be constructed and antibodies to a diverse array of antigens (including self-antigens) can be isolated essentially following the techniques described by Marks et al., J. Mol.

5   Biol., 222: 581-597 (1991), or Griffith et al., EMBO J., 12: 725-734 (1993).

In a natural immune response, antibody genes accumulate mutations at a high rate (somatic hypermutation). Some of the changes introduced will confer higher affinity, and B cells displaying high-affinity surface immunoglobulin are preferentially replicated and differentiated during subsequent antigen challenge. This natural process can be mimicked by

10   employing the technique known as "chain shuffling" (Marks et al., Bio/Technology, 10: 779-783 [1992]). In this method, the affinity of "primary" human antibodies obtained by phage display can be improved by sequentially replacing the heavy and light chain V region genes with repertoires of naturally occurring variants (repertoires) of V domain genes obtained from non-immunized donors. This technique allows the production of antibodies and antibody

15   fragments with affinities in the nM range. A strategy for making very large phage antibody repertoires has been described by Waterhouse et al., Nucl. Acids Res., 21: 2265-2266 (1993).

Gene shuffling can also be used to derive human antibodies from rodent antibodies, where the human antibody has similar affinities and specificities to the starting rodent antibody. According to this method, which is also referred to as "epitope imprinting", the

20   heavy or light chain V domain gene of rodent antibodies obtained by phage display technique is replaced with a repertoire of human V domain genes, creating rodent-human chimeras. Selection on antigen results in isolation of human variable capable of restoring a functional antigen-binding site, i.e., the epitope governs (imprints) the choice of partner. When the process is repeated in order to replace the remaining rodent V domain, a human antibody is

25   obtained (see PCT WO 93/06213, published Apr. 1, 1993). Unlike traditional humanization of rodent antibodies by CDR grafting, this technique provides completely human antibodies, which have no framework or CDR residues of rodent origin.

(vi) Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that
30   have binding specificities for at least two different antigens. In the present case, one of the

binding specificities will be to a prostate antigen according to the invention. Methods for

making   bispecific   antibodies   are   known   in   the   art.

Traditionally, the recombinant production of bispecific antibodies is based on the co-

expression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains

5   have different specificities (Milstein and Cuello, Nature, 305: 537-539 [1983]). Because of the

random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas)

produce a potential mixture of 10 different antibody molecules, of which only one has the

correct bispecific structure. The purification of the correct molecule, which is usually done by

affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar

10   procedures are disclosed in WO 93/08829 published May 13, 1993, and in Traunecker et al.,

EMBO J., 10: 3655-3659 (1991).

According to a different and more preferred approach, antibody-variable domains with

the desired binding specificities (antibody-antigencombining sites) are fused to

immunoglobulin constant-domain sequences. The fusion preferably is with an

15   immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and

CH3 regions. It is preferred to have the first heavy-chain constant region (CH1), containing the

site necessary for light-chain binding, present in at least one of the fusions. DNAs encoding

the immunoglobulin heavy chain fusions and, if desired, the immunoglobulin light chain, are

inserted into separate expression vectors, and are co-transfected into a suitable host organism.

20   This provides for great flexibility in adjusting the mutual proportions of the three polypeptide

fragments in embodiments when unequal ratios of the three polypeptide chains used in the

construction provide the optimum yields. It is, however, possible to insert the coding

sequences for two or all three polypeptide chains in one expression vector when the production

of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of

25   no particular significance. In a preferred embodiment of this approach, the bispecific

antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding

specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a

second binding specificity) in the other arm. It was found that this asymmetric structure

facilitates the separation of the desired bispecific compound from unwanted immunoglobulin

30   chain combinations, as the presence of an immunoglobulin light chain in only one half of the

36

bispecific   molecule   provides   for   a   facile   way   of   separation.

For further details of generating bispecific antibodies, see, for example, Suresh et al., Methods in Enzymology, 121: 210 (1986).

(vii) Heteroconjuqate Antibodies

5   Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/00373; and EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods.

10   Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.

The polynucleotides and polypeptides of the present invention may be utilized in gene delivery vehicles. The gene delivery vehicle may be of viral or non-viral origin (*see generally*, Jolly, *Cancer Gene Therapy* 1:51-64 (1994); Kimura, *Human Gene Therapy* 5:845-852

15   (1994); Connelly, *Human Gene Therapy* 1:185-193 (1995); and Kaplitt, *Nature Genetics* 6:148-153 (1994)). Gene therapy vehicles for delivery of constructs including a coding sequence of a therapeutic according to the invention can be administered either locally or systemically. These constructs can utilize viral or non-viral vector approaches. Expression of such coding sequences can be induced using endogenous mammalian or heterologous

20   promoters. Expression of the coding sequence can be either constitutive or regulated. Preferred vehicles for gene therapy include retroviral and adeno-viral vectors.

Representative examples of adenoviral vectors include those described by Berkner, *Biotechniques* 6:616-627 (Biotechniques); Rosenfeld *et al.*, *Science 252*:431-434 (1991); WO 93/19191; Kolls *et al.*, *P.N.A.S.* 215-219 (1994); Kass-Bisler et al., P.N.A.S. 90: 11498-11502

25   (1993); Guzman et al., *Circulation* 88: 2838-2848 (1993); Guzman *et al.*, *Cir. Res.* 73: 1202-1207 (1993); Zabner et al., *Cell* 75: 207-216 (1993); Li et al., *Hum. Gene Ther.* 4: 403-409 (1993); Cailaud et al., *Eur. J. Neurosci.* 5: 1287-1291 (1993); Vincent et al., *Nat. Genet.* 5: 130-134 (1993); Jaffe et al., *Nat. Genet.* 1: 372-378 (1992); and Levrero et al., *Gene* 101: 195-202 (1992). Exemplary adenoviral gene therapy vectors employable in this invention also

30   include those described in WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO

95/11984 and WO 95/00655. Administration of DNA linked to kill adenovirus as described in Curiel, *Hum. Gene Ther.* 3: 147-154 (1992) may be employed.

Other gene delivery vehicles and methods may be employed; including polycationic condensed DNA linked or unlinked to kill adenovirus alone, for example Curiel, *Hum. Gene*
5   *Ther.* 3: 147-154 (1992); ligand-linked DNA, for example see Wu, *J. Biol. Chem.* 264: 16985-16987 (1989); eukaryotic cell delivery vehicles cells, for example see U.S. Serial No. 08/240,030, filed May 9, 1994, and U.S. Serial No. 08/404,796; deposition of photopolymerized hydrogel materials; hand-held gene transfer particle gun, as described in U.S. Patent No. 5,149,655; ionizing radiation as described in U.S. Patent No. 5,206,152 and in
10   WO 92/11033; nucleic charge neutralization or fusion with cell membranes. Additional approaches are described in Philip, *Mol. Cell Biol.* *14*:2411-2418 (1994), and in Woffendin, *Proc. Natl. Acad. Sci.* *91*:1581-1585 (1994).

Naked DNA may also be employed. Exemplary naked DNA introduction methods are described in WO 90/11092 and U.S. Patent No. 5,580,859. Uptake efficiency may be
15   improved using biodegradable latex beads. DNA coated latex beads are efficiently transported into cells after endocytosis initiation by the beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm. Liposomes that can act as gene delivery vehicles are described in U.S. Patent No. 5,422,120, PCT Patent Publication Nos. WO 95/13
20   796, WO 94/23697, and WO 91/14445, and EP No. 0 524 968.

Further non-viral delivery suitable for use includes mechanical delivery systems such as the approach described in Woffendin et al., *Proc. Natl. Acad. Sci. USA* 91(24): 11581-11585 (1994). Moreover, the coding sequence and the product of expression of such can be delivered through deposition of photopolymerized hydrogel materials. Other conventional
25   methods for gene delivery that can be used for delivery of the coding sequence include, for example, use of hand-held gene transfer particle gun, as described in U.S. Patent No. 5,149,655; use of ionizing radiation for activating transferred gene, as described in U.S. Patent No. 5,206,152 and PCT Patent Publication No. WO 92/11033.

The subject antibodies or antibody fragments may be conjugated directly or indirectly
30   to effective moieties, e.g., radionuclides, toxins, chemotherapeutic agents, prodrugs, cytoslatic agents, enzymes and the like. In a preferred embodiment the antibody or fragment will be

38

attached to a therapeutic or diagnostic radiolabel directly or by use of a chelating agent. Examples of suitable radiolabels are well known and include ^{90}Y, ^{125}I, ^{131}I, ^{111}I, ^{105}Rh, ^{153}Sm, ^{67}Cu, ^{67}Ga, ^{166}Ho, ^{177}Lu, ^{186}Re and ^{188}Re.

Examples of suitable drugs that my be coupled to antibodies include methotrexate,
5 adriamycine and lymphokines such as interferons, interleukins and the like. Suitable toxins which may be coupled include ricin, cholera and diptheria toxin.

In a preferred embodiment, the subject antibodies will be attached to a therapeutic radiolabel and used for radioimmunotherapy.

Anti-sense Oligonucleotides

10 In certain circumstances, it may be desirable to modulate or decrease the amount of the protein expressed by a prostate cell. Thus, in another aspect of the present invention, anti-sense oligonucleotides can be made and a method utilized for diminishing the level of expression a prostate antigen according to the invention by a cell comprising administering one or more anti-sense oligonucleotides. By anti-sense oligonucleotides reference is made to
15 oligonucleotides that have a nucleotide sequence that interacts through base pairing with a specific complementary nucleic acid sequence involved in the expression of the target such that the expression of the gene is reduced. Preferably, the specific nucleic acid sequence involved in the expression of the gene is a genomic DNA molecule or mRNA molecule that encodes the gene. This genomic DNA molecule can comprise regulatory regions of the gene,
20 or the coding sequence for the mature gene.

The term complementary to a nucleotide sequence in the context of antisense oligonucleotides and methods therefor means sufficiently complementary to such a sequence as to allow hybridization to that sequence in a cell, i.e., under physiological conditions. Antisense oligonucleotides preferably comprise a sequence containing from about 8 to about
25 100 nucleotides and more preferably the antisense oligonucleotides comprise from about 15 to about 30 nucleotides. Antisense oligonucleotides can also contain a variety of modifications that confer resistance to nucleolytic degradation such as, for example, modified internucleoside linages [Uhlmann and Peyman, *Chemical Reviews* 90:543-548 (1990); Schneider and Banner, *Tetrahedron Lett.* 31:335, (1990) which are incorporated by reference],
30 modified nucleic acid bases as disclosed in 5,958,773 and patents disclosed therein, and/or sugars and the like.

Any modifications or variations of the antisense molecule which are known in the art to be broadly applicable to antisense technology are included within the scope of the invention. Such modifications include preparation of phosphorus-containing linkages as disclosed in U.S. Patents 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361, 5,625,050 and 5,958,773.

The antisense compounds of the invention can include modified bases. The antisense oligonucleotides of the invention can also be modified by chemically linking the oligonucleotide to one or more moieties or conjugates to enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. Such moieties or conjugates include lipids such as cholesterol, cholic acid, thioether, aliphatic chains, phospholipids, polyamines, polyethylene glycol (PEG), palmityl moieties, and others as disclosed in, for example, U.S. Patents 5,514,758, 5,565,552, 5,567,810, 5,574,142, 5,585,481, 5,587,371, 5,597,696 and 5,958,773.

Chimeric antisense oligonucleotides are also within the scope of the invention, and can be prepared from the present inventive oligonucleotides using the methods described in, for example, U.S. Patents 5,013,830, 5,149,797, 5,403,711, 5,491,133, 5,565,350, 5,652,355, 5,700,922 and 5,958,773.

In the antisense art a certain degree of routine experimentation is required to select optimal antisense molecules for particular targets. To be effective, the antisense molecule preferably is targeted to an accessible, or exposed, portion of the target RNA molecule. Although in some cases information is available about the structure of target mRNA molecules, the current approach to inhibition using antisense is via experimentation. mRNA levels in the cell can be measured routinely in treated and control cells by reverse transcription of the mRNA and assaying the cDNA levels. The biological effect can be determined routinely by measuring cell growth or viability as is known in the art.

Measuring the specificity of antisense activity by assaying and analyzing cDNA levels is an art-recognized method of validating antisense results. It has been suggested that RNA from treated and control cells should be reverse-transcribed and the resulting cDNA populations analyzed. [Branch, A. D., *T.I.B.S.* 23:45-50 (1998)].

The therapeutic or pharmaceutical compositions of the present invention can be administered by any suitable route known in the art including for example intravenous,

subcutaneous, intramuscular, transdermal, intrathecal or intracerebral. Administration can be either rapid as by injection or over a period of time as by slow infusion or administration of slow release formulation.

Additionally, the subject prostate tumor proteins can also be linked or conjugated with

5   agents that provide desirable pharmaceutical or pharmacodynamic properties. For example, the protein can be coupled to any substance known in the art to promote penetration or transport across the blood-brain barrier such as an antibody to the transferrin receptor, and administered by intravenous injection (see, for example, Friden et al., *Science* 259:373-377 (1993) which is incorporated by reference). Furthermore, the subject protein A or protein B

10   can be stably linked to a polymer such as polyethylene glycol to obtain desirable properties of solubility, stability, half-life and other pharmaceutically advantageous properties. [See, for example, Davis et al., *Enzyme Eng.* 4:169-73 (1978); Buruham, *Am. J. Hosp. Pharm.* 51:210-218 (1994) which are incorporated by reference].

The compositions are usually employed in the form of pharmaceutical preparations.

15   Such preparations are made in a manner well known in the pharmaceutical art. See, e.g. Remington Pharmaceutical Science, 18th Ed., Merck Publishing Co. Eastern PA, (1990). One preferred preparation utilizes a vehicle of physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers such as physiological concentrations of other non-toxic salts, five percent aqueous glucose solution, sterile water or the like may also be

20   used. It may also be desirable that a suitable buffer be present in the composition. Such solutions can, if desired, be lyophilized and stored in a sterile ampoule ready for reconstitution by the addition of sterile water for ready injection. The primary solvent can be aqueous or alternatively non-aqueous. The subject prostate tumor antigens, fragments or variants thereof can also be incorporated into a solid or semi-solid biologically compatible matrix which can be

25   implanted into tissues requiring treatment.

The carrier can also contain other pharmaceutically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmaceutically-acceptable excipients for modifying or maintaining release or absorption or

30   penetration across the blood-brain barrier. Such excipients are those substances usually and customarily employed to formulate dosages for parental administration in either unit dosage or

multi-dose form or for direct infusion into the cerebrospinal fluid by continuous or periodic infusion.

Dose administration can be repeated depending upon the pharmacokinetic parameters of the dosage formulation and the route of administration used.

5   It is also contemplated that certain formulations containing the subject antibody or nucleic acid antagonists are to be administered orally. Such formulations are preferably encapsulated and formulated with suitable carriers in solid dosage forms. Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, calcium silicate, microcrystalline cellulose,

10   polyvinylpyrrolidone, cellulose, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium, stearate, water, mineral oil, and the like. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained, or delayed release of the

15   active ingredients after administration to the patient by employing procedures well known in the art. The formulations can also contain substances that diminish proteolytic degradation and promote absorption such as, for example, surface active agents.

The specific dose is calculated according to the approximate body weight or body surface area of the patient or the volume of body space to be occupied. The dose will also be

20   calculated dependent upon the particular route of administration selected. Further refinement of the calculations necessary to determine the appropriate dosage for treatment is routinely made by those of ordinary skill in the art. Such calculations can be made without undue experimentation by one skilled in the art in light of the activity disclosed herein in assay preparations of target cells. Exact dosages are determined in conjunction with standard dose-

25   response studies. It will be understood that the amount of the composition actually administered will be determined by a practitioner, in the light of the relevant circumstances including the condition or conditions to be treated, the choice of composition to be administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the chosen route of administration.

30   In one embodiment of this invention, the protein may be therapeutically administered by implanting into patients vectors or cells capable of producing a biologically-active form of

the protein or a precursor of protein, *i.e.*, a molecule that can be readily converted to a biological-active form of the protein by the body. In one approach, cells that secrete the protein may be encapsulated into semipermeable membranes for implantation into a patient. The cells can be cells that normally express the protein or a precursor thereof or the cells can

5   be transformed to express the protein or a precursor thereof. It is preferred that the cell be of human origin and that the protein be a human protein when the patient is human. However, it is anticipated that non-human primate homologues of the protein discussed infra may also be effective.

                      Detection of Subject Prostate Proteins or Nucleic Acids

10   In a number of circumstances it would be desirable to determine the levels of protein or corresponding mRNA in a patient. Evidence disclosed infra suggests the subject prostate proteins may be expressed at different levels during some diseases, e.g., cancers, provides the basis for the conclusion that the presence of these proteins serves a normal physiological function related to cell growth and survival. Endogenously produced protein according to the

15   invention may also play a role in certain disease conditions.

         The term "detection" as used herein in the context of detecting the presence of protein in a patient is intended to include the determining of the amount of protein or the ability to express an amount of protein in a patient, the estimation of prognosis in terms of probable outcome of a disease and prospect for recovery, the monitoring of the protein levels over a

20   period of time as a measure of status of the condition, and the monitoring of protein levels for determining a preferred therapeutic regimen for the patient, e.g. one with prostate cancer.

         To detect the presence of a prostate protein according to the invention in a patient, a sample is obtained from the patient. The sample can be a tissue biopsy sample or a sample of blood, plasma, serum, CSF, urine or the like. It has been found that the subject proteins are

25   expressed at high levels in some cancers. Samples for detecting protein can be taken from prostate tissues. When assessing peripheral levels of protein, it is preferred that the sample be a sample of blood, plasma or serum. When assessing the levels of protein in the central nervous system a preferred sample is a sample obtained from cerebrospinal fluid or neural tissue. The sample may be obtained by non-invasive methods, such as from tissue collection(s)

30   or cultute(s), or using directly available tissue material (urine, saliva, stools, hair, etc.).

In some instances, it is desirable to determine whether the gene is intact in the patient or in a tissue or cell line within the patient. By an intact gene, it is meant that there are no alterations in the gene such as point mutations, deletions, insertions, chromosomal breakage, chromosomal rearrangements and the like wherein such alteration might alter production of the corresponding protein or alter its biological activity, stability or the like to lead to disease processes. Thus, in one embodiment of the present invention a method is provided for detecting and characterizing any alterations in the gene. The method comprises providing an oligonucleotide that contains the gene, genomic DNA or a fragment thereof or a derivative thereof. By a derivative of an oligonucleotide, it is meant that the derived oligonucleotide is substantially the same as the sequence from which it is derived in that the derived sequence has sufficient sequence complementarily to the sequence from which it is derived to hybridize specifically to the gene. The derived nucleotide sequence is not necessarily physically derived from the nucleotide sequence, but may be generated in any manner including for example, chemical synthesis or DNA replication or reverse transcription or transcription.

Typically, patient genomic DNA is isolated from a cell sample from the patient and digested with one or more restriction endonucleases such as, for example, TaqI and AluI. Using the Southern blot protocol, which is well known in the art, this assay determines whether a patient or a particular tissue in a patient has an intact prostate gene according to the invention or a gene abnormality.

Hybridization to a gene would involve denaturing the chromosomal DNA to obtain a single-stranded DNA; contacting the single-stranded DNA with a gene probe associated with the gene sequence; and identifying the hybridized DNA-probe to detect chromosomal DNA containing at least a portion of a gene.

The term "probe" as used herein refers to a structure comprised of a polynucleotide that forms a hybrid structure with a target sequence, due to complementarily of probe sequence with a sequence in the target region. Oligomers suitable for use as probes may contain a minimum of about 8-12 contiguous nucleotides which are complementary to the targeted sequence and preferably a minimum of about 20.

A gene according to the present invention can be DNA or RNA oligonucleotides and can be made by any method known in the art such as, for example, excision, transcription or chemical synthesis. Probes may be labeled with any detectable label known in the art such as,

for example, radioactive or fluorescent labels or enzymatic marker. Labeling of the probe can be accomplished by any method known in the art such as by PCR, random priming, end labeling, nick translation or the like. One skilled in the art will also recognize that other methods not employing a labeled probe can be used to determine the hybridization. Examples

5   of methods that can be used for detecting hybridization include Southern blotting, fluorescence in situ hybridization, and single-strand conformation polymorphism with PCR amplification.

       Hybridization is typically carried out at 25° - 45° C, more preferably at 32° -40° C and more preferably at 37° - 38° C. The time required for hybridization is from about 0.25 to about 96 hours, more preferably from about one to about 72 hours, and most preferably from about 4

10   to about 24 hours.

       Gene abnormalities can also be detected by using the PCR method and primers that flank or lie within the gene. The PCR method is well known in the art. Briefly, this method is performed using two oligonucleotide primers which are capable of hybridizing to the nucleic acid sequences flanking a target sequence that lies within a gene and amplifying the target

15   sequence. The terms "oligonucleotide primer" as used herein refers to a short strand of DNA or RNA ranging in length from about 8 to about 30 bases. The upstream and downstream primers are typically from about 20 to about 30 base pairs in length and hybridize to the flanking regions for replication of the nucleotide sequence. The polymerization is catalyzed by a DNA-polymerase in the presence of deoxynucleotide triphosphates or nucleotide analogs to

20   produce double-stranded DNA molecules. The double strands are then separated by any denaturing method including physical, chemical or enzymatic. Commonly, a method of physical denaturation is used involving heating the nucleic acid, typically to temperatures from about 80°C to 105°C for times ranging from about 1 to about 10 minutes. The process is repeated for the desired number of cycles.

25   The primers are selected to be substantially complementary to the strand of DNA being amplified. Therefore, the primers need not reflect the exact sequence of the template, but must be sufficiently complementary to selectively hybridize with the strand being amplified.

       After PCR amplification, the DNA sequence comprising the gene or a fragment thereof is then directly sequenced and analyzed by comparison of the sequence with the sequences

30   disclosed herein to identify alterations which might change activity or expression levels or the like.

45

In another embodiment, a method for detecting a tumor protein according to the invention is provided based upon an analysis of tissue expressing the gene. Certain tissues such as prostate tissues have been found to overexpress the subject gene. The method comprises hybridizing a polynucleotide to mRNA from a sample of tissue that normally 5   expresses the gene. The sample is obtained from a patient suspected of having an abnormality in the gene.

To detect the presence of mRNA encoding the protein, a sample is obtained from a patient. The sample can be from blood or from a tissue biopsy sample. The sample may be treated to extract the nucleic acids contained therein. The resulting nucleic acid from the 10   sample is subjected to gel electrophoresis or other size separation techniques.

The mRNA of the sample is contacted with a DNA sequence serving as a probe to form hybrid duplexes. The use of a labeled probes as discussed above allows detection of the resulting duplex.

When using the cDNA encoding the protein or a derivative of the cDNA as a probe, 15   high stringency conditions can be used in order to prevent false positives, that is the hybridization and apparent detection of the gene nucleotide sequence when in fact an intact and functioning gene is not present. When using sequences derived from the gene cDNA, less stringent conditions could be used, however, this would be a less preferred approach because of the likelihood of false positives. The stringency of hybridization is determined by a number 20   of factors during hybridization and during the washing procedure, including temperature, ionic strength, length of time and concentration of formamide. These factors are outlined in, for example, Sambrook et al. [Sambrook et al. (1989), *supra*].

In order to increase the sensitivity of the detection in a sample of mRNA encoding the protein A or protein B, the technique of reverse transcription/ polymerization chain reaction 25   (RT/PCR) can be used to amplify cDNA transcribed from mRNA encoding the prostate tumor antigen. The method of RT/PCR is well known in the art, and can be performed as follows. Total cellular RNA is isolated by, for example, the standard guanidium isothiocyanate method and the total RNA is reverse transcribed. The reverse transcription method involves synthesis of DNA on a template of RNA using a reverse transcriptase enzyme and a 3' end primer. 30   Typically, the primer contains an oligo(dT) sequence. The cDNA thus produced is then amplified using the PCR method and gene A or gene B specific primers. [Belyavsky et al.,

Nucl. Acid Res. 17:2919-2932 (1989); Krug and Berger, *Methods in Enzymology*, 152:316-325, Academic Press, NY (1987) which are incorporated by reference].

The polymerase chain reaction method is performed as described above using two oligonucleotide primers that are substantially complementary to the two flanking regions of the

5 DNA segment to be amplified. Following amplification, the PCR product is then electrophoresed and detected by ethidium bromide staining or by phosphoimaging.

The present invention further provides for methods to detect the presence of the protein in a sample obtained from a patient. Any method known in the art for detecting proteins can be used. Such methods include, but are not limited to immunodiffusion,

10 immunoelectrophoresis, immunochemical methods, binder-ligand assays, immunohistochemical techniques, agglutination and complement assays. [*Basic and Clinical Immunology*, 217-262, Sites and Terr, eds., Appleton & Lange, Norwalk, CT, (1991), which is incorporated by reference]. Preferred are binder-ligand immunoassay methods including reacting antibodies with an epitope or epitopes of the prostate tumor antigen protein and

15 competitively displacing a labeled prostate antigen according to the invention or derivative thereof.

As used herein, a derivative of the subject prostate tumor antigen is intended to include a polypeptide in which certain amino acids have been deleted or replaced or changed to modified or unusual amino acids wherein the derivative is biologically equivalent to gene and

20 wherein the polypeptide derivative cross-reacts with antibodies raised against the protein. By cross-reaction it is meant that an antibody reacts with an antigen other than the one that induced its formation.

Numerous competitive and non-competitive protein binding immunoassays are well known in the art. Antibodies employed in such assays may be unlabeled, for example as used

25 in agglutination tests, or labeled for use in a wide variety of assay methods. Labels that can be used include radionuclides, enzymes, fluorescers, chemiluminescers, enzyme substrates or co-factors, enzyme inhibitors, particles, dyes and the like for use in radioimmunoassay (RIA), enzyme immunoassays, *e.g.*, enzyme-linked immunosorbent assay (ELISA), fluorescent immunoassays and the like.

30

A further aspect of this invention relates to a method for selecting, identifying, screening, characterizing or optimizing biologically active compounds, comprising a determination of whether a candidate compound binds, preferably selectively, a target molecule as disclosed above. Such target molecules include nucleic acid sequences,

5   polypeptides and fragments thereof, typically prostate-specific antigens, even more preferably extracellular portions thereof. Binding may be assessed in vitro or in vivo, typically in vitro, in cell based or accellular systems. Typically, the target molecule is contacted with the candidate compound in any appropriate device, and the formation of a complex is determined. The target molecule and/or the candidate compound may be immobilized on a support. The compounds

10   identified or selected represent drug candidates or leads for treating cancer diseases, particularly prostate cancer.

While the invention has been described supra, including preferred embodiments, the following examples are provided to further illustrate the invention.

15

EXAMPLE

Tissue Sources:

Appropriate patient samples were procured for evaluation of research protocol. Samples were provided with relevant clinical parameters, and patient consent. Histological

20   assessment was performed on all samples and diagnosis by pathology confirmed the presence and/or absence of malignancy within each sample. Clinical data generally included patent history, physiopathology, and parameters relating to prostate cancer physiology. Ten normal and ten malignant samples were procured along with available clinical information. In addition, ten samples from organs other than normal prostate and prostate cancer were

25   procured to determine the tissue specific expression profile of epitopes. RNA derived from normal tissue samples was obtained from known commercial sources.

Generation of the DATAS Library

Samples were pooled based on their pathological diagnosis (normal vs. tumor).

30   Samples were pooled based on equivalent amounts of total RNA to produce total pooled RNA samples of 100ug. DATAS libraries were constructed as previously disclosed in U.S. Patent

48

No. 6,251,590, the disclosure of which is incorporated by reference in its entirety. Briefly, total RNA was isolated from the normal and tumor pooled samples and mRNA was subsequently purified from the total RNA for each pooled sample. Synthesis of cDNA was performed using a biotinylated oligo (dT) primer. The biotinylated cDNA was hybridized with

5   the mRNA of the opposite sample to form heteroduplexes between the cDNA and the mRNA. For example, the biotinylated cDNA of the pooled normal prostate sample was hybridized with prostate tumor mRNA. Similarly, prostate tumor biotinylated cDNA was hybridized with prostate normal RNA to generate the second DATAS library. Streptavidin coated beads were used to purify the complexes by binding the biotin present on the cDNA. The heteroduplexes

10   were digested with RNAse H to degrade the RNA that was complementary to the cDNA. All mRNA sequences that were different from the cDNA remained intact. These single stranded RNA fragments or "loops" were subsequently amplified with degenerate primers and cloned into either pGEM-T or pCR II TOPO vector (Company source) to produce the DATAS library.

15   **Clone sequencing and Bioinformatics Analysis:**

The DATAS library was used to transform E. coli so that individual clones could be isolated using standard molecular biology techniques. From these libraries, 10,665 individual clones were isolated and sequenced using an automated Applied Biosystems 3100 sequencer. The nucleotide sequences that were obtained were submitted to the bioinformatics pipeline for

20   analysis. As the DATAS library is prepared with PCR amplified DNA, many copies of the same sequence are present in the clones isolated from the libraries. Therefore it is important to reduce the redundancy of the clones to identify the number of unique, nonrepeating sequences that are isolated. From this large set of DATAS fragments, 1699 unique, nonredundant sequences were identified and each DATAS fragment was annotated with a candidate gene.

25   The annotation was performed by aligning the DATAS fragment to the human genome sequence by two methods; 1) a publicly available alignment and genome viewer tool, Blat (Kent et al., 2002); and 2) a commercially available genomic alignment and viewer tool, Prophecy (Doubletwist). Each DATAS fragment sequence was annotated with a corresponding gene that overlapped the genomic sequence containing the DATAS fragment.

30   Genes were annotated with either the RefSeq accession number, or a hypothetical gene prediction from different algorithms, for example, Genscan, Twinscan, or Fgenesh++.

.

Identified genes were either matched to the sequence of the DATAS fragment (in case of exon to fragment match), or overlapped with the DATAS fragment (in case of intron to fragment match), and the full length sequence of the gene was identified. These sequences were further analyzed to detect all potential membrane spanning proteins. Membrane proteins were
5   predicted through the use of different algorithms publicly available. For example, TMHMM (CBS) was used to identify membrane-spanning domains present within the amino acid sequence of the candidate gene. DATAS fragments were located within the sequence in an attempt to determine whether the spliced event affected intracellular or extraceullar domains. Genes associated with the sequence were ranked in order to maximize the identification of
10   successful therapeutic targets. The highest priority genes had characteristics where the gene was a known membrane protein, the function of the gene was known, and the DATAS fragment mapped to an intron on the extracellular domain of the protein, indicating that the DATAS fragment would be presented outside the cell, and available for therapeutic intervention by monoclonal antibodies.

15   Based on the bioinformatic analysis, clones were prioritized in three groups:

         A) Known transmembrane genes with DATAS fragments located in introns on the extracellular domain.

         B) Known and predicted transmembrane genes with DATAS fragments located in exons in either the extracellular or intracellular domain.

20   C) DATAS fragments that did not match the genome

Expression Monitoring:

          A valid epitope target for prostate cancer requires that the expression of the epitope be limited to prostate tissue, or preferably to prostate tumors. Assessment of the expression
25   profile for each prioritized sequence was performed by RT-PCR, a procedure well known in the art. A protocol known as touchdown PCR was used, described in the user's manual for the GeneAmp PCR system 9700, Applied Biosystems. Briefly, PCR primers were designed to the DATAS fragment and used for end point RT-PCR analysis. Each RT reaction contained 5 μg of total RNA and was performed in a 100 μl volume using Archive RT Kit (Applied
30   Biosystems). The RT reactions were diluted 1:50 with water and 4 μl of the diluted stock was used in a 50 μl PCR reaction consisting of one cycle at 94°C for 3 min, 5 cycles at 94°C for 30

seconds, 60°C for 30 seconds and 72°C for 45 seconds, with each cycle reducing the annealing

temperature by 0.5 degree. This was followed by 30 cycles at 94°C for 30 seconds, 55°C for

30 seconds, and 72 °C for 45 seconds. 15 μl was removed from each reaction for analysis and

the reactions were allowed to proceed for an additional 10 cycles. This produced reactions for

5   analysis at 30 and 40 cycles, and allowed the detection of differences in expression where the

40 cycle reactions had saturated. The level of expression profile of the DATAS fragment was

determined in normal and tumor prostate total RNA, as well as total RNA from normal

samples of brain, heart, liver, lung, kidney, colon, bone marrow, muscle, spleen, and testis.

Expression profiles were prioritized accordingly for specific expression in prostate tumor and

10   low expression found in normal tissues, including normal prostate.

Verification of RNA Structure:

DATAS identifies sequences that are altered between the experimental samples.

However, the exact sequence of the junctions or borders that the DATAS fragment represents

15   can not be determined directly from the isolated DATAS fragment sequence. The DATAS

fragment was used, however, to design experiments that elucidate the sequence of each

transcript present in each sample. Primers were designed to amplify a region of the gene larger

than the proposed DATAS fragment sequence. These amplicons were subsequently cloned

and sequenced for the identification of the exact junctions of all exons and introns. This

20   required partial cloning of the isoforms from an identified sample to verify the primary

structure (sequence) of the isoforms. All twenty samples (10 normal and 10 tumor samples)

initially used to generate the DATAS libraries were used for the verification of the mRNA

structure of the prioritized genes.

25   **Isolation of full-length clones of isoforms:**

Isolation of the full-length clones containing both isoforms was accomplished utilizing

the information and DNA fragments generated during the structure validation process. Several

methods are applicable to isolation of the full length clone. Where full sequence information

regarding the coding sequence is available, gene specific primers were designed from the

30   sequence and used to amplify the coding sequence directly from the total RNA of the tissue

samples. An RT-PCR reaction was set up using these gene specific primers. The RT reaction

51

was performed as described infra, using oligo dT to prime for cDNA. Second strand was produced by standard methods to produce double stranded cDNA. PCR amplification of the gene was accomplished using gene specific primers. PCR consisted of 30 cycles at 94°C for 30 seconds, 55°C for 30 seconds, and 72 °C for 45 seconds. The reaction products were

5   analyzed on 1% agarose gels and the amplicons were ligated into prepared vectors with A overhangs for amplicon cloning. 1 μl of the ligation mixture was used to transform E. coli for cloning and isolation of the amplicon. Once purified, the plasmid containing the amplicon was sequenced on an ABI 3100 automated sequencer.

10   Where limited sequence information was available, the oligo pulling method was utilized. Briefly, a gene-specific oligonucleotide was designed based on the DATAS fragment. The oligonucleotide was labeled with biotin and used to hybridize with a single stranded plasmid DNA library prepared from either normal prostate tissue or prostate tumor tissue following the procedures of Sambrook et al (1989). The hybridized cDNA was separated by streptavidin

15   conjugated beads and eluted by heating. The eluted cDNA was converted to double strand plasmid DNA and used to transform E. coli cells and the longest cDNA clone was subjected to · DNA sequencing.

RESULTS

20
Using methods described above, 1699 DNA fragments have been identified that putatively correspond to exons (novel splice variants) expressed exclusively or at an increased level in prostate tumor tissue when compared to matched normal prostate tissue.

These sequences were used to search public databases containing human genomic

25   sequences to identify related genes. This search identified 122 fragments that correspond to exons of either known or potential cell surface proteins.

Additionally, thirty seven distinct alternatively spliced isoforms were identified from the initial sequence tags that appear to contain novel sequence information of cell surface proteins.

30
These DNA sequences are disclosed in the Sequence Listing as well as in Table 1, and correspond to the nucleic acid sequences having SEQ ID NOS: 1-173, 175, 177, 179, and 181. Oligonucleotide primers were designed to each DATAS fragment to determine the specific

52

expression of the mRNA in a panel of normal human tissue. An example is shown in figure 1,
where the clone corresponding to Sequence ID: No. 92 displays specific expression in prostate
with very low levels detected in kidney (lane 4) and pancreas (lane 9). All clones that were
found to be either specifically expressed in prostate or highly expressed in prostate compared

5   to other tissues were analyzed for expression in tumor samples.

Figure 2 illustrates the expression profile of one DATAS clone in normal and tumor
prostate tissue. Expression of this clone is upregulated in two of the three tumor pooled
samples and is highly expressed in three of the four individual tumor samples. The high
expression of this splice event in tumor samples as compared to normal prostate, and the low

10 expression in other normal human tissues is an example of one candidate that has utility for
development as a novel epitope for prostate cancer.

The splice events for DATAS clones that displayed a specific expression profile for
prostate and a high differential expression profile for prostate tumors were isolated and the
sequences for each event was determined. An example is shown in figure 3, where the

15 sequence of the isolated event was mapped to the genome in Blat, and genomic viewer
developed by the bioinformatics department at UCSC (Kent et al., 2002). Five distinct clones
were isolated that mapped to the gene locus for STEAP2. One expressed sequence tag (EST),
AK092666, contained many similar domains as the splice events that were isolated using
DATAS. The sequences and predicted protein translations for all five clones are described in

20 SEQ NOS. 173 – 182 and are graphically illustrated in figure 3. The length of the open
reading frame and the predicted protein size for each isoform is described in Table 2. The
EST, AK092666 contains a large deletion in exon 5, the terminal 3' exon of STEAP2, with
two novel exons in the 5' region of the transcript. The nomenclature for the DATAS derived
events was based on AK092666 because of higher similarity when compared to the RefSeq

25 sequence for STEAP2. The first isoform identified, AK092666_01 (SEQ ID NO 173),
contains a novel C-terminal exon when compared to AK092666, and therefore generates a
novel junction, and a novel sequence for translation and generates a unique amino acid
sequence (SEQ ID NO 183). The same novel sequence was generated by isoform
AK092666_03 (SEQ ID NO 177), which contains the same novel exon with an additional

30 splicing event of an in frame truncation of exon 4, and by isoform AK092666_05 (SEQ ID NO
181), which contains a single codon deletion from AK092666_01. AK092666_02 (SEQ ID

NO 175) skipped exon 6 of AK092666 and generated the novel amino acid sequence in SEQ
ID NO 184. AK092666_04 (SEQ ID NO 179) contains a short out of frame truncation of exon
4, which results in the creation of 8 novel animo acids before encountering a premature stop
codon (SEQ ID NO 185).

5

Table 2. Length of the open reading frame and the predicted protein size for each novel
isoform.

Clone Name	ORF length (bp)	Protein size (KD)
STEAP2	1473	56
AK092666	1365	51.7
AK092666_01	1389	52.7
AK092666_02	1260	47.8
AK092666_03	900	34.1
AK092666_04	705	26.7
AK092666_05	1386	52.5

10   The novel amino acids found in SEQ ID NOS 183 and 184 represent novel epitopes
that are specifically expressed in prostate cancer in a membrane protein. These epitopes are
targets for monoclonal antibody immunotherapy for the treatment of prostate cancer. To
illustrate the different isoforms present, an antibody was generated from the invariant sequence
present in the 5' region (or the amino terminal portion of the protein) that recognizes all the
15   different isoforms.

        An antibody was generated against an amino acid sequence that was common to all
five isoforms, as well as present in STEAP2 and AK092666. Prostate cancer cell lines were
analyzed by western blot to determine what different isoforms would be expressed at the
protein level. Figure 4 illustrates two bands that were specifically detected by the antibody.
20   Band A potentially represents the glycosylated, wild type STEAP2 and band B indicates
isoforms AK092666, AK092666_01, or AK092666_05, which is unresolvable in the gel
analysis. In addition, multiple bands of the proper size were detected suggesting that isoforms
of the STEAP2 locus are expressed and represent targets for the immunotherapy in prostate
cancer.

25

54

Table 1. Sequence information of the DATAS fragments and the alternatively spliced
isoforms.

```
    Sequence ID: No. 1
5   Accession #: NM_005656
    Genomic sequence: chr21:39407238-39450894
    Sequence definition: transmembrane protease serine 2


10  Sequence ID: No. 2
    Accession #: NM_001423
    Genomic sequence: chr12:13265134-13265266
    Sequence definition: Homo sapiens epithelial membrane protein 1 EMP1


15  Sequence ID: No. 3
    Accession #: NM_000484
    Genomic sequence: chr21:23832850-24123073
    Sequence definition: beta amyloid A4


20  Sequence ID: No. 4
    Accession #: NM_002841
    Genomic sequence: chr3:62548596-63240788_1
    Sequence definition: protein tyrosine phosphatase G-type


25  Sequence ID: No. 5
    Accession #: NM_022124
    Genomic sequence: chr10:74968313-75112962
    Sequence definition: cadherin related 23 isoform 1 precursor


30  Sequence ID: No. 6
    Accession #: NM_033056
    Genomic sequence: chr10:55940286-56920530_02
    Sequence definition: protocadherin 15 precursor


35  Sequence ID: No. 7
    Accession #: NM_002847
    Genomic sequence: chr7:158586667-159621018_01
    Sequence definition: protein tyrosine phosphatase receptor type N


40  Sequence ID: No. 8
    Accession #: NM_002222
    Genomic sequence: chr3:5000696-5354641_1
    Sequence definition: ITPR inositol 145-triphosphate receptor type 1


45  Sequence ID: No. 9
    Accession #: AC078864.20
    Genomic sequence: chr12:52201280-52201714
    Sequence definition: Genscan prediction


50  Sequence ID: No. 10
    Accession #: NM_014554; NM_001844; NT_009785.3
    Genomic sequence: chr12:45785273-45856561
    Sequence definition: chr12_498 potential fusion of SENP1 and Collagen 2A;
    also overlaps GS perdiction
55
    Sequence ID: No. 11
    Accession #: AB064665
    Genomic sequence: chrM:9411-9524
    Sequence definition: Homo sapiens mRNA for OK/SW-CL.16
```

Sequence ID: No. 12
Accession #: NM_024029
Genomic sequence: chr19:10880041-10883719
5   Sequence definition: hypothetical protein MGC3262

Sequence ID: No. 13
Accession #: NT_008748.79
Genomic sequence: chr10:80881918-80882092
10   Sequence definition: Genscan prediction

Sequence ID: No. 14
Accession #: AB002360
Genomic sequence: chr13:112761227-112761344
15   Sequence definition: KIAA0362

Sequence ID: No. 15
Accession #: AK057572
Genomic sequence: chr16:14547315-14547422
20   Sequence definition: FLJ33010

Sequence ID: No. 16
Accession #: NT_034410.56/NM_033102.1
Genomic sequence: chr1:203503646-203554883/chr1:192169879-192474008
25   Sequence definition: Genscan - Elk4/LOC85414 - Homo sapiens prostein
protein LOC85414

Sequence ID: No. 17
Accession #: NT_019696.29
30   Genomic sequence: chrx:64173951-64275396
Sequence definition: Genscan prediction

Sequence ID: No. 18
Accession #: NT_007834.17
35   Genomic sequence: chr7:71656530-71727938
Sequence definition: Genscan prediction

Sequence ID: No. 19
Accession #: NT_005403.1000
40   Genomic sequence: chr2:208067141-208067324
Sequence definition: Genscan prediction

Sequence ID: No. 20
Accession #: NT_009654.19
45   Genomic sequence: chr12:116716120-116840364
Sequence definition: Genscan prediction

Sequence ID: No. 21
Accession #: AC126564.7
50   Genomic sequence: chr12:131440407-131440735
Sequence definition: genomic match

Sequence ID: No. 22
Accession #: NT_006171.64
55   Genomic sequence: chr4:172269202-172299375
Sequence definition: Genscan prediction

Sequence ID: No. 23
Accession #: NM_025149.1
60   Genomic sequence: chr17:61361324-61409903
Sequence definition: FLJ20920

Sequence ID: No. 24
Accession #: NT_026437.145
Genomic sequence: chr14:72272372-72462407
Sequence definition: Genscan prediction

5

Sequence ID: No. 25
Accession #: NT_030059.13
Genomic sequence: chr10:103933731-103955924
Sequence definition: Genscan prediction

10

Sequence ID: No. 26
Accession #: AK058112
Genomic sequence: chr19:1815692-1822319
Sequence definition: FLJ25383

15

Sequence ID: No. 27
Accession #: NM_002205.1
Genomic sequence: chr12:55541534-55565494
Sequence definition: Homo sapiens integrin alpha 5 fibronectin receptor

20 alpha polypeptide

Sequence ID: No. 28
Accession #: NM_004716.1
Genomic sequence: chr11:117114115-117114448
25 Sequence definition: Homo sapiens proprotein convertase subtilisin/kexin
type 7 PCSK7 mRNA

Sequence ID: No. 29
Accession #: NM_030774
30 Genomic sequence: chr11:5003431-5021099
Sequence definition: prostate specific G-protein coupled receptor [Homo
sapiens]

Sequence ID: No. 30
35 Accession #: AB007932
Genomic sequence: chr1:204846394-204846755
Sequence definition: Homo sapiens plexin A2 PLXNA2 mRNA

Sequence ID: No. 31
40 Accession #: AB023177
Genomic sequence: chr7:11157196-11157402
Sequence definition: Homo sapiens mRNA for KIAA0960 protein

Sequence ID: No. 32
45 Accession #: NT_004858.23
Genomic sequence: chr1:147688399-147725025
Sequence definition: Genscan prediction

Sequence ID: No. 33
50 Accession #: NT_004873.61
Genomic sequence: chr1:14678698-14732191
Sequence definition: Genscan prediction

Sequence ID: No. 34
55 Accession #: NT_029860.99
Genomic sequence: chr1:110751286-110854188
Sequence definition: Genscan prediction

Sequence ID: No. 35
60 Accession #: NM_032385.1
Genomic sequence: chr5:170086201-170251515
Sequence definition: Homo sapiens chromosome 5 open reading frame 4

C5orf4

Sequence ID: No. 36
Accession #: NM_014752.1
5 Genomic sequence: chr11:73182947-73211393
Sequence definition: KIAA0102

Sequence ID: No. 37
Accession #: NP_000295
10 Genomic sequence: chr17:15500091-15500332
Sequence definition: Homo sapiens peripheral myelin protein 22

Sequence ID: No. 38
Accession #: NM_020433
15 Genomic sequence: chr20:42528457-42528759
Sequence definition: Homo sapiens junctophilin 2

Sequence ID: No. 39
Accession #: NT_999999.2
20 Genomic sequence: chrM:9411-9524
Sequence definition: Genscan Gene Predictions

Sequence ID: No. 40
Accession #: NT_004754.1
25 Genomic sequence: chr1:117988850-117989247
Sequence definition: Genscan Gene Predictions

Sequence ID: No. 41
Accession #: NT_011568.108
30 Genomic sequence: chrX:47583156-47583796
Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions

Sequence ID: No. 42
Accession #: NP_061116
35 Genomic sequence: chr7:140900079-140900876
Sequence definition: transient receptor potential cation channel

Sequence ID: No. 43
Accession #: NT_011295.163
40 Genomic sequence: chr19:19799239-19804450
Sequence definition: Genscan prediction

Sequence ID: No. 44
Accession #: NP_056051
45 Genomic sequence: chr4:62284401-62284770
Sequence definition: lectomedin-3

Sequence ID: No. 45
Accession #: NT_033927.57
50 Genomic sequence: chr11:75518014-75562375
Sequence definition: Genscan prediction

Sequence ID: No. 46
Accession #: NM_030774
55 Genomic sequence: chr11:5003431-5021099
Sequence definition: prostate specific G-protein coupled receptor Homo
sapiens

Sequence ID: No. 47
60 Accession #: NM_022119
Genomic sequence: chr16:2939532-2939842
Sequence definition: protease serine 22

Sequence ID: No. 48
Accession #: NP_000155
Genomic sequence: chr19:46824678-46824801
5   Sequence definition: Homo sapiens gastric inhibitory polypeptide receptor

Sequence ID: No. 49
Accession #: NM_001627
Genomic sequence: chr3:104784804-104787209
10 Sequence definition: activated leukocyte cell adhesion molecule

Sequence ID: No. 50
Accession #: NP_056343
Genomic sequence: chr17:5263335-5263632
15 Sequence definition: Homo sapiens DKFZP566H073 protein

Sequence ID: No. 51
Accession #: NT_033275.9
Genomic sequence: chr15:19767754-19767842
20 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions

Sequence ID: No. 52
Accession #: NT_004511.105
Genomic sequence: chr1:37657082-37657508
25 Sequence definition: Genscan Gene Predictions

Sequence ID: No. 53
Accession #: NT_007819.76
Genomic sequence: chr7:2293638-2293859
30 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions

Sequence ID: No. 54
Accession #: NT_008046.179
Genomic sequence: chr8:101509107-101509191   .
35 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions

Sequence ID: No. 55
Accession #: NP_001668
Genomic sequence: chr1:166712801-166712951
40 Sequence definition: ATPase Na+/K+ transporting beta 1 polypeptide

Sequence ID: No. 56
Accession #: NP_061332
Genomic sequence: chr7:105724807-105753208
45 Sequence definition: B-cell receptor-associated protein BAP29

Sequence ID: No. 57
Accession #: NT_008251.42
Genomic sequence: chr8:36531104-36531405
50 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions

Sequence ID: No. 58
Accession #: NT_008984.116
Genomic sequence: chr11:97792879-97792961
55 Sequence definition: Genscan Gene Predictions

Sequence ID: No. 59
Accession #: NT_011176.84
Genomic sequence: chr19:11151260-11154382
60 Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions

Sequence ID: No. 60

Accession #: ENST00000255124
Genomic sequence: chr20:46047371-46047445
Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions

5   Sequence ID: No. 61
Accession #: ENST00000262657
Genomic sequence: chr20:29935469-29937596
Sequence definition: Acembly Gene Predictions/Genscan Gene Predictions

10   Sequence ID: No. 62
Accession #: NT_033903.44
Genomic sequence: chr11:58671001-58671164
Sequence definition: Genscan Gene Predictions

15   Sequence ID: No. 63
Accession #: NP_000360
Genomic sequence: chr14:78989775-78989913
Sequence definition: Homo sapiens thyroid stimulating hormone receptor

20   Sequence ID: No. 64
Accession #: NP_005219
Genomic sequence: chr7:54724858-54725037
Sequence definition: Homo sapiens epidermal growth factor receptor
erythroblastic leukemia viral v-erb-b oncogene homolog avian
25

Sequence ID: No. 65
Accession #: NP_149093
Genomic sequence: chr1:203548697-203549088
Sequence definition: Homo sapiens prostein protein
30

Sequence ID: No. 66
Accession #: NM_030774
Genomic sequence: chr11:5003431-5021099
Sequence definition: prostate specific G-protein coupled receptor Homo
35   sapiens

Sequence ID: No. 67
Accession #: NM_030774
Genomic sequence: chr11:5004995-5010301
40   Sequence definition: prostate specific G-protein coupled receptor Homo
sapiens

Sequence ID: No. 68
Accession #: NM_030774
45   Genomic sequence: chr11:5004983-5010305
Sequence definition: prostate specific G-protein coupled receptor Homo
sapiens

Sequence ID: No. 69
50   Accession #: NM_030774
Genomic sequence: chr11:5004983-5010305
Sequence definition: prostate specific G-protein coupled receptor Homo
sapiens

55   Sequence ID: No. 70
Accession #: NM_030774
Genomic sequence: chr11:4667240-4678100
Sequence definition: prostate specific G-protein coupled receptor Homo
sapiens
60

Sequence ID: No. 71
Accession #: NM_030774

Genomic sequence: chr11:4677792-4677987
Sequence definition: prostate specific G-protein coupled receptor Homo
sapiens

5   Sequence ID: No. 72
     Accession #: NM_030774
     Genomic sequence: chr11:5003430-5007773
     Sequence definition: prostate specific G-protein coupled receptor Homo
     sapiens
10
     Sequence ID: No. 73
     Accession #: AK075546
     Genomic sequence: chr11:36643617-36930167
     Sequence definition: predicted protein
15
     Sequence ID: No. 74
     Accession #: AK075546
     Genomic sequence: chr11:36643626-36931023
     Sequence definition: predicted protein
20
     Sequence ID: No. 75
     Accession #: AK075546
     Genomic sequence: chr11:36643617-36929351
     Sequence definition: predicted protein
25
     Sequence ID: No. 76
     Accession #: AK075546
     Genomic sequence: chr11:36643617-36929351
     Sequence definition: predicted protein
30
     Sequence ID: No. 77
     Accession #: AK075546
     Genomic sequence: chr11:36643617-36929351
     Sequence definition: predicted protein
35
     Sequence ID: No. 78
     Accession #: NT_033927.57
     Genomic sequence: chr11:75518014-75562375
     Sequence definition: Genscan prediction
40
     Sequence ID: No. 79
     Accession #: NM_000300
     Genomic sequence: chr1:19337078-19342056
     Sequence definition: phospholipase A2 group IIA platelets synovial
45
     Sequence ID: No. 80
     Accession #: NM_000300
     Genomic sequence: chr1:19337078-19342056
     Sequence definition: phospholipase A2 group IIA platelets synovial
50
     Sequence ID: No. 81
     Accession #: NM_000300
     Genomic sequence: chr1:19337078-19342056
     Sequence definition: phospholipase A2 group IIA platelets synovial
55
     Sequence ID: No. 82
     Accession #: NM_000300
     Genomic sequence: chr1:19337078-19342056
     Sequence definition: phospholipase A2 group IIA platelets synovial
60
     Sequence ID: No. 83
     Accession #: NM_000300

Genomic sequence: chr1:19337078-19342056
Sequence definition: phospholipase A2 group IIA platelets synovial

Sequence ID: No. 84
5   Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102 - refseq

Sequence ID: No. 85
10   Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102

Sequence ID: No. 86
15   Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102

Sequence ID: No. 87
20   Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102

Sequence ID: No. 88
25   Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102

Sequence ID: No. 89
30   Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102

Sequence ID: No. 90
35   Accession #: NM_032323
Genomic sequence: chr1:152017962-152027457
Sequence definition: hypothetical protein MGC13102

Sequence ID: No. 91
40   Accession #: AK092666
Genomic sequence: chr7:88376306-88402240
Sequence definition: STEAP2/AK092666

Sequence ID: No. 92
45   Accession #: AK092666
Genomic sequence: chr7:88376306-88402240
Sequence definition: STEAP2/AK092666

Sequence ID: No. 93
50   Accession #: AK092666
Genomic sequence: chr7:88376306-88402240
Sequence definition: STEAP2/AK092666

Sequence ID: No. 94
55   Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
Sequence definition: TMPRSS2

Sequence ID: No. 95
60   Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
Sequence definition: TMPRSS2

Sequence ID: No. 96
Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
5 Sequence definition: TMPRSS2

Sequence ID: No. 97
Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
10 Sequence definition: TMPRSS2

Sequence ID: No. 98
Accession #: NM_005656
Genomic sequence: chr21:39493446-39537043
15 Sequence definition: TMPRSS2

Sequence ID: No. 99
Accession #: NM_004476
Genomic sequence: chr11:50361918-50423952
20 Sequence definition: PSMA/FOLH1

Sequence ID: No. 100
Accession #: NM_004476
Genomic sequence: chr11:50361918-50423952
25 Sequence definition: PSMA/FOLH1

Sequence ID: No. 101
Accession #: NM_004476
Genomic sequence: chr11:50361918-50423952
30 Sequence definition: PSMA/FOLH1

Sequence ID: No. 102
Accession #: no match to index
Genomic sequence: No match BLAT
35 Sequence definition: No match BLAT

Sequence ID: No. 103
Accession #: AC105101.8
Genomic sequence: chr18:45441503-45442177
40 Sequence definition: genomic match

Sequence ID: No. 104
Accession #: BC043509
Genomic sequence: chr2:7566735-7567210
45 Sequence definition: genomic match

Sequence ID: No. 105
Accession #: no match to index
Genomic sequence: No match BLAT
50 Sequence definition: No match BLAT

Sequence ID: No. 106
Accession #: NT_007914.345
Genomic sequence: chr7:150965224-150965948
55 Sequence definition: Genscan prediction

Sequence ID: No. 107
Accession #: NM_002474
Genomic sequence: chr16:15123743-15124024
60 Sequence definition: smooth muscle myosin heavy chain 11 isoform

Sequence ID: No. 108

Accession #: no match to index
Genomic sequence: No match BLAT
Sequence definition: No match BLAT

5   Sequence ID: No. 109
       Accession #: AL450472.14
       Genomic sequence: chrX:132596913-132597349
       Sequence definition: genomic match

10   Sequence ID: No. 110
       Accession #: no match to index
       Genomic sequence: No match BLAT
       Sequence definition: No match BLAT

15   Sequence ID: No. 111
       Accession #: NM_024490
       Genomic sequence: chr15:18676827-18681314
       Sequence definition: ATPase Class V type 10A

20   Sequence ID: No. 112
       Accession #: NT_007741.24
       Genomic sequence: chr7:154483727-154484200
       Sequence definition: Genscan prediction

25   Sequence ID: No. 113
       Accession #: NT_010168.1
       Genomic sequence: chr14:100136759-100137109
       Sequence definition: Genscan prediction

30   Sequence ID: No. 114
       Accession #: AK074158
       Genomic sequence: chr7:2347770-2347996
       Sequence definition: Homo sapiens mRNA for FLJ00231 protein

35   Sequence ID: No. 115
       Accession #: no match to index
       Genomic sequence: No match BLAT
       Sequence definition: No match BLAT

40   Sequence ID: No. 116
       Accession #: AL549429
       Genomic sequence: chr11:9027915-9028089
       Sequence definition: genomic match

45   Sequence ID: No. 117
       Accession #: NM_015541
       Genomic sequence: chr3:65899978-65900329
       Sequence definition: leucine-rich repeats and immunoglobulin-like

50   Sequence ID: No. 118
       Accession #: NM_024897
       Genomic sequence: chr1:151978744-151978881
       Sequence definition: hypothetical protein FLJ22672

55   Sequence ID: No. 119
       Accession #: NM_006598
       Genomic sequence: chr5:1165896-1168793
       Sequence definition: solute carrier family 12 potassium/chloride

60   Sequence ID: No. 120
       Accession #: NM_021569
       Genomic sequence: chr9:131740238-131740388

Sequence definition: NMDA receptor 1 isoform NR1-2 precursor

Sequence ID: No. 121
Accession #: AL445467.6
5   Genomic sequence: chrX:15985515-15985779
Sequence definition: genomic match

Sequence ID: No. 122
Accession #: BM976799
10   Genomic sequence: chr1:54049149-54049432
Sequence definition: genomic/EST match

Sequence ID: No. 123
Accession #: no match to index
15   Genomic sequence: No match BLAT
Sequence definition: No match BLAT

Sequence ID: No. 124
Accession #: NT_007933.414
20   Genomic sequence: chr7:98285605-98286140
Sequence definition: Genscan prediction

Sequence ID: No. 125
Accession #: NM_020428
25   Genomic sequence: chr19:10964586-10965036
Sequence definition: Homo sapiens CTL2 gene CTL2 mRNA

Sequence ID: No. 126
Accession #: no match to index
30   Genomic sequence: No match BLAT
Sequence definition: No match BLAT

Sequence ID: No. 127
Accession #: NM_006292
35   Genomic sequence: chr11:19444265-19444422
Sequence definition: Homo sapiens tumor susceptibility gene 101 TSG101
mRNA

Sequence ID: No. 128
40   Accession #: NM_052932
Genomic sequence: chr11:102306433-102306907
Sequence definition: Homo sapiens pro-oncosis receptor inducing membrane
injury gene PORIMIN mRNA

45   Sequence ID: No. 129
Accession #: NM_000014
Genomic sequence: chr12:9416444-9416720
Sequence definition: Homo sapiens alpha-2-macroglobulin A2M mRNA

50   Sequence ID: No. 130
Accession #: NM_002337
Genomic sequence: chr4:3426547-3433294
Sequence definition: low density lipoprotein-related

55   Sequence ID: No. 131
Accession #: AL834445
Genomic sequence: chr20:23304135-23304477
Sequence definition: Homo sapiens mRNA; cDNA DKFZp761J109

60   Sequence ID: No. 132
Accession #: NM_004986
Genomic sequence: chr14:49879277-49880762

Sequence definition: kinectin 1

Sequence ID: No. 133
Accession #: NM_024295
5   Genomic sequence: chr8:124092754-124095061
Sequence definition: hypothetical protein MGC3067

Sequence ID: No. 134
Accession #: AC018457.14
10   Genomic sequence: chr3:165236534-165236724
Sequence definition: genomic match

Sequence ID: No. 135
Accession #: NM_004753
15   Genomic sequence: chr1:12208898-12258427
Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA

Sequence ID: No. 136
20   Accession #: NM_004753
Genomic sequence: chr1:12221576-12258383
Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA

25   Sequence ID: No. 137
Accession #: NM_004753
Genomic sequence: chr1:12221576-12258383
Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA
30
Sequence ID: No. 138
Accession #: NM_004753
Genomic sequence: chr1:12221576-12258383
Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
35   SDR1 mRNA

Sequence ID: No. 139
Accession #: NM_004753
Genomic sequence: chr1:12221576-12258383
40   Sequence definition: Homo sapiens short-chain dehydrogenase/reductase 1
SDR1 mRNA

Sequence ID: No. 140
Accession #: D87438
45   Genomic sequence: chr16:14996279-15058862
Sequence definition: Human mRNA for KIAA0251 gene partial cds

Sequence ID: No. 141
Accession #: D87438
50   Genomic sequence: chr16:15018972-15027737
Sequence definition: Human mRNA for KIAA0251 gene partial cds

Sequence ID: No. 142
Accession #: AB007932
55   Genomic sequence: chr1:204843635-205060532
Sequence definition: Homo sapiens plexin A2 long form PLXNA2 mRNA

Sequence ID: No. 143
Accession #: AB007932
60   Genomic sequence: chr1:204843635-205060532
Sequence definition: Homo sapiens plexin A2 long form PLXNA2 mRNA

Sequence ID: No. 144
Accession #: AB007932
Genomic sequence: chr1:204843635-205060532
Sequence definition: Homo sapiens plexin A2 long form PLXNA2 mRNA

5

Sequence ID: No. 145
Accession #: AB037745
Genomic sequence: chr1:108833848-108851509
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds

10

Sequence ID: No. 146
Accession #: AB037745
Genomic sequence: chr1:108851126-108851424
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds

15

Sequence ID: No. 147
Accession #: AB037745
Genomic sequence: chr1:108851126-108851424
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds

20

Sequence ID: No. 148
Accession #: AB037745
Genomic sequence: chr1:108851126-108851424
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds

25

Sequence ID: No. 149
Accession #: AB037745
Genomic sequence: chr1:108851126-108851424
Sequence definition: Homo sapiens mRNA for KIAA1324 protein partial cds

30

Sequence ID: No. 150
Accession #: NM_002253
Genomic sequence: chr4:55795152-55795458
Sequence definition: Homo sapiens kinase insert domain receptor a type
35   III receptor tyrosine kinase KDR mRNA

Sequence ID: No. 151
Accession #: NM_004879
Genomic sequence: chr11:125479160-125481382
40   Sequence definition: Homo sapiens etoposide induced 2.4 mRNA EI24 mRNA

Sequence ID: No. 152
Accession #: BC041788
Genomic sequence: chr8:144841449-144841809
45   Sequence definition: Homo sapiens Similar to RIKEN cDNA 1110025J15 gene
clone MGC:32881 IMAGE:4738372 mRNA complete cds

Sequence ID: No. 153
Accession #: AB033073
50   Genomic sequence: chr20:46925235-46925516
Sequence definition: Homo sapiens mRNA for KIAA1247 protein partial cds

Sequence ID: No. 154
Accession #: NT_011520.136
55   Genomic sequence: chr22:21548074-21562329
Sequence definition: Genscan prediction

Sequence ID: No. 155
Accession #: NM_005581
60   Genomic sequence: chr19:49998069-49998792
Sequence definition: Homo sapiens Lutheran blood group Auberger b antigen
included LU mRNA

Sequence ID: No. 156
Accession #: NM_004355
Genomic sequence: chr5:149769000-149775442
5   Sequence definition: Homo sapiens CD74 antigen invariant polypeptide of
major histocompatibility complex class II antigen-associated CD74 mRNA

Sequence ID: No. 157
Accession #: NM_000484
10 Genomic sequence: chr21:26174980-26175131
Sequence definition: Homo sapiens amyloid beta A4 precursor protein
protease nexin-II Alzheimer disease APP mRNA

Sequence ID: No. 158
15 Accession #: NM_005745
Genomic sequence: chrX:150566783-150575554
Sequence definition: Homo sapiens accessory protein BAP31 BCAP31 mRNA

Sequence ID: No. 159
20 Accession #: NM_005570
Genomic sequence: chr18:56780509-56781078
Sequence definition: Homo sapiens lectin mannose-binding 1 LMAN1 mRNA

Sequence ID: No. 160
25 Accession #: NT_029218.14
Genomic sequence: chr1:19080562-19080917
Sequence definition: Genscan prediction

Sequence ID: No. 161
30 Accession #: NT_011387.8
Genomic sequence: chr20:410654-410816
Sequence definition: Genscan prediction

Sequence ID: No. 162
35 Accession #: NM_002587
Genomic sequence: chr5:141227996-141231527
Sequence definition: Homo sapiens protocadherin 1 PDCH1

Sequence ID: No. 163
40 Accession #: NT_035036.5
Genomic sequence: chr10:51263955-51274232
Sequence definition: Genscan prediction

Sequence ID: No. 164
45 Accession #: NM_007176
Genomic sequence: chr14:74107662-74107815
Sequence definition: Homo sapien Chr 14 open reading frame

Sequence ID: No. 165
50 Accession #: AP000531.1
Genomic sequence: chr22:14703272-14703359
Sequence definition: poor genomic match to repeat

Sequence ID: No. 166
55 Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced
RNA TMEPAI mRNA

60 Sequence ID: No. 167
Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716

Sequence definition: Homo sapiens transmembrane prostate androgen induced
RNA TMEPAI mRNA

Sequence ID: No. 168
5   Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced
RNA TMEPAI mRNA

10   Sequence ID: No. 169
Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced
RNA TMEPAI mRNA

15

Sequence ID: No. 170
Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced
20   RNA TMEPAI mRNA

Sequence ID: No. 171
Accession #: NM_020182
Genomic sequence: chr20:56850452-56936716
25   Sequence definition: Homo sapiens transmembrane prostate androgen induced
RNA TMEPAI mRNA

Sequence ID: No. 172
Accession #: NM_020182
30   Genomic sequence: chr20:56850452-56936716
Sequence definition: Homo sapiens transmembrane prostate androgen induced
RNA TMEPAI mRNA

Sequence ID: No. 173
35   Accession #: AK092666_01
Sequence definition: Novel spliced isoform of STEAP2

Sequence ID: No. 174
Accession #: AK092666_01
40   Sequence definition: Protein translation of novel spliced isoform of
STEAP2

Sequence ID: No. 175
Accession #: AK092666_02
45   Sequence definition: Novel spliced isoform of STEAP2

Sequence ID: No. 176
Accession #: AK092666_02
Sequence definition: Protein translation of novel spliced isoform of
50   STEAP2

Sequence ID: No. 177
Accession #: AK092666_03
Sequence definition: Novel spliced isoform of STEAP2

55

Sequence ID: No. 178
Accession #: AK092666_03
Sequence definition: Protein translation of novel spliced isoform of
STEAP2

60

Sequence ID: No. 179
Accession #: AK092666_04

Sequence definition: Novel spliced isoform of STEAP2

Sequence ID: No. 180
Accession #: AK092666_04
5   Sequence definition: Protein translation of novel spliced isoform of
STEAP2

Sequence ID: No. 181
Accession #: AK092666_05
10   Sequence definition: Novel spliced isoform of STEAP2

Sequence ID: No. 182
Accession #: AK092666_05
Sequence definition: Novel spliced isoform of STEAP2
15

Sequence ID: No. 183
Accession #: AK092666_01aa
Sequence definition: Novel amino acids generated by spliced isoforms
AK092666_01, AK092666_03, AK092666_05
20

Sequence ID: No. 184
Accession #: AK092666_02aa
Sequence definition: Novel amino acids generated by spliced isoform
AK092666_02
25

Sequence ID: No. 185
Accession #: AK092666_04aa
Sequence definition: Novel amino acids generated by spliced isoform
AK092666_04
30

70

REFERENCES

Alcaraz et al., Cancer Res., 55:3998-4002, 1994.

Allhoff et al., World J. Urol., 7:12-16, 1989.

An et al., Proc. Amer. Assn. Canc. Res., 36:82, 1995.

An et al., Molec. Urol., 2: 305-309, 1998.

Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, Cold Spring Harbor, N.Y., 1988.

Babian et al., J. Urol., 156:432-437, 1996.

Badalament et al., J. Urol., 156:1375-1380, 1996.

Baichwal and Sugden, In: Gene Transfer, Kucherlapati (Ed.), Plenum Press, New York, pp 117-148, 1986.

Bangham et al., J. Mol. Biol. 13: 238-252, 1965.

Barinaga, Science, 271: 1233, 1996.

Bedzyk et al., J. Biol. Chem., 265:18615, 1990

Bell et al., "Gynecological and Genitourinary Tumors," In: Diagnostic Immunopathology, Colvin, Bhan and McCluskey (Eds.), 2nd edition, Ch. 31, Raven Press, New York, pp 579-597, 1995.

Bellus, J Macromol. Sci. Pure Appl. Chem., A31(1):1355-1376, 1994.

Benvenisty and Neshif, Proc. Nat. Acad Sci. USA, 83:9551-9555, 1986.

Bittner et al., Methods in Enzymol, 153:516-544, 1987.

Bookstein et al., Science, 247:712-715, 1990a.

Bookstein et al., Proc. Nat'l Acad. Sci. USA, 87:7762-7767, 1990b.

Bova et al., Cancer Res., 53:3869-3873, 1993

Brawn et al., The Prostate, 28:295-299, 1996.

Campbell, In: Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology, Burden and Von Knippenberg (Eds.), Vol.13:75-83, Elsevier, Amsterdam, 1984.

Capaldi et al., Biochem. Biophys. Res. Comm, 76:425, 1977.

Carter and Coffey, In: Prostate Cancer: The Second Tokyo Symposium, J. P. Karr and H. Yamanak

(Eds.), Elsevier, New York, pp 19-27, 1989.

Carter and Coffey, Prostate, 16:3948, 1990.

5   Carter et al., Proc. Nat'l Acad Sci. USA, 87:8751-8755, 1990.

Carter et al., Proc. Nat'l Acad Sci. USA93: 749-753, 1996.

Carter et al., J. Urol., 157:2206-2209, 1997.

10
Cech et al., Cell, 27:487496, 1981.

Chang et al., Hepatology, 14: 124A, 1991.

15   Chaudhary et al., Proc. Nat'l Acad. Sci., 87:9491, 1990

Chen and Okayama, MoL Cell Biol., 7:2745-2752, 1987.

Chen et al., Clin. Chem., 41:273-282, 1995a.

20
Chen et al., Proc. Am. Urol. Assn, 153:267A, 1995.

.   Chinault and Carbon, "Overlap Hybridization Screening: Isolation and Characterization of
Overlapping DNA Fragments Surrounding the LEU2 Gene on Yeast Chromosome III," Gene,
25   5:111-126, 1979.

Chomczynski and Sacchi, Anal. Biochem., 162:156-159, 1987.

Christensson et al., J. Urol., 150:100-105, 1993.

30
Coffin, In: Virology, Fields et al. (Eds.), Raven Press, New York, pp 1437-1500, 1990.

Colberre-Garapin et al., J. Mol. Biol., 150:1, 1981.

35   Colvin et al., Diagnostic Immunopathology, 2nd edition, Raven Press, New York, 1995.

Cooner et al., J. Urol., 143:1146-1154, 1990.

Couch et al., Am. Rev. Resp. Dis., 88:394-403, 1963.

40
Coupar et al., Gene, 68:1-10, 1988.

Culver et al., Science, 256:1550-1552, 1992.

45   Davey et al., EPO No. 329 822.

Deamer and Uster, "Liposome Preparation: Methods and Mechanisms," In: Liposomes, M. Ostro
(Ed.), 1983.

50   Diamond et al., J. Urol., 128:729-734, 1982.

Donahue et al., J. Biol. Chem., 269:8604-8609, 1994.

Dong et al., Science, 268:884-886, 1995.

Dubensky et al., Proc. Nat. Acad. Sci. USA, 81:7529-7533, 1984.

Dumont et al., J. Immunol., 152:992-1003, 1994.

Elledge et al., Cancer Res. 54:3752-3757, 1994

European Patent Application EPO No. 320 308

Fearon et al., Science, 247:47-56, 1990.

Fechheimeret al., Proc. Natl. Acad. Sci. USA, 84:8463-8467, 1987.

Forster and Symons, Cell, 49:211-220, 1987.

Fraley et al., Proc. Natl. Acad. Sci USA, 76:3348-3352, 1979.

Friedmann, Science, 244:1275-1281, 1989.

Freifelder, In: Physical Biochemistry Applications to Biochemistry and Molecular Biology, 2nd ed., Wm. Freeman and Co., New York, N.Y., 1982.

Frohman, In: PCR Protocols: A Guide to Methods and Applications, Academic Press, New York, 1990.

Gefter et al., Somatic Cell Genet., 3:231-236, 1977.

Gerlach et al., Nature (London), 328:802-805, 1987.

Ghosh-Choudhury et al., EMBO J., 6:1733-1739, 1987.

Gingeras et al., PCT Application WO 88/10315.

Ghosh and Bachhawat, In: Liver Diseases, Targeted Diagnosis and Therapy Using Specific Receptors and Ligands, Wu et al. (Eds.), Marcel Dekker, New York, pp 87-104, 1991.

Goding, In: Monoclonal Antibodies: Principles and Practice, 2nd ed., Academic Press, Orlando, Fla., pp 60-61, 65-66, 71-74, 1986.

Gomez-Foix et al., J. Biol. Chem., 267:25129-25134, 1992.

Gopal, Mol. Cell Biol., 5:1188-1190, 1985.

Graham et al., J. Gen. Virol., 36:59-72, 1977.

Graham and van der Eb, Virology, 52:456-467, 1973.

Graham and Prevec, In: Methods in Molecular Biology: Gene Transfer and Expression Protocols 7,

73

E. J. Murray (Ed.), Humana Press, Clifton, N.J., pp 205-225, 1991.

Gregoriadis (ed.), In: Drug Carriers in Biology and Medicine, pp 287-341, 1979.

5   Grunhaus and Horwitz, Sem. Virol., 3:237-252, 1992.

Harland and Weintraub, J. Cell Biol., 101:1094-1099, 1985.

Harris et al., J. Urol., 157:1740-1743, 1997.

10   Heng et al., Proc. Nat. Acad. Sci. USA, 89: 9509-9513, 1992.

Hermonat and Muzycska, Proc. Nat. Acad. Sci USA, 81:6466-6470, 1984.

15   Hersdorffer et al., DNA Cell Biol., 9:713-723, 1990.

Herz and Gerard, Proc. Natl Acad Sci. USA, 90:2812-2816, 1993.

Hess et al., J. Adv. Enzyme Reg., 7:149, 1968.

20   Hitzeman et al., J. Biol. Chem., 255:2073, 1980.

Holland et al., Biochemistry, 17:4900, 1978.

25   Horoszewicz, Kawinski and Murphy, Anticancer Res., 7:927-936, 1987.

Horwich, et al., J. Virol., 64:642-650, 1990.

Huang et al., Prostate, 23: 201-212, 1993.

30   Innis et al., In: PCR Protocols, Academic Press, Inc., San Diego Calif., 1990.

Inouye et al., Nucl. Acids Res., 13:3101-3109, 1985.

35   Isaacs et al., Cancer Res., 51:4716-4720, 1991.

Isaacs et al., Sem. Oncol., 21:1-18, 1994.

Israeli et al., Cancer Res., 54:1807-1811, 1994.

40   Jacobson et al., JAMA, 274:1445-1449, 1995.

Johnson et al., In: Biotechnology and Pharmacy, Pezzuto et al., (Eds.), Chapman and Hall, New York, 1993.

45   Jones, Genetics, 85:12, 1977.

Jones and Shenk, Cell, 13:181-188, 1978.

50   Joyce, Nature, 338:217-244, 1989.

Kaneda et al., Science, 243:375-378, 1989.

Kato el al., J. Biol. Chem., 266:3361-3364, 1991.

5   Kent, et al., Genome Res. 12:996-1006 (2002).

Kim and Cech, Proc. Natl. Acad. Sci. USA, 84:8788-8792, 1987.

Kingsman el al., Gene, 7:141, 1979.

10
Klein et al., Nature, 327:70-73, 1987.

Kohler and Milstein, Nature, 256:495-497, 1975.

15   Kohler and Milstein, Eur. J. Immunol., 6:511-519, 1976.

Kwoh et al., Proc. Nat. Acad. Sci. USA, 86:1173, 1989.

Landis et al., CA Cancer J. Clin., 48: 6-29, 1998.

20
Le Gal La Salle et al., Science, 259:988-990, 1993.

Levrero et al., Gene, 10 1: 195-202, 1991.

25   Liang and Pardee, Science, 257:967-971, 1992.

Liang and Pardee, U.S. Pat. No. 5,262,311, 1993.

Liang et al., Cancer Res., 52:6966-6968, 1992.

30
Lifton, Science, 272:676, 1996.

Lilja et al., Clin. Chem., 37:1618-1625, 1991.

35   Lithrup et al., Cancer, 74:3146-3150, 1994.

Lowy et al., Cell, 22:817, 1980.

Macoska et al., Cancer Res., 54:3824-3830, 1994.

40
Mann et al., Cell, 33:153-159, 1983.

Markowitz et al., J. Virol., 62:1120-1124, 1988.

45   Marley et al., Urology, 48(6A): 16-22, 1996.

McCormack et al., Urology, 45:729-744, 1995.

Michel and Westhof, J. Mol. Biol. 216:585-610, 1990.

50
Miki et al., Science, 266:66-71, 1994.

Miller et al., PCT Application, WO 89/06700.

Mok et al., Gynecol. Oncol., 52:247-252, 1994.

Morahan et al., Science 272:1811, 1996.

Mulligan et al., Proc. Nat'l Acad. Sci. USA, 78:2072, 1981.

Mulligan, Science, 260:926-932, 1993.

Murphy et al., Cancer, 78: 809-818, 1996.

Murphy et al., Prostate, 26:164-168, 1995.

Nakamura et al., In: Handbook of Experimental Immunology, (4th Ed.), Weir, E., Herzenberg, L. A.; Blackwell, C., Herzenberg, L. (Eds.), Vol. 1, Chapter 27, Blackwell Scientific Publ., Oxford, 1987.

Nicolas and Rubinstein, In: Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Rodriguez and Denhardt (Eds.), Butterworth, Stoneham, p 494-513, 1988.

Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190, 1982.

O'Dowd et al., J. Urol., 158:687-698, 1997.

O'Hare et al., Proc. Nat'l Acad Sci. USA, 78:1527, 1981.

Oesterling et al., J. Urol., 154:1090-1095, 1995.

Ohara et al., Proc. Nat'l Acad. Sci. USA, 86:5673-5677, 1989.

Orozco et al., Urology, 51:186-195, 1998.

Parker et al., CA Cancer J. Clin., 65:5-27, 1996.

Partin and Oesterling, Urology, 48 (6A):1-3, 1996.

Partin and Oesterling, J. Urol., 152:1358-1368, 1994.

Partin and Oesterling (Eds.), Urology, 48(6A) Supplement:1-87, 1996.

Paskind et al., Virology, 67:242-248, 1975.

PCT Application No. PCT/US87/00880

Pettersson et al., Clin. Chem., 41(10):1480-1488, 1995.

Piironen et al., Clin. Chem. 42:1034-1041, 1996.

Potter et al., Proc. Nat. Acad. Sci. USA, 81:7161-7165, 1984.

Racher et al., Biotechnology Techniques, 9:169-174, 1995.

Ragot et al., Nature, 361:647-650, 1993.

Ralph and Veltri, Advanced Laboratory, 6:51-56, 1997.

Ralph et al., Proc. Natl. Acad. Sci. USA, 90(22):10710-10714, 1993.

Reinhold-Hurek and Shub, Nature, 357:173-176, 1992.

Renan, Radiother. Oncol., 19:197-218, 1990.

Ribas de Pouplana and Fothergill-Gilmore, Biochemistry, 33:7047-7055, 1994.

Rich et al., Hum. Gene Ther., 4:461-476, 1993.

Ridgeway, In: Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Rodriguez R L, Denhardt D T (Eds.), Butterworth, Stoneham, pp 467-492, 1988.

Rippe et al., Mol. Cell Biol., 10:689-695, 1990.

Rosenfeld et al., Science, 252:431-434, 1991.

Rosenfeld et al., Cell, 68:143-155, 1992.

Roux et al., Proc. Nat'l Acad. Sci. USA, 86:9079-9083, 1989.

Sager et al., FASEB J., 7:964-970, 1993.

Sambrook et al., (ed.), In: Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.

Santerre et al., Gene, 30: 147-156, 1984.

Sarver, et al., Science, 247:1222-1225, 1990.

Scanlon et al., Proc Natl Acad Sci USA, 88:10591-10595, 1991.

Sidransky et al., Science, 252:706-709, 1991.

Sidransky et al., Cancer Res., 52:2984-2986, 1992.

Silver et al., Clin. Cancer Res., 3:81-85, 1997.

Slamon et al., Science, 224:256-262, 1984.

Slamon et al., Science, 235:177-182, 1987.

Slamon et al., Science, 244:707-712, 1989.

Smith, U.S. Pat. No. 4,215,051.

Soh et al., J. Urol., 157:2212-2218, 1997.

5   Stenman et al., Cancer Res., 51:222-226, 1991.

Stinchcomb et al., Nature, 282:39, 1979.

Stratford-Perricaudet and Perricaudet, In: Human Gene Transfer, O. Cohen-Haguenauer et al.,
10   (Eds.), John Libbey Eurotext, France, pp 51-61, 1991.

Stratford-Perricaudet et al., Hum. Gene. Ther., 1:241-256, 1990.

Sun and Cohen, Gene, 137:127-132, 1993.
15
Szoka and Papahadjopoulos, Proc. Nat'l. Acad. Sci. USA, 75: 4194-4198, 1978.

Szybalska et al., Proc. Nat'l Acad. Sci. USA, 48:2026, 1962.   .

20   Takahashi et al., Cancer Res., 54:3574-3579, 1994.

Taparowsky et al., Nature, 300:762-764, 1982.

Temin, In: Gene Transfer, Kucherlapati R. (Ed.), Plenum Press, New York, pp 149-188:, 1986.
25
Tooze, In: Molecular Biology of DNA Tumor Viruses, 2nd ed., Cold Spring Harbor Laboratory,
Cold Spring Harbor, N.Y., 1991.

Top et al., J. Infect. Dis., 124:155-160, 1971.
30
Tschemper et al., Gene, 10:1 57, 1980.

Tur-Kaspa et al., Mol. Cell Biol., 6:716-718, 1986.

35   U.S. patent application Ser. No. 08/692,787

U.S. Pat. No. 4,196,265

U.S. Pat. No. 4,215,051
40
U.S. Pat. No. 4,683,195

U.S. Pat. No. 4,683,202

45   U.S. Pat. No. 4,800,159

U.S. Pat. No. 4,883,750

U.S. Pat. No. 5,354,855
50
U.S. Pat. No. 5,359,046

Varmus et al., Cell, 25:23-36, 1981.

Veltri et al., J. Cell Biochem., 19(suppl):249-258, 1994.

5

Veltri et al., Urology, 48: 685-691, 1996.

Veltri et al., Sem. Urol. Oncol., 16:106-117, 1998.

10   Veltri et al., Urology, 53:139-147, 1999.

Visakorpi et al., Am. J. Pathol., 145:1-7, 1994.

Wagner et al., Science, 260:1510-1513, 1993.

15

Walker et al., Proc. Nat'l Acad. Sci. USA, 89:392-396, 1992.

Watson et al., Cancer Res., 54:4598-4602, 1994.

20   Welsh et al., Nucl. Acids Res., 20:4965-4970, 1992.

Wigler et at, Cell, 11:223, 1977.

Wigler et al., Proc. Nat'l Acad. Sci. USA, 77:3567, 1980.

25

Wingo et al., CA Cancer J. Clin., 47: 239-242, 1997.

WO 90/07641, filed Dec. 21, 1990.

30   Wong et al., Int. J. Oncol., 3:13-17, 1993.

Wu and Wu, J. Biol. Chem., 262: 4429-4432, 1987.

Wu and Wu, Biochemistry, 27: 887-892, 1988.

35

Wu and Wu, Adv. Drug Delivery Rev., 12: 159-167, 1993.

Wu el al., Genomics, 4:560, 1989.

40   Yang et al., Proc. Natl. Acad. Sci. USA, 87:9568-9572, 1990.

Yokoda et al., Cancer Res. 52, 3402-3408, 1992.

Zlotta et al, J. Urol., 157:1315-1321, 1997.

45

WHAT IS CLAIMED IS:

1.   An isolated nucleic acid sequence that is expressed by human prostate cancer cells, selected from the group consisting of:

    (i)   the nucleic acid sequence contained in SEQ ID NOS.: 1 to 173, 175, 177, 179, 181;

    (ii)   variants thereof, wherein such variants have a nucleic acid sequence that is at least 70% identical to the sequence of (i) when aligned without allowing for gaps; and

    (iii)   fragments of (i) or (ii) having a size of at least 20 nucleotides in length.

2.   The nucleic acid sequence of Claim 1 which comprises the nucleic acid sequence contained in any one of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181 or a fragment thereof.

3.   A primer mixture that comprises primers that result in the specific amplification of one of the nucleic acid sequences of Claim 1.

4.   A method of detecting prostate cancer comprising determining whether a human prostate cell sample expresses a target nucleic acid molecule, wherein said target nucleic acid molecule comprises the sequence of a gene or RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181 or of a fragment of said gene or RNA having a size of at least 20 nucleotides in length.

5.   The method of Claim 4, wherein said method comprises detecting the expression of said target nucleic acid molecule using a nucleic acid sequence that specifically hybridizes thereto.

6.   The method of Claim 5, wherein said method comprises detecting the expression of said target nucleic acid molecule using primers that result in the amplification thereof.

7.   The method of Claim 5, wherein the expression of said target nucleic acid molecule is detected by assaying for the antigen encoded by said nucleic acid.

8.   The method of Claim 7, wherein said assay involves the use of a monoclonal antibody or fragment that specifically binds to said antigen.

9.   The method of Claim 8, wherein said assay comprises an ELISA or competitive binding assay.

10.   An antigen expressed by human prostate cancer cells, wherein said antigen is selected from the group consisting of:

(i)   the antigen encoded by a nucleic acid sequence having at least 90% sequence identity in SEQ ID NOS.: 1 to 173, 175, 177, 179, 181;

(ii)   an antigen derived from a protein comprising a sequences having at least 90% identity in SEQ ID NOS. 174, 176, 178, 180, 182-185; and

(iii)   an antigenic fragment of (i) or (ii).

11.   A prostate antigen comprising (i) the amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs.: 1 to 173, 175, 177, 179, 181or (ii) an amino acid sequence selected from SEQ ID NOS. : 174, 176, 178, 180, and 182-185, or (iii)an antigenic fragment of (i) or (ii).

12.   A monoclonal antibody or antigen-binding fragment thereof that specifically binds to a target polypeptide molecule selected from:

(i)   a polypeptide encoded by a nucleic acid molecule comprising the sequence of a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181, or by a fragment of said gene or RNA having a size of at least 20 nucleotides in length, or a polypeptide derived from SEQ ID NOS. :174, 176, 178, 180, and 182 - 185

(ii)   an antigen according to Claim 10 or 11, and

81

(iii)   an antigenic fragment of (i) or (ii).

13.   A monoclonal antibody or fragment thereof that specifically binds the antigen of Claim 11.

14.   The antigen of Claim 10 or 11 which is attached directly or indirectly to a detectable label.

15.   The antibody of Claim 12 or 13 which is attached directly or indirectly to a detectable label.

16.   A diagnostic kit for detection of prostate cancer which comprises a DNA according to Claim 1 and a detectable label.

17.   A diagnostic kit for detection of prostate cancer which comprises primers according to Claim 3 and a diagnostically acceptable carrier.

18.   A diagnostic kit for detection of prostate cancer which comprises a monoclonal antibody according to Claim 12 or 13 and a detectable label.

19.   A method for treating prostate cancer, which comprises administering to a subject a therapeutically effective amount of a ligand which specifically binds a target molecule selected from (i) a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181, a variant thereof or a fragment of said gene or RNA having a size of at least 20 nucleotides in length, and (ii) a protein or polypeptide encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181, a variant thereof or a fragment of said gene or RNA having a size of at least 20 nucleotides in length, or a polypeptide derived from SEQ ID NOS. :174, 176, 178, 180, and 182 - 185.

20.   The method of claim 19, wherein the ligand is a ribozyme or antisense

oligonucleotide that inhibits the expression of a gene having a DNA sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181or a fragment, or variant thereof, or a polypeptide derived from SEQ ID NOS. :174, 176, 178, 180, and 182 - 185.

.

5   21.   The method of claim 19 or 20, wherein the ligand is directly or indirectly attached to an effector moiety.

       22.   The method of Claim 21, wherein said effector moiety is a therapeutic radiolabel, enzyme, cytotoxin, growth factor, or drug.

10

       23.   A method for treating prostate cancer comprising administering to a subject a therapeutically effective amount of an antigen according to Claim 10 or 11, and optionally an adjuvant that elicits a humoral or cytotoxic T-lymphocyte response to said antigen.

15   24.   A method for treating prostate cancer comprising administering to a subject a therapeutically effective amount of a ligand which specifically binds to a protein encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181or a fragment, or variant thereof, or a polypeptide derived from SEQ ID NOS. :174, 176, 178, 180, and 182 - 185 optionally directly or indirectly attached to a

20   therapeutic effector moiety.

       25.   The method of Claim 24, wherein said effector moiety is a radiolabel, enzyme, cytotoxin, growth factor, or drug.

25   26.   The method of Claim 25 wherein the radiolabel is yttrium.

       27.   The method of Claim 25 wherein the radiolabel is indium.

       28.   The method of claim 24 wherein said ligand is a monoclonal antibody or

30   fragment thereof.

29.   The method of claim 24 wherein said ligand is a small molecule.

30. The method of claim 24 wherein said ligand is a peptide.

5   31. The method of claim 24, wherein said ligand binds an extracellular domain of said protein.

32. A molecule, selected from:

(i)   a polypeptide comprising the sequence of an extracellular domain of a
10   protein encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.: 1 to 185; and

(ii)   a nucleic acid molecule encoding a polypeptide of (i).

33. The molecule of claim 32, wherein said polypeptide has 8 to 100 amino acids in
15   length.

34. A method for selecting, identifying, screening, characterizing or optimizing biologically active compounds, comprising contacting a candidate compound with a target molecule and determining whether the candidate compound binds said target molecule,
20   wherein said target molecule is selected from (i) a nucleic acid molecule comprising the sequence of a gene or RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS.: 1 to 173, 175, 177, 179, 181, (ii) a fragment of said gene or RNA having a size of at least 20 nucleotides in length, and (iii) a polypeptide encoded by (i) or (ii) or a polypeptide derived from SEQ ID NOs. :174, 176, 178, 180, and 182 - 185.

Figure 1

Figure 2

2/2

Figure 3

Figure 4

B0213WO seq list.ST25.txt
SEQUENCE LISTING

<110> EXONHIT THERAPEUTICALS

<120> PROSTATE SPECIFIC GENES AND THE USE THEREOF AS TARGETS FOR PROSTATE
CANCER THERAPY AND DIAGNOSIS

<130> B0213WO

<160> 185

<170> PatentIn version 3.1

<210> 1
<211> 151
<212> DNA
<213> Homo sapiens

<400> 1
ccggcccagg catgcacaca ctcttctgga gcacacgcga ccctccctag accgcctgct   60

tctcggctcc cctgcacatt agagcttctc aagacacggc ctgcacttgc cacctctgca   120

tttcccactc tcgctttgct gcctcccggc c   151

<210> 2
<211> 138
<212> DNA
<213> Homo sapiens

<400> 2
ggaggggaag ttcggctcca gccacatagg tgtgtgtcct ccttatcctc tgaccaaagc   60

ttgtccttcc tacatatgct cctttgctag cactcccacc tgaatgcatc cctatgatcc   120

ttccaccttc cctgctcc   138

<210> 3
<211> 459
<212> DNA
<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 3
ggaaccctac gaagaaccac agggagaaca ccagcattgc caccaccacc accaccacca   60

cagagtctgt ggaagaggtg gttcgagttc ctacaacagc agccagtacc cctgatgccg   120

ttgacaagta tctcgagaca cctggggatg agaatgaaca tgcccatttc cagaaagcca   180

aagagaggct tgaggccaag caccgagaga gaatgtccca ggtcatgaga gaatgggaag   240

aggcagaacg tcaagcaaag aacttgccta aagctgataa gaaggcagtt atccagcatt   300

tccaggagaa agtggaatct ttggaacagg aagcagccaa cgagagacag cagctggtgg   360

agacacacat ggccagagtg gaagccatgc tcaatgaccg ccgccgcctg gccctggaga   420

actacatcac cgctctgcag gctgttcctc ctcccggcc   459

<210> 4

<211> 562

<212> DNA

<213> Homo sapiens

<400> 4
tggggggagg gcaggaaaat gaactcaatg agataaccag ggacaagatg atatgatgcc   60

tttcttctag cactcaggga tttcggaatc aaatctgaga gaggcaagaa attgtgagaa   120

gattgtaagc agagatgaaa cagaaaagat acctgaaact ctgatcttgg agcttttctt   180

ccgtgatata agatctaaca gggtccactg catagagctg ttgtgaggat gacaagagat   240

cactaacact gtaaactctc aatccacagc cttcacataa ctgggtctca agacatgccc   300

tctcccttct cctctgcact tcttcatgtg tttaagggag aatgtgggga ggggcttatg   360

taaaataggg gactacaggt atcagactga accaatccta cttgttgaac tttatctact   420

ggatggccaa ggttataagg aacaccacca ccttctcatg ccctggggtg ccctagagaa   480

aggtaagcag accaagggtc tcagactccc tgtggaagaa agaccactgc acccaagctt   540

tacaaacgca tccctcggcc gt   562

<210> 5

<211> 328

<212> DNA

<213> Homo sapiens

<400> 5
gggcaccctа gctgcaaggg aggttagaaa aaatgaggga caggattatc atggtcagca   60

tattacttgg gggccagata tatcacttcc cacacaaaag caggcctctg tcagtgagga   120

Page 2

B0213WO seq list.ST25.txt
```
agaagtggag aatggatttg gggtgggcat ctgacagcat ttgccacact gccctcccca      180

atcctaatgc aggccagtca acgcaccacc cccactcccc acccacactc caacccccac      240

agtcctaggg tctctcaggg agaccatcgg tggaatccat aacattctaa gaccctgcag      300

tttgtaggca aaatcaggct tcctttgg                                        328
```

<210> 6

<211> 168

<212> DNA

<213> Homo sapiens

<400> 6
```
gacctcgaat tacaggcatg agccaccgtg cctggccttt tcttttcttt taagctactt       60

tttaatatat agtaatgact gttaatatag tatatactat gctattcatc aatgctgtaa      120

ctttcttagt ttcattttct cactcaattg aagtccaggt acccaggt                  168
```

<210> 7

<211> 317

<212> DNA

<213> Homo sapiens

<400> 7
```
agaaccctgg agcacttgag ggaccagaga cccggcatgg tccagacgaa ggtactgtca       60

gtctctcctc cgggacgcag acccattcaa ggtgcctctc tgcggccgtg ttcctgagag      120

gagcacgggg agggcctggt ttaatgtgag ccgcacaccg attgctctgc tctgaccgac      180

ctcgtccatg ccggccttgc atgggcgggg tcacttctgg gcccccaaag gtccactggc      240

gtttcctgca acacctccag atgcagccac atctcaagtc ctaggaactc gatccactgg      300

ctctttccat tcactag                                                    317
```

<210> 8

<211> 277

<212> DNA

<213> Homo sapiens

<400> 8
```
gggtgcgagg attcttgggc ctcatcctac agcacagctt tagtaagctg ggttgacaga       60

gtcctggcgt cagtatattt ggaaacaata agtctgatga acatccccct cgttaagaat      120

ccctgagacc aactttcatt ttacagatga aaaaactgag accggtaggg gtaaaatgcc      180
```

B0213WO seq list.ST25.txt
```
acagtcatga tcatgccgct agtaggtggc agagtgccat ctacaattca tttgtcatct     240
gagcttgact ggggctcctc ttaccacttc ctcctcg                             277
```

<210> 9
<211> 441
<212> DNA
<213> Homo sapiens

<400> 9
```
ggggggcagga gatagccaga tgtggtggca caccccctgta gtcccagcta ctggggaggc     60
tgagatagga ggatcacttg agcccaggag tttgagacta gaatgagcca tgattgtgcc    120
actgcactcc agcctggtga aagagtgata ccctgttttc ataagaaaaa aataacaaaa    180
acaaaaacaa gaaaggagag agttggctaa gctttatcac ctttgtgggt ttggaaccct    240
tacttgatcc ttcactaaag tacttcttgg gcatccagtg aggttcagtg tgtattgaga    300
ggatggtgag gatggcagcc aggcgtggga tctgtattca agaagaagct gccccactcg    360
ctggccatct atggatttcc agccaacaag catttccaac cacctatgga tttccaacaa    420
ctgagaactc atgagactgg c                                              441
```

<210> 10
<211> 508
<212> DNA
<213> Homo sapiens

<400> 10
```
aggctatgag ttgaaaattg gctctccttg gacagtcctc aagcactaca ttttttttcag     60
tgactctcac cagacccaca gatgaattta ccttctctgc gtatgccttt tgactggttc    120
tgtttcaggg aaccgcaagc tcaataagct ccactgttct accaagctgg acaaacagcc    180
acgtctctgt tctcttggcc agaccctgag gcctggagtt ctgccttcag gaattccaga    240
attctagaaa gttagagcta gacaagacct cagccttcat ctagtcttgc tccaaccact    300
gtgcggatgg ggaaacaagg catgggctgg ggatgactta aggggtataa aatgttgggc    360
tttcttttgt caagcccagc atgtgcctcc tataggcacc agtggtctct gcaagtcctg    420
gcctgctggc ctcgcagcca cagagagctc ggactctctc aggcagctca cttcattgct    480
ggaacaatag caatgttctt cctaatgc                                      508
```

<210> 11
<211> 135
<212> DNA

B0213WO seq list.ST25.txt

<213> Homo sapiens

<400> 11
agaagcgtta tacgggggag gctggagtgg taaaaggctc agaaaaatcc tgcgaagaaa   60

aaaacttctg aggtaataaa taggattatc ccgtatcgaa ggccttttg gacaggtggt   120

gtgtggtggc ctgcg   135

<210> 12
<211> 248
<212> DNA
<213> Homo sapiens

<400> 12
gaggatgagg tggaggagga gagtgacaag gccgcgctcc tgcaggagca gcagcagcag   60

cagcagccgg gattctggac cttcagctac tatcagagct tctttgacgt ggacacctca   120

caggtcctgg accggatcaa aggctcactg ctgccccggc ctggccacaa ctttgtgcgg   180

caccatctgc ggaatcggcc ggatctgtat ggccccttct ggatctgtgc cacgttggcc   240

tttgtcct   248

<210> 13
<211> 183
<212> DNA
<213> Homo sapiens

<400> 13
cccgccgacc tggcagggac atgcttagga aaagatggtg tcaacagacc cacaacacag   60

aaccacactg tggggtgggg aagcagagag gcgggaccag ccacttccag caggaagttt   120

ccaacctgga ctgggttggg acggtgaggg gatagtcatc tgccatcagt ttacataggt   180

ggt   183

<210> 14
<211> 124
<212> DNA
<213> Homo sapiens

<400> 14
cggcaggcat cacacaagag ggtgtcccta agatgcatca cgtccgtgga gaaaacaaag   60

B0213WO seq list.ST25.txt
caggacacac gtgtgagtcg tcacacccтt ggtcacccgg cttggccgtc acacatgcct   120

ccct   124

<210> 15

<211> 132

<212> DNA

<213> Homo sapiens

<400> 15
gtaggggagg gaaccagcta ctagatggtt cgattagtct ttcgcccta tacccaggtc   60

ggacgaccga tttgcacgtc aggaccgcta cggacctcca ccagagtttc ctctggcttc   120

gccctggggc cg   132

<210> 16

<211> 124

<212> DNA

<213> Homo sapiens

<400> 16
cacaccttgg ggacaggcat gaggaacaga ttaatgtgag atattctaga ggtacatgca   60

tcaggccatg gtgaccaatt gtctgtggag ggtgaggcag aaggaattgt tgaggatgac   120

tgag   124

<210> 17

<211> 489

<212> DNA

<213> Homo sapiens

<400> 17
gggaggcaat cattgagaga taatagctga gagttttтca gaaaggaaaa gaggtatgag   60

tttcagggag aaagggcggg ccaaggacta agccaaataa ataaaataag tctataccta   120

gacactttgt gggaaattca cagaccatca aagataaggg aaaaacctca tgggctacag   180

cagaaaagag acccattcta cacaaagaac aagttcacaa tatgagacag agccacgcac   240

agaggatgac tgctatgacc tgacgacggg gaagtgtctt gttctctggt aagccgcctc   300

taaagatggc caaagacatg gttttтccta ggtttgaggt gcactacttc agggttcctg   360

cttacctcct gctcgttctc tggccctcat tgtgaccatg cttcactctc ccatcctgtg   420

ctgggacaac cattttтcтt тcctтattgc tgctactgca gagtgaggta gggctgtggc   480

Page 6

B0213WO seq list.ST25.txt
ctcgcaccg   489

<210> 18
<211> 244
<212> DNA
<213> Homo sapiens

<400> 18
cggtgggagg cggccccgca ctaaggtagg gacccagatg gaaatgggac gctctctgca   60
ccatgggagg caaaaataca aattccatca ccaagagggc acgccatgcg gtgttgttcc   120
ataagggtga gcaaagctgc caggcccaca ggagagagag cccacaggag ccctggatcc   180
tgtgggactt tggatcctac acagtgagtg atctcagaac tttgcaaggc tgaggcaggg   240
agac   244

<210> 19
<211> 195
<212> DNA
<213> Homo sapiens

<400> 19
gggcgggacc agtgagagaa aggatagagc gtgtgagatg aaagggctgg tcttattaag   60
ccctacaata ctctggggtc caagcaatcc tgctgtggga ccctgctaag tgaacataat   120
gccgaggaag aacagctctc ctcttttgc caaagcctgc caaggtgtca aggcttgaga   180
aagagtggtg gccta   195

<210> 20
<211> 346
<212> DNA
<213> Homo sapiens

<400> 20
ccggtgcagg cattgtgata atagttggaa tgcagaggtg aattaaagag tatgggcttg   60
tctatataaa taaataaata tatatgtata tggtgtgtat aaccctatta tatatattat   120
gtattaggtg gtgttgtata tatatgttta tatatgtgtg tgtttatgta taagtatata   180
tgtgataaga gtttataatc ctatatagag acagatgtat taaaatggat tttttttttt   240
tgagacagag tcttactctg tcatcaaagc tggagtgcag tggtgcaatc taggctcaca   300
gtgacctaca cctcccatgt tcaaacgatt ctcctgcctc ggccgg   346

Page 7

B0213WO seq list.ST25.txt

<210> 21

<211> 168

<212> DNA

<213> Homo sapiens

<400> 21
cgctgggagg ctgtgcgtgt ttgcttttgt tgatctgttt aactgcagcc cgatttatgt   60

ttctggatcc tggaattgag ttgacactat cggtagtatg aaagtgacag acaccaggat   120

gaagtcactc ttgtcagacc cagaggaaac agggtcagga ggcctggg   168

<210> 22

<211> 435

<212> DNA

<213> Homo sapiens

<400> 22
agccggcagg actgtatcat caacgcaagt ctcttgagat gccttgttga tcggtagatc   60

aagttatagc ctcggtttct gattttgctg tggtgatact ggatgtagca ttcaaggagt   120

aaatggagaa tccacaaaat aactttccca aggattataa ccgtctgaac tttcaatggg   180

tttgtgtaat ttcctgggca cttgtcctca tttggattag gataagaaca aagcacacct   240

gttaaaaatg ctaaaacaac aaacacgaga tgaataaacc acagaagatt cactatgatg   300

actgtaggaa gaggatggaa tcggggtcta aagtgagctt gtaatgagtg gtgtgggaga   360

agctgggcat ccagaagtgg gtcgtcttca atactctggg tgatatccaa ggaaccgtcc   420

tccatcctgc cgcgg   435

<210> 23

<211> 199

<212> DNA

<213> Homo sapiens

<400> 23
cggggaaagg acaggcctgc tgctttattc acagatttag atgtcgttcc atctgctctc   60

gaagtttgaa tttctggatc tttcctgaaa tggtgagggg gtagtttgtg acaaacacga   120

tgtacttcgg aatcttgaag tgagagatct tccctttgca gaaagctttt atctcctcca   180

ccgtggtctc ctctcggcg   199

<210> 24

B0213WO seq list.ST25.txt

<211> 258

<212> DNA

<213> Homo sapiens

<400> 24
```
gggcgcaggc tatggaggag accgtggtgg tggcagtggc tacggtggag accgaagtgg     60

aggctatgga ggagacagga gtggtggcgg ctatggagga gaccgaggtg ggggctacgg    120

aggagaccga ggtggctatg gaggcaaaat gggaggaaga aacgactaca gaaatgatca    180

gcgcaaccga ccatactgat gactgttttg aatgttcctt tgtctctgac atgatccata    240

gtgaaattgc cagagttt                                                  258
```

<210> 25

<211> 171

<212> DNA

<213> Homo sapiens

<400> 25
```
ggttcaggca ggtcagcaag gaacacaaag gcatctgcca cctgagcaag tatcgaacac     60

catcacctgc atccttcaag ggttccaggt agatctccag cctcttgtag gagagaacca    120

agttgaaaag gtcaaacgct ggggacttgg taggaaaagg tggagactcc a             171
```

<210> 26

<211> 223

<212> DNA

<213> Homo sapiens

<400> 26
```
cagtgcgagg agccgtcact ctgctaagcc tgtatctgct gttcggctac ggagcgtctc     60

tgctgtgcaa tctcatcgga tttgtgtacc ccgcatatgc ctcaatcaaa gctatcgaga    120

gcccaagcaa ggacgacgac actgtgtggc tcacctactg ggtggtgtac gccctgtttg    180

ggctggccga gttcttcagc gatctactcc tgtcctgccc ccc                      223
```

<210> 27

<211> 249

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

```
<400>  27
tggggagagg tgagcagctt tgaacttttt cttagggagt gtcagaacga ggccagtctg     60

cctttatgcc atgtggcctc aggcacctac agtgaagtct taaaaccagt ggatgctctc    120

tacagtgcct tctagctgtg gtagtctgtg tctccaagga ccaacccttc catttctgag    180

gcttcagaat aaattctggc agttatttct tctctcagac tctatttcag aaaagtgtac    240

ctgcccccа                                                             249
```

```
<210>  28
<211>  334
<212>  DNA
<213>  Homo sapiens
```

```
<400>  28
caggctggag tgtggtagca tgagcatggc tcactgcaat ctccacctcc caggctcaag     60

cgatcctccc acctcaccct ccccggtagt gggaccacag gtgcacacca ccacacctgg    120

ctatatgctt cttttgagat tgctttttttc actcacataa tttgcttgaa atttatccac    180

cagcattttt taaaaattaa ctgtgcatca tcttcagtga gatgtgtgca tttcgtctttt    240

gttcatgcct tttccactgc ctagaatgcc ctctaccaac cctgtctacc gatctgtatt    300

catttccttc agtgtgtctc actgctgtgt gcct                                334
```

```
<210>  29
<211>  226
<212>  DNA
<213>  Homo sapiens
```

```
<400>  29
aggtccaaag tggaaagatg gaaaagctca gatgatacag gcctacagac tagattttttt     60

gtttatttgt ttctgtacac tactactaca aaggatagca aatagagctg aaggaaaagg    120

atggagatac tcaaagtcct aaaaatggaa aggagaaaag ggaatgtcaa cctcaaggac    180

aactgagatg ttcacagaac ttctgcagat tcttgtcccc cacctc                   226
```

```
<210>  30
<211>  372
<212>  DNA
<213>  Homo sapiens
```

```
<400>  30
```

BO213WO seq list.ST25.txt

gggataggggg	agagaagaag	aagctgggga	gctgggaaca	tcatctcagg	ctggaggaca	60
agcctgcgac	aggaccggtt	ccacagagga	gtcaaaagag	ttaaagccca	gaaggcagct	120
ggaagagaag	gcaaagctgg	aaaaggaagt	aaaagcagca	gctgttctga	ttttgaagga	180
gagtaaatgg	gcttatttgc	tttatggtct	aaggagcaga	gaaaactcat	tctcctctgg	240
ttataaattc	ccgagttgca	gaaggaagtc	tcctaactac	tgatcggttc	ctcttggggt	300
gggaaaatct	ctgagctaca	gtgagtcatt	cccaggatgc	caacaatggc	ctccacttct	360
ccctctgccc	ct					372

<210> 31

<211> 207

<212> DNA

<213> Homo sapiens

<400> 31

cctctgttct	tccagcttgg	cttggagaag	aactggcaga	tgaacacgtc	ctgcatggtg	60
gaatgccctg	tgaactgtca	gctttctgat	tggtctcctt	ggtcagaatg	ttctcaaaca	120
tgtggcctca	caggtttgtt	tgtaccataa	cttatattag	gctcctggtc	aaggaatatg	180
aaataaaata	tccctcttgc	tttaacc				207

<210> 32

<211> 179

<212> DNA

<213> Homo sapiens

<400> 32

tggtgggagg	tcactgcttg	aaggagtcac	atagacgtgg	tgtgtgacac	ttgtgcccat	60
ttcctgtgcc	tgatgtgtag	caaagaaagg	ttgcatgctc	ccttgctccc	tgttctcttc	120
cagaccgtct	atgaccagta	tttcatcacc	ctgtataaca	tcgtgtacac	ctaacgccc	179

<210> 33

<211> 484

<212> DNA

<213> Homo sapiens

<400> 33

tgaggaggtg	aaggaccgga	tcctggagaa	catctcgctg	tcggtgaaga	agttgcagag	60
ctattttgct	gcatgtgagg	atgagacccc	tgccatccgg	aaccatgaca	aggtcctaca	120

B0213WO seq list.ST25.txt

```
gcgtctgtgt gagcacctgg accacgccct gctgtacgga ctgcaagacc tctcctctgg    180

ctactgggtg ctcgtggtgc attttactcg gagagaggcc atcaagcaga tcgaggtgct    240

gcagcacgtg gccaccaacc tggggcgcag ccgtgcctgg ctgtacctgg ccctcaacga    300

gaactccttg gagagctacc tgcggttgtt ccaggagaac ctgggcctgc tgcataagta    360

ctacgtcaag aatgccctgg tctgcagcca cgatcacctg acgctcttcc tgaccttggt    420

gtccgggcta gagttcattc gtttcgagct ggatctggat gccccttacc tagacctccc    480

cacg                                                                484
```

<210> 34

<211> 443

<212> DNA

<213> Homo sapiens

<400> 34

```
ggggaggtga ttccatccag agtcatatct gttgtcaccc caataagtcg atcagcaagg     60

ctgacaggct gtgaggaaac cccggccttg tagcctgtca cctctggggg gatgatgact    120

gcctggcaga cgtaggctgt gatagatttg gagaaccctg actcaccctc aggaatccgg    180

aggtcagtga cattgtcggt gcacacagac attttcctac cctggtttcc acagagactg    240

agggtaaagt gatggaagta tttcaacccт ttggaagtga agcttggccc tccagcaaga    300

gtgacggtgt ttgccaaagc ggagaagttg tagttgaaag tcctggttgg agtgttgcgt    360

gagaaggtgc aatcattgta gcacagagag tggatcttgt tgttcttggt ccctggacca    420

cagggcacac agacctcgcc gca                                            443
```

<210> 35

<211> 272

<212> DNA

<213> Homo sapiens

<400> 35

```
ggacaggggt ctctccacca tttgaggaag ggatagagga agaccaccat ggggaaagat     60

atcatgcact ggttgaaaag aactgtgcgg atagactggc gcagtttcac aggatccaca    120

ggttcattct tgccgacctg aattcggtag cgagagatga agttaggttt tcctgttgtg    180

tcaaccacca atagaagccc attgaagctc cagaagaaga gacaaggcac ttggatggca    240

cctataaaga agaggatcca ctccttccct ac                                  272
```

<210> 36

<211> 224

B0213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

<400> 36
gatggaaagg ctgtagtggg gctggtggtg cttccaactg cgggacagga agtggccgta   60

gcggcttgtt ggataagtgg aagatagatg ataagcctgt aaaaattgac aagtgggatg   120

gatcagctgt gaaaaactct ttggatgatt ctgccaaaaa ggtacttctg gaaaaataca   180

aatatgtgga gaattttggt ctaattgatg gtcgccttgt aacc   224

<210> 37

<211> 342

<212> DNA

<213> Homo sapiens

<400> 37
tgtcttgagg cactgtagta tcaatcagac caggaatatc cttctctcct tttttttacaa   60

tagccaagtt gcaatgcaac cgcgaactga ttttctcttt ctttctccag gtctccttgg   120

tcttcctaaa caatcaacag caacccccac ctccactgct ttctgtttgg tttggtttga   180

gtttgggatt ttgggctagc tcttttttct ttgtctgctt tctggtttcc cttcctccct   240

tccctatgta cgctcagagc ctcagacaga ccgtctgggc gcctcattcg cgtgagaagg   300

gccaggggga aggccaccag gccaggatgt aggcgaaacc gt   342

<210> 38

<211> 315

<212> DNA

<213> Homo sapiens

<400> 38
tcgggggagg tgggacctga gcatgctgtg ttccagaaaa ggctggagca cagactcaga   60

gagagagaga gtggggtgga cgaggctgga gagattggca aagcccagat tatgagggtt   120

ttgtgggtca cagtgaggag cttgaacttc atccttctag tagattctag gctacccctt   180

cagacactcc ttaggaccag ggacacattc cccgagctgc caggagtgtt agcagctgac   240

agatcctggc tgggtatttc tctccaacaa agggagctgc ctccttcaca tctaatgact   300

gtaatgacct accac   315

<210> 39

<211> 127

BO213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

<400> 39
```
tgcttttgag gctggagtgg taaaaggctc agaaaaatcc tgcgaagaaa aaaacttctg      60
aggtaataaa taggattatc ccgtatcgaa ggccttttttg gacaggtggt gtgtggtggc     120
ctggccc                                                               127
```

<210> 40

<211> 408

<212> DNA

<213> Homo sapiens

<400> 40
```
gggggaggca cattctcact gaagataaag aactccgcat gccatcaccc cttcctcacc      60
acaaccccgc gaaacaaaag ctataaacac acacaagtca gaggatctat aaaccagtgg     120
gagaaaaaaa attagatgaa ggttaaccat taaaaagctg cagttgggaa aacacacact     180
cgattgttac atcagaaagt gccgtgggga gaagagccgt gtgctggtaa acatgtccgc     240
gctcagaact tgacatgcag aaaagagaga gcgccaagtc ccacctgaga ttagagagga     300
ctggttttta gtgtaacaca ctttgtttta aaatatcact gtcctcttct tgccccaatt     360
gctcctagaa cgtccctctg tcactccccct cccgggccag cctctccg               408
```

<210> 41

<211> 314

<212> DNA

<213> Homo sapiens

<400> 41
```
ggcgtggagg tacaagcagt cagttctcgg caggggccga ccgggcaact tccccccttg      60
tgtccctcta ccctgctttg gagtgccggg ccctcattca gcagatgtcc ccctctgcct     120
ttggtctgaa tgactgggat gatgatgaga tcctagcttc ggtgctggca gtgtcccaac     180
aggaatacct agacagtatg aagaaaaaca aagtgcacag agacccgccc ccagacaaga     240
gttgatggag acccagggat tggacaccat ctcccaaccc cagtactcct gctctccggt     300
gccacctcac cgcc                                                       314
```

<210> 42

<211> 352

B0213WO seq list.ST25.txt

<212>   DNA

<213>   Homo sapiens

<400>   42
tctggggagg tggtccccat gtctgtcgta ggacagcaac aggttgtaca tctggcaggc   60

aaaggttttg ttgggctgga ggatgaggat gtgtaacact gtgtttccca gggagtcctg   120

ggcccggatg tcagctccat gctcaatgag cagccgcacg atctcctcac tgttcacaca   180

ggcagcaaag gacaaagggt gctccccaaa gtagatgagg ttgcagggac tacggcggaa   240

ggcagtgcct gtggctctgg cagagacact ggccctgcgg gcaagcaggg ctcgcaccag   300

gttcatgttc tggttcacaa cagcgatgtg cagtgcagtc tgacctccat cc   352

<210>   43

<211>   292

<212>   DNA

<213>   Homo sapiens

<400>   43
ggctgggggt aaggaccctg acagggcctc aggtggggac ttgcgcttca ggccgggatc   60

aggtgctgtg aagctgcctg tggagctggc cttggctttc cggaactcct ccagcttctg   120

tcggtagtac ttgtacccct ggctattggg ctcatacaga aagctgaatg cctggttctc   180

acggttgttc tggagggcaa tggtttccac ctcgggaccc ccgtccgcta tgaacctggc   240

caactttтct gcaaggttct tgacctcttc gtcctctggg ggtgaaactt tc   292

<210>   44

<211>   372

<212>   DNA

<213>   Homo sapiens

<400>   44
ttcttagttt aagtgccagt gatcctgctt tgtacctctt caactatgat tcagttttta   60

caagtgaggt tcaattaagc tgagatgtag ttgaaatatt tgagcaccag aatcaccttc   120

tgaactccca atcatctggg gcttaggtgt agttacctcc caggaacaga tctcccagcc   180

caaggtccca cattgtacct tgatgtttct ttactgccta tcaaaatgag ccccaggtac   240

ctacgttatt actgggtttt gctctccaat ttccttattt tcccttgctc ccaaccacat   300

caacagaaca acaacaaaaa gaatccttta tcttcatgca acactacagt agtacagagc   360

aaagaactgg tg   372

Page 15

B0213WO seq list.ST25.txt

<210> 45

<211> 158

<212> DNA

<213> Homo sapiens

<400> 45
aggcctgaga gggaagtttc tggagttcag atactctctg ttgggaacag gacatctcaa   60

cagtctcagg ttcgatcagt gggtcttttg gcactttgaa ccttgaccac agggaccaag   120

aagtggcaat gaggacacct gcaggagggg ctagcctt   158

<210> 46

<211> 157

<212> DNA

<213> Homo sapiens

<400> 46
gagggcttaa gaaagtaccc agctctgggt ccaataaaga ctcttgttat ctgtcagcac   60

tgcatgtggt agcatgggca aaaggcatta agaaagtaaa tatacgtccc tgtgttcccc   120

ttgctctccc tccatgcctg ctcttttctt caccctg   157

<210> 47

<211> 310

<212> DNA

<213> Homo sapiens

<400> 47
aggacagcac tgacagcgag tggccctgga tcgtgagcat ccagaagaat gggacccacc   60

actgcgcagg ttctctgctc accagccgct gggtgatcac tgctgcccac tgtttcaagg   120

agtatgtaca gccggcctgg ggcacttgat cttctaaggc cctgggcttt gtgccccagg   180

ccctgggctc cctttacagg ctctgcttcc gggcctctgt tcaatcttgg tgccccctcga   240

ttctacctag aagcctctcc tgccttcagg ggccttcaca cccatgctgt tcccccaggt   300

acctcctccc   310

<210> 48

<211> 124

<212> DNA

<213> Homo sapiens

Page 16

B0213WO seq list.ST25.txt

<400> 48
cccggcacct ggggaagggg gagtagagct aagagataga aaaactctag actcaccgat   60

caccaagctc atttggtcgg tagggcccgc ccaccggact tgagaacaca cacattctct   120

aagg   124

<210> 49

<211> 191

<212> DNA

<213> Homo sapiens

<400> 49
aatctcctaa tattaatggc aggtattata gtaaaattat catttccct gaagagaatg   60

ttacattaac ttgcacagca gaaaaccaac tggagagaac agtaaactcc ttgaatgtct   120

ctgctaatga aaacagagaa aaggtgaatg accaggcaaa actaattgtg ggaatcgttg   180

ttggtctcct c   191

<210> 50

<211> 305

<212> DNA

<213> Homo sapiens

<400> 50
ccgaagtttt tctgtcacct gtgttaggct ccgtcccctt tccgcgtttt atccccgtac   60

cagaaaagga tacatttagt gcctcccacc cagctccact aaacgggttg gatatctcat   120

tctttgagtt ggtgttcctt ccccggcgcc cccatgtagc tgggaagtgg gacctggggg   180

tggttggacc cctgggatcc taaaggaggg gcagggaggg cgcagaactc cgcttctgct   240

ccttgctacc aggacgcgcg gcctcctcag cctctttcct cccgctgcca tgcaccctac   300

gctcg   305

<210> 51

<211> 108

<212> DNA

<213> Homo sapiens

<400> 51
ggctgacagg gtgggattct cgctccttca tttcaggtta ctcgttcttc agcaagttgg   60

B0213WO seq list.ST25.txt
caaaacagac atcatgctgg tgagtgccac gttactcccc tggggtgc   108

<210> 52

<211> 439

<212> DNA

<213> Homo sapiens

<400> 52
cgcggcgagg ggagaggtct ccttgagtcc cacctgagct gcctcagtgc cccccagctg   60

ctgcaggtga gggcctgtca ccatcaagcc atcagtggga caaaaaactt gggccctcaa   120

cccaccagca ctgctctgca ttctctgaag ccctggagat aagctgggga ccatggcccc   180

cacactctca gacacagatg acacaagtgg gaccattctg agcctaagag attttaccaa   240

aaatacctca atatggtttg gctacgtccc cacccaaatc ttatcttgaa ttgtaatcgc   300

cgtaatcccc acgtgttgag ggagggatcc agtggaaggt gattaggtca tggaggtggt   360

tttccccatg ctgttctcat gatagtgagg gagtttttcac aagatctgat ggttttataa   420

gccagtttcc cctccggcc   439

<210> 53

<211> 234

<212> DNA

<213> Homo sapiens

<400> 53
ccgagacagg accaactcac acacctgcca gaaagcctca ctctccagcc tcaggaccaa   60

cttacacacc tgccagaaag cctcactctc cagcctcagg accaacttac acacctgcca   120

gaaagcctca ctctccagcc tcaggaccaa cttacacacc tgctagaaag cctcactctc   180

cagcctcagg accaacttac acacctgcca gaaagcctca ctctcctccc cggg   234

<210> 54

<211> 92

<212> DNA

<213> Homo sapiens

<400> 54
gcctgcgagg agctttattc ttccagctta atatggttgc tgcgggaaca ctgcaggatg   60

aaactgactt tttttgtggt gatgtttctc ct   92

<210> 55

B0213WO seq list.ST25.txt

<211> 164

<212> DNA

<213> Homo sapiens

<400> 55
cggggggtacc tgtaccgtgg aacatggaag ggaagaggag gcaagtacag cagtcctggg   60

tctacattca caaatcagca tactgatagc ttgctggata ttatatcaag acataaaaat   120

tgacacacac ggtctctctt tctctctctc atggaggttc ctgc   164

<210> 56

<211> 202

<212> DNA

<213> Homo sapiens

<400> 56
tggggtggac caggagaaac tgaaaactga attaaggaag acttcagatg cccttctaa   60

ggcacaaaat gatgtgatgg aaatgaagat gcagtcagag agattttcga aagaatatga   120

tcaactcctg aaagaacact ctgaacttca ggttttgtc tattctactt aactacctcc   180

ttatgaggaa gtggtctctc ca   202

<210> 57

<211> 314

<212> DNA

<213> Homo sapiens

<400> 57
caggggggagg agttcagagc ttacggtgag ccgccatcac gctattgcac tccaacttgg   60

gtgacagacc gagatcctag cttaaaaaaa aaaagaagtt ggtggggaaa atgggaaaat   120

agggtgccat gaaaaagaaa aagaaaaaca caccataatg gcattgtaag ttgggcttac   180

aactgttgtt tactttctta aagtttctg aggatgtaag aggaaaaaaa tattgtaaac   240

cttcaagatc tacttgtaat taaaattccc tgctgcttaa aaaagagtga aatctttgga   300

aggtcctccc ccca   314

<210> 58

<211> 92

<212> DNA

<213> Homo sapiens

BO213WO seq list.ST25.txt

<400> 58
ggacgggacc acagttctaa acgaataaac gaatgagacg caaatttttt atgttcagtc   60
ctttcatctc tatgaaaacc ctatatggtc gt   92

<210> 59
<211> 179
<212> DNA
<213> Homo sapiens

<400> 59
cggggccagg atcccagagc cacagccaac atcaagaacg atcttgtcct tgaagtcggt   60
gtggttttgc aggatggcgc gctggtaggt gcctgtccgt ttttagtcct gcatcatgtt   120
ctgctgctgg acaggtagc cataaaactg gaagtacttc tttgcagaag actcctctt   179

<210> 60
<211> 89
<212> DNA
<213> Homo sapiens

<400> 60
tcgcggggag gcgtgaatat tgtgggctg aatcctcagg gccgtggggg gctgcatggc   60
tgatgaccat gaggactggc ctcccgccc   89

<210> 61
<211> 169
<212> DNA
<213> Homo sapiens

<400> 61
tgggggttcc aggtatagga gggcaggctg agcatgcttg aagatgtgca tgatgaagat   60
ggtaaggccc aggccgaaga tgtaggctgc aaagctggtg tagaagtagg tgtgggtatt   120
cttcttcaag ctgatgtcaa agcgcagcag caaggcaatg aagatccat   169

<210> 62
<211> 171
<212> DNA
<213> Homo sapiens

<div align="center">Page 20</div>

B0213WO seq list.ST25.txt

<400> 62
cagcggtacc atagttcact aggaaaggca ctcatccacc aagttcagag aggtggccat   60

ccgcattgct aaacagaata aaacaaaaat tcactttgtc attttcctga cattggcctt   120

gctataagat agcctcataa actgcctgaa aggccttatt tttttcaaag g   171

<210> 63

<211> 140

<212> DNA

<213> Homo sapiens

<400> 63
aaggcaattc ttaggtactc tcgtgattga acctctgcac caaagaggga aaagtataag   60

ttagaaagga atttataagc accatacaca aaaatagcca tgactcaggc ctccacatct   120

catttgtgct gtcacttccc   140

<210> 64

<211> 195

<212> DNA

<213> Homo sapiens

<400> 64
tatttggagg ggggtatggg agggaaagag cttaggaaac ggctctccct gcaaagtcca   60

accaaacttt aacgttaacc aaaccattaa tgttgccatg aatttgaagt gaaccagagg   120

gaggtggcag aagaagctta atggggaata gttccggtag agaaatgagg cttaagatga   180

actacccttc tccca   195

<210> 65

<211> 397

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (364)..(364)

<223> n = a t c or g

Page 21

BO213WO seq list.ST25.txt

<400> 65

```
tgccagctga ataaactcag tcacctggtt tcccatctct aagcccctta acctgcagct      60

tcgtttaatg tagctcttgc atgggagttt ctaggatgaa acactcctcc atgggatttg     120

aacatatgaa agttatttgt aggggaagag tcctgagggg caacacacaa gaaccaggtc     180

ccctcagccc acagcactgt cttttttgctg atccacccccc ctcttacctt ttatcaggat   240

gtggcctgtt ggtccttctg ttgccatcac agagacacag gcatttaaat atttaactta     300

tttatttaac aaagtagaag ggaatccatt gctagctttt ctgtgttggt gtctaatatt     360

tggngtaggg tggggatcc ccaacaatca ggtcccc                               397
```

<210> 66

<211> 2799

<212> DNA

<213> Homo sapiens

<400> 66

```
ctcacacacc ctgaagacac agtgagttag caccaccacc aggaattggc cttttagctc      60

tgtgcctgtc tccagtcagg ctggaataag tctcctcata tttgcaagct cggccctccc     120

ctggaatcta aagcctcctc agccttctga gtcagcctga aaggaacagg ccgaactgct     180

gtatgggctc tactgccagt gtgacctcac cctctccagt caccccctcct cagttccagc     240

tatgagttcc tgcaacttca cacatgccac ctttgtgctt attggtatcc caggattaga     300

gaaagcccat ttctgggttg gcttccccct ccctttccatg tatgtagtgg caatgtttgg    360

aaactgcatc gtggtcttca tcgtaaggac ggaacgcagc ctgcacgctc cgatgtacct     420

ctttctctgc atgcttgcag ccattgacct ggccttatcc acatccacca tgcctaagat     480

ccttgccctt ttctggtttg attcccgaga gattagcttt gaggcctgtc ttacccagat     540

gttctttatt catgccctct cagccattga atccaccatc ctgctggcca tggcctttga     600

ccgttatgtg gccatctgcc acccactgcg ccatgctgca gtgctcaaca atacagtaac     660

agcccagatt ggcatcgtgg ctgtggtccg cggatccctc ttttttttcc cactgcctct     720

gctgatcaag cggctggcct tctgccactc caatgtcctc tcgcactcct attgtgtcca     780

ccaggatgta atgaagttgg cctatgcaga cactttgccc aatgtggtat atggtcttac     840

tgccattctg ctggtcatgg gcgtggacgt aatgttcatc tccttgtcct attttctgat     900

aatacgaacg gttctgcaac tgccttccaa gtcagagcgg gccaaggcct ttggaacctg     960

tgtgtcacac attggtgtgg tactcgcctt ctatgtgcca cttattggcc tctcagttgt    1020

acaccgcttt ggaaacagcc ttcatcccat tgtgcgtgtt gtcatgggtg acatctacct    1080

gctgctgcct cctgtcatca atcccatcat ctatggtgcc aaaaccaaac agatcagaac    1140

acgggtgctg gctatgttca agatcagctg tgacaaggac ttgcaggctg tgggaggcaa    1200
```

B0213WO seq list.ST25.txt

```
gtgacccctta acactacact tctccttatc tttattggct tgataaacat aattatttct    1260

aacactagct tatttccagt tgcccataag cacatcagta cttttctctg gctggaatag    1320

taaactaaag tatggtacat ctacctaaag gactattatg tggaataata catactaatg    1380

aagtattaca tgatttaaag actacaataa aaccaaacat gcttataaca ttaagaaaaa    1440

caataaagat acatgattga aaccaagttg aaaaatagca tatgccttgg aggaaatgtg    1500

ctcaaattac taatgattta gtgttgtccc tactttctct ctcttttttc tttctttttt    1560

ttttattatg gttagctgtc acatacaact tttttttttt tgagatgggg tctcgctctg    1620

tcaccaggct ggagtgcagt ggcgcgatct cggctcactg caacctccac atcccatgtt    1680

gaagtaattc ttctgcctca gcctcccgag tagctgggac tagaggaacg tgccaccatg    1740

actggctaat tttctgtatt ttttagtaga gacagagttt caccatgttg gccaggatgg    1800

tctcgatctc ctgaccttgt gatccacccg cctcagcctc ccaaagtgtt gggattacag    1860

gtgtgaacca ctgtgcccgg cctgtgtaca acttttttaaa tagggaatat gatagcttcg    1920

catggtggtg tgcacctata gcccccactg cctggaaagc tgaggtggga gaatcgcttg    1980

agtccaggag tttgaggtta cagtgatcca cgatcgtacc actacactcc agcctgggca    2040

acggagcaag accctgtctc aaagcataaa atggaataac atatcaaatg aaacagggaa    2100

aatgaagctg acaatttatg gaagccaggg cttgtcacag tctctactgt tattatgcat    2160

tacctgggaa tttatataag ccccttaataa taatgccaat gaacatctca tgtgtgctca    2220

caatgttctg gcactattat aagtgcttca caggttttat gtgttcttcg taactttatg    2280

gagtaggtac catttgtgtc tctttattat aagtgagaga aatgaagttt atattatcaa    2340

ggggactaaa gtcacacggc ttgtgggcac tgtgccaaga tttaaaatta aatttgatgg    2400

ttgaatacag ttacttaatg accatgttat attgcttcct gtgtaacatc tgccatttat    2460

ttcctcagct gtacaaatcc tctgttttct ctctgttaca cactaacatc aatggctttg    2520

tacttgtgat gagagataac cttgccctag ttgtgggcaa cacatgcaga ataatcctgt    2580

tttacagctg cctttcgtga tcttattgct tgcttttttc cagattcagg gagaatgttg    2640

ttgtctattt gtctcttaca tctccttgat catgtcttca tttttttaatg tgctctgtac    2700

ctgtcaaaaa ttttgaatgt acaccacatg ctattgtctg aacctgagta taagataaaa    2760

taaaatttta ttttaaattt taaaaaaaaa aaaaaaaaa                            2799
```

<210> 67

<211> 1982

<212> DNA

<213> Homo sapiens

<400> 67
```
tactcaaagt cctaaaaatg gaaaggagaa aagggaatgt caacctcaag gacaactgag    60
```

B0213WO seq list.ST25.txt

```
atgttcacag aacttctgca gattctcgtc ccccacctca cctcacaaat gctaacctgt    120

ggacagtcct cctgtccaac agtcctggca gcttataagc ttccatctat aggaaattgg    180

taatgtagac accgagactg ggtggggttgc agaacaaatg tcatgctctg accaagatgg    240

ataagctcac aatgagttgg ggactttcct aaaagccagg gcactagtag tcacatggcc    300

actgttgtag ctacgtgaac atggtagtgg tggtgaagat ggaaataaga ggaaacatgc    360

aaaagatttt tagaaggaaa aatagacaag atcggttgaa taattggatg tgaaggatga    420

ggaaatgcta tgtatcttaa gttcctgtct cacatgacta aattcataag cacttccact    480

tcgtcctcct caaattcacc ctcccaacag cttctggaat agcaatctga aacacatgtc    540

tagttgtgat gtccctgctt aaaaccattt attcacctcc caattcctac aggatgaagt    600

ccttgagttc acagcatatc atcagttcac atccattgac ctctccagtt tctctttcct    660

ttttggttga ctctatgctt cagccaagct acaactcttc gtaattcttc tatagaaaat    720

tctgtttctt tcatgatttt ctgcctgctg aaataccctc tttttggacc cacccaatga    780

ctaaataaat acccttctca agttcctata aaaatctgtg gcattcactg ctctttcata    840

ccatttcagg tttgtttggg taggtgtgta tgaccaccct gaaggcaagg actttgtctt    900

attcacctct ggcaccctaa actcagcaca gtgcctgcac aaaactagcc ttgagaatgt    960

gcttattaca caatgaatga attaattaac tccattgcca gatatagatg accaataaat   1020

acttaatggc tgatggaagt acttctgttt ctgtgttcaa agattacagt gacaatgaca   1080

aagcaagact catgtgtgag gcatacttag aaaggatggc agatagaaca ggttagtgtt   1140

aaatattaat aaagtatgaa ggtaaccctg ctgggtatga cgtaggggac acgtcactgg   1200

aagacagcca tcaagcatca tgaggtactg aggatacctc aatatcctgg agaaggtagt   1260

tggggtgagt tttttttatc tattttgctt ataacattgt aagcctttga caaacatttg   1320

tttaatgtga ataaacagtc ggaatacctg gttctccaac caatattatc actaattaac   1380

tatatgacct aggacaaaaa gctgtcatat catctgggct ttatctgtaa tctaggagca   1440

atgaagagca gctttgatac attaagggct gttttgttaa ccagaagaaa ggttagggaa   1500

agatatggag aattgcatgc ccctattttg aattatgaa ctatactttt gtattttag    1560

agaggatgca aactcctaaa gcccaaggac catgcctagt cacatatgat gtctgctggt   1620

catgggcgtg gacgtaatgt tcatctcctt gtcctatttt ctgataatac gaacggttct   1680

gcaactgcct tccaatcaga gcgggccaag gcctttggaa cctgtgtgtc acacattggt   1740

gtggtactcg ccttctatgt gccacttatt ggcctctcag tggtacaccg ctttggaaac   1800

agccttcatc ccattgtgcg tgttgtcatg ggtgacatct acctgctgct gcctcctgtc   1860

atcaatccca tcatctatgg tgccaaaacc aaacagatca gaacacgggt gctggctatg   1920

ttcaagatca gctgtgacaa ggacttgcag gctgtgggag gcaagtgacc cttaacacta   1980

ca                                                                  1982
```

<210> 68

B0213WO seq list.ST25.txt

<211>   2306

<212>   DNA

<213>   Homo sapiens

<400>   68
gagatactca aagtcctaaa aatggaaagg agaaaaggga atgtcaacct caaggacaac   60

tgagatgttc acagaacttc tgcagattct cgtcccccac ctcacctcac aaatgctaac   120

ctgggacagt cctcctgtcc aacagtcctg gcagcttata agcttccatc tataggaaat   180

tggtaatgta gacaccgaga ctgggtgggt tgcagaacaa atgtcatgct ctgaccaaga   240

tggataagct cacaatgagt tggggacttt cctaaaagcc agagcactag tagtcacatg   300

gccactgttg tagctacgtg aacatggtag tggtggtgaa gatggaaata agaggaaaca   360

tgcaaaagat ttttagaagg aaaaatagac aagatcggtt gaataattgg atgtgaagga   420

tgaggaaatg ctatgtatct taagttcctg tctcacatga ctaaattcat aagcacttcc   480

acttcgtcct cctcaaattc accctcccaa cagcttctgg aatagcaatc tgaaacacat   540

gtctagttgt gatgtccctg cttaaaacca tttattcacc tcccaattcc tacaggatga   600

agtccttgag ttcacagcat atcatcagtt cacatccatt gacctctcca gtttctcttt   660

cctttttggt tgactctatg cttcagccaa gctacaactc ttcgtaattc ttctatagaa   720

aattctgttt ctttcatgat tttctgcctg ctgaaatacc ctctttttgg acccacccaa   780

tgactaaata aatacccttc tcaagttcct ataaaaatct gtggcattca ctgctctttc   840

ataccatttc aggtttgttt gggtaggtgt gtatgaccac cctgaaggca aggactttgt   900

cttattcacc tctggcaccc taaactcagc acagtgcctg cacaaaagta gccttgagaa   960

tgtgcttatt acacaatgaa tgaattaatt aactccattg ccagatatag atgaccaata   1020

aatacttaat ggctgatgga agtacttctg tttctgtgtt caaagattac agtgacaatg   1080

acaaagcaag actcatgtgt gaggcatact tagaaaggat ggcagataga acaggttagt   1140

gttaaatatt aataaagtat gaaggtaacc ctgctgggta tgacgtaggg gacacgtcac   1200

tggaagacag ccatcaagca tcatgaggta ctgaggatac atcaatatcc tggagaaggt   1260

agttgggact gccagtgtga cctcaccctc tccagtcacc cctcctcagt tccagctatg   1320

agttcctgca acttcacaca tgccaccttt gtgcttattg gtatcccagg attagagaaa   1380

gcccatttct gggttagctt ccccctcctt tccatgtatg tagtggcaat gtttggaaac   1440

tgcatcgtgg tcttcatcgt aaggacggaa cgcagcctgc acgctccgat gtacctcttt   1500

ctctgcatgc ttgcagccat tgacctggcc ttatccacat ccaccatgcc taagatcctt   1560

gccctttttct ggtttgattc ccgagagatt agctttgagg cctgtcttac ccagatgttc   1620

tttattcatg ccctctcagc cattgaatcc accatcctgc tggccatggc ctttgaccgt   1680

tatgtggcca tctgccaccc actgcgccat gctgcagtgc tcaacaatac agtaacagcc   1740

B0213WO seq list.ST25.txt

```
cagattggca tcgtggctgt ggtccgcgga tccctctttt ttttcccact gcctctgctg    1800

atcaagcggc tggccttctg ccactccaat gtcctctcgc actcctattg tgtccaccag    1860

gatgtaatga agttggccta tgcagacact ttgcccaatg tggtatatgg tcttactgcc    1920

attctgctgg tcatgggcgt ggacgtaatg ttcatctcct tgtcctattt tctgataata    1980

cgaacggttc tgcaactgcc ttccaagtca gagcgggcca aggcctttgg aacctgtgtg    2040

tcacacattg gtgtggtact cgccttctat gtgccactta ttggcctctc agttgtacac    2100

cgctttggaa acagccttca tcccattgtg cgtgttgtca tgggtgacat ctacctgctg    2160

ctgcctcctg tcatcaatcc catcatctat ggtgccaaaa ccaaacagat cagaacacgg    2220

gtgctggcta tgttcaagat cagctgtgac aaggacttgc aggctgtggg aggcaagtga    2280

cccttaacac tacacttctc cttatc                                        2306
```

<210> 69

<211> 2767

<212> DNA

<213> Homo sapiens

<400> 69

```
gagatactca aagtcctaaa aatggaaagg agaaaaggga atgtcaacct caaggacaac     60

tgagatgttc acagaacttc tgcagattct cgtcccccac ctcacctcac aaatgctaac    120

ctgtggacag tcctcctgtc caacagtcct ggcagcttat aagcttccat ctataggaaa    180

ttggtaatgt agacaccgag actgggtggg ttgcagaaca aatgtcatgc tctgaccaag    240

atggataagc tcacaatgag ttggggactt tcctaaaagc cagagcacta gtagtcacat    300

ggccactgtt gtagctacgt gaacatggta gtggtggtga agatggaaat aagaggaaac    360

atgcaaaaga tttttagaag gaaaaataga caagatcggt tgaataattg gatgtgaagg    420

atgaggaaat gctatgtatc ttaagttcct gtctcacatg actaaattca taagcacttc    480

cacttcgtcc tcctcaaatt caccctccca acagcttctg gaatagcaat ctgaaacaca    540

tgtctagttg tgatgtccct gcttaaagcc atttattcac ctcccaattc ctacaggatg    600

aagtccttga gttcacagca tatcatcagt tcacatccat tgacctctcc agtttctctt    660

tcctttttgg ttgactctat gcttcagcca agctacaact cttcgtaatt cttctataga    720

aaattctgtt tctttcatga ttttctgcct gctgaaatac cctctttttg gacccaccca    780

atgactaaat aaatacccct ctcaagttcc tataaaaatc tgtggcattc actgctcttt    840

cataccattt caggtttgtt tgggtaggtg tgtatgacca ccctgaaggc aaggactttg    900

tcttattcac ctctggcacc ctaaactcag cacagtgcct gcacaaaagt agccttgaga    960

atgtgcttat tacacaatga atgaattaat taactccatt gccagatata gatgaccaat   1020

aaatgcttaa tggctgatgg aagtacttct gtttctgtgt tcaaagatta cagtgacaat   1080
```

B0213WO seq list.ST25.txt

```
gacgaagcaa gactcatgtg tgaggcatac ttagaaagga tggcagatag aacaggttag   1140

tgttaaatat taataaagta tgaaggtaac cctgctgggt atgacgtagg ggacacgtca   1200

ctggaagaca gccatcaagc atcatgaggt actgaggata catcaatatc ctggagaagg   1260

tagttggggt gagttttttt tatctatttt gcttataaca ttgtaagcct ttgacaaaca   1320

tttgtttaat gtgaataaac agtcggaata cctggttctc caaccaatat tatcactaat   1380

tagctatatg acctaggaca aaaagctgtc atatcatctg ggctttatct gtaatctagg   1440

agcaatgaag agcagctttg atacattaag ggctgttttg ttaaccagaa gaaaggttag   1500

ggaaagatat ggagaattgc atgcccctat tttgaattat ggaactatac ttttgtattt   1560

ttagagagga tgcaaactcc taaagcccaa ggaccatgcc tagtcacata tgatgtctgc   1620

tgcgtctagc agagtggcac atgaagaaac acactaatcc tgtggctgac tgtgtgtgct   1680

tggtttagct tggagaagtg ggagcagatt gtcgagagcc ctgtatatac tgccagtgtg   1740

acctcaccct ctccagtcac ccctcctcag ttccagctat gagttcctgc aacttcacac   1800

atgccacctt tgtgcttatt ggtatcccag gattagagaa agcccatttc tgggttggct   1860

tcccccctcct ttccatgtat gtagtggcaa tgtttggaaa ctgcatcgtg gtcttcatcg   1920

taaggacgga acgcagcctg cacgctccga tgtacctctt tctctgcatg cttgcagcca   1980

ttgacctggc cttatccaca tccaccatgc ctaagatcct tgcccttttc tggtttgatt   2040

cccgagagat tagctttgag gcctgtctta cccagatgtt ctttattcat gccctctcag   2100

ccattgaatc caccatcctg ctggccatgg cctttgaccg ttatgtggcc atctgccacc   2160

cactgcgcca tgctgcagtg ctcaacaata cagtaacagc ccagattggc atcgtggctg   2220

tggtccgcgg atccctcttt tttttcccac tgcctctgct gatcaagcgg ctggccttct   2280

gccactccaa tgtcctctcg cactcctatt gtgtccacca ggatgtaatg aagttggcct   2340

atgcagacac tttgcccaat gtggtatatg gtcttactgc cattctgctg gtcatgggcg   2400

tggacgtaat gttcatctcc ttgtcctatt ttctgataat acgaacggtt ctgcaactgc   2460

cttccaagtc agagcgggcc aaggcctttg gaacctgtgt gtcacacatt ggtgtggtac   2520

tcgccttcta tgtgccactt attggcctct cagtggtaca ccgctttgga aacagccttc   2580

atcccattgt gcgtgttgtc atgggtgaca tctacctgct gctgcctcct gtcatcaatc   2640

ccatcatcta tggtgccaaa accaaacaga tcagaacacg ggtgctggct atgttcaaga   2700

tcagctgtga caaggacttg caggctgtgg gaggcaagtg acccttaaca ctacacttct   2760

ccttatc                                                             2767
```

<210> 70

<211> 322

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 70

```
tgtgaacatc tcagttgtcc ttgaggttga cattcccttt tctcctttcc attttttagga    60

ctttgagtat ctccgtgtgg gtgagaaagt ccaattcatc tagagtcaag cattttcact    120

gaacaaaaca gttttactta cagagcccat acagcagttc ggcctgttcc tttcaggctg    180

actcagaagg ctgaggaggc tttagattcc aggggagggc cgagcttgca aatatgagga    240

gacttattcc agcctgactg gagacaggca cagagctgaa aggccaattc ctggtggtgg    300

tgctaactca ctgtgtcttc ag                                            322
```

<210> 71

<211> 206

<212> DNA

<213> Homo sapiens

<400> 71

```
gaatctaaag cctcctcagc ccaccatacc aacatctaat ctaattctgc acattgtgag    60

gaaattactc cctgtgggtg agaaagtcca attcatctag agtcaagcat tttcattgaa    120

caaaacagtt ttacttacag agcccataca gcagttcggc ctgttccttt caggctgact    180

cagaaggctg aggaggcttt agattc                                        206
```

<210> 72

<211> 4344

<212> DNA

<213> Homo sapiens

<400> 72

```
ctgggtccca tttctctgga acacagtggt ctagtgatct gacctctctt cagggaaggt    60

tccttagttc tgtcccatat atttcagtat gatttgttta aagttctata tccccttccc    120

caagctatga cggatacaga aatggatgga tggatgcaag atgcaaacta tcttgtatct    180

cactaaagga tgcaatcatc tgcttctgaa aagggctttt catgttctga tagcaactgg    240

gagccaaata tgggatttaa tatttgtcaa ggagcttagc tgttttgtct gcacaagttc    300

tgaaggtgga gaagagaaaa tacaggcaga agtatgggtt ttgtaacctt caaaccccaa    360

atctgtcctt ctttgcttat ccaagatggg gagaatccag ttcaaatctc tttgtactaa    420

ttttatcata ttgtacttta agatcactgg tatctaaccc ctctacatta aggccaaact    480

gaagggcatc tcccagctgc agtaagaact cagatgatga gtgaagaatt ctggggttgg    540

gggagtgcaa tataagcaag ctaacctgtt tcaatgaaac agatgatcaa tgaagacact    600

gcatcatttg tttccaaaag ttaggccttg cagccaaggc tttggctttt tagagaaaat    660
```

B0213WO seq list.ST25.txt

```
tagctctaaa gaccagggca cctaggcaac ctagcagaga agaagtttca tgaagtcaga    720

gcccaggtgt ttgggtgagg gtagggagtt ggggcaaagc aacactgggc ttctaaaaaa    780

gaaatgtctc ccctgagatg aatgacttgt tggcacaagt ttcaggaaag acaaagctct    840

aaaaatatca ttgtaaaatt aataatactt ctccaaagta aggactcaac tcaaactatc    900

cttggatgca attaaaatgg ccttggaaga agctttcagg tgcggaggta ctcaccagtg    960

tcctgccagc accttcatct ctgaagaagt catcggaggg agccactacc ttgattttat   1020

gaccacagat gagtttcctt taatccgaaa gagattgact tttggcattt ttttcttagt   1080

ttttgtttat ttatattctt ttaagctttta aaaaaaagtg tcattgctgt gcttcttatt   1140

cctctggctg actttagaat tgaggactgg gaatcctgaa aatttgcaaa gttatctcct   1200

atcctcactg ccttggaaca cccattattc cactctgtct aatttctact catgtttcaa   1260

gtctaaacag gaagattcct ctgtgatcat gcctctccct ttctcatgaa ttaaatgcat   1320

atattatgct agtaatgctt ctggaatgaa tgaataatag aaagaaagaa agtgggggga   1380

gggaagcagg gaaagtaaaa tgagaaaggc agccttatct ggaaggagct cccaaaagtg   1440

tatctcttaa cacctatcag aaaaaaaagg gccaacaaat atccaggcaa cgaaggtatg   1500

gaccagtagg aagaatctga gggaattaca ttttggaaaa agcattgctc tcccaagatt   1560

ccctttttaaa aatttaaata aaccttgaga gtagtgatgc ataaatgaat ttgatctgtc   1620

acagtcccgc ctttggaaga gggcctcaga gcttatgaaa gaccctaagt gggggtggga   1680

gaagacaaaa ggggtgggat gtcagtttca agtttccagg gcattctctg attgtgctct   1740

atgtccctgc agactgccag tgtgacctca ccctctccag tcacccctcc tcagttccag   1800

ctatgagttc ctgcaacttc acacatgcca cctttgtgct tattggtatc ccaggattag   1860

agaaagccca tttctgggtt ggcttccccc tcctttccat gtatgtagtg gcaatgtttg   1920

gaaactgcat cgtggtcttc atcgtaagga cggaacgcag cctgcacgct ccgatgtacc   1980

tctttctctg catgcttgca gccattgacc tggccttatc cacatccacc atgcctaaga   2040

tccttgccct tttctggttt gattcccgag agattagctt tgaggcctgt cttacccaga   2100

tgttctttat tcatgccctc tcagccattg aatccaccat cctgctggcc atggcctttg   2160

accgttatgt ggccatctgc cacccactgc gccatgctgc agtgctcaac aatacagtaa   2220

cagcccagat tggcatcgtg gctgtggtcc gcggatccct cttttttttc ccactgcctc   2280

tgctgatcaa gcggctggcc ttctgccact ccaatgtcct ctcgcactcc tattgtgtcc   2340

accaggatgt aatgaagttg gcctatgcag acactttgcc caatgtggta tatggtctta   2400

ctgccattct gctggtcatg ggcgtggacg taatgttcat ctccttgtcc tattttctga   2460

taatacgaac ggttctgcaa ctgccttcca agtcagagcg ggccaaggcc tttggaacct   2520

gtgtgtcaca cattggtgtg gtactcgcct tctatgtgcc acttattggc ctctcagtgg   2580

tacaccgctt tggaaacagc cttcatccca ttgtgcgtgt tgtcatgggt gacatctacc   2640

tgctgctgcc tcctgtcatc aatcccatca tctatggtgc caaaaccaaa cagatcagaa   2700
```

B0213WO seq list.ST25.txt

```
cacgggtgct ggctatgttc aagatcagct gtgacaagga cttgcaggct gtgggaggca    2760

agtgaccctt aacactacac ttctccttat ctttattggc ttgataaaca taattatttc    2820

taacactagc ttatttccag ttgcccataa gcacatcagt acttttctct ggctggaata    2880

gtaaactaaa gtatggtaca tctacctaaa ggactattat gtggaataat acatactaat    2940

gaagtattac atgatttaaa gactacaata aaaccaaaca tgcttataac attaagaaaa    3000

acaataaaga tacatgattg aaaccaagtt gaaaaatagc atatgccttg gaggaaatgt    3060

gctcaaatta ctaatgattt agtgttgtcc ctactttctc tctctttttt ctttcttttt    3120

ttttattat ggttagctgt cacatacaac tttttttttt tttgagatgg ggtctcgctc     3180

tgtcaccagg ctggagtgca gtggcgcgat ctcggctcac tgcaacctcc acatcccatg    3240

ttgaagtaat tcttctgcct cagcctcccg agtagctggg actagaggaa cgtgccacca    3300

tgactggcta attttctgta tttttagta gagacagagt ttcaccatgt tggccaggat     3360

ggtctcgatc tcctgacctt gtgatccacc cgcctcagcc tcccaaagtg ttgggattac    3420

aggtgtgaac cactgtgccc ggcctgtgta caactttta aatagggaat atgatagctt     3480

cgcatggtgg tgtgcaccta tagcccccac tgcctggaaa gctgaggtgg gagaatcgct    3540

tgagtccagg agtttgaggt tacagtgatc cacgatcgta ccactacact ccagcctggg    3600

caacagagca agaccctgtc tcaaagcata aaatggaata acatatcaaa tgaaacaggg    3660

aaaatgaagc tgacaattta tggaagccag ggcttgtcac agtctctact gttattatgc    3720

attacctggg aatttatata agcccttaat aataatgcca atgaacatct catgtgtgct    3780

cacaatgttc tggcactatt ataagtgctt cacaggtttt atgtgttctt cgtaacttta    3840

tggagtaggt accatttgtg tctctttatt ataagtgaga gaaatgaagt ttatattatc    3900

aaggggacta aagtcacacg gcttgtgggc actgtgccaa gatttaaaat taaatttgat    3960

ggttgaatac agttacttaa tgaccatgtt atattgcttc ctgtgtaaca tctgccattt    4020

atttcctcag ctgtacaaat cctctgtttt ctctctgtta cacactaaca tcaatggctt    4080

tgtacttgtg atgagagata accttgccct agttgtgggc aacacatgca gaataatcct    4140

gttttacagc tgcctttcgt gatcttattg cttgcttttt tccagattca gggagaatgt    4200

tgttgtctat ttgtctctta catctccttg atcatgtctt catttttaa tgtgctctgt      4260

acctgtcaaa aattttgaat gtacaccaca tgctattgtc tgaacttgag tataagataa    4320

aataaaattt tattttaaat tttg                                          4344
```

<210> 73

<211> 2969

<212> DNA

<213> Homo sapiens

<400> 73

BO213WO seq list.ST25.txt

```
agcaacgacg ccgggcagcg ggagcggcgg ccgcgccatg tggctgctgg ggccgctgtg      60

cctgctgctg agcagcgccg cggagagcca gctgctcccc gggaacaact tcaccaatga     120

gtgcaacata ccaggcaact tcatgtgcag caatggacgg tgcatcccgg gcgcctggca     180

gtgtgacggg ctgcctgact gcttcgacaa gagtgatgag aaggagtgcc ccaaggctaa     240

gtcgaaatgt ggcccaacct tcttcccctg tgccagcggc atccattgca tcattggtcg     300

cttccggtgc aatgggtttg aggactgtcc cgatggcagc gatgaagaga actgcacagc     360

aaaccctctg ctttgctcca ccgcccgcta ccactgcaag aacggcctct gtattgacaa     420

gagcttcatc tgcgatggac agaataactg tcaagacaac agtgatgagg aaagctgtga     480

aagttctcaa gaacccggca gtgggcaggt gtttgtgact tcagagaacc aacttgtgta     540

ttaccccagc atcacctatg ccatcatcgg cagctccgtc atttttgtgc tggtggtggc     600

cctgctggca ctggtcttgc accaccagcg gaagcggaac aacctcatga cgctgcccgt     660

gcaccggctg cagcaccctg tgctgctgtc ccgcctggtg gtcctggacc acccccacca     720

ctgcaacgtc acctacaacg tcaataatgg catccagtat gtggccagcc aggcggagca     780

gaatgcgtcg gaagtaggct ccccacccctc ctactccgag gccttgctgg accagaggcc     840

tgcgtggtat gaccttcctc caccgcccta ctcttctgac acggaatctc tgaaccaagc     900

cgacctgccc ccctaccgct cccggtccgg gagtgccaac agtgccagct cccaggcagc     960

cagcagcctc ctgagcgtgg aagacaccag ccacagcccg gggcagcctg cccccagga    1020

gggcactgct gagcccaggg actctgagcc cagccagggc actgaagaag tataagtccc    1080

agttattcca aagtccatat gggttaatct gctctgactt gttgccattc taacaatttg    1140

tgctcatggg aagctcttta agcacctgta aggatgtctc aagttacagt ttgggatatt    1200

aactatctct gcattcccct cctcccccag acttcagaga tgtttttctg gcgtctcagt    1260

tgacatgatc tgttgtgcgt cttttctgtc aggtcactct tcccttggga cccgagatca    1320

caccctcatt tttcacatta ttctgtttct gttggagaga cagcatataa aacagtattg    1380

aaataggctg ggagagagca atgtttctgt gctatattgg atgctcagaa gtgcaggaga    1440

cgctggaccc aattctctct gctgggtagt taccttatag catttgggga tttgggttag    1500

atgatctaac caggaggcca tcactggatg gtcacccccc caaaaaaatt ccatttgagc    1560

atcaaaacct gctttgcaca atcctatttg atgcccccag ttcagcagag tcagtggcca    1620

aagaaaactt tggacgtgag taacacccctt cagcagtcgc aacgttattt tggttttgtg    1680

aaggactctg aaaccatcta ccctgtataa attctggctt tagaaatttg cccaagaatg    1740

ctcattctga gagctttcct cagcagcata tatcatcagc ctcatcctaa aataggcagg    1800

gagcccctcc catgagttta tccaagttct cagctcctaa aatgcaggct gccaagaccc    1860

tacacctgcc ctggctctac agccacttac ctggtttctg gactgtcacc ctcccagctg    1920

acctgcccgt agccaaggaa tgaggaccta acttgagttg gcccaaagtc tgacctggct    1980

gtatgtccct gtggcccaca cccagcctgt cttgctcatt catgcagcct caacactggc    2040
```

B0213WO seq list.ST25.txt

```
ctccaaagtt cccttaacac ttgcaaagtc ctttttacct gtgcatttgg acttgaggac    2100

actggtttct atcacaggtg agagccatgt tcaatacctc cagcaagctc tcctggctcc    2160

ctgcactgtg cacgctcctc ttcccaaggt cccaatacca gcacctctag ttagagttag    2220

ggtcagggtc aggcctctcc caacatccca gtagtttctc ctctgagaca catgggcaag    2280

agacaatttg gagtcaagat tttccatttg gatctatttt aaatctttta gaaatgcatt    2340

tgaaacagtg tgtttgtttt ttcccttcta gttaagggac tatttatatg tgtataggaa    2400

agctgtctct tttttgtttt ttcctttaac aaggtccaaa gaaagatgca aaaggagatc    2460

acacccttgc cccgctgagc cccgtgataa caagtcactc cagactaacc tgtgtgccag    2520

acatttgtgc attgttgcac tttgaggtta ttatttatca agttcttgaa ggaagcagaa    2580

agagggactc ctctctccct ccgtgtatag tctctatgtt tgtgctagtt tttctttttt    2640

ttctctgtgt ccagtcagcc acagggcccg cctccctgca ggaataaggg gtaaaacgtt    2700

aggtgttgtt tggcaagaaa ccacactgac tgatgagggg taaaatggaa ccaggtagag    2760

ccactccggg cagctgtcac ccattcagaa cttctttccg cagctgaaga aatgttcagt    2820

aacctgtttg acgctaatta aaacagagcc tgcaggaagt ggggctaaag tggcattcag    2880

tgatcctgtt ctgtagactt ttctttcttt ttttaaccaa atccaaagga tgttacagaa    2940.

aagctagcca ctggtatttt gttttgttt                                      2969
```

<210> 74

<211> 350

<212> DNA

<213> Homo sapiens

<400> 74

```
gccagtcatc acagtgtaac taatttaatg ctaaaataaa acacggatct catttgagaa     60

aaaaagagat gagactattt tctggttggc gtagatttag gcaatgtata aaaaagcttc    120

ctggttggaa tgagttaaaa aatattgctg gacactaatg tgccatcttg agttggaaaa    180

caaacccct cccccaaaa aaaaccctgc cgctttggtg tcctatttat atatttttaa    240

aaacattcat taaaaaaatc aaatctataa taaaaatgtc cctgtttgtt ttaaaaaagc    300  ·

attagtaggc atcccttatc tactaaaacc atttgttttt cctaagatgc                350
```

<210> 75

<211> 2006

<212> DNA

<213> Homo sapiens

<400> 75

BO213WO seq list.ST25.txt

```
agcaacgacg ccgggcagcg ggagcggcgg ccgcgccatg tggctgctgg ggccgctgtg      60

cctgctgctg agcagcgccg cggccaaggc taagtcgaaa tgtggcccaa ccttcttccc     120

ctgtgccagc ggcatccatt gcatcattgg tcgcttccgg tgcaatgggt ttgaggactg     180

tcccgatggc agcgatgaag agaactgcac agcaaaccct ctgctttgct ccaccgcccg     240

ctaccactgc aagaacggcc tctgtattga caagagcttc atctgcgatg gacagaataa     300

ctgtcaagac aacagtgatg aggaaagctg tgaaagttct caagaacccg gcagtgggca     360

ggtgtttgtg acttcagaga accaacttgt gtattacccc agcatcacct atgccatcat     420

cggcagctcc gtcattttg tgctggtggt ggccctgctg gcactggtct tgcaccacca     480

gcggaagcgg aacaacctca tgacgctgcc cgtgcaccgg ctgcagcacc ctgtgctgct     540

gtcccgcctg gtggtcctgg accaccccca ccactgcaac gtcacctaca acgtcaataa     600

tggcatccag tatgtggcca gccaggcgga gcagaatgcg tcggaagtag gctccccacc     660

ctcctactcc gaggccttgc tggaccagag gcctgcgtgg tatgaccttc tccaccgcc      720

ctactcttct gacacggaat ctctgaacca agccgacctg ccccctacc gctcccggtc      780

cgggagtgcc aacagtgcca gctcccaggc agccagcagc ctcctgagcg tggaagacac     840

cagccacagc ccggggcagc ctggcccca ggagggcact gctgagccca gggactctga     900

gcccagccag ggcactgaag aagtataagt cccagttatt ccaaagtcca tatgggttaa     960

tctgctctga cttgttgcca ttctaacaat ttgtgctcat gggaagctct ttaagcacct    1020

gtaaggatgt ctcaagttac agtttgggat attaactatc tctgcattcc cctcctcccc    1080

cagacttcag agatgttttt ctggcgtctc agttgacatg atctgttgtg cgtcttttct    1140

gtcaggtcac tcttcccttg ggacccgaga tcacaccctc atttttcaca ttattctgtt    1200

tctgttggag agacagcata taaaacagta ttgaaatagg ctgggagaga gcaatgtttc    1260

tgtgctatat tggatgctca gaagtgcagg agacgctgga cccaattctc tctgctgggt    1320

agttaccttα tagcatttgg ggatttgggt tagatgatct aaccaggagg ccatcactgg    1380

atggtcaccc ccccaaaaaa attccatttg agcatcaaaa cctgctttgc acaatcctat    1440

ttgatgcccc cagttcagca gagtcagtgg ccaaagaaaa ctttggacgt gagtaacacc    1500

cttcagcagt cgcaacgtta ttttggtttt gtgaaggact ctgaaaccat ctaccctgta    1560

taaattctgg ctttagaaat ttgcccaaga atgctcattc tgagagcttt cctcagcagc    1620

atatatcatc agcctcatcc taaaataggc agggagcccc tcccatgagt ttatccaagt    1680

tctcagctcc taaaatgcag gctgccaaga ccctacacct gccctggctc tacagccact    1740

tacctggttt ctggactgtc accctcccag ctgacctgcc cgtagccaag gaatgaggac    1800

ctaacttgag ttggcccaaa gtctgacctg ctgtatgtc cctgtggccc acaccagcc     1860

tgtcttgctc attcatgcag cctcaacact ggcctccaaa gttcccttaa cacttgcaaa    1920

gtcctttta cctgtgcatt tggacttgag gacactggtt tctatcacag gtgagagcca    1980

tgttcaatac ctccagcaag ctctcc                                         2006
```

Page 33

B0213WO seq list.ST25.txt

<210> 76

<211> 3094

<212> DNA

<213> Homo sapiens

<400> 76

```
agcaacgacg ccgggcagcg ggagcggcgg ccgcgccatg tggctgctgg ggccgctgtg     60

cctgctgctg agcagcgccg cgggtctgtg actactttgc tccaatacca agatggacag    120

aacagccctt tgattaccca gggagactgt caagtttgca tctggtcaat ctctgtttta    180

tatataagga aactgaggca cagggtggag agccagctgc tccccgggaa caacttcacc    240

aatgagtgca acataccagg caacttcatg tgcagcaatg acggtgcat  cccgggcgcc    300

tggcagtgtg acgggctgcc tgactgcttc gacaagagtg atgagaagga gtgccccaag    360

gctaagtcga aatgtggccc aaccttcttc ccctgtgcca gcggcatcca ttgcatcatt    420

ggtcgcttcc ggtgcaatgg gtttgaggac tgtcccgatg gcagcgatga agagaactgc    480

acagcaaacc ctctgctttg ctccaccgcc cgctaccact gcaagaacgg cctctgtatt    540

gacaagagct tcatctgcga tggacagaat aactgtcaag acaacagtga tgaggaaagc    600

tgtgaaagtt ctcaagaacc cggcagtggg caggtgtttg tgacttcaga gaaccaactt    660

gtgtattacc ccagcatcac ctatgccatc atcggcagct ccgtcatttt tgtgctggtg    720

gtggccctgc tggcactggt cttgcaccac cagcggaagc ggaacaacct catgacgctg    780

cccgtgcacc ggctgcagca ccctgtgctg ctgtcccgcc tggtggtcct ggaccacccc    840

caccactgca acgtcaccta caacgtcaat aatggcatcc agtatgtggc cagccaggcg    900

gagcagaatg cgtcggaagt aggctcccca ccctcctact ccgaggcctt gctggaccag    960

aggcctgcgt ggtatgacct tcctccaccg ccctactctt ctgacacgga atctctgaac   1020

caagccgacc tgcccccta ccgctcccgg tccgggagtg ccaacagtgc cagctcccag   1080

gcagccagca gcctcctgag cgtggaagac accagccaca gcccggggca gcctggcccc   1140

caggagggca ctgctgagcc cagggactct gagcccagcc agggcactga agaagtataa   1200

gtcccagtta ttccaaagtc catatgggtt aatctgctct gacttgttgc cattctaaca   1260

atttgtgctc atgggaagct ctttaagcac ctgtaaggat gtctcaagtt acagtttggg   1320

atattaacta tctctgcatt ccccctcctcc cccagacttc agagatgttt ttctggcgtc   1380

tcagttgaca tgatctgttg tgcgtctttt ctgtcaggtc actcttccct tgggacccga   1440

gatcacaccc tcatttttca cattattctg tttctgttgg agagacagca tataaaacag   1500

tattgaaata ggctgggaga gagcaatgtt tctgtgctat attggatgct cagaagtgca   1560

ggagacgctg gacccaattc tctctgctgg gtagttacct tatagcattt ggggatttgg   1620

gttagatgat ctaaccagga ggccatcact ggatggtcac ccccccaaaa aaattccatt   1680
```

B0213WO seq list.ST25.txt

```
tgagcatcaa aacctgcttt gcacaatcct atttgatgcc cccagttcag cagagtcagt    1740

ggccaaagaa aactttggac gtgagtaaca ccccttcagca gtcgcaacgt tattttggtt    1800

ttgtgaagga ctctgaaacc atctaccctg tataaattct ggctttagaa atttgcccaa    1860

gaatgctcat tctgagagct ttcctcagca gcatatatca tcagcctcat cctaaaatag    1920

gcagggagcc cctcccatga gtttatccaa gttctcagct cctaaaatgc aggctgccaa    1980

gaccctacac ctgccctggc tctacagcca cttacctggt ttctggactg tcaccctccc    2040

agctgacctg cccgtagcca aggaatgagg acctaacttg agttggccca aagtctgacc    2100

tggctgtatg tccctgtggc ccacacccag cctgtcttgc tcattcatgc agcctcaaca    2160

ctggcctcca aagttccctt aacacttgca aagtcctttt tacctgtgca tttggacttg    2220

aggacactgg tttctatcac aggtgagagc catgttcaat acctccagca agctctcctg    2280

gctccctgca ctgtgcacgc tcctcttccc aaggtcccaa taccagcacc tctagttaga    2340

gttagggtca gggtcaggcc tctcccaaca tcccagtagt ttctcctctg agacacatgg    2400

gcaagagaca atttggagtc aagattttcc atttggatct attttaaatc ttttagaaat    2460

gcatttgaaa cagtgtgttt gtttttttccc ttctagttaa gggactattt atatgtgtat    2520

aggaaagctg tctcttttttt tgtttttttcct ttaacaaggt ccaaagaaag atgcaaaagg    2580

agatcacacc cttgccccgc tgagcccgt dataacaagt cactccagac taacctgtgt    2640

gccagacatt tgtgcattgt tgcactttga ggttattatt tatcaagttc ttgaaggaag    2700

cagaaagagg gactcctctc tccctccgtg tatagtctct atgtttgtgc tagtttttct    2760

ttttttttctc tgtgtccagt cagccacagg gcccgcctcc ctgcaggaat aaggggtaaa    2820

acgttaggtg ttgtttggca agaaaccaca ctgactgatg aggggtaaaa tggaaccagg    2880

tagagccact ccgggcagct gtcacccatt cagaacttct ttccgcagct gaagaaatgt    2940

tcagtaacct gtttgacgct aattaaaaca gagcctgcag gaagtggggc taaagtggca    3000

ttcagtgatc ctgttctgta gacttttctt tctttttttta accaaatcca aaggatgtta    3060

cagaaaagct agccactggt attttgtttt gttt                                3094
```

```
<210>   77
<211>   3024
<212>   DNA
<213>   Homo sapiens


<400>   77
ctggggccgc tgtgcctgct gctgagcagc gccgcgggaa agtgcctgga aaaatagatg      60

acagccagaa agagagcttg gagaaaaaaa tgactccaag gagaaggtgg tcatttccta     120

gagtctggct tgtcagttag agccagctgc tccccgggaa caacttcacc aatgagtgca     180

acataccagg caacttcatg tgcagcaatg gacggtgcat cccgggcgcc tggcagtgtg     240
```

B0213WO seq list.ST25.txt

```
acgggctgcc tgactgcttc gacaagagtg atgagaagga gtgccccaag gctaagtcga    300

aatgtggccc aaccttcttc ccctgtgcca gcggcatcca ttgcatcatt ggtcgcttcc    360

ggtgcaatgg gtttgaggac tgtcccgatg gcagcgatga agagaactgc acagcaaacc    420

ctctgctttg ctccaccgcc cgctaccact gcaagaacgg cctctgtatt gacaagagct    480

tcatctgcga tggacagaat aactgtcaag acaacagtga tgaggaaagc tgtgaaagtt    540

ctcaagaacc cggcagtggg caggtgtttg tgacttcaga gaaccaactt gtgtattacc    600

ccagcatcac ctatgccatc atcggcagct ccgtcatttt tgtgctggtg gtggccctgc    660

tggcactggt cttgcaccac cagcggaagc ggaacaacct catgacgctg cccgtgcacc    720

ggctgcagca ccctgtgctg ctgtcccgcc tggtggtcct ggaccacccc caccactgca    780

acgtcaccta caacgtcaat aatggcatcc agtatgtggc cagccaggcg gagcagaatg    840

cgtcggaagt aggctcccca ccctcctact ccgaggcctt gctggaccag aggcctgcgt    900

ggtatgacct tcctccaccg ccctactctt ctgacacgga atctctgaac caagccgacc    960

tgcccccta ccgctcccgg tccgggagtg ccaacagtgc cagctcccag gcagccagca   1020

gcctcctgag cgtggaagac accagccaca gcccggggca gcctggcccc caggagggca   1080

ctgctgagcc cagggactct gagcccagcc agggcactga agaagtataa gtcccagtta   1140

ttccaaagtc catatgggtt aatctgctct gacttgttgc cattctaaca atttgtgctc   1200

atgggaagct ctttaagcac ctgtaaggat gtctcaagtt acagtttggg atattaacta   1260

tctctgcatt cccctcctcc cccagacttc agagatgttt ttctggcgtc tcagttgaca   1320

tgatctgttg tgcgtctttt ctgtcaggtc actcttccct tgggacccga gatcacaccc   1380

tcatttttca cattattctg tttctgttgg agagacagca tataaacag tattgaaata   1440

ggctgggaga gagcaatgtt tctgtgctat attggatgct cagaagtgca ggagacgctg   1500

gacccaattc tctctgctgg gtagttacct tatagcattt ggggatttgg gttagatgat   1560

ctaaccagga ggccatcact ggatggtcac cccccaaaa aaattccatt tgagcatcaa   1620

aacctgcttt gcacaatcct atttgatgcc cccagttcag cagagtcagt ggccaaagaa   1680

aactttggac gtgagtaaca cccttcagca gtcgcaacgt tattttggtt ttgtgaagga   1740

ctctgaaacc atctaccctg tataaattct ggctttagaa atttgcccaa gaatgctcat   1800

tctgagagct ttcctcagca gcatatatca tcagcctcat cctaaaatag gcagggagcc   1860

cctcccatga gtttatccaa gttctcagct cctaaaatgc aggctgccaa gaccctacac   1920

ctgccctggc tctacagcca cttacctggt ttctggactg tcaccctccc agctgacctg   1980

cccgtagcca aggaatgagg acctaacttg agttggccca aagtctgacc tggctgtatg   2040

tccctgtggc ccacacccag cctgtcttgc tcattcatgc agcctcaaca ctggcctcca   2100

aagttccctt aacacttgca aagtccttt tacctgtgca tttggacttg aggacactgg   2160

tttctatcac aggtgagagc catgttcaat acctccagca agctctcctg gctccctgca   2220

ctgtgcacgc tcctcttccc aaggtcccaa taccagcacc tctagttaga gttagggtca   2280
```

Page 36

B0213WO seq list.ST25.txt

```
gggtcaggcc tctcccaaca tcccagtagt ttctcctctg agacacatgg gcaagagaca   2340

atttggagtc aagatttttcc atttggatct attttaaatc ttttagaaat gcatttgaaa   2400

cagtgtgttt gttttttccc ttctagttaa gggactattt atatgtgtat aggaaagctg   2460

tctcttttttt tgttttttcct ttaacaaggt ccaaagaaag atgcaaaagg agatcacacc   2520

cttgccccgc tgagccccgt gataacaagt cactccagac taacctgtgt gccagacatt   2580

tgtgcattgt tgcactttga ggttattatt tatcaagttc ttgaaggaag cagaaagagg   2640

gactcctctc tccctccgtg tatagtctct atgtttgtgc tagttttttct ttttttttctc   2700

tgtgtccagt cagccacagg gcccgcctcc ctgcaggaat aaggggtaaa acgttaggtg   2760

ttgtttggca agaaaccaca ctgactgatg aggggtaaaa tggaaccagg tagagccact   2820

ccgggcagct gtcacccatt cagaacttct ttccgcagct gaagaaatgt tcagtaacct   2880

gtttgacgct aattaaaaca gagcctgcag gaagtggggc taaagtggca ttcagtgatc   2940

ctgttctgta gacttttctt tctttttttta accaaatcca aaggatgtta cagaaaagct   3000

agccactggt attttgtttt gttt                                         3024
```

<210> 78

<211> 1668

<212> DNA

<213> Homo sapiens

<400> 78

```
atgggtcctg gggcgcggct ggcggcgctg ctggcggtgc tggcgctcgg gacaggagac   60

ccagaaaggg ctgcggctcg gggcgacacg ttctcggcgc tgaccagcgt ggcgcgcgcc   120

ctggcgcccg agcgccggct gctggggctg ctgaggcggt acctgcgcgg ggaggaggcg   180

cggctgcggg acctgactag attctacgac aaggtacttt ctttgcatga ggattcaaca   240

acccctgtgg ctaaccctct gcttgcattt actctcatca aacgcctgca gtctgactgg   300

aggaatgtgg tacatagtct ggaggccagt gagaacatcc gagctctgaa ggatggctat   360

gagaaggtgg agcaagacct tccagccttt gaggaccttg agggagcagc aagggccctg   420

atgcggctgc aggacgtgta catgctcaat gtgaaaggcc tggcccgagg tgtctttcag   480

agagtcactg gctctgccat cactgacctg tacagcccca acggctcttt ttctctcaca   540

ggggatgact gcttccaagt tggcaaggtg gcctatgaca tggggggatta ttaccatgcc   600

attccatggc tggaggaggc tgtcagtctc ttccgaggat cttacggaga gtggaagaca   660

gaggatgagg caagtctaga agatgccttg gatcacttgg cctttgctta tttccgggta   720

agggagccag ttaggagatt tgaaagatct agtggagcca agaatgaatt agcttccaat   780

tctctgggga agaataggtt gggtcctttt gcaataggct ttggctttct ggacttctct   840

ttcattgcac ttatcatatt ttgttgccca gataataaga ggatggccag gaatgtcttg   900
```

Page 37

B0213WO seq list.ST25.txt

```
aaatatgaaa ggctcttggc agagagcccc aaccacgtgg tagctgaggc tgtcatccag    960

aggcccaata taccccacct gcagaccaga gacacctacg aggggctatg tcagaccctg   1020

ggttcccagc ccactctcta ccagatccct agcctctact gttcctatga gaccaattcc   1080

aacgcctacc tgctgctcca gcccatccgg aaggaggtca tccacctgga gccctacatt   1140

gctctctacc atgacttcgt cagtgactca gaggctcaga aaattagaga acttgcagaa   1200

ccatggctac agaggtcagt ggtggcatca ggggagaagc agttacaagt ggagtaccgc   1260

atcagcaaaa gtgcctggct gaaggacact gttgacccaa aactggtgac cctcaaccac   1320

cgcattgctg ccctcacagg ccttgatgtc cggcctccct atgcagagta tctgcaggtg   1380

gtgaactatg gcatcggagg acactatgag cctcactttg accatgctac gctgagctcg   1440

gtggaagctg gaggagccac agccttcatc tatgccaacc tcagcgtgcc tgtggttagg   1500

aatgcagcac tgttttggtg gaacctgcac aggagtggtg aaggggacag tgacacactt   1560

catgctggct gtcctgtcct ggtgggagat aagtgggtgg ccaacaagtg gatacatgag   1620

tatggacagg aattccgcag accctgcagc tccagccctg aagactga                 1668
```

<210> 79

<211> 997

<212> DNA

<213> Homo sapiens

<400> 79

```
gaaggaaaaa gagcaacaga tccagggagc attcacctgc cctgtctcca aacagccttg     60

tgcctcacct accccaacc tcccagaggg agcagctatt taaggggagc aggagtgcag    120

aacaaacaag acggcctggg gatacaactc tggagtcctc tgagagagcc accaaggagg    180

agcaggggag cgacggccgg ggcagaagtt gagaccaccc agcagaggag ctaggccagt    240

ccatctgcat ttgtcaccca agaactctta ccatgaagac cctcctactg ttggcagtga    300

tcatgatctt tggcctactg caggcccatg ggaatttggt gaatttccac agaatgatca    360

agttgacgac aggaaaggaa gccgcactca gttatggctt ctacggctgc cactgtggcg    420

tgggtggcag aggatccccc aaggatgcaa cggatcgctg ctgtgtcact catgactgtt    480

gctacaaacg tctggagaaa cgtggatgtg gcaccaaatt tctgagctac aagtttagca    540

actcggggag cagaatcacc tgtgcaaaac aggactcctg cagaagtcaa ctgtgtgagt    600

gtgataaggc tgctgccacc tgttttgcta gaaacaagac gacctacaat aaaaagtacc    660

agtactattc caataaacac tgcagaggga gcaccctcg ttgctgagtc ccctcttccc    720

tggaaacctt ccacccagtg ctgaatttcc ctctctcata ccctccctcc ctaccctaac    780

caagttcctt ggccatgcag aaagcatccc tcacccatcc tagaggccag gcaggagccc    840

ttctataccc acccagaatg agacatccag cagatttcca gccttctact gctctcctcc    900
```

B0213WO seq list.ST25.txt
```
acctcaactc cgtgcttaac caaagaagct gtactccggg gggtctcttc tgaataaagc    960

aattagcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa                              997
```

<210> 80

<211> 260

<212> DNA

<213> Homo sapiens

<400> 80
```
tgagaggtgg gtgtgatcac tcatttgctg tttaaaggcc cagaaaggag acagagaagg     60

gatggacaga gagggagaag gggaactgag cgagaaggtc aaggagtcag taaggaaatg    120

gttagcaagg gccaagtgaa cagggagtcc tccatgaaaa gggccaacaa ggctcccctg    180

gatgttgagg cagaaacgca tgagggactc aggggaagct gtttccatgg agtcgggggg    240

gcaaagccag attagaccag                                                260
```

<210> 81

<211> 201

<212> DNA

<213> Homo sapiens

<400> 81
```
ttcctttcct gtcgtcaact tgatcattca aagatcatga tcactgccaa cagtaggagg     60

gtcttcatgg taagagttct tgggtgacaa atgcagatgg actggcctag ctcctctgct    120

gggtggtctc aacttctgcc ccggccgtcg ctcccctgct cctccttggt ggctctgttt    180

ggagacaggg caggtgaatg a                                              201
```

<210> 82

<211> 272

<212> DNA

<213> Homo sapiens

<400> 82
```
tcattcacct gccctgtctc caacaggttg gatgggagag catgtctgtg tgtctcagag     60

ccaccaagga ggagcagggg agcgacggcc ggggcagaag ttgagaccac ccagcagagg    120

agctaggcca gtccatctgc atttgtcacc caagaactct taccatgaag accctcctac    180

tgttggcagt gatcatgatc tttggcctac tgcaggccca tgggaatttg gtgaatttcc    240

acagaatgat caagttgacg acaggaaagg aa                                  272
```

B0213WO seq list.ST25.txt

<210> 83

<211> 258

<212> DNA

<213> Homo sapiens

<400> 83
tcattcacct gccctgtctc caaacagagc caccaaggag gagcagggga gcgacggccg   60

gggcagaagt tgagaccacc cagcagagga gctaggccag tccatctgca tttgtcaccc   120

aagaactctt accatgaaga ccctcctact gttggcagtg atcatgatct ttggcctact   180

gcaggcccat gggaatttgg tgaatttcca cagaatgatc aagttgacga caggaaagga   240

agccgcactc agttatga   258

<210> 84

<211> 2226

<212> DNA

<213> Homo sapiens

<400> 84
ggcagcatgg cgtctttccg gcttctccaa acccttgcga aaaactttat tggcaaagct   60

atcagagaac ggacagtgta cccactgagg cggccaaagc ttaactggat cagggcagga   120

tgacatgacc ttgtggtaga tcccagaact gaggccccag gatgacagaa caggagaccc   180

tggccctact ggaagtgaag aggtctgatt ccccagagaa gagctcaccc caggccttgg   240

ttcccaatgg ccggcagcca gaaggggaag gtggggccga atccccggga gctgagtccc   300

tcagagtggg gtcttcagct ggatctccca cagccataga gggggctgag gatggtctag   360

acagcacagt aagtgaggct gccaccttgc cctgggggac tggccctcag cccagtgctc   420

cgttcccgga tcccccctggc tggcgggaca ttgaaccaga gcccctgag tcagaaccac   480

ttaccaagct agaggagctg cccgaagacg atgccaacct gctgcctgag aaagcggccc   540

gtgccttcgt gcctattgac ctacagtgca ttgagcggca gccccaagaa gaccttatcg   600

tgcgctgtga ggcaggcgag ggcgagtgcc gaaccttcat gccccccgcg gtcacccacc   660

ccgacccccac tgagcgcaag tgggctgagg cagtggtgag gccgcctggc tgttcctgtg   720

ggggctgcgg gagctgtgga gaccgtgagt ggctaagggc tgtggcctcc gtgggagccg   780

cactcattct cttcccttgc ctactatacg gggcatatgc cttcctgccg tttgatgtcc   840

cacggctgcc caccatgagt tcccgcctga tctacacact gcgctgcggg gtctttgcca   900

ccttcccccat tgtgctgggg atcctggtgt acgggctgag cctgttatgc ttttctgccc   960

ttcggcccctt tggggagcca cggcgggagg tggagatcca ccggcgatat gtggcccagt   1020

B0213WO seq list.ST25.txt

```
cggtccagct ctttattctc tacttcttca acctggccgt gctttccact tacctgcccc   1080

aggataccct caaactgctc cctctgctca ctggtctctt tgccgtctcc cggctgatct   1140

actggctgac ctttgccgtg ggccgctcct tccgaggctt cggctacggc ctgacgtttc   1200

tgccactgct gtcgatgctg atgtggaacc tctactacat gttcgtggtg gagccggagc   1260

gcatgctcac tgccaccgag agccgcctgg actacccgga ccacgcccgc tcggcctccg   1320

actacaggcc ccgcccctgg ggctgagcct ctccgccctc gccctcggag tagggggtag   1380

cggcttgggt ctgacacatc tttgaacctt gtggccaggc ctggacttcg cccccaggcc   1440

taggaccgcg gtgggtggaa ccctgctact gccccaacag ggactccaat caatcggagt   1500

tctccccttg ccggagctgc ccttcacctt tggggcccga gacagtcata agggatggac   1560

ttagtttttct tgcagggaaa aaggtggaca gccgtgtttc ttaaggatgc tgagggcatg   1620

gggccaggac caggggagag gcacagctcc ttcctgagca gcctctcacc actgccacaa   1680

ggctccctaa tgctggtctc tgctccactc cccggcttcc cgtgaggcag gaggcagagc   1740

cacagccaag gccctgacca cttctgtgcc agttgtctaa gcagagcgcc tcagggacgc   1800

tggaaatgcc ttaaggatag aggctgggca tcacatcaaa tgggactgtg gtgtttggtg   1860

aaaaccttcc tgaggatctg gattcaggac cctccatgac tggcctattt actgtttaca   1920

gctggccagt gcagagctgc tgctcttttta ccttttttagg cccctgtaac ttcccacctt   1980

taaactgccc agaaggcatg cctctcccac aggaagaggg gagcagacag ggaaatctgc   2040

ctaccaagag gggtgtgtgt gtctttgtgc ccacacgtgg tggctgggga gtgcctggat   2100

ggtgcggtgg ttgatgttaa cctagtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtaaca   2160 ·

ataaattact accagtcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa   2220

aaaaaa                                                             2226
```

<210> 85

<211> 328

<212> DNA

<213> Homo sapiens

<400> 85

```
tgaggccgcc tggctgttcc tgtgggggct gcgggagctg tggagaccgt gagtggctaa   60

gggctgtggc ctccgtggga gccgcactca ttctcttccc ttgcctacta tacggggcat   120

atgccttcct gccgtttgat gtcccacggc tgcccaccat gagttcccgc ctgatctaca   180

cactgcgctg cggggtcttt gccaccttcc ccattgtgct ggggatcctg gtgtacgggc   240

tgagcctgtt atgcttttct gcccttcggc cctttgggga gccacggcgg gaggtggaga   300

tccaccggcg atatgtggcc cagtcggt                                     328
```

<210> 86

BO213WO seq list.ST25.txt

<211>   1469

<212>   DNA

<213>   Homo sapiens

<400>   86
cagagaacgg acagtgtacc cactgaggcg gccaaagctt aactggatca gggcaggatg   60

acatgacctt gtggtagatc ccagaactga ggccccagga tgacagaaca ggagaccctg   120

gccctactgg aagtgaagag gtctgattcc ccagagaaga gctcacccca ggccttggtt   180

cccaatggcc ggcagccaga aggggaaggt ggggccgaat ccccgggagc tgagtccctc   240

agagtggggt cttcagctgg atctcccaca gccatagagg gggctgagga tggtctagac   300

agcacagtaa gtgaggctgc caccttgccc tggggggactg gccctcagcc cagtgctccg   360

ttcccggatc cccctggctg gcgggacatt gaaccagagc cccctgagtc agaaccactt   420

accaagctag aggagctgcc cgaagacgat gccaacctgc tgcctgagaa agcggcccgt   480

gccttcgtgc ctattgacct acagtgcatt gagcggcagc cccaagaaga ccttatcgtg   540

cgctgtgagg caggcgaggg cgagtgccga accttcatgc cccccgggt cacccacccc   600

gaccccactg agcgcaagtg ggctgaggca gtggtgaggc cgcctggctg ttcctgtggg   660

ggctgcggga gctgtggaga ccgtgagtgg ctaagggctg tggcctccgt gggagccgca   720

ctcattctct tcccttgcct actatacggg gcatatgcct tcctgccgtt tgatgtccca   780

cggctgccca ccatgagttc ccgcctgatc tacacactgc gctgcggggt ctttgccacc   840

ttccccattg tgctgggtga gccygtgaga agaaaggggg catcgggaag tggacttgag   900

gagggcaggg cctgcctggt gtggggagca ggaggatttc ccttcacttg acctgggccc   960

ctcagggtct cccacccct gccagtctgc atgcccatct cctcccagga ccacctccac   1020

cccactgtgt agagcccatg cactgcccac agtgaatctg cccccagctt actgcctctt   1080

gtgcccttcc cctgcctttt ctgaccctac ccygtttccc aactccaccc agggatcctg   1140

gtgtacgggc tgagcctgtt atgctttct gcccttcggc cctttgggga gccacggcgg   1200

gaggtggaga tccaccggcg atatgtggcc cagtcggtcc agctctttat tctctacttc   1260

ttcaacctgg ccgtgctttc cacttacctg ccccaggata ccctcaaact gctccctctg   1320

ctcactggtc tctttgccgt ctcccggctg atctactggc tgacctttgc cgtgggccgc   1380

tccttccgag gcttcggcta cggcctgacg tttctgccac tgctgtcgat gctgatgtgg   1440

aacctctact acatgttcgt ggtggagcc   1469

<210>   87

<211>   180

<212>   DNA

<213>   Homo sapiens

B0213WO seq list.ST25.txt

<400> 87
tcagagaacg gacagtgtac ccactgaggc ggccaaagct taactggatc agggcaggct   60

gatctactgg ctgacctttg ccgtgggccg ctccttccga ggcttcggct acggcctgac   120

gtttctgcca ctgctgtcga tgctgatgtg gaacctctac tacatgttcg tggtggagcc   180

<210>   88
<211>   477
<212>   DNA
<213>   Homo sapiens

<400>   88
cagagaacgg acagtgtacc cactgaggcg gccaaagctt aactggatca gggcaggatg   60

acatgacctt gtggtagatc ccagaactga ggccccagga tgacagaaca ggagaccctg   120

gccctactgg aagtgaagag ggatcctggt gtacgggctg agcctgttat gcttttctgc   180

ccttcggccc tttggggagc cacggcggga ggtggagatc caccggcgat atgtggccca   240

gtcggtccaa ctctttattc tctacttctt caacctggcc gtgctttcca cttacctgcc   300

ccaggatacc ctcaaactgc tccctctgct cactggtctc tttgccgtct cccggctgat   360

ctactggctg acctttgccg tgggccgctc cttccgaggc ttcggctacg gcctgacgtt   420

tctgccactg ctgtcgatgc tgatgtggaa cctctactac atgttcgtgg tggagcc   477

<210>   89
<211>   1013
<212>   DNA
<213>   Homo sapiens

<400>   89
cagagaacgg acagtgtacc cactgaggcg gccaaagctt aactggatca gggcaggatg   60

acatgacctt gtggtagatc ccagaactga ggccccagga tgacagaaca ggagaccctg   120

gccctactgg aagtgaagag gtctgattcc cagagaaga gctcacccca ggccttggtt   180

cccaatggcc ggcagccaga aggggaaggt ggggccgaat ccccgggagc tgagtccctc   240

agagtggggt cttcagctgg atctcccaca gccatagagg gggctgagga tggtctagac   300

agcacagtaa gtgaggctgc cgccttgccc tggggggactg ccctcagcc cagtgctccg   360

ttcccggatc cccctggctg gcgggacatt gaaccagagc ccctgagtc agaaccactt   420

accaagctag aggagctgcc cgaagacgat gccaacctgc tgcctgagaa agcggcccgt   480

gccttcgtgc ctattgacct acagtgcatt gagcggcagc cccaagaaga ccttatcatg   540

BO213WO seq list.ST25.txt

cgctgtgagg caggcgaggg cgagtgccga accttcatgc cccccgggt cacccacccc   600

gaccccactg agcgcaagtg ggctgaggca gtggtgaggc cgcctggctg ttcctgtggg   660

ggctgcggga gctgtggaga cggatctggt gtacggctga cctgttatgc tttctgcctt   720

cggccctttg gggagccacg gcgggaggtg gagatccacc ggcgatatgt ggcccagtcg   780

gtccagctct ttattctcta cttcttcaac ctggccgtgc tttccactta cctgccccag   840

gatacccctca aactgctccc tctgctcact ggtctctttg ccgtctcccg gctgatctac   900

tggctgacct ttgccgtggg ccgctccttc cgaggcttcg gctacggcct gacgtttctg   960

ccactgctgt cgatgctgat gtggaacctc tactacatgt tcgtggtgga gcc   1013

<210> 90

<211> 737

<212> DNA

<213> Homo sapiens

<400> 90
ccccaggatg acagaacagg agaccctggc cctactggaa gtgaagagtg cattgagcgg   60

cagcccaag aagaccttat cgtgcgctgt gaggcaggcg agggcgagtg ccgaaccttc   120

atgcccccc gggtcaccca ccccgacccc actgagcgca agtgggctga ggcagtggtg   180

aggccgcctg gctgttcctg tgggggctgc gggagctgtg agaccgtga gtggctaagg   240

gctgtggcct ccgtgggagc cgcactcatt ctcttccctt gcctactata cggggcatat   300

gccttcctgc cgtttgatgt cccacggctg cccaccatga gttcccgcct gatctacaca   360

ctgcgctgcg gggtctttgc caccttcccc attgtgctgg ggatcctggt gtacgggctg   420

agcctgttat gcttttctgc ccttcggccc tttggggagc cacggcggga ggtggagatc   480

caccggcgat atgtggccca gtcggtccag ctctttattc tctacttctt caacctggcc   540

gtgctttcca cttacctgcc ccaggatacc ctcaaactgc tccctctgct cactggtctc   600

tttgccgtct cccggctgat ctactggctg acctttgccg tgggccgctc cttccgaggc   660

ttcggctacg gcctgacgtt tctgccactg ctgtcgatgc tgatgtggaa cctctactac   720

atgttcgtgg tggagcc   737

<210> 91

<211> 2469

<212> DNA

<213> Homo sapiens

<400> 91
agcgttcctc gggccctcgg cgccacaagc tgtccgggca cgcagcccct agcggcgcgt   60

B0213WO seq list.ST25.txt

```
cgctgccaag ccggcctccg cgcgcctccc tccttccttc tcccctggct gttcgcgatc    120

cagcttgggt aggcggggaa gcagctggag tgcgaccgcc acggcagcca ccctgcaacc    180

gccagtcgga ggtgcagtcc gtaggccctg gcccccgggt gggcccttgg ggagtcggcg    240

ccgctcccga ggagctgcaa ggctcgcccc tgcccggcgt ggagggcgcg gggggcgcgg    300

aggatattct tggtgatctt ggaagtgtcc gtatcatgga atcaatctct atgatgggaa    360

gccctaagag ccttagtgaa acttgtttac ctaatggcat aaatggtatc aaagatgcaa    420

ggaaggtcac tgtaggtgtg attggaagtg gagattttgc caaatccttg accattcgac    480

ttattagatg cggctatcat gtggtcatag gaagtagaaa tcctaagttt gcttctgaat    540

tttttcctca tgtggtagat gtcactcatc atgaagatgc tctcacaaaa acaaatataa    600

tatttgttgc tatacacaga gaacattata cctccctgtg ggacctgaga catctgcttg    660

tgggtaaaat cctgattgat gtgagcaata acatgaggat aaaccagtac ccagaatcca    720

atgctgaata tttggcttca ttattcccag attctttgat tgtcaaagga tttaatgttg    780

tctcagcttg ggcacttcag ttaggaccta aggatgccag ccggcaggtt tatatatgca    840

gcaacaatat tcaagcgcga caacaggtta ttgaacttgc ccgccagttg aatttcattc    900

ccattgactt gggatcctta tcatcagcca gagagattga aaatttaccc ctacgactct    960

ttactctctg gagagggcca gtggtggtag ctatgagctt ggccacattt tttttccttt   1020

attcctttgt cagagatgtg attcatccat atgctagaaa ccaacagagt gacttttaca   1080

aaattcctat agagattgtg aataaaacct tacctatagt tgccattact ttgctctccc   1140

tagtatacct tgcaggtctt ctggcagctg cttatcaact ttattacggc accaagtata   1200

ggagatttcc accttggttg gaaacctggt tacagtgtag aaaacagctt ggattactaa   1260

gttttttctt cgctatggtc catgttgcct acagcctctg cttaccgatg agaaggtcag   1320

agagatattt gtttctcaac atggcttatc agcaggttca tgcaaatatt gaaaactctt   1380

ggaatgagga agaagtttgg agaattgaaa tgtatatctc ctttggcata atgagccttg   1440

gcttactttc cctcctggca gtcacttcta tcccttcagt gagcaatgct ttaaactgga   1500

gagaattcag ttttattcag tctacacttg gatatgtcgc tctgctcata agtactttcc   1560

atgtttttaat ttatggatgg aaacgagctt ttgaggaaga gtactacaga ttttatacac   1620

caccaaactt tgttcttgct cttgtttttgc cctcaattgt aattctggat cttttgcagc   1680

tttgcagata cccagactga gctggaactg gaatttgtct tcctattgac tctacttctt   1740

taaaagcggc tgcccattac attcctcagc tgtccttgca gttaggtgta catgtgactg   1800

agtgttggcc agtgagatga agtctcctca aaggaaggca gcatgtgtcc tttttcatcc   1860

cttcatcttg ctgctgggat tgtggatata acaggagccc tggcagctgt ctccagagga   1920

tcaaagccac acccaaagag taaggcagat tagagaccag aaagaccttg actacttccc   1980

tacttccact gcttttttcct gcatttaagc cattgtaaat ctgggtgtgt tacatgaagt   2040

gaaaattaat tctttctgcc cttcagttct ttatcctgat accatttaac actgtctgaa   2100
```

Page 45

B0213WO seq list.ST25.txt

```
ttaactagac tgcaataatt ctttcttttg aaagctttta aaggataatg tgcaattcac   2160
attaaaattg attttccatt gtcaattagt tatactcatt ttcctgcctt gatctttcat   2220
tagatatttt gtatctgctt ggaatatatt atcttctttt taactgtgta attggtaatt   2280
actaaaactc tgtaatctcc aaaatattgc tatcaaatta cacaccatgt tttctatcat   2340
tctcatagat ctgccttata aacatttaaa taaaaagtac tatttaatga tttaacttct   2400
gttttgaaat gttgtataca cgtggatttt tttctcatta ataataatt  ctagtaaaaa   2460
aaaaaaaag                                                           2469
```

<210> 92

<211> 2562

<212> DNA

<213> Homo sapiens

<400> 92
```
agcgttcctc gggccctcgg cgccacaagc tgtccgggca cgcagcccct agcggcgcgt   60
cgctgccaag ccggcctccg cgcgcctccc tccttccttc tcccctggct gttcgcgatc   120
cagcttgggt aggcggggaa gcagctggag tgcgaccgcc acggcagcca ccctgcaacc   180
gccagtcgga ggtgcagtcc gtaggccctg gcccccgggt gggcccttgg ggagtcggcg   240
ccgctcccga ggagctgcaa ggctcgcccc tgcccggcgt ggagggcgcg ggggggcgcgg  300
aggatattct tggtgatctt ggaagtgtcc gtatcatgga atcaatctct atgatgggaa   360
gccctaagag ccttagtgaa acttgtttac ctaatggcat aaatggtatc aaagatgcaa   420
ggaaggtcac tgtaggtgtg attggaagtg gagatttgc  caaatccttg accattcgac   480
ttattagatg cggctatcat gtggtcatag gaagtagaaa tcctaagttt gcttctgaat   540
tttttcctca tgtggtagat gtcactcatc atgaagatgc tctcacaaaa acaaatataa   600
tatttgttgc tatacacaga gaacattata cctccctgtg ggacctgaga catctgcttg   660
tgggtaaaat cctgattgat gtgagcaata acatgaggat aaaccagtac ccagaatcca   720
atgctgaata tttggcttca ttattcccag attctttgat tgtcaaagga tttaatgttg   780
tctcagcttg ggcacttcag ttaggaccta aggatgccag ccggcaggtt tatatatgca   840
gcaacaatat tcaagcgcga caacaggtta ttgaacttgc ccgccagttg aatttcattc   900
ccattgactt gggatcctta tcatcagcca gagagattga aaatttaccc ctacgactct   960
ttactctctg gagagggcca gtggtggtag ctatgagctt ggccacattt ttttttccttt  1020
attcctttgt cagagatgtg attcatccat atgctagaaa ccaacagagt gactttttaca  1080
aaattcctat agagattgtg aataaaacct tacctatagt tgccattact ttgctctccc   1140
tagtatacct tgcaggtctt ctggcagctg cttatcaact ttattacggc accaagtata   1200
ggagatttcc accttggttg gaaacctggt tacagtgtag aaaacagctt ggattactaa   1260
```

B0213WO seq list.ST25.txt

```
gttttttcctt cgctatggtc catgttgcct acagcctctg cttaccgatg agaaggtcag    1320

agagatattt gtttctcaac atggcttatc agcaggttca tgcaaatatt gaaaactctt    1380

ggaatgagga agaagtttgg agaattgaaa tgtatatctc ctttggcata atgagccttg    1440

gcttactttc cctcctggca gtcacttcta tcccttcagt gagcaatgct ttaaactgga    1500

gagaattcag ttttattcag tctacacttg gatatgtcgc tctgctcata agtactttcc    1560

atgtttttaat ttatggatgg aaacgagctt ttgaggaaga gtactacaga ttttatacac    1620

caccaaactt tgttcttgct cttgtttttgc cctcaattgt aattctggta gagacggagt    1680

ttcaccgtgt tagccaggat ggtctcgatc tcctgacctc gtgatccgcc cgccttggcc    1740

tccaaagtgc tgggattaca gatcttttgc agctttgcag atacccagac tgagctggaa    1800

ctggaatttg tcttcctatt gactctactt ctttaaaagc ggctgcccat tacattcctc    1860

agctgtcctt gcagttaggt gtacatgtga ctgagtgttg gccagtgaga tgaagtctcc    1920

tcaaaggaag gcagcatgtg tccttttttca tcccttcatc ttgctgctgg gattgtggat    1980

ataacaggag ccctggcagc tgtctccaga ggatcaaagc cacacccaaa gagtaaggca    2040

gattagagac cagaaagacc ttgactactt ccctacttcc actgctttttt cctgcatttta    2100

agccattgta aatctgggtg tgttacatga agtgaaaatt aattctttct gcccttcagt    2160

tctttatcct gataccattt aacactgtct gaattaacta gactgcaata attctttctt    2220

ttgaaagctt ttaaaggata atgtgcaatt cacattaaaa ttgattttcc attgtcaatt    2280

agttatactc attttcctgc cttgatcttt cattagatat tttgtatctg cttggaatat    2340

attatcttct ttttaactgt gtaattggta attactaaaa ctctgtaatc tccaaaatat    2400

tgctatcaaa ttacacacca tgttttctat cattctcata gatctgcctt ataaacattt    2460

aaataaaaag tactatttaa tgatttaact tctgtttttga aatgttgtat acacgtggat    2520

ttttttctca ttaaataata attctagtaa aaaaaaaaaa ag                        2562
```

<210> 93

<211> 2321

<212> DNA

<213> Homo sapiens

<400> 93
```
agcgttcctc gggccctcgg cgccacaagc tgtccgggca cgcagcccct agcggcgcgt     60

cgctgccaag ccggcctccg cgcgcctccc tccttccttc tcccctggct gttcgcgatc    120

cagcttgggt aggcggggaa gcagctggag tgcgaccgcc acggcagcca ccctgcaacc    180

gccagtcgga ggtgcagtcc gtaggccctg gccccgggt gggcccttgg ggagtcggcg    240

ccgctcccga ggagctgcaa ggctcgcccc tgcccggcgt ggagggcgcg ggggcgcgg    300

aggatattct tggtgatctt ggaagtgtcc gtatcatgga atcaatctct atgatgggaa    360
```

B0213WO seq list.ST25.txt

```
gccctaagag cccttagtgaa acttgtttac ctaatggcat aaatggtatc aaagatgcaa     420

ggaaggtcac tgtaggtgtg attggaagtg gagattttgc caaatccttg accattcgac     480

ttattagatg cggctatcat gtggtcatag gaagtagaaa tcctaagttt gcttctgaat     540

tttttcctca tgtggtagat gtcactcatc atgaagatgc tctcacaaaa acaaatataa     600

tatttgttgc tatacacaga gaacattata cctccctgtg ggacctgaga catctgcttg     660

tgggtaaaat cctgattgat gtgagcaata acatgaggat aaaccagtac ccagaatcca     720

atgctgaata tttggcttca ttattcccag attctttgat tgtcaaagga tttaatgttg     780

tctcagcttg ggcacttcag ttaggaccta aggatgccag ccggcaggtt tatatatgca     840

gcaacaatat tcaagcgcga caacaggtta ttgaacttgc ccgccagttg aatttcattc     900

ccattgactt gggatcctta tcatcagcca gagagattga aaatttaccc ctacgactct     960

ttactctctg gagagggcca gtggtggtag ctatgagctt ggccacattt ttttttccttt    1020

attcctttgt cagagatgtg attcatccat atgctagaaa ccaacagagt gacttttaca    1080

aaattcctat agagattgtg aataaaacct tacctatagt tgccattact ttgctctccc    1140

tagtatacct tgcaggtctt ctggcagctg cttatcaact ttattacggc accaagtata    1200

ggagatttcc accttggttg gaaacctggt tacagtgtag aaaacagctt ggattactaa    1260

gttttttctt cgctatggtc catgttgcct acagcctctg cttaccgatg agaaggtcag    1320

agagatattt gtttctcaac atggcttatc agcaggttca tgcaaatatt gaaaactctt    1380

ggaatgagga agaagtttgg agaattgaaa tgtatatctc ctttggcata atgagccttg    1440

gcttactttc cctcctggca gtcacttcta tcccttcagt gagcaatgct ttaaactgga    1500

gagaattcag ttttattcag atcttttgca gctttgcaga tacccagact gagctggaac    1560

tggaatttgt cttcctattg actctacttc tttaaaagcg gctgcccatt acattcctca    1620

gctgtccttg cagttaggtg tacatgtgac tgagtgttgg ccagtgagat gaagtctcct    1680

caaaggaagg cagcatgtgt cctttttcat cccttcatct tgctgctggg attgtggata    1740

taacaggagc cctggcagct gtctccagag gatcaaagcc acacccaaag agtaaggcag    1800

attagagacc agaaagacct tgactacttc cctacttcca ctgctttttc ctgcatttaa    1860

gccattgtaa atctgggtgt gttacatgaa gtgaaaatta attctttctg cccttcagtt    1920

ctttatcctg ataccattta acactgtctg aattaactag actgcaataa ttctttcttt    1980

tgaaagcttt taaaggataa tgtgcaattc acattaaaat tgattttcca ttgtcaatta    2040

gttatactca ttttcctgcc ttgatctttc attagatatt ttgtatctgc ttggaatata    2100

ttatcttctt tttaactgtg taattggtaa ttactaaaac tctgtaatct ccaaaatatt    2160

gctatcaaat tacacaccat gttttctatc attctcatag atctgcctta taaacattta    2220

aataaaaagt actatttaat gatttaactt ctgttttgaa atgttgtata cacgtggatt    2280

                                                                      2321
tttttctcat taaataataa ttctagtaaa aaaaaaaaaa g
```

<210> 94

B0213WO seq list.ST25.txt

<211> 3226

<212> DNA

<213> Homo sapiens

<400> 94
```
cgcgagctaa gcaggaggcg gaggcggagg cggagggcga ggggcgggga gcgccgcctg      60

gagcgcggca ggtcatattg aacattccag ataccatca ttactcgatg ctgttgataa      120

cagcaagatg gctttgaact cagggtcacc accagctatt ggaccttact atgaaaacca      180

tggataccaa ccggaaaacc cctatcccgc acagcccact gtggtcccca ctgtctacga      240

ggtgcatccg gctcagtact acccgtcccc cgtgccccag tacgccccga gggtcctgac      300

gcaggcttcc aaccccgtcg tctgcacgca gcccaaatcc ccatccggga cagtgtgcac      360

ctcaaagact aagaaagcac tgtgcatcac cttgaccctg gggaccttcc tcgtgggagc      420

tgcgctggcc gctggcctac tctggaagtt catgggcagc aagtgctcca actctgggat      480

agagtgcgac tcctcaggta cctgcatcaa cccctctaac tggtgtgatg gcgtgtcaca      540

ctgccccggc ggggaggacg agaatcggtg tgttcgcctc tacggaccaa acttcatcct      600

tcagatgtac tcatctcaga ggaagtcctg gcaccctgtg tgccaagacg actggaacga      660

gaactacggg cgggcggcct gcagggacat gggctataag aataattttt actctagcca      720

aggaatagtg gatgacagcg gatccaccag ctttatgaaa ctgaacacaa gtgccggcaa      780

tgtcgatatc tataaaaaac tgtaccacag tgatgcctgt tcttcaaaag cagtggtttc      840

tttacgctgt atagcctgcg gggtcaactt gaactcaagc cgccagagca ggatcgtggg      900

cggtgagagc gcgctcccgg gggcctggcc ctggcaggtc agcctgcacg tccagaacgt      960

ccacgtgtgc ggaggctcca tcatcacccc cgagtggatc gtgacagccg cccactgcgt     1020

ggaaaaacct cttaacaatc catggcattg gacggcattt gcggggattt tgagacaatc     1080

tttcatgttc tatggagccg gataccaagt agaaaaagtg atttctcatc caaattatga     1140

ctccaagacc aagaacaatg acattgcgct gatgaagctg cagaagcctc tgactttcaa     1200

cgacctagtg aaaccagtgt gtctgcccaa cccaggcatg atgctgcagc cagaacagct     1260

ctgctggatt ccgggtgggg ggccaccga ggagaaaggg aagacctcag aagtgctgaa      1320

cgctgccaag gtgcttctca ttgagacaca gagatgcaac agcagatatg tctatgacaa     1380

cctgatcaca ccagccatga tctgtgccgg cttcctgcag gggaacgtcg attcttgcca     1440

gggtgacagt ggagggcctc tggtcacttc gaagaacaat atctggtggc tgataggggga     1500

tacaagctgg ggttctggct gtgccaaagc ttacagacca ggagtgtacg ggaatgtgat     1560

ggtattcacg gactggattt atcgacaaat gagggcagac ggctaatcca catggtcttc     1620

gtccttgacg tcgttttaca agaaacaat ggggctggtt ttgcttcccc gtgcatgatt       1680

tactcttaga gatgattcag aggtcacttc atttttatta aacagtgaac ttgtctggct     1740
```

Page 49

B0213WO seq list.ST25.txt

```
ttggcactct ctgccattct gtgcaggctg cagtggctcc cctgcccagc ctgctctccc       1800

taacccttg tccgcaaggg gtgatggccg gctggttgtg ggcactggcg gtcaagtgtg       1860

gaggagaggg gtggaggctg ccccattgag atcttcctgc tgagtccttt ccaggggcca      1920

attttggatg agcatggagc tgtcacctct cagctgctgg atgacttgag atgaaaaagg      1980

agagacatgg aaagggagac agccaggtgg cacctgcagc ggctgccctc tggggccact      2040

tggtagtgtc cccagcctac ctctccacaa ggggatttttg ctgatgggtt cttagagcct     2100

tagcagccct ggatggtggc cagaaataaa gggaccagcc cttcatgggt ggtgacgtgg      2160

tagtcacttg taaggggaac agaaacattt ttgttcttat ggggtgagaa tatagacagt     2220

gcccttggtg cgagggaagc aattgaaaag gaacttgccc tgagcactcc tggtgcaggt      2280

ctccacctgc acattgggtg gggctcctgg gagggagact cagccttcct cctcatcctc      2340

cctgaccctg ctcctagcac cctggagagt gcacatgccc cttggtcctg gcagggcgcc      2400

aagtctggca ccatgttggc ctcttcaggc ctgctagtca ctggaaattg aggtccatgg      2460

gggaaatcaa ggatgctcag tttaaggtac actgtttcca tgttatgttt ctacacattg      2520

ctacctcagt gctcctggaa acttagcttt tgatgtctcc aagtagtcca ccttcattta     2580

actctttgaa actgtatcac ctttgccaag taagagtggt ggcctatttc agctgctttg      2640

acaaaatgac tggctcctga cttaacgttc tataaatgaa tgtgctgaag caaagtgccc      2700

atggtggcgg cgaagaagag aaagatgtgt tttgtttttgg actctctgtg gtcccttcca    2760

atgctgtggg tttccaacca ggggaagggt cccttttgca ttgccaagtg ccataaccat      2820

gagcactact ctaccatggt tctgcctcct ggccaagcag gctggtttgc aagaatgaaa      2880

tgaatgattc tacagctagg acttaacctt gaaatggaaa gtcttgcaat cccatttgca      2940

ggatccgtct gtgcacatgc ctctgtagag agcagcattc ccagggacct tggaaacagt      3000

tggcactgta aggtgcttgc tccccaagac acatcctaaa aggtgttgta atggtgaaaa      3060

cgtcttcctt ctttattgcc ccttcttatt tatgtgaaca actgtttgtc ttttttttgta    3120

tctttttttaa actgtaaagt tcaattgtga aaatgaatat catgcaaata aattatgcga     3180

ttttttttttc aaagcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa                     3226
```

<210>   95

<211>   3106

<212>   DNA

<213>   Homo sapiens

<400>   95
```
cgcgagctaa gcaggaggcg gaggcggagg cggagggcga ggggcgggga gcgccgcctg         60

gagcgcggca ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa        120

cagcaagatg gctttgaact cagggtcacc accagctatt ggaccttact atgaaaacca        180
```

B0213WO seq list.ST25.txt

```
tggataccaa ccggaaaacc cctatcccgc acagcccact gtggtcccca ctgtctacga     240

ggtgcatccg gctcagtact acccgtcccc cgtgccccag tacgccccga gggtcctgac     300

gcaggcttcc aaccccgtcg tctgcacgca gcccaaatcc ccatccggga cagtgtgcac     360

ctcaaagact aagaaagcac tgtgcatcac cttgaccctg gggaccttcc tcgtgggagc     420

tgcgctggcc gctggcctac tctggaagtt cattcgcctc tacggaccaa acttcatcct     480

tcagatgtac tcatctcaga ggaagtcctg gcaccctgtg tgccaagacg actggaacga     540

gaactacggg cgggcggcct gcagggacat gggctataag aataattttt actctagcca     600

aggaatagtg gatgacagcg gatccaccag ctttatgaaa ctgaacacaa gtgccggcaa     660

tgtcgatatc tataaaaaac tgtaccacag tgatgcctgt tcttcaaaag cagtggtttc     720

tttacgctgt atagcctgcg gggtcaactt gaactcaagc cgccagagca ggatcgtggg     780

cggtgagagc gcgctcccgg gggcctggcc ctggcaggtc agcctgcacg tccagaacgt     840

ccacgtgtgc ggaggctcca tcatcacccc cgagtggatc gtgacagccg cccactgcgt     900

ggaaaaacct cttaacaatc catggcattg gacggcattt gcggggattt tgagacaatc     960

tttcatgttc tatggagccg gataccaagt agaaaaagtg atttctcatc caaattatga    1020

ctccaagacc aagaacaatg acattgcgct gatgaagctg cagaagcctc tgactttcaa    1080

cgacctagtg aaaccagtgt gtctgcccaa cccaggcatg atgctgcagc cagaacagct    1140

ctgctggatt ccgggtgggg gggccaccga ggagaaaggg aagacctcag aagtgctgaa    1200

cgctgccaag gtgcttctca ttgagacaca gagatgcaac agcagatatg tctatgacaa    1260

cctgatcaca ccagccatga tctgtgccgg cttcctgcag gggaacgtcg attcttgcca    1320

gggtgacagt ggagggcctc tggtcacttc gaagaacaat atctggtggc tgatagggga    1380

tacaagctgg ggttctggct gtgccaaagc ttacagacca ggagtgtacg ggaatgtgat    1440

ggtattcacg gactggattt atcgacaaat gagggcagac ggctaatcca catggtcttc    1500

gtccttgacg tcgttttaca agaaaacaat ggggctggtt ttgcttcccc gtgcatgatt    1560

tactcttaga gatgattcag aggtcacttc attttttatta aacagtgaac ttgtctggct    1620

ttggcactct ctgccattct gtgcaggctg cagtggctcc cctgcccagc ctgctctccc    1680

taaccccttg tccgcaaggg gtgatggccg gctggttgtg ggcactggcg gtcaagtgtg    1740

gaggagaggg gtggaggctg ccccattgag atcttcctgc tgagtccttt ccaggggcca    1800

attttggatg agcatggagc tgtcacctct cagctgctgg atgacttgag atgaaaaagg    1860

agagacatgg aaaggagac agccaggtgg cacctgcagc ggctgccctc tggggccact    1920

tggtagtgtc cccagcctac ctctccacaa ggggattttg ctgatgggtt cttagagcct    1980

tagcagccct ggatggtggc cagaaataaa gggaccagcc cttcatgggt ggtgacgtgg    2040

tagtcacttg taaggggaac agaaacattt ttgttcttat ggggtgagaa tatagacagt    2100

gcccttggtg cgagggaagc aattgaaaag gaacttgccc tgagcactcc tggtgcaggt    2160

ctccacctgc acattgggtg gggctcctgg gagggagact cagccttcct cctcatcctc    2220
```

Page 51

B0213WO seq list.ST25.txt
```
cctgaccctg ctcctagcac cctggagagt gcacatgccc cttggtcctg gcagggcgcc   2280

aagtctggca ccatgttggc ctcttcaggc ctgctagtca ctggaaattg aggtccatgg   2340

gggaaatcaa ggatgctcag tttaaggtac actgtttcca tgttatgttt ctacacattg   2400

ctacctcagt gctcctggaa acttagcttt tgatgtctcc aagtagtcca ccttcattta   2460

actctttgaa actgtatcac ctttgccaag taagagtggt ggcctatttc agctgctttg   2520

acaaaatgac tggctcctga cttaacgttc tataaatgaa tgtgctgaag caaagtgccc   2580

atggtggcgg cgaagaagag aaagatgtgt tttgtttttgg actctctgtg gtcccttcca   2640

atgctgtggg tttccaacca ggggaagggt cccttttgca ttgccaagtg ccataaccat   2700

gagcactact ctaccatggt tctgcctcct ggccaagcag gctggtttgc aagaatgaaa   2760

tgaatgattc tacagctagg acttaacctt gaaatggaaa gtcttgcaat cccatttgca  ·2820

ggatccgtct gtgcacatgc ctctgtagag agcagcattc ccagggacct tggaaacagt   2880

tggcactgta aggtgcttgc tccccaagac acatcctaaa aggtgttgta atggtgaaaa   2940

cgtcttcctt ctttattgcc ccttcttatt tatgtgaaca actgtttgtc ttttttttgta   3000

tcttttttaa actgtaaagt tcaattgtga aaatgaatat catgcaaata aattatgcga   3060

tttttttttc aaagcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa                   3106
```

<210> 96

<211> 3003

<212> DNA

<213> Homo sapiens

<400> 96
```
cgcgagctaa gcaggaggcg gaggcggagg cggagggcga ggggcgggga gcgccgcctg     60

gagcgcggca ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa    120

cagcaagatg gctttgaact caagactaag aaagcactgt gcatcacctt gaccctgggg    180

accttcctcg tgggagctgc gctggccgct ggcctactct ggaagttcat gggcagcaag    240

tgctccaact ctgggataga gtgcgactcc tcaggtacct gcatcaaccc ctctaactgg    300

tgtgatggcg tgtcacactg ccccggcggg gaggacgaga atcggtgtgt tcgcctctac    360

ggaccaaact tcatccttca gatgtactca tctcagagga agtcctggca ccctgtgtgc    420

caagacgact ggaacgagaa ctacgggcgg gcggcctgca gggacatggg ctataagaat    480

aatttttact ctagccaagg aatagtggat gacagcggat ccaccagctt tatgaaactg    540

aacacaagtg ccggcaatgt cgatatctat aaaaaactgt accacagtga tgcctgttct    600

tcaaaagcag tggtttcttt acgctgtata gcctgcgggg tcaacttgaa ctcaagccgc    660

cagagcagga tcgtgggcgg tgagagcgcg ctcccggggg cctggccctg gcaggtcagc    720

ctgcacgtcc agaacgtcca cgtgtgcgga ggctccatca tcacccccga gtggatcgtg    780
```

B0213WO seq list.ST25.txt

```
acagccgccc actgcgtgga aaaacctctt aacaatccat ggcattggac ggcatttgcg    840

gggattttga dacaatcttt catgttctat ggagccggat accaagtaga aaaagtgatt    900

tctcatccaa attatgactc caagaccaag aacaatgaca ttgcgctgat gaagctgcag    960

aagcctctga ctttcaacga cctagtgaaa ccagtgtgtc tgcccaaccc aggcatgatg   1020

ctgcagccag aacagctctg ctggatttcc gggtgggggg ccaccgagga gaaagggaag   1080

acctcagaag tgctgaacgc tgccaaggtg cttctcattg agacacagag atgcaacagc   1140

agatatgtct atgacaacct gatcacacca gccatgatct gtgccggctt cctgcagggg   1200

aacgtcgatt cttgccaggg tgacagtgga gggcctctgg tcacttcgaa gaacaatatc   1260

tggtggctga tagggggatac aagctggggt tctggctgtg ccaaagctta cagaccagga   1320

gtgtacggga atgtgatggt attcacggac tggatttatc gacaaatgag ggcagacggc   1380

taatccacat ggtcttcgtc cttgacgtcg ttttacaaga aaacaatggg gctggttttg   1440

cttccccgtg catgatttac tcttagagat gattcagagg tcacttcatt tttattaaac   1500

agtgaacttg tctggctttg gcactctctg ccattctgtg caggctgcag tggctcccct   1560

gcccagcctg ctctccctaa cccccttgtcc gcaaggggtg atggccggct ggttgtgggc   1620

actggcggtc aagtgtggag gagagggggtg gaggctgccc cattgagatc ttcctgctga   1680

gtcctttcca ggggccaatt ttggatgagc atggagctgt cacctctcag ctgctggatg   1740

acttgagatg aaaaaggaga gacatggaaa gggagacagc caggtggcac ctgcagcggc   1800

tgccctctgg ggccacttgg tagtgtcccc agcctacctc tccacaaggg gatttttgctg   1860

atgggttctt agagccttag cagccctgga tggtggccag aaataaaggg accagcccttt   1920

catgggtggt gacgtggtag tcacttgtaa ggggaacaga aacattttttg ttcttatggg   1980

gtgagaatat agacagtgcc cttggtgcga gggaagcaat tgaaaaggaa cttgccctga   2040

gcactcctgg tgcaggtctc cacctgcaca ttgggtgggg ctcctgggag ggagactcag   2100

ccttcctcct catcctccct gaccctgctc ctagcaccct ggagagtgca catgccccttt   2160

ggtcctggca gggcgccaag tctggcacca tgttggcctc ttcaggcctg ctagtcactg   2220

gaaattgagg tccatggggg aaatcaagga tgctcagttt aaggtacact gtttccatgt   2280

tatgtttcta cacattgcta cctcagtgct cctggaaact tagcttttga tgtctccaag   2340

tagtccacct tcatttaact ctttgaaact gtatcacctt tgccaagtaa gagtggtggc   2400

ctatttcagc tgctttgaca aaatgactgg ctcctgactt aacgttctat aaatgaatgt   2460

gctgaagcaa agtgcccatg gtggcggcga agaagagaaa gatgtgtttt gttttggact   2520

ctctgtggtc ccttccaatg ctgtgggttt ccaaccaggg gaagggtccc ttttgcattg   2580

ccaagtgcca taaccatgag cactactcta ccatggttct gcctcctggc caagcaggct   2640

ggtttgcaag aatgaaatga atgattctac agctaggact taaccttgaa atggaaagtc   2700

ttgcaatccc atttgcagga tccgtctgtg cacatgcctc tgtagagagc agcattccca   2760

gggaccttgg aaacagttgg cactgtaagg tgcttgctcc ccaagacaca tcctaaaagg   2820
```

Page 53

B0213WO seq list.ST25.txt

```
tgttgtaatg gtgaaaacgt cttccttctt tattgcccct tcttatttat gtgaacaact   2880

gtttgtcttt ttttgtatct ttttttaaact gtaaagttca attgtgaaaa tgaatatcat   2940

gcaaataaat tatgcgattt tttttttcaaa gcaaaaaaaa aaaaaaaaa aaaaaaaaaa   3000

aaa          .                                                        3003
```

<210> 97

<211> 3102

<212> DNA

<213> Homo sapiens

<400> 97
```
cgcgagctaa gcaggaggcg gaggcggagg cggagggcga ggggcgggga gcgccgcctg    60

gagcgcggca ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa   120

cagcaagatg gctttgaact cagggtcacc accagctatt ggaccttact atgaaaacca   180

tggataccaa ccggaaaacc cctatcccgc acagcccact gtggtcccca ctgtctacga   240

gagactaaga aagcactgtg catcaccttg accctgggga ccttcctcgt gggagctgcg   300

ctggccgctg gcctactctg gaagttcatg ggcagcaagt gctccaactc tgggatagag   360

tgcgactcct caggtacctg catcaacccc tctaactggt gtgatggcgt gtcacactgc   420

cccggcgggg aggacgagaa tcggtgtgtt cgcctctacg accaaacttt catccttcag   480

atgtactcat ctcagaggaa gtcctggcac cctgtgtgcc aagacgactg gaacgagaac   540

tacgggcggg cggcctgcag ggacatgggc tataagaata atttttactc tagccaagga   600

atagtggatg acagcggatc caccagcttt atgaaactga acacaagtgc cggcaatgtc   660

gatatctata aaaaactgta ccacagtgat gcctgttctt caaaagcagt ggtttctttta   720

cgctgtatag cctgcggggt caacttgaac tcaagccgcc agagcaggat cgtgggcggt   780

gagagcgcgc tcccgggggc ctggccctgg caggtcagcc tgcacgtcca gaacgtccac   840

gtgtgcggag gctccatcat cacccccgag tggatcgtga cagccgccca ctgcgtggaa   900

aaacctctta caatccatg gcattggacg gcatttgcgg ggattttgag acaatctttc   960

atgttctatg gagccggata ccaagtagaa aaagtgattt ctcatccaaa ttatgactcc   1020

aagaccaaga acaatgacat tgcgctgatg aagctgcaga agcctctgac tttcaacgac   1080

ctagtgaaac cagtgtgtct gcccaaccca ggcatgatgc tgcagccaga acagctctgc   1140

tggatttccg ggtggggggc caccgaggag aaagggaaga cctcagaagt gctgaacgct   1200

gccaaggtgc ttctcattga dacacagaga tgcaacagca gatatgtcta tgacaacctg   1260

atcacaccag ccatgatctg tgccggcttc ctgcagggga acgtcgattc ttgccagggt   1320

gacagtggag ggcctctggt cacttcgaag aacaatatct ggtggctgat aggggataca   1380

agctgggggtt ctggctgtgc caaagcttac agaccaggag tgtacgggaa tgtgatggta   1440
```

Page 54

B0213WO seq list.ST25.txt
```
ttcacggact ggatttatcg acaaatgagg gcagacggct aatccacatg gtcttcgtcc   1500

ttgacgtcgt tttacaagaa aacaatgggg ctggttttgc ttccccgtgc atgatttact   1560

cttagagatg attcagaggt cacttcattt ttattaaaca gtgaacttgt ctggctttgg   1620

cactctctgc cattctgtgc aggctgcagt ggctcccctg cccagcctgc tctccctaac   1680

cccttgtccg caaggggtga tggccggctg gttgtgggca ctggcggtca agtgtggagg   1740

agaggggtgg aggctgcccc attgagatct tcctgctgag tcctttccag gggccaattt   1800

tggatgagca tggagctgtc acctctcagc tgctggatga cttgagatga aaaaggagag   1860

acatggaaag ggagacagcc aggtggcacc tgcagcggct gccctctggg gccacttggt   1920

agtgtcccca gcctacctct ccacaagggg attttgctga tgggttctta gagccttagc   1980

agccctggat ggtggccaga aataaaggga ccagcccttc atgggtggtg acgtggtagt   2040

cacttgtaag gggaacagaa acatttttgt tcttatgggg tgagaatata gacagtgccc   2100

ttggtgcgag ggaagcaatt gaaaaggaac ttgccctgag cactcctggt gcaggtctcc   2160

acctgcacat tgggtggggc tcctgggagg gagactcagc cttcctcctc atcctccctg   2220

accctgctcc tagcaccctg gagagtgcac atgccccttg gtcctggcag ggcgccaagt   2280

ctggcaccat gttggcctct tcaggcctgc tagtcactgg aaattgaggt ccatggggga   2340

aatcaaggat gctcagttta aggtacactg tttccatgtt atgtttctac acattgctac   2400

ctcagtgctc ctggaaactt agcttttgat gtctccaagt agtccacctt catttaactc   2460

tttgaaactg tatcaccttt gccaagtaag agtggtggcc tatttcagct gctttgacaa   2520

aatgactggc tcctgactta acgttctata aatgaatgtg ctgaagcaaa gtgcccatgg   2580

tggcggcgaa gaagagaaag atgtgttttg ttttggactc tctgtggtcc cttccaatgc   2640

tgtgggtttc caaccagggg aagggtccct tttgcattgc caagtgccat aaccatgagc   2700

actactctac catggttctg cctcctggcc aagcaggctg gtttgcaaga atgaaatgaa   2760

tgattctaca gctaggactt aaccttgaaa tggaaagtct tgcaatccca tttgcaggat   2820

ccgtctgtgc acatgcctct gtagagagca gcattcccag ggaccttgga aacagttggc   2880

actgtaaggt gcttgctccc caagacacat cctaaaaggt gttgtaatgg tgaaaacgtc   2940

ttccttcttt attgcccctt cttatttatg tgaacaactg tttgtctttt tttgtatctt   3000

ttttaaactg taaagttcaa ttgtgaaaat gaatatcatg caaataaatt atgcgatttt   3060

tttttcaaag caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa                       3102
```

<210> 98

<211> 2916

<212> DNA

<213> Homo sapiens

<400> 98

BO213WO seq list.ST25.txt

```
cgcgagctaa gcaggaggcg gaggcggagg cggagggcga ggggcgggga gcgccgcctg      60

gagcgcggca ggtcatattg aacattccag atacctatca ttactcgatg ctgttgataa     120

cagcaagatg gctttgaact catgggcagc aagtgctcca actctgggat agagtgcgac     180

tcctcaggta cctgcatcaa cccctctaac tggtgtgatg gcgtgtcaca ctgccccggc     240

ggggaggacg agaatcggtg tgttcgcctc tacggaccaa acttcatcct tcagatgtac     300

tcatctcaga ggaagtcctg gcaccctgtg tgccaagacg actggaacga gaactacggg     360

cgggcggcct gcagggacat gggctataag aataattttt actctagcca aggaatagtg     420

gatgacagcg gatccaccag ctttatgaaa ctgaacacaa gtgccggcaa tgtcgatatc     480

tataaaaaac tgtaccacag tgatgcctgt tcttcaaaag cagtggtttc tttacgctgt     540

atagcctgcg gggtcaactt gaactcaagc cgccagagca ggatcgtggg cggtgagagc     600

gcgctcccgg gggcctggcc ctggcaggtc agcctgcacg tccagaacgt ccacgtgtgc     660

ggaggctcca tcatcacccc cgagtggatc gtgacagccg cccactgcgt ggaaaaacct     720

cttaacaatc catggcattg gacggcattt gcggggattt tgagacaatc tttcatgttc     780

tatggagccg gataccaagt agaaaaagtg atttctcatc caaattatga ctccaagacc     840

aagaacaatg acattgcgct gatgaagctg cagaagcctc tgactttcaa cgacctagtg     900

aaaccagtgt gtctgcccaa cccaggcatg atgctgcagc cagaacagct ctgctggatt     960

tccgggtggg gggccaccga ggagaaaggg aagacctcag aagtgctgaa cgctgccaag    1020

gtgcttctca ttgagacaca gagatgcaac agcagatatg tctatgacaa cctgatcaca    1080

ccagccatga tctgtgccgg cttcctgcag gggaacgtcg attcttgcca gggtgacagt    1140

ggagggcctc tggtcacttc gaagaacaat atctggtggc tgatagggga tacaagctgg    1200

ggttctggct gtgccaaagc ttacagacca ggagtgtacg ggaatgtgat ggtattcacg    1260

gactggattt atcgacaaat gagggcagac ggctaatcca catggtcttc gtccttgacg    1320

tcgtttttaca agaaacaat ggggctggtt ttgcttcccc gtgcatgatt tactcttaga    1380

gatgattcag aggtcacttc attttttatta aacagtgaac ttgtctggct ttggcactct    1440

ctgccattct gtgcaggctg cagtggctcc cctgcccagc ctgctctccc taaccccttg    1500

tccgcaaggg gtgatggccg gctggttgtg ggcactggcg gtcaagtgtg gaggagaggg    1560

gtggaggctg ccccattgag atcttcctgc tgagtccttt ccaggggcca attttggatg    1620

agcatggagc tgtcacctct cagctgctgg atgacttgag atgaaaaagg agagacatgg    1680

aaagggagac agccaggtgg cacctgcagc ggctgccctc tggggccact tggtagtgtc    1740

cccagcctac ctctccacaa ggggattttg ctgatgggtt cttagagcct tagcagccct    1800

ggatggtggc cagaaataaa gggaccagcc cttcatgggt ggtgacgtgg tagtcacttg    1860

taagggaac agaaacattt ttgttcttat ggggtgagaa tatagacagt gcccttggtg    1920

cgagggaagc aattgaaaag gaacttgccc tgagcactcc tggtgcaggt ctccacctgc    1980

acattgggtg gggctcctgg gagggagact cagccttcct cctcatcctc cctgaccctg    2040
```

B0213WO seq list.ST25.txt
```
ctcctagcac cctggagagt gcacatgccc cttggtcctg gcagggcgcc aagtctggca    2100

ccatgttggc ctcttcaggc ctgctagtca ctggaaattg aggtccatgg gggaaatcaa    2160

ggatgctcag tttaaggtac actgtttcca tgttatgttt ctacacattg ctacctcagt    2220

gctcctggaa acttagcttt tgatgtctcc aagtagtcca ccttcattta actctttgaa    2280

actgtatcac ctttgccaag taagagtggt ggcctatttc agctgctttg acaaaatgac    2340

tggctcctga cttaacgttc tataaatgaa tgtgctgaag caaagtgccc atggtggcgg    2400

cgaagaagag aaagatgtgt tttgttttgg actctctgtg gtcccttcca atgctgtggg    2460

tttccaacca ggggaagggt cccttttgca ttgccaagtg ccataaccat gagcactact    2520

ctaccatggt tctgcctcct ggccaagcag gctggtttgc aagaatgaaa tgaatgattc    2580

tacagctagg acttaacctt gaaatggaaa gtcttgcaat cccatttgca ggatccgtct    2640

gtgcacatgc ctctgtagag agcagcattc ccagggacct tggaaacagt tggcactgta    2700

aggtgcttgc tccccaagac acatcctaaa aggtgttgta atggtgaaaa cgtcttcctt    2760

ctttattgcc ccttcttatt tatgtgaaca actgtttgtc ttttttttgta tctttttttaa   2820

actgtaaagt tcaattgtga aaatgaatat catgcaaata aattatgcga ttttttttttc    2880

aaagcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa                                2916
```

```
<210>   99
<211>   2653
<212>   DNA
<213>   Homo sapiens


<400>   99
ctcaaaaggg gccggatttc cttctcctgg aggcagatgt tgcctctctc tctcgctcgg    60

attggttcag tgcactctag aaacactgct gtggtggaga aactggaccc caggtctgga   120

gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga gagactttac   180

cccgccgtgg tggttggagg gcgcgcagta gagcagcagc acaggcgcgg gtcccgggag   240

gccggctctg ctcgcgccga gatgtggaat ctccttcacg aaaccgactc ggctgtggcc   300

accgcgcgcc gcccgcgctg gctgtgcgct ggggcgctgg tgctggcggg tggcttcttt   360

ctcctcggct tcctcttcgg gtggtttata aaatcctcca atgaagctac taacattact   420

ccaaagcata atatgaaagc attttttggat gaattgaaag ctgagaacat caagaagttc   480

ttatataatt ttacacagat accacatttta gcaggaacag aacaaaactt tcagcttgca   540

aagcaaattc aatcccagtg gaaagaattt ggcctggatt ctgttgagct agcacattat   600

gatgtcctgt tgtcctaccc aaataagact catcccaact acatctcaat aattaatgaa   660

gatggaaatg agattttcaa cacatcatta tttgaaccac ctccccagg atatgaaaat   720

gtttcggata ttgtaccacc tttcagtgct ttctctcctc aaggaatgcc agagggcgat   780
```

B0213WO seq list.ST25.txt

```
ctagtgtatg ttaactatgc acgaactgaa gacttcttta aattggaacg ggacatgaaa    840
atcaattgct ctgggaaaat tgtaattgcc agatatggga aagttttcag aggaaataag    900
gttaaaaatg cccagctggc aggggccaaa ggagtcattc tctactccga ccctgctgac    960
tactttgctc ctggggtgaa gtcctatcca gatggttgga atcttcctgg aggtggtgtc   1020
cagcgtggaa atatcctaaa tctgaatggt gcaggagacc ctctcacacc aggttaccca   1080
gcaaatgaat atgcttatag gcgtggaatt gcagaggctg ttggtcttcc aagtattcct   1140
gttcatccaa ttggatacta tgatgcacag aagctcctag aaaaaatggg tggctcagca   1200
ccaccagata gcagctggag aggaagtctc aaagtgccct acaatgttgg acctggcttt   1260
actggaaact tttctacaca aaaagtcaag atgcacatcc actctaccaa tgaagtgaca   1320
agaatttaca atgtgatagg tactctcaga ggagcagtgg aaccagacag atatgtcatt   1380
ctgggaggtc accgggactc atgggtgttt ggtggtattg accctcagag tggagcagct   1440
gttgttcatg aaattgtgag gagctttgga acactgaaaa aggaagggtg gagacctaga   1500
agaacaattt tgtttgcaag ctgggatgca gaagaatttg gtcttcttgg ttctactgag   1560
tgggcagagg agaattcaag actccttcaa gagcgtggcg tggcttatat taatgctgac   1620
tcatctatag aaggaaacta cactctgaga gttgattgta caccgctgat gtacagcttg   1680
gtacacaacc taacaaaaga gctgaaaagc cctgatgaag ctttgaagg caaatctctt   1740
tatgaaagtt ggactaaaaa aagtccttcc ccagagttca gtggcatgcc caggataagc   1800
aaattgggat ctggaaatga ttttgaggtg ttcttccaac gacttggaat tgcttcaggc   1860
agagcacggt atactaaaaa ttgggaaaca aacaaattca gcggctatcc actgtatcac   1920
agtgtctatg aaacatatga gttggtggaa aagttttatg atccaatgtt taaatatcac   1980
ctcactgtgg cccaggttcg aggagggatg gtgtttgagc tagccaattc catagtgctc   2040
ccttttgatt gtcgagatta tgctgtagtt ttaagaaagt atgctgacaa aatctacagt   2100
atttctatga aacatccaca ggaaatgaag acatacagtg tatcatttga ttcacttttt   2160
tctgcagtaa agaattttac agaaattgct tccaagttca gtgagagact ccaggacttt   2220
gacaaaagca acccaatagt attaagaatg atgaatgatc aactcatgtt tctggaaaga   2280
gcatttattg atccattagg gttaccagac aggcctttttt ataggcatgt catctatgct   2340
ccaagcagcc acaacaagta tgcaggggag tcattcccag gaatttatga tgctctgttt   2400
gatattgaaa gcaaagtgga cccttccaag gcctggggag aagtgaagag acagatttat   2460
gttgcagcct tcacagtgca ggcagctgca gagactttga gtgaagtagc ctaagaggat   2520
tctttagaga atccgtattg aatttgtgtg gtatgtcact cagaaagaat cgtaatgggt   2580
atattgataa attttaaaat tggtatattt gaaataaagt tgaatattat atataaaaaa   2640
aaaaaaaaaa aaa                                                      2653
```

<210>   100

<211>   2466

B0213WO seq list.ST25.txt

<212>   DNA

<213>   Homo sapiens

<400>   100

ctcaaaaggg	gccggatttc	cttctcctgg	aggcagatgt	tgcctctctc	tctcgctcgg	60
attggttcag	tgcactctag	aaacactgct	gtggtggaga	aactggaccc	caggtctgga	120
gcgaattcca	gcctgcaggg	ctgataagcg	aggcattagt	gagattgaga	gagactttac	180
cccgccgtgg	tggttggagg	gcgcgcagta	gagcagcagc	acaggcgcgg	gtcccgggag	240
gccggctctg	ctcgcgccga	gatgtggaat	ctccttcacg	aaaccgactc	ggctgtggcc	300
accgcgcgcc	gcccgcgctg	gctgtgcgct	ggggcgctgg	tgctggcggg	tggcttcttt	360
ctcctcggct	tcctcttcgg	gtggtttata	aaatcctcca	atgaagctac	taacattact	420
ccaaagcata	atatgaaagc	attttttggat	gaattgaaag	ctgagaacat	caagaagttc	480
ttatataatt	ttacacagat	accacattta	gcaggaacag	aacaaaactt	tcagcttgca	540
aagcaaattc	aatcccagtg	gaaagaattt	ggcctggatt	ctgttgagct	agcacattat	600
gatgtcctgt	tgtcctaccc	aaataagact	catcccaact	acatctcaat	aattaatgaa	660
gatggaaatg	agattttcaa	cacatcatta	tttgaaccac	ctcctccagg	atatgaaaat	720
gtttcggata	ttgtaccacc	tttcagtgct	ttctctcctc	aaggaatgcc	agagggcgat	780
ctagtgtatg	ttaactatgc	acgaactgaa	gacttcttta	aattggaacg	ggacatgaaa	840
atcaattgct	ctgggaaaat	tgtaattgcc	agatatggga	aagttttcag	aggaaataag	900
aatatgctta	taggcgtgga	attgcagagg	ctgttggtct	tccaagtatt.cctgttcatc	960
caattggata	ctatgatgca	cagaagctcc	tagaaaaaat	gggtggctca	gcaccaccag	1020
atagcagctg	gagaggaagt	ctcaaagtgc	cctacaatgt	tggacctggc	tttactggaa	1080
acttttctac	acaaaaagtc	aagatgcaca	tccactctac	caatgaagtg	acaagaattt	1140
acaatgtgat	aggtactctc	agaggagcag	tggaaccaga	cagatatgtc	attctgggag	1200
gtcaccggga	ctcatgggtg	tttggtggta	ttgaccctca	gagtggagca	gctgttgttc	1260
atgaaattgt	gaggagcttt	ggaacactga	aaaaggaagg	gtggagacct	agaagaacaa	1320
ttttgtttgc	aagctgggat	gcagaagaat	ttggtcttct	tggttctact	gagtgggcag	1380
aggagaattc	aagactcctt	caagagcgtg	gcgtggctta	tattaatgct	gactcatcta	1440
tagaaggaaa	ctacactctg	agagttgatt	gtacaccgct	gatgtacagc	ttggtacaca	1500
acctaacaaa	agagctgaaa	agccctgatg	aaggctttga	aggcaaatct	ctttatgaaa	1560
gttggactaa	aaaaagtcct	tccccagagt	tcagtggcat	gcccaggata	agcaaattgg	1620
gatctggaaa	tgattttgag	gtgttcttcc	aacgacttgg	aattgcttca	ggcagagcac	1680
ggtatactaa	aaattgggaa	acaaacaaat	tcagcggcta	tccactgtat	cacagtgtct	1740
atgaaacata	tgagttggtg	gaaaagtttt	atgatccaat	gtttaaatat	cacctcactg	1800

B0213WO seq list.ST25.txt

```
tggcccaggt tcgaggaggg atggtgtttg agctagccaa ttccatagtg ctcccttttg   1860

attgtcgaga ttatgctgta gttttaagaa agtatgctga caaaatctac agtatttcta   1920

tgaaacatcc acaggaaatg aagacataca gtgtatcatt tgattcactt ttttctgcag   1980

taaagaattt tacagaaatt gcttccaagt tcagtgagag actccaggac tttgacaaaa   2040

gcaacccaat agtattaaga atgatgaatg atcaactcat gtttctggaa agagcattta   2100

ttgatccatt agggttacca gacaggcctt tttataggca tgtcatctat gctccaagca   2160

gccacaacaa gtatgcaggg gagtcattcc caggaattta tgatgctctg tttgatattg   2220

aaagcaaagt ggacccttcc aaggcctggg gagaagtgaa gagacagatt tatgttgcag   2280

ccttcacagt gcaggcagct gcagagactt tgagtgaagt agcctaagag gattctttag   2340

agaatccgta ttgaatttgt gtggtatgtc actcagaaag aatcgtaatg ggtatattga   2400

taaattttaa aattggtata tttgaaataa agttgaatat tatatataaa aaaaaaaaa   2460

aaaaaa                                                              2466
```

\<210\>   101

\<211\>   2560

\<212\>   DNA

\<213\>   Homo sapiens

\<400\>   101
```
ctcaaaaggg gccggatttc cttctcctgg aggcagatgt tgcctctctc tctcgctcgg     60

attggttcag tgcactctag aaacactgct gtggtggaga aactggaccc caggtctgga    120

gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga gagactttac    180

cccgccgtgg tggttggagg gcgcgcagta gagcagcagc acaggcgcgg gtcccgggag    240

gccggctctg ctcgcgccga gatgtggaat ctccttcacg aaaccgactc ggctgtggcc    300

accgcgcgcc gcccgcgctg gctgtgcgct ggggcgctgg tgctggcggg tggcttcttt    360

ctcctcggct tcctcttcgg gtggtttata aaatcctcca atgaagctac taacattact    420

ccaaagcata atatgaaagc atttttggat gaattgaaag ctgagaacat caagaagttc    480

ttatataatt ttacacagat accacattta gcaggaacag aacaaaactt tcagcttgca    540

aagcaaattc aatcccagtg gaaagaattt ggcctggatt ctgttgagct agcacattat    600

gatgtcctgt tgtcctaccc aaataagact catcccaact acatctcaat aattaatgaa    660

gatggaaatg agattttcaa cacatcatta tttgaaccac ctcctccagg atatgaaaat    720

gtttcggata ttgtaccacc tttcagtgct ttctctcctc aaggaatgcc agagggcgat    780

ctagtgtatg ttaactatgc acgaactgaa gacttcttta aattggaacg ggacatgaaa    840

atcaattgct ctgggaaaat tgtaattgcc agatatggga agttttcag aggaaataag    900

gttaaaaatg cccagctggc aggggccaaa ggagtcattc tctactccga ccctgctgac    960
```

B0213WO seq list.ST25.txt

```
tactttgctc ctggggtgaa gtcctatcca gatggttgga atcttcctgg aggtggtgtc    1020

cagcgtggaa atatcctaaa tctgaatggt gcaggagacc ctctcacacc aggttaccca    1080

gcaaatgaat atgcttatag gcgtggaatt gcagaggctg ttggtcttcc aagtattcct    1140

gttcatccaa ttggatacta tgatgcacag aagctcctag aaaaaatggg tggctcagca    1200

ccaccagata gcagctggag aggaagtctc aaagtgccct acaatgttgg acctggcttt    1260

actggaaact tttctacaca aaaagtcaag atgcacatcc actctaccaa tgaagtgaca    1320

agaatttaca atgtgatagg tactctcaga ggagcagtgg aaccagacag atatgtcatt    1380

ctgggaggtc accgggactc atgggtgttt ggtggtattg accctcagag tggagcagct    1440

gttgttcatg aaattgtgag gagctttgga acactgaaaa aggaagggtg gagacctaga    1500

agaacaattt tgtttgcaag ctgggatgca gaagaatttg gtcttcttgg ttctactgag    1560

tgggcagagg agaattcaag actccttcaa gagcgtggcg tggcttatat taatgctgac    1620

tcatctatag aaggaaacta cactctgaga gttgattgta caccgctgat gtacagcttg    1680

gtacacaacc taacaaaaga gctgaaaagc cctgatgaag gctttgaagg caaatctctt    1740

tatgaaagtt ggactaaaaa aagtccttcc ccagagttca gtggcatgcc caggataagc    1800

aaattgggat ctggaaatga ttttgaggtg ttcttccaac gacttggaat tgcttcaggc    1860

agagcacggt atactaaaaa ttgggaaaca aacaaattca gcggctatcc actgtatcac    1920

agtgtctatg aaacatatga gttggtggaa aagtttatg atccaatgtt taaatatcac    1980

ctcactgtgg cccaggttcg aggagggatg gtgtttgagc tagccaattc catagtgctc    2040

ccttttgatt gtcgagatta tgctgtagtt ttaagaaagt atgctgacaa aatctacagt    2100

atttctatga aacatccaca ggaaatgaag acatacagtg tatcatttga ttcactttt    2160

tctgcagtaa agaattttac agaaattgct tccaagttca gtgagagact ccaggacttt    2220

gacaaaagca agcatgtcat ctatgctcca agcagccaca caagtatgc aggggagtca    2280

ttcccaggaa tttatgatgc tctgtttgat attgaaagca agtggaccc ttccaaggcc    2340

tggggagaag tgaagagaca gatttatgtt gcagccttca cagtgcaggc agctgcagag    2400

actttgagtg aagtagccta agaggattct ttagagaatc cgtattgaat ttgtgtggta    2460

tgtcactcag aaagaatcgt aatgggtata ttgataaatt ttaaaattgg tatatttgaa    2520

ataaagttga atattatata taaaaaaaaa aaaaaaaaa                           2560
```

<210> 102

<211> 212

<212> DNA

<213> Homo sapiens

<400> 102
```
ggagtgcacc cgctgtccac atgccgcgat ctggtggcgg tcgtgcatcg tccagcaaac      60
```

Page 61

B0213WO seq list.ST25.txt

ggaagatgac cctgggaacg ttcaaaccgg gcgtccagca gcggctgact gtagagctcc   120

tatctgatag ctgcgtgttc agggtagatg gtgaagtgtt cgagacgatc cggccttccg   180

acatggcgga tggatatatc tgggtcccca cg   212

<210> 103

<211> 675

<212> DNA

<213> Homo sapiens

<400> 103

ctagactgac tgaatcaaaa tccctggggt tgtgtgcaca tgacggttcg agaaacgcca · 60

gcctaaggga ccctctgcag tctgtccagc ttgtcccttc aacctcatgc caaccaacac   120

actccagact caaagtgcct tctctcaacc cccgctattg aagtacctga ccccaagcca   180

gttacaagtt cattcctgtt tcattttctc tggagggctg ccatcaatga gattgttatt   240

tatgttggta tgtcctcacc aaagtgtctg ccaggcctat cacagtcctg gagctcaggg   300

gagacccaag caaaccaaca cacatttgcc aggcacccag gatggaccta agcaagctgt   360

ctgggcccac caggagttcc tggttgggcc aggaggacct gcctgttaca catgaactat   420

gattcaaaac gtagacatat agtcttcaat taataataac atttaaaaaa gacaaaaagt   480

aggtatacat tttgaatgag aatacaaatg agaaatgccc ccattcctcc aagtgcactt   540

tgttgaaaaa tgagaaggaa agggaggtgc ctggtggttt caggggaagg aatgtgtgga   600

acgcaggtct tccatgagca tggggctggc agtaggaaca aagactcgct tgcactgggc   660

ttgcgcctgc gctgg   675

<210> 104

<211> 476

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (464)..(464)

<223> n = a t g or c

<400> 104

ctgctccctc acactctcca ttggctcact cagccccttt cctgtgcttc tttttatgtg   60

tttgtcacac tgtccttggt tttgtggagg ccagttcacc atcctaactt ataaattctc   120

B0213WO seq list.ST25.txt

aagagcaagg	accagggctt	gttgtgtgtt	gcattttgga	ttaccccaag	aagcagactg	180
tgggatgaca	tttaggtaca	ggccatttaa	caaaggagct	cctttgagga	acacacttgt	240
gaaagtggag	gtgggagaag	aagcataatt	agaaagaaga	agaagtcaga	tgtgatggag	300
acccagggac	agcttccata	cctgaggaat	tctggagcta	gctagtggtc	gctggcagtt	360
gtcccaaatt	gaaaagagat	ggccaggcat	tgataaacct	gatatttaga	gacagatagt	420
ggctctgggc	agaaagatca	tctgatggtg	ttctcagcac	cggngaacaa	catttc	476

<210> 105

<211> 265

<212> DNA

<213> Homo sapiens

<400> 105

gaccaggaaa	tcgaagggaa	gcgtccgcgc	acagaacgtg	gcccgatcct	tgccgtgatc	60
gatacccag	ggtcgatgca	cggactacca	gagcaggtgg	ctaaagctat	cgtgctggaa	120
gcgcttcgaa	cagcgcatga	agaaaagcgc	cgatgtttcc	tttacgccta	cagtggacca	180
gggcaagtcc	ttgagcacga	gcttgatctt	tcaccggacg	gcatggggcg	gcttctagaa	240
tttctcggct	tctcttttgg	tggcg				265

<210> 106

<211> 726

<212> DNA

<213> Homo sapiens

<400> 106

cgtaattgtg	gaaggagtca	cgggaagtgg	agacaggaaa	ggctgtgagg	agccaaggga	60
aagaggcgaa	gagaaaggcg	gacaggagag	aggacgagaa	tgaaagagaa	atcaacaggg	120
ggaaagagaa	caacaggcag	agggaaaagg	aagtaagttt	gctgaattct	atattaagaa	180
actggtaaat	gtcctgtagg	tcaataaaac	cataaacttt	gaggttatct	ttgctattag	240
tcagaaaaaa	atgagaaccc	tttgtcagat	ttctgcaagt	taaccgctaa	ttttacaggg	300
ttgtaaaaca	cctgggtctc	aatcaattgc	tagtgaaaca	caattaccct	tcccatgagt	360
cagatgacct	tcaggtggac	atgatattca	caggttgtga	aaccatgttt	tgcccttttt	420
caaatgttag	gctactttt	cctgaaaatc	ctctgcatga	aaaattctac	cgcccttagt	480
gtgtctcaca	caaggataac	ttcaacccaa	gctgtgttca	acctggcctc	caggtccctg	540
tccttagggc	gggacccatc	ctctgcttcc	cgaataacca	acactccttt	ccattgccca	600
gaaaccatcc	ctgctacctc	gtgaggaatt	aactttaccc	aaagaaaggc	ctgacctctg	660

Page 63

B0213WO seq list.ST25.txt

```
tcccaggtcc tgggagaaag tccctgaact cctagaaggt cccaagcgac aggagtgtct    720

gttcac                                                               726
```

<210> 107

<211> 253

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (98)..(98)

<223> n = a t g or c

<400> 107
```
cggggatgag aacgtatctg ggaggagcac tgcgggcaag gggtgctgaa ggattccatg     60

tgccggcagg gcattcccaa ccgtgaatcg tctccagnga gtccgccaac gcttcgagat    120

cctggcggcg aatgccatcc ccaaaggctt catggacggg aagcaggcct gcattctcat    180

gatcaaagcc ctggaacttg accccaactt atacaggata gggcagagca aaatcttctt    240

ccgaactggc gtc                                                       253
```

<210> 108

<211> 448

<212> DNA

<213> Homo sapiens
.

<400> 108
```
ccggcaggct gttggttccc gatctccgag cgcaggctcg atcccgtggc gccgccggaa     60

cgccgcaagc gcgctctctt gccgcgcgag cttgcgagtc aacgcgtcga tctcggcgcg    120

ccgcgtgagg gcaagcgccg ctatattttc gcggaaagcc cgttcgtccg cgcgtgtcca    180

tcttgaggta ccaccgccgg actgccggcg cttggtgcag gacgtgatcg tcatgcgctc    240

ggcgcgagct tcgatctgcc gttcaatgat gccgagatga cggcttgtct cgagaagtgc    300

attttccatg cgcaggagta aggccgattg aggcgtgagc gacatcagaa tgccctccat    360

ggcctgaccc ataacgcttc tcaatcacta gtgcggccgc ctgcaggtcg accatatggg    420

agagctccca acgcgttgga tgcatagc                                       448
```

<210> 109

<211> 437

B0213WO seq list.ST25.txt

<212> DNA

<213> Homo sapiens

<400> 109
cagaggttgc agtgagccga gatcatgcca ctgtactgca gtctgggcga cagagcaaga   60

ttccatctca taaaaactgt gaactaggca aagtttgttt ccaggaaata atcacatccc   120

catcttaata atcccatccc tatctaatat taggcacaat tcttagctgg ccccatgatc   180

tccaatcctt ggtgttacat cctgtataat attctttcct tgagtgtggg tgggacctgt   240

gacttgcttc tagttgagat tatctacatt acataaggct ccatcttgga gtaagagatt   300

tctctgctgg ccctgaagta gcagctatgt tgtgaacagc caatggagaa agccatatgg   360

cagagacctg caacagaagg tggacctgaa ggtggcctct ggtcaccagc aacagcccca   420

aggaaatgaa ttctgcc   437

<210> 110

<211> 244

<212> DNA

<213> Homo sapiens

<400> 110
ctggcaggtc gtagcaggcc ggccctgggt aggcccccat actgtcgggg ccgagcgtca   60

ctatgtcgcc tctcacgcgc gcaacgctgc cacctccgag agcggccgat ctgagaagaa   120

tccaaggtgt cttcagcggt attccaaaga agtttgtctc ctcggaggtt aacggttctc   180

cgttaacgac gatcccgatc ttcgccgtag ttccaccgac atcaagcgag ataacctccc   240

caga   244

<210> 111

<211> 272

<212> DNA

<213> Homo sapiens

<400> 111
gtgacgagaa gagcagatta aagaagatta gataccactg gtcaatcatg gtagatgcag   60

agaagccaca gaaaaactgg aaccaaaaca ggaggcccac gaacattgtg tttttgtaga   120

agaagtacag caccatgttg gcaagtcggg agtagcacca atgcccgtga agaatcaaga   180

gcctctccag gtatcggaat ttcggcactg caaagtcgct ggccatcact gccttcaaag   240

ggagagggat tcctgttact ggtgatgccg ac   272

B0213wo seq list.ST25.txt

<210> 112

<211> 413

<212> DNA

<213> Homo sapiens

<400> 112

gtggagccca	cagaaaggag	agggcatcaa	agacacactt	cgctggctgc	accatttgct	60
cagggttggg	cccagctccg	gttacagctc	cataatccat	tgtgttcacc	actgtttgct	120
taggtttaac	tcggagttag	aattctggtt	ttgtttctca	cttagggaaa	aaaaatagct	180
ttgtaaaggg	aggttactaa	ataaaacttt	gagaactcta	ttcaccctca	caggatgact	240
tttggcttgc	aattcaatcc	ctggcaggtt	actgttcatg	tatagaattt	ccaggcgact	300
agaaggcatt	tgaaaggaat	tcttaccgaa	cattaacctg	ccttggtaac	cacagaaggc	360
atttctacct	gccaagctca	ggctgggagc	tttggtgcag	tccgacctgc	gcc	413

<210> 113

<211> 541

<212> DNA

<213> Homo sapiens

<400> 113

gtcaggctga	cctggttctt	ggtcatctcc	tcccgggatg	ggggcagggt	gtacacctgt	60
ggttctcggg	gctgtccttt	ggttttggag	atggttttct	cgatgggggc	tgggagggct	120
ttgttggaga	ccttgcactt	gtactccttg	ccgttcagcc	agtcctggtg	caggacggtg	180
aggacgctga	ccacacggaa	cgtgctgttg	gactgctcct	cccgcggctt	tgtcttggca	240
ttatgcacct	accacgccgt	ccacgttaca	gttaaacttg	acctcagggt	cttcgtggct	300
cacgtccacc	accacgcatg	tgacctcagg	ggtccgggag	atcatgaggg	tgtccttggg	360
ttttgggggg	aagaggaaga	actgacggtc	cccccaggag	ttcaggtgct	gggcacggtg	420
ggcatgtgtg	agttttgtca	caagatttgg	gctcaactct	cttgtccacc	atggtgttgc	480
tgggcttgtg	attcactttg	cagatgtaag	tctcatgaat	acggttttct	aattcccgcg	540
g						541

<210> 114

<211> 226

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 114
```
gtggtgaggc cagggcttcc agcctcgtgc tgtctcggga ctcctgaccg tggtgtgcgt    60

gtgtgcccat ctgtgacttt ctactcacca aggttgaaga aaggaaacgg ggaaaatcaa   120

aaggggttca aaccccacct cagtaggtgg aggggagcgc ctgccattgg ttgtattttt   180

gttctgagtt ttcggtgccg tgttcctaac tactccatcc catgac               226
```

<210> 115
<211> 439
<212> DNA
<213> Homo sapiens

<400> 115
```
tttgagccaa gatacggcgt atatgcaagg gtttgcgagt ttattagaag ggattgtgaa    60

gccggtatag ctagtgcttt tttaaaaagt tgtttaaaaa agagccgtat taaacattaa   120

tatggctctt ttttattgtt gagtttttat tattacaaaa tcaatttaaa caaataaaag   180

ccaattgccg ttgctaataa cgtcagcccc acatgtaacc caatcagtcc taaacccgca   240

agcagtttgc cgttatggat aaaggtaaat acttcagcac taaaggtact aaaagtcgtc   300

agtccgccca aaaaaccagt tatgacaaac aacctgacat tgggagacaa gtcgctgcac   360

ataacgcttc tcaatcacta gtgcggccgc ctgcaggtcg accatatggg agagctccca   420

acgcgttgga tgcatagct                                             439
```

<210> 116
<211> 175
<212> DNA
<213> Homo sapiens

<400> 116
```
gggagtgaag atttctcacc tcgggtcttc ctagaccttc aggtcacacg ggaattgttc    60

tgtttataga cggcgctggc cttagtactc actctccctc tattttcctt gcttccttat   120

aactaggttt ccctactcac ttcctcaaaa agagtgatgt aggtccacgt gtacc        175
```

<210> 117
<211> 521
<212> DNA
<213> Homo sapiens

<400> 117

B0213WO seq list.ST25.txt

```
gctacaacca catttgttca caggagtttt tggtgcgggg tgggaaggat ggaaggcctt          60

ggatttatat tgcacttcat agacccctag gctgctgtgc ggtgggactc cacatgcgcc         120

ggaaggagct tcaggtgagc actgctcatg tgtggatgcc cctgcaacag gcttccctgt         180

ctgtagagcc aggggtgcaa gtgccatcca cacttgcagt gaatggcttt tccttttagg         240

tttaagtcct gtctgtctgt aaggcgtaga atctgtccgt ctgtaaggcg tagaatgagg         300

gttgttaatc catcacaagc aaaaggtcag aacagttaaa cactgccttt cctcctcctc         360

ttattttatg ataaaagcaa atgtggcctt ctcagtatca ttcgattgct atttgagact         420

tttaaattaa ggtaaaggct gctggtgttg gtacctgtgg atttttctat actgatgttt         480

tcgttttgcc aatataatga gtattacatt ggcctctcgt a                            521
```

<210> 118

<211> 131

<212> DNA

<213> Homo sapiens

<400> 118
```
ctgaagatgc ccctatattc tgtcaaaggt tggcggggggg aggtgttggg gtcctttcat          60

ctggctccgt ttctggtgct tctggaagtc tctgctcagc acagggaaga actaacacga         120

ctaacctagg c                                                             131
```

<210> 119

<211> 212

<212> DNA

<213> Homo sapiens

<400> 119
```
gtggtggaga tggttgaaaa cgacatatct gctttcacct acgagaggac actaatgatg          60

gagcagaggt cgcagatgct gaagcagatg cagctgtcca agaacgagca ggagcgagag         120

gcccagctga tccacgacag gaacaccgcg tcccacaccg cggcggcagc caggacccaa         180

gcgccgccta cgccagacaa ggtgcagatg ac                                       212
```

<210> 120

<211> 137

<212> DNA

<213> Homo sapiens

<400> 120
```

B0213WO seq list.ST25.txt
accgaagggc tgcatttctt tgtgggctta ttctcgagaa aactgggggc agatccctcc        60

tcaaggaggg gagggccacc ttggtttcca gtcaagtatt gtgaaaatta tccaacactc       120

aggcaatcca cccaacc                                                      137


<210>  121
<211>  265
<212>  DNA
<213>  Homo sapiens


<400>  121
gtggcagtga aggaaaaatc ccacaacagc cttggaatac cagagctcct gaccgtgggt        60

tagaatggtc ttttattatg aaggacaacc cattgaattt gagaagtcta cagtgaaagc       120

aaaatgtgtt cttaaaatgc aatactatct cgaggcagtt taaattctaa caataggagc       180

ctacatacca gatggctttg aaatatttac aggtcctctt tgcctgaatt tttagttatc       240

caggaacaac cattataact tatac                                            265


<210>  122
<211>  285
<212>  DNA
<213>  Homo sapiens


<400>  122
gtcctcgcat cagcgtcatc gtgtgcaccg gcttgggggg ctggagttcc ggtttttcttt       60

gttttttctc tttattcgtc ctttctcaaa gatgggatac tgatcagaat tgctctgtat       120

atgcttggga ctggatggaa agactttgga gcagctgtgg ggggtggggg gacaccgaca       180

accaaacaga cgtgctggct ccagtcctgt ttttactttc aaaaaccaac aagcccgaca       240

gtggagcctg tcccctcccg ggagggtgct catggcccca ctcac                      285


<210>  123
<211>  269
<212>  DNA
<213>  Homo sapiens


<400>  123
gggccggatc tacgccatag attgcacatt gatttctata ctcaatagta cgtataggaa        60

tattaaaaac catacgccct tctggtaata acatacctat cgttccacaa taaattgagc       120

gaggagatga ctctaattgt tcaatatatt tcatggtact taatttatgt ggcggggata       180

B0213WO seq list.ST25.txt

```
acgcttctca atcactagtg cggccgcctg caggtcgacc atatgggaga gctcccaacg    240

cgttggatgc atagcttgag tattctata                                      269
```

<210> 124
<211> 203
<212> DNA
<213> Homo sapiens

<400> 124
```
gccgacgatc tcctcggttc tgcctcttca ccacaaacac cctctgtcct gacaccgtca     60

ccagcagtgt gtgttctcca aagaccacag acaggcgctt gaagggcaca ttcatgccgc    120

ggtgcggccg gaaaccgcag gctgtgctga ccagctcaga gatggcactg gctgcctgct    180

catcattctc caggtccacc cga                                            203
```

<210> 125
<211> 239
<212> DNA
<213> Homo sapiens

<400> 125
```
atacagaaga ggggtttgct ggggatgagg acagcagggc agtcaccatc tcgaagcacc     60

tcagccactc ctttattgtt cttgaagcca ggaacacaga actgcttata gtactcaaag    120

tcccgggagc tgcgagcatt caggtacgtg aggtagcggt cggggcattt ttccacgcag    180

atctggggag cgggacattg gaattccagc agaaccaggg ggctggcaca tttcacaat    239
```

<210> 126
<211> 461
<212> DNA
<213> Homo sapiens

<400> 126
```
gacgtcgcat gctcccggcc gccatggccg cgggattagc gttatcggcg gcaggcgtca     60

gtccgtatac atcaacataa gttttcgcac ggacctgtgt ttttagtaaa cagtcgcttt    120

cccctagcct ctgcgaccac cccacgccca ccaaccgcaa gagtcggcga cccaaggtgg    180

ctccccatct cccaaagtta cggggacaat ttgccgaatt ccttaaccac agttcacccg    240

caagccttag tatactcaac ccaactacca gcgtcggttt cgggtacggg caacaccacc    300

actcgcttag aggcttttct cgacagcaca ggatcaccac catcaccaca aacgtggcta    360
```

B0213WO seq list.ST25.txt
cgcatcacgc ctcctctgca taacgcttct caatcactag tgcggccgcc tgcaggtcga   420

ccatatggga gagctcccaa cgcgttggat gcatagcttg a   461

<210> 127
<211> 284
<212> DNA
<213> Homo sapiens

<400> 127
tcaccgaatc tactgataaa aggaagagaa gaatacttta agaagagctc aacctccagc   60

tggtatcaga gaagtcagta gaggtcactg agaccggcag tctttcttgc tttttgcatt   120

agtgccctca gctggaactg tttacgggac agaagacgta catgcttcag gaagacatcc   180

aggtcggtac cataacgctt ctaatcacta gtgcggccgc ctgcaggtcg accatatggg   240

agagctccca acgcgttgga tgcatagctt gagtattcta tagt   284

<210> 128
<211> 252
<212> DNA
<213> Homo sapiens

<400> 128
accatgaaac ctacagcggc atctaataca acaacaccag ggatggtctc aacaaatatg   60

acttctacca ccttaaagtc tacacccaaa acaacaagtg tttcacagaa cacatctcag   120

atatcaacat ccacaatgac cgtaacccac aatagttcag tgacatctgc tgcttcatca   180

gtaacaatca caacaactat gcattctgaa gcaaagaaag gatcaaaatt tgatactggg   240

agctttgttg gt   252

<210> 129
<211> 382
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (380)..(380)
<223> n = a t c or g

B0213wo seq list.ST25.txt

```
<400>   129
gcaggccagg aattaacctt gactataaat aggccatcaa tgacctttcc agagaatgtt        60

cagagacctc aactttgttt agaggtcttg tgtgggtgga acttcctgtt tgcacacaga       120

gcagcataaa gcccagttgc tttgggaagt gtttgggacc agatggattg ttgggagtag       180

ggtacaatac agtctggtct cctccagctc cttctttctg caacatgggg aagaacaaac       240

tccttcatcc aagtctggtt cttctcctct tggtcctcct cgctataacg cttctcaatc       300

actagtgcgg ccgcctgcag gtcgaccata tgggagagct cccaacgcgt tggatgcata       360

gcttgagtat tctatagtgn tc                                                382
```

```
<210>   130
<211>   305
<212>   DNA
<213>   Homo sapiens
```

```
<400>   130
ggctaatgac gttctcgtgg atttcttcgg tcctgctcag ggtctccagc aggacgttgt        60

actcgtgaac tttctctttg tgatgcagga actcccgcca gagcttgtcc agttcttcgc       120

cggagaattt cccagaggtc ttcgccttgt gccacagctt ttccagcctg gggtcatcca       180

gcccgtcttc ctgggtgcca ctgagagagt tgctggtcac ctgccgagcg tccttctttc       240

cgtccagacc atacttggcc aagatgacat tgaggttgcg tatgagtctc gcttccttct       300

ccccc                                                                   305
```

```
<210>   131
<211>   337
<212>   DNA
<213>   Homo sapiens
```

```
<400>   131
atatattatt aggtggggaa acaaaacccc acttttctct ctgatcattt tttcataaga        60

gattctaaga gggagtgaaa aagtaccaac tggactccat tccaggtctt acctctagaa       120

gacagccagc tctcatttaa gaatctcaga acttggaagg aaggaggaaa tccacattaa       180

attctagggc ccaacagaca gagtgtcttc attgccaccc ccagtagtgg ggactacagt       240

gcacctgtag tcccagtaga tgctctgaca tcacagagct tcctgctcta ccagcccacc       300

tcatgcatgt caccaccata actatagcct gcaagtc                                337
```

```
<210>   132
<211>   174
```

B0213WO seq list.ST25.txt

<212>   DNA

<213>   Homo sapiens

<400>   132
ataaaaaggt ggaaactctc atggtaccat caaaaaggca agaagcattg cccctccacc   60

aagagactaa acaagaaagt ggatcaggga agaagaaagc ttcatcaaag aaacaaaaga   120

cagaaaatgt cttcgtagat gaacccctta ttcgtgcaac tacttatatt cctc   174

<210>   133

<211>   113

<212>   DNA

<213>   Homo sapiens

<400>   133
cataaagtac tgacatgatc agaggaatca tcagcaactg catatccatt gctaagccag   60

taatcacgat gcaaatccag ttaaagagga gcatgaataa atagtctgct ggc   113

<210>   134

<211>   191

<212>   DNA

<213>   Homo sapiens

<400>   134
aaattatgca tctgtgagga gagaagagag ggaaaaaaaa aggaaaaaca aaccaagaaa   60

gtatgccttt ttactttcct attatcctga atagggcata ctccattcac ccttaaggtt   120

ctagaatgaa ccagtcttac tatgtatcta taaccttgcc tttatctcta ttctaatatg   180

gtaatctgtt a   .   191

<210>   135

<211>   1481

<212>   DNA

<213>   Homo sapiens

<400>   135
ggcacgaggg ggacgcctct ctcctcctta ttcggtttac tatttattgt tcggggtgtt   60

ttttaattcc tgtattgctc ggcccgggga gtttcgcccc ctgcccggct ccgcggcgcg   120

gaggatggtg tggaaacggc tgggcgcgct ggtgatgttc cctctacaga tgatctatct   180

BO213WO seq list.ST25.txt

```
ggtggtgaaa gcagccgtcg gactggtgct gcccgccaag ctgcgggacc tgtcgcggga    240

gaacgtcctc atcaccggcg gcgggagagg catcgggcgt cagctcgccc gcgagttcgc    300

ggagcgcggc gccagaaaga ttgttctctg gggccggact gagaaatgcc tgaaggagac    360

gacggaggag atccggcaga tgggcactga gtgccattac ttcatctgtg atgtgggcaa    420

ccgggaggag gtgtaccaga cggccaaggc cgtccgggag aaggtgggtg acatcaccat    480

cctggtgaac aatgccgccg tggtccatgg gaagagccta atggacagtg atgatgatgc    540

cctcctcaag tcccaacaca tcaacaccct gggccagttc tggaccacca aggccttcct    600

gccgcgtatg ctggagctgc agaatggcca catcgtgtgc ctcaactccg tgctggcact    660

gtctgccatc cccggtgcca tcgactactg cacatccaaa gcgtcagcct tcgccttcat    720

ggagagcctg accctggggc tgctggactg tccgggagtc agcgccacca cagtgctgcc    780

cttccacacc agcaccgaga tgttccaggg catgagagtc aggtttccca acctctttcc    840

cccactgaag ccggagacgg tggcccggag gacagtggaa gctgtgcagc tcaaccaggc    900

cctcctcctc ctcccatgga caatgcatgc cctcgttatc ttgaaaagca tacttccaca    960

ggctgcactc gaggagatcc acaaattctc aggaacctac acctgcatga acacttcaa    1020

agggcggaca tagagacagg atgaagacat gcttgaggag ccacggagtt tgggggccac    1080

agcacctggg cacacacccg agcacctgtc cattggcatg cttctgctgg gtgagcagga    1140

cagctcctgt ccccagcgaa gaatccggct gcccctgggc cagtcccagg acctttgcac    1200

aggactgatg ggtataactg accccacag ggaggcagga aaacagccag aagccacctt    1260

gacacttttg aacatttcca gttctgtaga gtttattgtc aattgcttct caagtctaac    1320

cagcctcagc agtgtgcata gaccatttcc aggagggtct gtccccagat gctctgcctc    1380

ccgttccaaa acccactcat cctcagcttg cacaaactgg ttgaacggca ggaatgaaaa    1440

ataaagagag atggcttttg tgaaaaaaaa aaaaaaaaa a                         1481
```

<210> 136

<211> 344

<212> DNA

<213> Homo sapiens

<400> 136
```
gggtgttttt taattcctgt attgctcggc ccggggagtt tcgcccctg cccggctccg      60

cggcgcggag gatggtgtgg aaacggctgg gcgcgctggt gatgttccct ctacagacga    120

tctatctggt ggtgaaagca gccgtcggac tggtgctgcc cgccaagctg cgggacctgt    180

cgcgggagaa cgtcctcatc accggcggcg ggagaggcat cgggcgtcag ctcgcccgcg    240

agttcgcgga gcgcggcgcc agaatgattg ttctctgggg ccggactgag aaatgcctga    300

aggagacgac ggaggagatc cggcagatgg gcactgagtg ccat                     344
```

B0213WO seq list.ST25.txt

<210> 137

<211> 1088

<212> DNA

<213> Homo sapiens

<400> 137

tgatctatct	ggtggtgaaa	gcagccgtcg	gactggtgct	gcccgccaag	ctgcgggacc	60
tgtcgcggga	gaacgtcctc	atcaccggcg	gcgggagagg	catcgggcgt	cagctcgccc	120
gcgagttcgc	ggagcgcggc	gccagaaaga	ttgttctctg	gggccggact	gagaaatgcc	180
tgaaggagac	gacagaggag	atccggcaga	tgggcactga	gtgccattac	ttcatctgtg	240
atgtgggcaa	ccgggaggag	gtgtaccaga	cggccaaggc	cgtccgggag	aaggtgggtg	300
acatcaccat	cctggtgaac	aatgccgccg	tggtccatgg	gaagagccta	atggacagtg	360
atgatgatgc	cctcctcaag	tcccaacaca	tcaacaccct	gggccagttc	tggaccacca	420
aggccttcct	gccgcgtatg	ctggagctgc	agaatggcca	catcgtgtgc	ctcaactccg	480
tgctggcact	gtctgccatc	cccggtgcca	tcgactactg	cacatccaaa	gcgtcagcct	540
tcgccttcat	ggagagcctg	accctggggc	tgctggactg	tccgggagtc	agcgccacca	600
cagtgctgcc	cttccacacc	agcaccgaga	tgttccaggg	catgagagtc	aggtttccca	660
acctctttcc	cccactgaag	ccggagacgg	tggcccggag	gacagtggaa	gctgtgcagc	720
tcaaccaggc	cctcctcctc	ctcccatgga	caatgcatgc	cctcgttatc	ttgaaaagca	780
tacttccaca	ggctgcactc	gaggagatcc	acaaattctc	aggaacctac	acctgcatga	840
acactttcaa	agggcggaca	tagagacagg	atgaagacat	gcttgaggag	ccacggagtt	900
tgggggccac	agcacctggg	cacacacccg	agcacctgtc	cattggcatg	cttctgctgg	960
gtgagcagga	cagctcctgt	ccccagcgaa	gaatccggct	gcccctgggc	cagtcccagg	1020
acctttgcac	aggactgatg	ggtataactg	acccccacag	ggaggcagga	aaacagccag	1080
aagccacc						1088

<210> 138

<211> 399

<212> DNA

<213> Homo sapiens

<400> 138

tgcattgtcc	atgggaggag	gaggagggcc	tggttgagct	gcacagcttc	cactgtcctc	60
cgggccaccg	tctccggctt	cagtggggga	aagaggttgg	gaaaccttct	cccggacggc	120
cttggccgtc	tggtacacct	cctcccggtt	gcccacatca	cagatgaagt	aatggcactc	180

Page 75

B0213WO seq list.ST25.txt

```
agtgcccatc tgccggatct cctccgtcgt ctccttcagg catttctcag tccggcccca      240

gagaacaatc tttctggcgc cgcgctccgc gaactcgcgg gcgagctgac gcccgatgcc      300

tctcccgccg ccggtgatga ggacgttctc ccgcgacagg tcccgcagct tggcgggcag      360

caccagtccg acggctgctt tcaccaccag atagatcat                             399
```

<210> 139

<211> 745

<212> DNA

<213> Homo sapiens

<400> 139
```
ggtggcttct ggctgttttc ctgcctccct gtgggggtca gttacaccca tcagtcctgt       60

gcaaaggtcc tgggactggc ccaggggcag ccggattctt cgctggggac aggagctgtc      120

ctgctcaccc agcagaagca tgccaatgga caggtgctcg ggtgtgtgcc caggtgctgt      180

ggcccccaaa ctccgtggct cctcaagcat gtcttcatcc tgtctctatg tccgcccttt      240

gaaagtgttc atgcaggtgt aggttcctga gaatttgtgg atctcctcga gtgcagcctg      300

tggaagtatg ctgactctca tgccctggaa catctcggtg ctggtgtgga agggcagcac      360

tgtggtggcg ctgactcccg gacagtccag cagccccagg gtcaggctct ccatgaaggc      420

gaaggctgac gctttggatg tgcagtagtc gacggcaccg gggatggcag acagtgccag      480

cacggagttg aggcacacga tgtggccatt ctgcagctcc agcatacgcg gcaggaaggc      540

cttggtggtc cagaactggc ccagggtgtt gatgtgttgg gacttgagga gggcatcatc      600

atcactgtcc attaggctct tcccatggac cacggcggca ttgttcacca ggatggtgat      660

gtcacccacc ttctcccgga cggccttggc cgtctggtac acctcctccc ggttgcccac      720

atcacagatg aagtaatggc actca                                           745
```

<210> 140

<211> 3875

<212> DNA

<213> Homo sapiens

<400> 140
```
cggggggacgt cagcgctgcc agcgtggaag gagctgcggg gcgcgggagg aggaagtaga       60

gcccgggacc gccaggccac caccggccgc ctcagccatg gacgcgtccc tggagaagat      120

agcagacccc acgttagctg aaatgggaaa aaacttgaag gaggcagtga agatgctgga      180

ggacagtcag agaagaacag aagaggaaaa tggaaagaag ctcatatccg gagatattcc      240

aggcccactc cagggcagtg ggcaagatat ggtgagcatc ctccagttag ttcagaatct      300
```

B0213WO seq list.ST25.txt

```
catgcatgga gatgaagatg aggagcccca gagccccaga atccaaaata ttggagaaca    360

aggtcatatg gctttgttgg gacatagtct gggagcttat atttcaactc tggacaaaga    420

gaagctgaga aaacttacaa ctaggatact ttcagatacc accttatggc tatgcagaat    480

tttcagatat gaaaatgggt gtgcttattt ccacgaagag gaaagagaag gacttgcaaa    540

gatatgtagg cttgccattc attctcgata tgaagacttc gtagtggatg gcttcaatgt    600

gttatataac aagaagcctg tcatatatct tagtgctgct gctagacctg gcctgggcca    660

ataccttgt aatcagctcg gcttgccctt ccctgcttg tgccgtgtac cctgtaacac    720

tgtgtttgga tcccagcatc agatggatgt tgccttcctg gagaaactga ttaaagatga    780

tatagagcga ggaagactgc ccctgttgct tgtcgcaaat gcaggaacgg cagcagtagg    840

acacacagac aagattggga gattgaaaga actctgtgag cagtatggca tatggcttca    900

tgtggagggt gtgaatctgg caacattggc tctgggttat gtctcctcat cagtgctggc    960

tgcagccaaa tgtgatagca tgacgatgac tcctggcccg tggctgggtt tgccagctgt   1020

tcctgcggtg acactgtata aacacgatga ccctgccttg actttagttg ctggtcttac   1080

atcaaataag cccacagaca aactccgtgc cctgcctctg tggttatctt tacaatactt   1140

gggacttgat gggtttgtgg agaggatcaa gcatgcctgt caactgagtc aacggttgca   1200

ggaaagtttg aagaaagtga attacatcaa aatcttggtg gaagatgagc tcagctcccc   1260

agtggtggtg ttcagatttt tccaggaatt accaggctca gatccggtgt ttaaagccgt   1320

cccagtgccc aacatgacac cttcaggagt cggccgggag aggcactcgt gtgacgcgct   1380

gaatcgctgg ctgggagaac agctgaagca gctggtgcct gcaagcggcc tcacagtcat   1440

ggatctggaa gctgagggca cgtgtttgcg gttcagccct ttgatgaccg cagcagtttt   1500

aggaactcgg ggagaggatg tggatcagct cgtagcctgc atagaaagca aactgccagt   1560

gctgtgctgt acgctccagt tgcgtgaaga gttcaagcag gaagtggaag caacagcagg   1620

tctcctatat gttgatgacc ctaactggtc tggaataggg gttgtcaggt atgaacatgc   1680

taatgatgat aagagcagtt tgaaatcaga tcccgaaggg gaaaacatcc atgctggact   1740

cctgaagaag ttaaatgaac tggaatctga cctaaccttt aaaataggcc ctgagtataa   1800

gagcatgaag agctgccttt atgtcggcat ggcgagcgac aacgtcgatg ctgctgagct   1860

cgtggagacc attgcggcca cagcccggga gatagaggag aactcgaggc ttctggaaaa   1920

catgacagaa gtggttcgga aaggcattca ggaagctcaa gtggagctgc agaaggcaag   1980

tgaagaacgg cttctggaag aggggggtgtt gcggcagatc cctgtagtgg gctccgtgct   2040

gaattggttt tctccggtcc aggctttaca gaagggaaga actttttaact tgacagcagg   2100

ctctctggag tccacagaac ccatatatgt ctacaaagca caaggtgcag gagtcacgct   2160

gcctccaacg ccctcgggca gtcgcaccaa gcagaggctt ccaggccaga agcctttaa   2220

aaggtccctg cgaggttcag atgctttgag tgagaccagc tcagtcagtc acattgaaga   2280

cttagaaaag gtggagcgcc tatccagtgg gccggagcag atcaccctcg aggccagcag   2340
```

BO213WO seq list.ST25.txt

```
cactgaggga cacccagggg ctcccagccc tcagcacacc gaccagaccg aggccttcca   2400

gaaaggggtc ccacacccag aagatgacca ctcacaggta gaaggaccgg agagcttaag   2460

atgagactca ttgtgtggtt tgagactgta ctgagtattg tttcagggaa gatgaagttc   2520

tattggaaat gtgaactgtg ccacatacta atataaatta ctgttgtttg tgcttcactg   2580

ggattttggc acaaatatgt gcctgaaagg taggctttct aggaggggag tcagcttgtc   2640

taacttcatg tacatgtaga accacgtttg ctgtcctact acgacttttc cctaagttac   2700

cataaacaca ttttattcac aaaaaacact tcgaatttca agtgtctacc agtagcaccc   2760

ttgctctttc taaacataag cctaagtata tgaggttgcc cgtggcaact ttttggtaaa   2820

acagcttttc attagcactc tccaggttct ctgcaacact tcacagaggc gagactggct   2880

gtatcctttg ctgtcggtct ttagtacgat caagttgcaa tatacagtgg gactgctaga   2940

cttgaaggag agcagtgatt gtgggattgt aaataagagc atcagaagcc ctccccagct   3000

actgctcttc gtggagactt agtaaggact gtgtctactt gagctgtggc aaggctgctg   3060

tctgggactg tcctctgcca caaggccatt tctcccatta tataccgttt gtaaagagaa   3120

actgtaaagt ctcctcctga ccatatattt ttaaatactg gcaaagcttt taaaattggc   3180

acacaagtac agactgtgct catttctgtt tagtatctga aaacctgata gatgctaccc   3240

ttaagagctt gctcttccgt gtgctacgta gcacccacct ggttaaaatc tgaaaacaag   3300

tacccctttg acctgtctcc cactgaagct tctactgccc tggcagctcg cctgggccca   3360

actcagaaac aggagccagc agagcactct ctcacgctga tccagccggg caccctgctt   3420

aagtcagtag aagctcgctg gcactgcccg ttcctacttt tccgaagtac tgcgtcactt   3480

tgtcgtaagt aatggcccct gtgccttctt aatccagcag tcaagctttt gggagacctg   3540

aaaatgggaa aattcacact gggtttctgg actgtagtat tggaagcctt agttatagta   3600

tattaagcct ataattatac tctgatttga tgggattttt gacatttaca cttgtcaaaa   3660

tgcaggggggt tttttttggt gcagatgatt aaacagtctt ccctatttgg tgcaatgaag   3720

tatagcagat aaaatggggg aggggtaaat tatcaccttc aagaaaatta catgttttta   3780

tatatatttg gaattgttaa attggttttg ctgaaacatt tcacccttga gatattattt   3840

gaatgttggt ttcaataaag gttcttgaaa ttgtt                             3875
```

<210> 141

<211> 493

<212> DNA

<213> Homo sapiens

<400> 141

```
aggcagtgaa gatgctggag gacagtcaga gaagaacaga agaggaaaat ggaaagaagc    60

tcatatccgg agatattcca ggcccactcc agggcagtgg gcaagatatg gtgagcatcc   120
```

B0213WO seq list.ST25.txt

```
tccagttagt tcacaatcta atgcatggag atgaagatga ggagccccag agccccagaa      180

tgcaaaatat tggagaacaa gggcatatgg ctttgttgag acatagtctg ggagcttata      240

tttcaactct ggacaaagag aagctgagaa aacttacaac taggatactt tcagatacca      300

ccttatggct atgcagaatt ttcagatatg aaaatgggtg tgcttatttc cacgaagagg      360

aaagagaagg acttgcaaag atatgtaggc ttgccattca ttctcgatat gaagacttcg      420

tagtggatgg cttcaatgtg ttatataaca agaagcctgt catatatctt agtgctgctg      480

ctagacctgg cct                                                        493
```

<210> 142

<211> 6263

<212> DNA

<213> Homo sapiens

<400> 142

```
gtggatttgg tcgtctccct gattccgagc tgcgggcagg gagaggggcc tcgcgccgcc       60

ctcagcagcc ggcggcggcc gaggtagacc gagcggggac ggaaggacag accgacgtcg      120

ccgagctgga atcatgtgag ggccaaccgg ggaaggtgga gcagatgagc acacacagga      180

gccgtctcct caccgccgcc cctctcagca tggaacagag gcggccctgg ccccgggccc      240

tggaggtgga cagccgctct gtggtcctgc tctcagtggt ctgggtgctg ctggcccccc      300

cagcagccgg catgcctcag ttcagcacct tccactctga gaatcgtgac tggaccttca      360

accacttgac cgtccaccaa gggacggggg ccgtctatgt gggggccatc aaccgggtct      420

ataagctgac aggcaacctg accatccagg tggctcataa gacagggcca gaagaggaca      480

acaagtcttg ttacccgccc ctcatcgtgc agccctgcag cgaagtgctc accctcacca      540

acaatgtcaa caagctgctc atcattgact actctgagaa ccgcctgctg gcctgtggga      600

gcctctacca gggggtctgc aagctgctgc ggctggatga cctcttcatc ctggtggagc      660

catcccacaa gaaggagcac tacctgtcca gtgtcaacaa gacgggcacc atgtacgggg      720

tgattgtgcg ctctgagggt gaggatggca agctcttcat cggcacggct gtggatggga      780

agcaggatta cttcccgacc ctgtccagcc ggaagctgcc ccgagaccct gagtcctcag      840

ccatgctcga ctatgagcta cacagcgatt ttgtctcctc tctcatcaag atcccttcag      900

acaccctggc cctggtctcc cactttgaca tcttctacat ctacggcttt gctagtgggg      960

gctttgtcta ctttctcact gtccagcccg agaccctga gggtgtggcc atcaactccg      1020

ctggagacct cttctacacc tcacgcatcg tgcggctctg caaggatgac cccaagttcc      1080

actcatacgt gtccctgccc ttcggctgca cccgggccgg ggtggaatac cgcctcctgc      1140

aggctgctta cctggccaag cctgggggact cactggccca ggccttcaat atcaccagcc      1200

aggacgatgt actctttgcc atcttctcca aagggcagaa gcagtatcac cacccgcccg      1260
```

B0213WO seq list.ST25.txt

```
atgactctgc cctgtgtgcc ttccctatcc gggccatcaa cttgcagatc aaggggcgcc   1320

tacagtcctg ctaccagggc gagggcaacc tggagctcaa ctggctgctg gggaaggacg   1380

tccagtgcac caaggcgcct gtccccatcg atgataactt ctgtggactg gacatcaacc   1440

agcccctggg aggctcaact ccagtggagg gcctgaccct gtacaccacc agcagggacc   1500

gcatgacctc tgtggcctcc tacgtttaca acggctacag cgtggttttt gtggggacta   1560

agagtggcaa gctgaaaaag attcgggccg acggtccccc ccatggtggg gtccagtacg   1620

agatggtctc tgtgctcaag gacggaagcc ccatcctccg ggacatggcc ttctccattg   1680

atcagcgcta cctgtacgtc atgtctgaga gacaggtcac caggggtcccc gtggagtcat   1740

gtgagcagta tacgacttgt ggggagtgcc tgagctctgg ggaccctcac tgtggctggt   1800

gtgccctgca caacatgtgc tcccgcaggg acaaatgcca acaggcctgg gaacctaatc   1860

gatttgctgc cagcatcagc cagtgtgtga gccttgcagt gcatcccagc agcatctcag   1920

tatctgagca cagccggttg cttagcctgg tagtgagtga tgctcctgat ctatctgcgg   1980

gtatcgcctg tgcctttggg aacctgacag aggtggaggg gcaggtgtcc gggagccagg   2040

tcatctgcat ctcacctggg cccaaggatg tccctgtcat ccgctggat caagactggt   2100

ttgggctgga gctacagctg aggtccaagg agacagggaa gatatttgtc agcaccgagt   2160

tcaagttta caactgcagt gcccaccaac tgtgcctgtc ctgtgtcaac agcgccttcc   2220

gctgccattg gtgcaagtac cgcaacctct gcactcatga ccccaccacc tgctccttcc   2280

aggagggccg gatcaatatt tcagaggact gtccccagct ggtgcccaca gaggagatct   2340

tgattccagt cggggaggta aagccaatca cccttaaggc gcgaaatctg ccccagccgc   2400

agtccggcca gcgaggctat gagtgtgtcc tcaacataca aggagccatc caccgggtcc   2460

ccgctctgcg cttcaacagc tccagcgttc agtgtcagaa cagctcgtac cagtatgatg   2520

gcatggacat cagcaatctg gccgtggatt tcgctgtggt gtggaacggc aatttcatca   2580

ttgacaaccc tcaggacctg aaagtccatc tctacaagtg tgcagcccag cgggagagct   2640

gcggcctctg cctcaaggcc gaccggaagt ttgagtgtgg ctggtgcagc ggcgagcgca   2700

ggtgcaccct ccaccagcac tgtaccagcc cttccagccc ctggctcgac tggtccagcc   2760

acaatgtcaa gtgctccaac cctcaaatca ccgagatttt gacggtgtct ggaccgccgg   2820

aaggagggac gcgagtgacc atccatggcg tgaacctggg tctggacttc tccgagatcg   2880

cccaccatgt gcaggtggct ggggtgcccct gcacgcccct cccaggggaa tacatcatcg   2940

ctgagcagat tgtctgtgag atgggccatg ccctcgtggg aaccacctcc gggccagtac   3000

gcctgtgtat tggcgagtgt aagccagagt tcatgacgaa gtcccatcag cagtacacct   3060

tcgtgaaccc ttctgtgctg tcactcaacc caatccgagg tcccgagtca ggaggcacta   3120

tggtgaccat taccggccat taccttgggg ctgggagcag cgtggcagtc tacctgggca   3180

accagacctg cgagttctac gggaggtcaa tgagtgagat cgtgtgtgtc tcacccccat   3240

catccaatgg ccttggcccg gtccctgttt ctgtgagtgt cgaccgagcc catgtggata   3300
```

Page 80

B0213WO seq list.ST25.txt

```
gcaacctgca gtttgagtac atagatgacc ctcgggtcca gcgcatcgag ccagagtgga    3360

gcattgccag tggccacaca cccctgacca tcacaggctt caacctggat gtcattcagg    3420

agccaaggat ccgagtcaaa ttcaatggca aagaatctgt caatgtgtgt aaagttgtga    3480

acacaaccac cctcacctgc ctggcaccct ctctgaccac ggactaccgc cctggcctgg    3540

acactgtgga acgcccagat gagtttggat ttgtctttaa caatgtccaa tccttgctaa    3600

tttacaacga caccaagttt atctactacc ccaacccgac cttttgaactg cttagcccta    3660

ctggagtctt ggatcaaaag ccaggatcgc ccatcattct gaagggcaaa aacctctgcc    3720

ctcctgcctc tggaggggcc aaactcaact acactgtgct catcggagag accccttgtg    3780

ctgtcaccgt atctgagacc cagcttctct gcgagcctcc caacctcacc gggcagcaca    3840

aggtcatggt tcacgtgggc gggatggtgt tctcgcctgg ctcggtgagt gtcatctcag    3900

acagcttgct gaccctgcca gccatcgtca gcatcgcggc cggcggcagc ctcctcctca    3960

tcatcgtcat catcgtcctc attgcctaca agcgcaagtc tcgagaaaat gacctcactc    4020

tcaagcggct gcaaatgcag atggacaatc tggagtcccg tgtggccttg gagtgcaagg    4080

aagcttttgc tgagctccag acggatatca atgagttgac cagtgacctg gaccgctcag    4140

gaatccctta cctggactat cgtacctacg ctatgcgagt cctgttcccg ggcatcgagg    4200

accaccccgt cctgcgggag ctggaggtac aaggaaacgg gcagcagcac gtggagaagg    4260

ccctgaagct ctttgcccag ctcatcaaca acaaggtgtt cctgctgacc ttcatccgca    4320

ccctggagct gcagcgcagt ttctccatgc gcgaccgggg caacgtggct cgctcatca    4380

tgaccggcct gcagggccgc ctggaatatg ccactgatgt cctcaagcag ctgctctctg    4440

acctcatcga taagaacctg gagaacaaga accaccccaa gctgctactc cggaggacag    4500

agtctgtggc tgaaaagatg ctgaccaatt ggttcgcctt cctcctgcac aagttcctaa    4560

aggagtgcgc aggggagcca ctcttcatgc tatactgtgc catcaagcag cagatggaga    4620

agggccccat tgatgccatc acgggcgagg cccgctactc cctgagcgag gacaagctca    4680

tccggcagca gatcgagtac aagaccctga tcctgaactg cgtcaaccct gacaacgaga    4740

acagtccaga gatcccagtg aaggtgttaa actgtgacac catcacacag gtcaaggaga    4800

agattcttga tgccgtgtat aagaatgtgc cctattccca gcggccgagg gcagtggaca    4860

tggacttgga gtggcgccaa ggccggatcg cccgggtcgt gctgcaagat gaggacatca    4920

ccaccaagat tgagggtgac tggaagcggc tcaacacact gatgcattat caggtgtcag    4980

acaggtcggt ggtggctctg gtccccaaac agacctcctc ctacaacatc cctgcctctg    5040

ccagcatctc ccggacgtcc atcagcagat atgactcctc cttcaggtat acgggcagcc    5100

ccgacagcct gcggtcccgg gcccccgatga tcacccccaga cctggaaagt ggggtcaagg    5160

tgtggcatct ggtgaagaac catgaccacg gtgaccagaa ggagggtgac cggggcagca    5220

agatggtgtc cgagatctac ctgacccggc tactggccac caagggcacc ctgcagaagt    5280

ttgtggacga cttgtttgag accttgttca gcactgtgca ccggggcagc gctctccccc    5340
```

Page 81

BO213WO seq list.ST25.txt
```
tggccatcaa gtacatgttt gatttcctag atgagcaggc agacaggcac agcatccatg    5400

acacagatgt gcggcacacc tggaaaagca actgcctccc tctgcgcttc tgggtgaacg    5460

tgattaagaa cccccagttc gtgtttgaca tccacaaggg cagcatcacg gacgcctgcc    5520

tctctgtggt ggcccagacc ttcatggact cttgttcaac gtcagagcac cggctgggca    5580

aggactcccc ctccaacaag ctgctctatg ccaaggacat ccccagctac aagagctggg    5640

tggagagata ctacgcagac atcgccaagc tcccagccat cagtgaccag gacatgaatg    5700

cctacctcgc cgagcagtcc cgcctgcacg ccgtggagtt caacatgctg agtgccctca    5760

atgagatcta ctcctatgtc agcaagtata gtgaggagct catcgggggcc ctagagcagg    5820

atgagcaggc acggcggcag cggctggctt ataaggtgga gcagctcatt aatgccatgt    5880

ccattgagag ctgagaggag gagcctcgca ttcctgggaa gagggacctg tccaagctgt    5940

cacactggga gtctcagatg gaaggacaag tgatggggat caggccccag agcttgctgt    6000

cccctgagac cccatcctgg ggagagggga ggactcctct ccctacgcca gccaagtttc    6060

gtcatagcca gttccagctg ggagagacag tgggcgtcgt ccatcctcag tgagaacacc    6120

agagaacccg gggccgggag aaggtggttc ttcaagccga gaggcacgag ctggggacag    6180

ttctgcctct gtgactgctg ctttgcatga aaactcattt gatgtatatt ggggaaataa    6240

tgagaacttt atttaatttt ttt                                            6263
```

<210> 143

<211> 1725

<212> DNA

<213> Homo sapiens

<400> 143
```
tgtgtcaaca gcgccttccg ctgccattgg tgcaagtacc gcaacctctg cactcatgac      60

cccaccacct gctccttcca ggagggccgg atcaatattt cagaggactg tccccagctg     120

gtgcccacag aggagatctt gattccagtc ggggaggtaa agccaatcac ccttaaggcg     180

cgaaatctgc cccagccgca gtccggccag cgaggctatg agtgtgtcct caacatacaa     240

ggagccatcc accgggtccc cgctctgcgc ttcaacagct ccagcgttca gtgtcagaac     300

agctcgtacc agtatgatgg catggacatc agcaatctgg ccgtggattt cgctgtggtg     360

tggaacggca atttcatcat tgacaaccct caggacctga agtccatct ctacaagtgt      420

gcagcccagc gggagagctg cggcctctgc ctcaaggccg accggaagtt tgagtgtggc     480

tggtgcagcg gcgagcgcag gtgcaccctc caccagcact gtaccagccc ttccagcccc     540

tggctcgact ggtccagcca caatgtcaag tgctccaacc ctcaaatcac cgagattttg     600

acggtgtctg gaccgccgga aggagggacg cgagtgacca tccatggcgt gaacctgggt     660

ctggacttct ccgagatcgc ccaccatgtg caggtggctg gggtgccctg cacgcccctc     720
```

B0213WO seq list.ST25.txt

```
ccaggggaat acatcatcgc tgagcagatt gtctgtgaga tgggccatgc cctcgtggga      780

accacctccg ggccagtacg cctgtgtatt ggcgagtgta agccagagtt catgacgaag      840

tcccatcagc agtacacctt cgtgaaccct tctgtgctgt cactcaaccc aatccgaggt      900

cccgagtcag gaggcactat ggtgaccatt accggccatt accttggggc tgggagcagc      960

gtggcagtct acctgggcaa ccagacctgc gagttctacg ggaggtcaat gagtgagatc      1020

gtgtgtgtct cacccccatc atccaatggc cttggcccgg tccctgtttc tgtgagtgtc      1080

gaccgagccc atgtggatag caacctgcag tttgagtaca tagatgaccc tcgggtccag      1140

cgcatcgagc cagagtggag cattgccagt ggccacacac ccctgaccat cacaggcttc      1200

aacctggatg tcattcagga gccaaggatc cgagtcaaat tcaatggcaa agaatctgtc      1260

aatgtgtgta aagttgtgaa cacaaccacc ctcacctgcc tggcaccctc tctgaccacg      1320

gactaccgcc ctggcctgga cactgtggaa cgcccagatg agtttggatt tgtctttaac      1380

aatgtccaat ccttgctaat ttacaacgac accaagttta tctactaccc caacccgacc      1440

tttgaactgc ttagccctac tggagtcttg gatcaaaagc caggatcgcc catcattctg      1500

aagggcaaaa acctctgccc tcctgcctct ggaggggcca aactcaacta cactgtgctc      1560

atcggagaga ccccttgtgc tgtcaccgta tctgagaccc agcttctctg cgagcctccc      1620

aacctcaccg ggcagcacaa ggtcatggtt cacgtgggcg ggatggtgtt ctcgcctggc      1680

tcggtgagtg tcatctcaga cagcttgctg accctgccag ccatc                     1725
```

<210> 144

<211> 558

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (462)..(462)

<223> n = a t c or g

<400> 144

```
gggcccttct ccatctgctg cttgatggca cagtatagca tgaagagtgg ctcccctgcg      60

cactccttta ggaacttgtg caggaggaag gcgaaccaat tggtcagcat cttttcagcc      120

acagactctg tcctccggag tagcagcttg gggtggttct tgttctccag gttcttatcg      180

atgaggtcag agagcagctg cttgaggaca tcagtggcat attccaggcg gccctgcagg      240

ccggtcatga tgagcgaagc cacgttgccc cggtcgcgca tggagaaact gcgctgcagc      300

tccagggtgc ggatgaaggt cagcaggaac accttgttgt tgatgagctg ggcaaagagc      360
```

B0213WO seq list.ST25.txt

```
ttcagggcct tctccacgtg ctgctgcccg tttccttgta cctccagctc ccgcaggacg    420

gggtggtcct cgatgcccgg gaacaggact cgcatagcgt angtacgata gtccaggtaa    480

gggattcctg agcggtccag gtcactggtc aactcattga tatccgtctg gagctcagca    540

aaagcttcct tgcactcc                                                  558
```

<210> 145

<211> 5567

<212> DNA

<213> Homo sapiens

<400> 145

```
atggtggaac acgctgccca caaacatgga aacgaccgtt ctcagtggga tcaacttcga     60

gtacaagggc atgacaggct gggaggtggc tggtgatcac atttacacag ctgctggagc    120

ctcagacaat gacttcatga ttctcactct ggttgtgcca ggatttagac ctccgcagtc    180

ggtgatggca gacacagaga ataaagaggt ggccagaatc acatttgtct ttgagaccct    240

ctgttctgtg aactgtgagc tctacttcat ggtgggtgtg aattctagga ccaacactcc    300

tgtggagacg tggaaaggtt ccaaaggcaa acagtcctat acctacatca ttgaggagaa    360

cactaccacg agcttcacct gggccttcca gaggaccact tttcatgagg caagcaggaa    420

gtacaccaat gacgttgcca agatctactc catcaatgtc accaatgtta tgaatggcgt    480

ggcctcctac tgccgtccct gtgccctaga agcctctgat gtgggctcct cctgcacctc    540

ttgtcctgct ggttactata ttgaccgaga ttcaggaacc tgccactcct gcccccctaa    600

cacaattctg aaagcccacc agccttatgg tgtccaggcc tgtgtgccct gtggtccagg    660

gaccaagaac aacaagatcc actctctgtg ctacaatgat tgcaccttct cacgcaacac    720

tccaaccagg actttcaact acaacttctc cgctttggca aacaccgtca ctcttgctgg    780

agggccaagc ttcacttcca aagggttgaa atacttccat cactttaccc tcagtctctg    840

tggaaaccag ggtaggaaaa tgtctgtgtg caccgacaat gtcactgacc tccggattcc    900

tgagggtgag tcagggttct ccaaatctat cacagcctac gtctgccagg cagtcatcat    960

cccccccagag gtgacaggct acaaggccgg ggtttcctca gcctgtgtca gccttgctga   1020

tcgacttatt ggggtgacaa cagatatgac tctggatgga atcacctccc cagctgaact   1080

tttccacctg gagtccttgg aataccggga cgtgatcttc ttttataggt ccaatgatgt   1140

gacccagtcc tgcagttctg ggagatcaac caccatccgc gtcaggtgca gtccacagaa   1200

aactgtccct ggaagtttgc tgctgccagg aacgtgctca gatgggacct gtgatggctg   1260

caacttccac ttcctgtggg agagcgcggc tgcttgcccg ctctgctcag tggctgacta   1320

ccatgctatc gtcagcagct gtgtggctgg gatccagaag actacttacg tgtggcgaga   1380

acccaagcta tgctctggtg gcatttctct gcctgagcag agagtcacca tctgcaaaac   1440
```

B0213WO seq list.ST25.txt
```
catagatttc tggctgaaag tgggcatctc tgcaggcacc tgtactgcca tcctgctcac    1500

cgtcttgacc tgctactttt ggaaaaagaa tcaaaaacta gagtacaagt actccaagct    1560

ggtgatgaat gctactctca aggactgtga cctgccagca gctgacagct gcgccatcat    1620

ggaaggcgag gatgtagagg acgacctcat ctttaccagc aagaagtcac tctttgggaa    1680

gatcaaatca tttacctcca agcagccagc tcctgtcacc atctctcttt cagaggactc    1740

ctgatggatt tgactcagtg ccgctgaaga catcctcagg aggcccagac atggacctgt    1800

gagaggcact gcctgcctca cctgcctcct caccttgcat agcacctttg caagcctgcg    1860

gcgatttggg tgccagcatc ctgcaacacc cactgctgga aatctcttca ttgtggcctt    1920

atcagatgtt tgaatttcag atctttttt atagagtacc caaaccctcc tttctgcttg    1980

cctcaaacct gccaaatata cccacacttt gtttgtaaat tatgcccttg cttgtatctt    2040

gtttcccaaa atggcccatc cgccagagcc atagcttcgt ctgctcataa ttcttatagc    2100

tttggaatga aaatatttct atcttcttaa gtatagaaac tatttcctct gtcctctaac    2160

ttaagggcag aaacagctgg gagttttcct cgcatgccct cagctcatga tctcttcagg    2220

agagaggctg ggtgaggagg gtgtcggggt tccctggtgg ataatcttca tagcagcctg    2280

gatccatttc ccctggataa ccagctcaaa gggagtgaaa atggtagtct gagggcaagg    2340

ggagcaaggc ctgggtaaga aaagccttga aaagcataaa aagaggccgg gcgcggtggc    2400

tcacgcctgt aatcccagca ctttgggagg ccgaggcggg cagatcatga ggtcgggaga    2460

ttgagaccat cctggctaac acggtgaagc cccgtctcta ctggaaatac aaaaaattag    2520

ccgggcgtgg tggcgggtgc ctgtggtccc agctactcgg gaggctgagg cgggagaata    2580

gcgtgggcct ggaaggcgga gcttgcagtg agccgagatc gcgccactgc actccatcca    2640

gcctgggtga cagagtgaga ctctgcctca aaaaaaaaaa aaaaaagaa aagcacaaag    2700

agaggcaaca aggaatgttt ttgtttttga gacaggctct cactctgtca cctaggctgg    2760

agtgcagtgg cgtaatcact gttcagtgca gcctcaagct cttgggctca ggctatcctc    2820

ccatctcagc tctcaagta gctgggacta cgagtgtgca ccaccaggct cactaatttt    2880

tgtgtttttt gtagacacgg ggtttcaccg tgttgcccag gctggtctcc aactcctggg    2940

ctcaagtgat ctgtccgcct cggcctccca aactgctggg attacaggca taagccactg    3000

cactcagcct tttatttgtt ttttaaacca cgtagctcat tgccttctct taagtaaatg    3060

atagatattc tcactgaagc caaaggaata agttcatcaa gaaaatgccc aaagccctgg    3120

tggatacatc ctccctatct ttttttaaa ccttccacta tcactctatg acactgaaaa    3180

gaaccaggta agccccaaac ccagatgttc cagccttatc ctctattggg tttacccaca    3240

gacatagcaa accctgtcag tgaggaaaat tccccatcct tgagtgcccc cgtcctagaa    3300

gtttgggcca tattatggaa caggggtctc ttatttgaaa agagcacaag gaggccaaga    3360

ttttaatggg gcactttagg ggatacagcc cacaatggca tgggcctgag gtggccgtga    3420

tgtctgcttc taagcttaac gcatctgctc aggcacagaa taaacgtcta ggctggccaa    3480
```

Page 85

B0213WO seq list.ST25.txt

```
aaaaggaact gaatcccagg cccatacgcc agcaccagaa tcaaaccagt cttcaaggaa   3540

ggaaggctag gagagtttaa caagattttc actgggccca gcatggtggc tcacacctgt   3600

aatcccaagg cagaatggtg gcttgagctc aggagttcaa gaccagcctg ggcaacacag   3660

tgagaccctg tctctaaaaa atttaaaaat aaacaaggtg ttcaccaagc tgggatactt   3720

ctcactatta agccccatc tttctctttt tttcattctc aattgctttg tgtgataaaa    3780

aactaaagag acttctggtc caatttctgg caacatccct tctgaaaggt gagtagagtg   3840

ggtgtcttct atgcccattt tccccaattt tacacaaact attatcaatg aacttttaag   3900

tacctagaat gggtaaaacc agagcaagac tttaaattac cttcttcttt cttctactgg   3960

cagttctgcc tccatcacta tcaggctagg gtgaccttcc cttggtcaag ccccaattgc   4020

ccatgatttg tgcctgtgcc ctttctccag tgaccatttg gtgaccagat ggtagatata   4080

gaaaggggat ggcatttgca agtgactagt ctgccacaaa atgctcatct gattagccac   4140

tgctgccctg gcaatggctt tgtaagagtc aatgagaact agagccaggc tgtggtccct   4200

ggccatcaac agtgttggtg acggcaggga gtccctttgg tttaataaat ccagtttttc   4260

tttgggtatc caaattctcc cctccttttg taggagtcag gctctcagaa cctgtgtcca   4320

tgttggaact tcccccagtg tggatgcaga tacgcagctc ctgagctcca gcctaaagtc   4380

ttctgtagcc tcagcaatac ttgggcacct gctgtctcac tgaatagctt tcttttgtga   4440

caaaggccac agacagccct tagactattc cggaaacagt aggaaaaatt acatatgtct   4500

ttgacttctt tattctgact ccactgattt tagccataat actttaagga gctacttttt   4560

actacccctt accgtgctga cttctgcagg tctgccctgt gacctgtcag gaactcctga   4620

gttacgctac tggggtcacc tgttgctccc ctagcaagtt aggcatgtca tatattttta   4680

acagctttat tgagatataa ttcacatatt atacaattca cctttaaaac atacgattca   4740

atggttttca gcaaactcac agagttgtcc gcccacttga gagcaaacac atgttcaatt   4800

ttctttttcct ttttttttttt gagacagagt cagctttgtc gcccaggctg gagtgcagtg   4860

ccatgatctt ggctcactgc agcctcccca tcctgggttc aagtgatcct tctgcttcag   4920

cctccccagt agctgggatt acaggcatgc gccaccacgc ctagctaatt tttgtgtttt   4980

tagtagagat ggggtttcac cgtgttggcc aggctggtct caaactcctg gactcaagtg   5040

atccacccac ctcggcctcc caaagtgctg ggattgcagg tgtgagccac cgtgcctggc   5100

ctacgtgttc aattttctat gaacaaaggc tttagtcctt gacccagggc taaagtggtc   5160

tgtccaagct gttgttggta gagggagtat gataaaatgt ttaaatctca tttggttacc   5220

ttgagtcctg gaacacgcag taactgtcat gctatagtca tcatctgtat ttggctggga   5280

atacaaatga agattgtggt gtattcaagc agtagggttt ttgcttttgt ttttgtttta   5340

gtgccaacaa aactttttt tgtctgacta cattaaagat aagactgact atatttatac    5400

aacagaaact ttgtaataga tttttttcagc tttgtgaaat cgaattttt ttcatcaggg    5460

ctggttggat ttcctttta ccctgtaatc caagcgttaa tagtttgtta gaagatgggt   5520
```

Page 86

B0213WO seq list.ST25.txt
tattgcatgt cacttttttt tttttgtaaa ataaaaacat accttac   5567

<210>   146
<211>   299
<212>   DNA
<213>   Homo sapiens

<400>   146
gtaaaaagga aatccaacca gccctgatga aaaaaaattc gatttcacaa agctgaaaaa   60

atctattaca aagtttctgt tgtataaata tagtcagtct tatctttaat gtagtcagac   120

aaaaaaaagt tttgttggca ctaaaacaaa aacaaaagca aaaaccctac tgcttgaata   180

caccacaatc ttcatttgta ttcccagcca aatacagatg acgactatag catgacagtt   240

actgcgtgtt ccaggactca aggtaaccaa atgagattta aacattttat catactccc   299

<210>   147
<211>   1326
<212>   DNA
<213>   Homo sapiens

<400>   147
gactcaggca ctgggctagg tgcttgggat acatccgtga gccacacaaa gttccccacc   60

ccagaggagc tcttacctgg cccagaatct ggatctctgc ccccagcccc tatcctcaag   120

gtagagtccc aaagatgtcc taaatctcac acaggctgag ttgtgcttaa tccatttctg   180

cagacacaac tcatgtacaa atgggccaag ccgaaaatct gtagcgagga ccttgagggg   240

gcagtgaagc tgcctgcctc tggtgtgaag acccactgcc caccctgcaa cccaggcttc   300

ttcaaaacca acaacagcac ctgccagccc tgcccatatg gttcctactc caatggctca   360

gactgtaccc gctgccctgc agggactgaa cctgctgtgg gatttgaata caaatggtgg   420

aacacgctgc ccacaaacat ggaaacgacc gttctcagtg ggatcaactt cgagtacaag   480

ggcatgacag gctgggaggt ggctggtgat cacatttaca cagctgctgg agcctcagac   540

aatgacttca tgattctcac tctggttgtg ccaggattta gacctccgca gtcggtgatg   600

gcagacacag agaataaaga ggtggccaga atcacatttg tctttgagac cctctgttct   660

gtgaactgtg agctctactt catggtgggt gtgaattcta ggaccaacac tcctgtggag   720

acgtggaaag gttccaaagg caaacagtcc tatacctaca tcattgagga gaacactacc   780

acgagcttca cctgggcctt ccagaggacc acttttcatg aggcaagcag gaagtacacc   840

aatgacgttg ccaagatcta ctccatcaat gtcaccaatg ttatgaatgg tgtggcctcc   900

tactgccgtc cctgtgccct agaagcctct gatgtgggct cctcctgcac ctcttgtcct   960

B0213WO seq list.ST25.txt
```
gctggttact atattgaccg agattcagga acctgccact cctgccccac taacacaatt   1020

ctgaaagccc accagcctta tggtgtccag gcctgtgtgc cctgtggtcc agggaccaag   1080

aacaacaaga tccactctct gtgctacaac gattgcacct tctcacgcaa cactccgacc   1140

aggactttca actacaactt ctccgctttg gcaaacactg tcactcttgc tggagggcca   1200

agcttcactt ccaaagggct gaaatacttc catcacttta ccctcagtct ctgtggaaac   1260

cagggtagga aaatgtctgt gtgcaccgac aatgtcactg acctccggat tcctgagggt   1320

gagtca                                                               1326
```

<210> 148

<211> 698

<212> DNA

<213> Homo sapiens

<400> 148
```
cttccatgat ggcgcagctg tcagctgctg gcaggtcaca gtccttgaga gtagcattca    60

tcaccagctt ggagtacttg tactctagtt tttgattctt tttccaaaag tagcaggtca   120

agacggtgag caggatggca gtacaggtgc ctgcagagat gcccactttc agccagaaat   180

ctatggtttt gcagatggtg actctctgct caggcagaga aatgccacca gagcatagct   240

tgggttctcg ccacacgtaa gtagtcttct ggatcccagc cacacagctg ctgacgatag   300

catggtagtc agccactgag cagagcgggc aagcagccgc gctctcccac aggaagtgga   360

agttgcagcc atcacaggtc ccatctgagc acgttcctgg cagcagcaaa cttccaggga   420

cagttttctg tggactgcac ctgacgcgga tggtggttga tctcccagaa ctgcaggact   480

gggtcacatc attggaccta taaaagaaga tcacgtccgg tattcccaag gactccaggt   540

ggaaaagttc agctggggag gtgattccat ccagagtcat atctgttgtc accccaataa   600

gtcgatcagc aaggctgaca ggctgtgagg aaaccccggc cttgtagcct gtcacctctg   660

gggggatgat gactgcctgg cagacgtagg ctgtgata                           698
```

<210> 149

<211> 478

<212> DNA

<213> Homo sapiens

<400> 149
```
cttccatgat ggcgcagctg tcagctgctg gcaggtcaca gtccttgaga gtagcattca    60

tcaccagctt ggagtacttg tactctagtt tttgattctt tttccaaaag tagcaggtca   120

agacggtgag caggatggca gtacaggtgc ctgcagagat gcccactttc agccagaaat   180
```

Page 88

B0213WO seq list.ST25.txt

```
ctatggtttt gcagatggtg actctctgct caggcagaga aatgccacca gagcatagct    240

tgggttctcg ccacacgtaa gtagtcttct ggccacctct ttattctctg tgtctgccat    300

caccgactgc ggaggtctaa atcctggcac aaccagagtg agaatcatga agtcattgtc    360

tgaggctcca gtagctgtgt aaatgtgatc accagccacc tcccagcctg tcatgccctt    420

gtactcgaag ttgatcccac tgagaacggt cgtttccgtg tttgtgggca gcgtgttc     478
```

<210> 150

<211> 315

<212> DNA

<213> Homo sapiens

<400> 150
```
cgtgggtagg gcacggggtc tgttctgaaa tgtaaagggt tcagacgggg tttctggttt     60

tagaaggttg cgtggtcttc gagttgggct aaagtagagt tcgttgtgct gtttctgact    120

cctaatgaga gttccttcca gaccgttacg tgtctcctgg ccaagcccca ggaaggaaat    180

gatgcagctc tggctccttg tctcccaggc tgatccttta ttcagaatac cacaaagaaa    240

ggacattcag ctcaaggctc cctgccgtgt tgaagagttc tgactgcaca aaccagcttc    300

tggtttcttc tggaa                                                    315
```

<210> 151

<211> 219

<212> DNA

<213> Homo sapiens

<400> 151
```
tttgagggca agtagtgtct tggcacagag aagagcccag agtatagagc ggaagcaaga     60

gagtgagcca cgtattgtta gtagaatttt ccagtgttgt gcttggaatg gtggagtgtt    120

ctggttcagt ctcctcttgt tttatcgagt atttattcct gtgcttcagt cggtaacagc    180

ccgaattatc ggtgacccat cactacatgg agatgtttg                          219
```

<210> 152

<211> 351

<212> DNA

<213> Homo sapiens

<400> 152
```
gcctttaacc atgtacaact ggctggcggc caggaccgac agggcagcaa ggctccaggg     60
```

BO213WO seq list.ST25.txt

```
gtgctttcgc cggaagtccc cacaacagct gaggacgatg agagagatga agaacacagc    120

ataggagaca tagtaggtcc aaacattctc ccggacaaag cccttcacct ccgcaacaga    180

agtgaacaca gacaccgtgg acagggtcac cgacagctgc aaggtcagca ctaggaacac    240

cttgcggatg aaggcctgtc ggatgctctt gtcatcccag ttggtggcag ggaagtcctg    300

gttgtcatag taagatgggg gaccctcctc ctggtgaaat tgataacgct t            351
```

<210> 153

<211> 286

<212> DNA

<213> Homo sapiens

<400> 153
```
tgagctgagg gttagtggtg actttttgat acgaaaaaat gcattttgtg cagctggtga     60

ggtataatcc aaagcaaaag caggggcaaa aatggacttc ctgaagttat ctctgctcct    120

gctggttatc ctccagaatc tgtcatgttg actgagagtg cgtgcttgct ttctcaggcc    180

tcctggctaa tagcacaggt ctgctggaaa tcacccacat ggttttcat tgcctgtgca     240

gtcaggtgat gcctctatgt ttttggaggt ccaccccttt actcaa                  286
```

<210> 154

<211> 419

<212> DNA

<213> Homo sapiens

<400> 154
```
gttaggtagg ctatggatga ggctgactat tactgtcagg cgtgggacag caacattgct     60

tatgtcttcg gaactgggac caaggtcacc gtcttaggtc agcccaaggc caaccccact    120

gtcactctgt tcccgccctc ctctgaggag ctccaagcca acaaggccac actagtgtgt    180

ctgatcagtg acttctaccc gggagctgtg acagaggcct ggaaggcaga tggcagcccc    240

gtcaaggcgg gagtggagac caccaaaccc tccaaacaga gcaacaacaa gtacgcggcc    300

agcagctacc tgagcctgtc cataataacg cttctcaatc actagtgcgg ccgcctgcag    360

gtcgaccata tgggagagct cccaacgcgt tggatgcata gcttgagtat tctatagtg     419
```

<210> 155

<211> 424

<212> DNA

<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 155

```
tagggggagg tctgggggct cacggcgccg aagtggaaga catggcgctt gttcccgtgg      60

gggttggagg cttcacagga gatgccatcg cggctcaggg cgctggtcac tttcagggtc     120

agagagctgc tcacccaacc ctgccgtccg gggattggct ctgcggggct gccccccaat     180

tggctccagc tgagtttggg gtctggatgg ccgcgggcag agcagatgag tgtgacttcg     240

tctccttccc tccagctgcc atctgccttg ggctctattt ccgctgtctt tagctctggc     300

gagccttgga ccagcagcgt gaagttctgg gtgcggctga ggaccgggac tgtgggcagg     360

gaggcctcac atacgtaggt gccattggaa tcgaaggtga tagaactgag cgacagcatg     420

gggc                                                                  424
```

<210> 156

<211> 396

<212> DNA

<213> Homo sapiens

<400> 156

```
gcagggaagg tcagaagcca gtcatggatg accagcgcga ccttatctcc aacaatgagc      60

aactgcccat gctgggccgg cgccctgggg ccccggagag caagtgcagc cgcggagccc     120

tgtacacagg cttttccatc ctggtgactc tgctcctcgc tggccaggcc accaccgcct     180

acttcctgta ccagcagcag ggccggctgg acaaactgac agtcacctcc cagaacctgc     240

agctggagaa cctgcgcatg aagcttccca agcctcccaa gcctgtgagc aagatgcgca     300

tggccacccc gctgctgatg caggcgctgc ccatgggagc cctgccccag gggcccatgc     360

agaatgccac caagtatggc aacatgacag aggacc                               396
```

<210> 157

<211> 161

<212> DNA

<213> Homo sapiens

<400> 157

```
gcagaggggg ggtggggagg ggtgctctgc tggtcttcaa ttaccaagaa ttctccaaaa      60

caattttctg caggatgatt gtacagaatc attgcttatg acatgatcgc tttctacact     120

gtattacata aataaattaa ataaaataac cccgggtcct a                         161
```

<210> 158

<211> 382

<212> DNA

B0213WO seq list.ST25.txt

<213> Homo sapiens

<400> 158
acgtcgcggg gattgttctg gaggttcacc ttttccgtca catcatcata cttccgaatt   60

tcgcgcacgg catcgatgac caacagcaca aggatgacaa tgagaaccac aaagaaggtg   120

ttgccatagg acactaacaa ctccaccagc cgggacttga aaatcttctg ccatctttta   180

ggagaaatga agggaatgca gagaagcaac acaacaaaga cctccgcata gaggaaggtg   240

gcaactgcag tccactgcag actcatcctg ttgctagaag gtttcccaca ggaagatgtg   300

agcttgtttc cgagtttccc acagtcaacg tgcaggcccc gccgcagcaa ccgaactctc   360

ccacagcagc cccccattcc ca   382

<210> 159

<211> 292

<212> DNA

<213> Homo sapiens

<400> 159
gtacaggcag gcttgaagat gggagttttc atggcttgac catgaatgat ctcaagatga   60

tttcataaga ttaaaagcca tcacgaaaat actgaaagca acaggtaata atctggattc   120

agtctgtagt tgctcatgaa ccacgcgttt taataaaagg aacattaagt aaattgtagg   180

tataaaagaa tcagtgcata tctgttaatg tcattgacaa taaaaataca ttatcttctc   240

agctcagctc taaattaaca aaacacctat ttttttttcc cactcctagc ca   292

<210> 160

<211> 447

<212> DNA

<213> Homo sapiens

<400> 160
ggggggagg tggagtctgg agacgacgtg cagaaatggc acctcgaaag gggaaggaaa   60

agaaggaaga acaggtcatc agcctcggac ctcaggtggc tgaaggagag aatgtatttg   120

gtgtctgcca tatctttgca tccttcaatg acacttttgt ccatgtcact gatctttctg   180

gcaaggaaac catctgccgt gtgactggtg ggatgaaggt aaaggcagac cgagatgaat   240

cctcaccata tgctgctatg ttggctgccc aggatgtggc ccagaggtgc aaggagctgg   300

gtatcaccgc cctacacatc aaactccggg ccacaggagg aaataggacc aagacccctg   360

gacctccacc caataacgct tctcaatcac tagtgcggcc gcctgcaggt cgaccatatg   420

B0213WO seq list.ST25.txt
ggagagctcc caacgcgttg gatgcat   447

<210>   161
<211>   239
<212>   DNA
<213>   Homo sapiens

<400>   161
ttgggtaagg catcatagat aaacgtaatt gtttggggag ttaaatttaa tgaacttatc   60
taactttgta acccatcttg gctttagtaa ctttatcaag gtggtggctt tagtgaatat   120
aatggtaaac tttagaggac gctaaagcct cactaaaata acgcttctca atcactagtg   180
cggccgcctg caggtcgacc atatgggaga gctcccaacg cgttggatgc atagcttga   239

<210>   162
<211>   410
<212>   DNA
<213>   Homo sapiens

<400>   162
tgctgggagg tcctcacggt ccaccgggcc ctgaacagtg ataagtccag tgttcctgtc   60
cagtcgaaga agacgcctca caacttcggg cgcctggtgg aatgtgtatt cgatttctgc   120
attggcacct tggtctgagt cattgacctt cacctggatg accgagtggc ctatggggct   180
attctcagat agttcggcct cataggaggg ccgctcaaac ttgggggcgt tgtcattggt   240
gtcaagcacg gtgacacgca gcagggcact gctggcgcgt gggggggctgc cgccatcctg   300
caccttgatg gtgaggtcat aggagtccca gcgctcacgg tccaggttgc ccatcacaat   360
gagctgtggt tgcttctcct cctggtcctc tgccacctcg gccccataac   410

<210>   163
<211>   327
<212>   DNA
<213>   Homo sapiens

<400>   163
tgaggaaggc catgttctgg gtttccttca atcctagccg aagaccattc attgcaccaa   60
acgcagcccc tgtcatgcaa catcctccaa tcgtaaagaa ggccagctca aatctgcccc   120
gggtttttatt agctccggta ggtaaaataa actcatctgt atcctgcacg aggtatcgtg   180
gatccacatt taaataagga gacagagggt tcataccagt tagcgggacg ccagccaaat   240

B0213WO seq list.ST25.txt
```
ccgcgtgcga gtaacctgct ccgccggctc cgaaaaagca ggccaatccc cctgtggttt    300
tgttgccgct tccccgcct cccccca                                         327
```

<210> 164
<211> 300
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (204)..(204)
<223> n = a t c or g

<400> 164
```
tagcgggaga aagatgggaa ctccgtttcc acctgcactc tctcgcgccc ctctattctt    60
tcaccacatt gctttatcct tttacccttt tttttatttt aaattaaaga atgaactgaa    120
aagatataac atgacgtaca attaaagaat aattttaaag tgaatactac gtaactccat    180
ccaagtcaag aaattgccag cttncggaag cccactgtgc tcctcccct cataacgctt    240
ctcatcctag tgcgccgcct gcagcgacca tatggagagc tccaacgcgt ggatgcata    300
```

<210> 165
<211> 351
<212> DNA
<213> Homo sapiens

<400> 165
```
cggagccagg caatacaaaa aatgcaatta tccattgcaa tggaaccacc aaagaatgcc    60
tcgcaaccga atataccatc ccctttttgg gtccggtttt attcgctccc aagcgcctaa    120
tctttgagtt taagccgtcg ttaaaggatt caagtcaggc atttaaggaa cgacactacg    180
agatgggatg aggccgaaga tgatcaattt taaaggcgcc gcccgcaaac gggcctccga    240
caccgcctcc ccgtaataac gcttctcaat cactagtgcg gccgcctgca ggtcgaccat    300
atgggagagc tcccaacgcg ttggatgcat agcttgagta ttctatagtg t            351
```

<210> 166
<211> 4839
<212> DNA
<213> Homo sapiens

B0213WO seq list.ST25.txt

<400> 166
```
ggaaagctag cggcagaggc tcagccccgg cggcagcgcg cgccccgctg ccagcccatt      60

ttccggacgc cacccgcggg cactgccgac gcccccgggg ctgccgaggg gaggccgggg     120

gggcgcagcg gagcgcggtc ccgcgcactg agccccgcgg cgccccggga acttggcggc     180

gacccgagcc cggcgagccg gggcgcgcct cccccgccgc gcgcctcctg catgcggggc     240

cccagctccg ggcgccggcc ggagccccc ccggccgccc ccgagccccc cgcgccccgc     300

gccgcgccgc cgcgccgtcc atgcaccgct tgatgggggt caacagcacc gccgccgccg     360

ccgccgggca gcccaatgtc tcctgcacgt gcaactgcaa acgctctttg ttccagagca     420

tggagatcac ggagctggag tttgttcaga tcatcatcat cgtggtggtg atgatggtga     480

tggtggtggt gatcacgtgc ctgctgagcc actacaagct gtctgcacgg tccttcatca     540

gccggcacag ccaggggcgg aggagagaag atgccctgtc ctcagaagga tgcctgtggc     600

cctcggagag cacagtgtca ggcaacggaa tcccagagcc gcaggtctac gccccgcctc     660

ggcccaccga ccgcctggcc gtgccgccct tcgcccagcg ggagcgcttc caccgcttcc     720

agcccaccta tccgtacctg cagcacgaga tcgacctgcc acccaccatc tcgctgtcag     780

acggggagga gcccccaccc taccagggcc cctgcaccct ccagcttcgg gaccccgagc     840

agcagctgga actgaaccgg gagtcggtgc gcgcacccccc aaacagaacc atcttcgaca     900

gtgacctgat ggatagtgcc aggctgggcg gccctgccc ccccagcagt aactcgggca     960

tcagcgccac gtgctacggc agcggcgggc gcatggaggg gccgccgccc acctacagcg    1020

aggtcatcgg ccactacccg gggtcctcct tccagcacca gcagagcagt gggccgccct    1080

ccttgctgga ggggacccgg ctccaccaca cacacatcgc gcccctagag agcgcagcca    1140

tctggagcaa agagaaggat aaacagaaag gacaccctct ctagggtccc caggggggcc    1200

gggctggggc tgcgtaggtg aaaaggcaga acactccgcg cttcttagaa gaggagtgag    1260

aggaaggcgg ggggcgcagc aacgcatcgt gtggccctcc cctcccacct ccctgtgtat    1320

aaatatttac atgtgatgtc tggtctgaat gcacaagcta agagagcttg caaaaaaaaa    1380

aagaaaaaag aaaaaaaaaa accacgtttc tttgttgagc tgtgtcttga aggcaaaaga    1440

aaaaaatttt ctacagtagt cttctcttgtt tctagttgag ctgcgtgcgt gaatgcttat    1500

tttctttttgt ttatgataat ttcacttaac tttaaagaca tatttgcaca aaacctttgt    1560

ttaaagatct gcaatattat atatataaat atatataaga taagagaaac tgtatgtgcg    1620

agggcaggag tatttttgta ttagaagagg cctattaaaa aaaaaagttg ttttctgaac    1680

tagaagagga aaaaatggc aattttttgag tgccaagtca gaaagtgtgt attaccttgt    1740

aaagaaaaaa attacaaagc aggggtttag agttatttat ataaatgttg agattttgca    1800

ctatttttta atataaatat gtcagtgctt gcttgatgga aacttctctt gtgtctgttg    1860

agactttaag ggagaaatgt cggaatttca gagtcgcctg acggcagagg gtgagccccc    1920
```

B0213WO seq list.ST25.txt

```
gtggagtctg cagagaggcc ttggccagga gcggcgggct ttcccgaggg gccactgtcc   1980

ctgcagagtg gatgcttctg cctagtgaca ggttatcacc acgttatata ttccctaccg   2040

aaggagacac cttttccccc ctgacccaga acagcctta  aatcacaagc aaaataggaa   2100

agttaaccac ggaggcaccg agttccaggt agtggttttg cctttcccaa aaatgaaaat   2160

aaactgttac cgaaggaatt agttttttcct cttctttttt ccaactgtga aggtccccgt   2220

ggggtggagc atggtgcccc tcacaagccg cagcggctgg tgcccgggct accagggaca   2280

tgccagaggg ctcgatgact tgtctctgca gggcgctttg gtggttgttc agctggctaa   2340

aggttcaccg gtgaaggcag gtgcggtaac tgccgcactg gaccctagga agccccaggt   2400

attcgcaatc tgacctcctc ctgtctgttt cccttcacgg atcaattctc acttaagagg   2460

ccaataaaca acccaacatg aaaaggtgac aagcctgggt ttctcccagg ataggtgaaa   2520

gggttaaaat gagtaaagca gttgagcaaa caccaacccg agcttcgggc gcagaattct   2580

tcaccttctc ttccccctttc catctccttt ccccgcggaa acaacgcttc ccttctggtg   2640

tgtctgttga tctgtgtttt catttacatc tctcttagac tccgctcttg ttctccaggt   2700

tttcaccaga tagatttggg gttggcggga cctgctggtg acgtgcaggt gaaggacagg   2760

aaggggcatg tgagcgtaaa tagaggtgac cagaggagag catgaggggt ggggctttgg   2820

gacccaccgg ggccagtggc tggagcttga cgtctttcct ccccatgggg gtgggagggc   2880

ccccagctgg aagagcagac tcccagctgc tacccctcc  cttcccatgg gagtggcttt   2940

ccattttggg cagaatgctg actagtagac taacataaaa gatataaaag gcaataacta   3000

ttgtttgtga gcaactttt  tataacttcc aaaacaaaaa cctgagcaca gttttgaagt   3060

tctagccact cgagctcatg catgtgaaac gtgtgcttta cgaaggtggc agctgacaga   3120

cgtgggctct gcatgccgcc agcctagtag aaagttctcg ttcattggca acagcagaac   3180

ctgcctctcc gtgaagtcgt cagcctaaaa tttgtttctc tcttgaagag gattctttga   3240

aaaggtcctg cagagaaatc agtacaggtt atcccgaaag gtacaaggac gcacttgtaa   3300

agatgattaa aacgtatctt tcctttatgt gacgcgtctc tagtgcctta ctgaagaagc   3360

agtgacactc ccgtcgctcg gtgaggacgt tcccggacag tgcctcactc acctgggact   3420

ggtatcccct cccagggtcc accaagggct cctgcttttc agacacccca tcatcctcgc   3480

gcgtcctcac cctgtctcta ccagggaggt gcctagcttg gtgaggttac tcctgctcct   3540

ccaacctttt tttgccaagg tttgtacacg actcccatct aggctgaaaa cctagaagtg   3600

gaccttgtgt gtgtgcatgg tgtcagccca aagccaggct gagacagtcc tcatatcctc   3660

ttgagccaaa ctgtttgggt ctcgttgctt catggtatgg tctggatttg tgggaatggc   3720

tttgcgtgag aaaggggagg agagtggttg ctgccctcag ccggcttgag gacagagcct   3780

gtccctctca tgacaactca gtgttgaagc ccagtgtcct cagcttcatg tccagtggat   3840

ggcagaagtt catggggtag tggcctctca aaggctgggc gcatcccaag acagccagca   3900

ggttgtctct ggaaacgacc agagttaagc tctcggcttc tctgctgagg gtgcacccttt   3960
```

B0213WO seq list.ST25.txt

```
tcctctagat ggtagttgtc acgttatctt tgaaaactct tggactgctc ctgaggaggc    4020

cctcttttcc agtaggaagt tagatggggg ttctcagaag tggctgattg gaaggggaca    4080

agcttcgttt caggggtctg ccgttccatc ctggttcaga gaaggccgag cgtggctttc    4140

tctagccttg tcactgtctc cctgcctgtc aatcaccacc tttcctccag aggaggaaaa    4200

ttatctcccc tgcaaagccc ggttctacac agatttcaca aattgtgcta agaaccgtcc    4260

gtgttctcag aaagcccagt gttttgcaa agaatgaaaa gggaccccat atgtagcaaa    4320

aatcagggct ggggggagagc cgggttcatt ccctgtcctc attggtcgtc cctatgaatt    4380

gtacgtttca gagaaatttt ttttcctatg tgcaacacga agcttccaga accataaaat    4440

atcccgtcga taaggaaaga aaatgtcgtt gttgttgttt ttctggaaac tgcttgaaat    4500

cttgctgtac tatagagctc agaaggacac agcccgtcct cccctgcctg cctgattcca    4560

tggctgttgt gctgattcca atgctttcac gttggttcct ggcgtgggaa ctgctctcct    4620

ttgcagcccc atttcccaag ctctgttcaa gttaaactta tgtaagcttt ccgtggcatg    4680

cggggcgcgc acccacgtcc ccgctgcgta agactctgta tttggatgcc aatccacagg    4740

cctgaagaaa ctgcttgttg tgtatcagta atcattagtg gcaatgatga cattctgaaa    4800

agctgcaata cttatacaat aaattttaca attctttgg                          4839
```

<210> 167

<211> 200

<212> DNA

<213> Homo sapiens

<400> 167
```
cccagcaagg gatgccatca gggacttcag gggttcaccc cactttccag aggagaaact    60

ggggatgaga gaggtggaac atttgccgga ggccacactg cttgtcactg ccggtgtgaa    120

gagcccacag cctattccgt cctccctcaa gtgctgggga gagtgacggt gcctggacat    180

tccagaaggc accagccctg                                                200
```

<210> 168

<211> 355

<212> DNA

<213> Homo sapiens

<400> 168
```
aggggggaaa aggtgtctcc ttcggtaggg aatatataac gtggtgataa cctgtcacta    60

ggcagaagca tccactctgc agggacagtg gcccctcggg aaagcccgcc gctcctggcc    120

aaggcctctc tgcagactcc acgggggctc accctctgcc gtcaggcgac tctgaaattc    180
```

Page 97

```
                            B0213WO seq list.ST25.txt
cgacatttct cccttaaagt ctcaacagac acaagagaag tttccatcaa gcaagcactg      240

acatatttat attaaaaaat agtgcaaaat ctcaacattt atataaataa ctctaaaccc      300

ctgctttgta attttttttct ttacaaggta atacacactt tctgacttgg cactc         355
```

<210> 169

<211> 579

<212> DNA

<213> Homo sapiens

<400> 169
```
ttcccagtat gcaagtcgca tcagcatcag gagtggaaga gtctctgctg gtccttaagg       60

tctccaggag gggccagttc catcactggc tttgggagca tgaaagtgac aaatccagcc      120

atgaatttgc ctgagtgtca gtggttaaga atacaaaaag gggtcccctt ctcctcccaa      180

ctgctccctc cctgggcccc taagaagggt ctgtgaccgt ctgcccgagc ctttgcccag      240

cgacaggagc cagtgcgcag ggctcccttt ctgccagtca gctcacgctg tgcatctgca      300

gaacggctcc aggaggctct gagagcagag agcagggcct tcctcctgcc tgtcccgtta      360

cctccttccg cggagctgga gtttgttcag atcatcatca tcgtggtggt gatgatggtg      420

atggtggtgg tgatcacgtg cctgctgagc cactacaagc tgtctgcacg gtccttcatc      480

agccggcaca gccagggggcg gaggagagaa gatgccctgt cctcagaagg atgcctgtgg      540

ccctcggaga gcacagtgtc aggcaacgga atcccagag                             579
```

<210> 170

<211> 310

<212> DNA

<213> Homo sapiens

<400> 170
```
tccttgggtt cgggtgaaag cgcttggggg ttcagtgggc catgatcccc gagctgctgg       60

agaactgaag gcggacagtc tcctgcgaaa ccaggcaatg gcggagctgg agtttgttca      120

gatcatcatc atcgtggtgg tgatgatggt gatggtggtg gtgatcacgtg gcctgctgag      180

ccactacaag ctgtctgcac ggtccttcat cagccggcac agccaggggc ggaggagaga      240

agatgccctg tcctcagaag gatgcctgtg gccctcggag agcacagtgt caggcaacgg      300

aatcccagag                                                             310
```

<210> 171

<211> 301

<212> DNA

B0213WO seq list.ST25.txt

<213> Homo sapiens

<400> 171
ggacagggca tcttctctcc tccgcccctg gctgtgccgg ctgatgaagg accgtgcaga   60

cagcttgtag tggctcagca ggcacgtgat caccaccacc atcaccatca tcaccaccac   120

gatgatgatg atctgaacaa actccagctc cgctagacca gagcgaattc atcctgaaga   180

actcagagaa agccggtgca ggaagtgggt tcccgctctc cctgcacagg cacagtgatg   240

ctgccagagc tctcccagaa agaccaggag gcttgttctg gagaagtcaa gcccagggat   300

g   301

<210> 172
<211> 529
<212> DNA
<213> Homo sapiens

<400> 172
ctctgggatt ccgttgcctg acactgtgct ctccgagggc cacaggcatc cttctgagga   60

cagggcatct tctctcctcc gccccctggct gtgccggctg atgaaggacc gtgcagacag   120

cttgtagtgg ctcagcaggc acgtgatcac caccaccatc accatcatca ccaccacgat   180

gatgatgatc tgaacaaact ccagctccgc tttttgtatt cttaaccact gacactcagg   240

caaattcatg gctggatttg tcactttcat gctcccaaag ccagtgatgg aactggcccc   300

tcctggagac cttaaggacc agcagagact cttccactcc tgatgctgat gcgacttgca   360

tactgggaat ccatgacaac ctagaccaga gcgaattcat cctgaagaac tcagagaaag   420

ccggtgcagg aagtgggttc ccgttctccc tgcacaggca cagtgatgct gccagagctc   480

tcccagaaag accaggaggc ttgttctgga gaagtcaagc ccagggatg   529

<210> 173
<211> 1429
<212> DNA
<213> Homo sapiens

<400> 173
ttggaagtgt ccgtatcatg gaatcaatct ctatgatggg aagccctaag agccttagtg   60

aaacttgttt acctaatggc ataaatggta tcaaagatgc aaggaaggtc actgtaggtg   120

tgattggaag tggagatttt gccaaatcct tgaccattcg acttattaga tgcggctatc   180

atgtggtcat aggaagtaga aatcctaagt ttgcttctga attttttcct catgtggtag   240

Page 99

B0213WO seq list.ST25.txt

```
atgtcactca tcatgaagat gctctcacaa aaacaaatat aatatttgtt gctatacaca     300

gagaacatta tacctccctg tgggacctga gacatctgct tgtgggtaaa atcctgattg     360

atgtgagcaa taacatgagg ataaaccagt acccagaatc caatgctgaa tatttggctt     420

cattattccc agattctttg attgtcaaag gatttaatgt tgtctcagct tgggcacttc     480

agttaggacc taaggatgcc agccggcagg tttatatatg cagcaacaat attcaagcgc     540

gacaacaggt tattgaactt gcccgccagt tgaatttcat tcccattgac ttgggatcct     600

tatcatcagc cagagagatt gaaaatttac ccctacgact ctttactctc tggagagggc     660

cagtggtggt agctataagc ttggccacat ttttttttcct ttattccttt gtcagagatg     720

tgattcatcc atatgctaga aaccaacaga gtgacttttta caaaattcct atagagattg     780

tgaataaaac cttacctata gttgccatta ctttgctctc cctagtatac cttgcaggtc     840

ttctggcagc tgcttatcaa ctttattatg gcaccaagta taggagattt ccaccttggt     900

tggaaacctg gttacagtgt agaaaacagc ttggattact aagttttttc ttcgctatgg     960

tccatgttgc ctacagcctc tgcttaccga tgagaaggtc agagagatat ttgtttctca    1020

acatggctta tcagcaggtt catgcaaata ttgaaaactc ttggaatgag gaagaagttt    1080

ggagaattga aatgtatatc tcctttggca taatgagcct tggcttactt tccctcctgg    1140

cagtcacttc tatcccttca gtgagcaatg ctttaaactg gagagaattc agttttattc    1200

agtctacact tggatatgtc gctctgctca taagtacttt ccatgtttta atttatggat    1260

ggaaacgagc ttttgaggaa gagtactaca gattttatac accaccaaac tttgttcttg    1320

ctcttgtttt gccctcaatt gtaattctgg tagagacgga gtttcaccgt gttagccagg    1380

atggtctcga tctcctgacc tcgtgatccg cccgccttgg cctccaaag               1429
```

<210> 174

<211> 462

<212> PRT

<213> Homo sapiens

<400> 174

```
Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
1               5                   10                  15


Cys Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr
                20                  25                  30


Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
            35                  40                  45


Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
        50                  55                  60
```

Page 100

B0213WO seq list.ST25.txt

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
65   70   75   80

Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
            85   90   95

His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
            100   105   110

Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
        115   120   125

Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
    130   135   140

Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
145   150   155   160

Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
            165   170   175

Gln Val Ile Glu Leu Ala Arg Gln Leu Asn Phe Ile Pro Ile Asp Leu
            180   185   190

Gly Ser Leu Ser Ser Ala Arg Glu Ile Glu Asn Leu Pro Leu Arg Leu
        195   200   205

Phe Thr Leu Trp Arg Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr
    210   215   220

Phe Phe Phe Leu Tyr Ser Phe Val Arg Asp Val Ile His Pro Tyr Ala
225   230   235   240

Arg Asn Gln Gln Ser Asp Phe Tyr Lys Ile Pro Ile Glu Ile Val Asn
            245   250   255

Lys Thr Leu Pro Ile Val Ala Ile Thr Leu Leu Ser Leu Val Tyr Leu
            260   265   270

Ala Gly Leu Leu Ala Ala Ala Tyr Gln Leu Tyr Tyr Gly Thr Lys Tyr
        275   280   285

Arg Arg Phe Pro Pro Trp Leu Glu Thr Trp Leu Gln Cys Arg Lys Gln
    290   295   300

Leu Gly Leu Leu Ser Phe Phe Phe Ala Met Val His Val Ala Tyr Ser
305   310   315   320

Leu Cys Leu Pro Met Arg Arg Ser Glu Arg Tyr Leu Phe Leu Asn Met
            325   330   335

Page 101

B0213WO seq list.ST25.txt

Ala Tyr Gln Gln Val His Ala Asn Ile Glu Asn Ser Trp Asn Glu Glu
        340   345   350

Glu Val Trp Arg Ile Glu Met Tyr Ile Ser Phe Gly Ile Met Ser Leu
        355   360   365

Gly Leu Leu Ser Leu Leu Ala Val Thr Ser Ile Pro Ser Val Ser Asn
    370 .   375   380

Ala Leu Asn Trp Arg Glu Phe Ser Phe Ile Gln Ser Thr Leu Gly Tyr
385   390   395   400

Val Ala Leu Leu Ile Ser Thr Phe His Val Leu Ile Tyr Gly Trp Lys
            405   410   415

Arg Ala Phe Glu Glu Glu Tyr Tyr Arg Phe Tyr Thr Pro Pro Asn Phe
            420   425   430

Val Leu Ala Leu Val Leu Pro Ser Ile Val Ile Leu Val Glu Thr Glu
            435   440   445

Phe His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu Thr Ser
    450   455   460

<210> 175

<211> 1329

<212> DNA

<213> Homo sapiens

<400> 175

```
atggaatcaa tctctatgat gggaagccct aagagcctta gtgaaacttt tttacctaat      60
ggcataaatg gtatcaaaga tgcaaggaag gtcactgtag gtgtgattgg aagtggagat     120
tttgccaaat ccttgaccat tcgacttatt agatgcggct atcatgtggt cataggaagt     180
agaaatccta agtttgcttc tgaatttttt cctcatgtgg tagatgtcac tcatcatgaa     240
gatgctctca caaaaacaaa tataatattt gttgctatac acagagaaca ttatacctcc     300
ctgtgggacc tgagacatct gcttgtgggt aaaatcctga ttgatgtgag caataacatg     360
aggataaacc agtacccaga atccaatgct gaatatttgg cttcattatt cccagattct     420
ttgattgtca aaggatttaa tgttgtctca gcttgggcac ttcagttagg acctaaggat     480
gccagccggc aggtttatat atgcagcaac aatattcaag cgcgacaaca ggttattgaa     540
cttgcccgcc agttgaattt cattcccatt gacttgggat ccttatcatc agccagagag     600
attgaaaatt taccccctacg actctttact ctctggagag ggccagtggt ggtagctata     660
agcttggcca catttttttt cctttattcc tttgtcagag atgtgattca tccatatgct     720
```

B0213WO seq list.ST25.txt

```
agaaaccaac agagtgactt ttacaaaatt cctatagaga ttgtgaataa aaccttacct    780

atagttgcca ttactttgct ctccctagta tacctcgcag gtcttctggc agctgcttat    840

caactttatt acggcaccaa gtataggaga tttccacctt ggttggaaac ctggttacag    900

tgtagaaaac agcttggatt actaagtttt ttcttcgcta tggtccatgt tgcctacagc    960

ctctgcttac cgatgagaag gtcagagaga tatttgtttc tcaacatggc ttatcagcag    1020

gttcatgcaa atattgaaaa ctcttggaat gaggaagaag tttggagaat tgaaatgtat    1080

atctcctttg gcataatgag ccttggctta ctttccctcc tggcagtcac ttctatccct    1140

tcagtgagca atgctttaaa ctggagagaa ttcagtttta ttcagatctt ttgcagcttt    1200

gcagataccc agactgagct ggaactggaa tttgtcttcc tattgactct acttctttaa    1260

aagcggctgc ccattacatt cctcagctgt ccttgcagtt aggtgtacat gtgactgagt    1320

gttggccag                                                          1329
```

<210> 176

<211> 419

<212> PRT

<213> Homo sapiens

<400> 176

```
Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
1               5                   10                  15


Phe Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr
                20                  25                  30


Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
        35                  40                  45


Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
    50                  55                  60


Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
65                  70                  75                  80


Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
                85                  90                  95


His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
                100                 105                 110


Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
        115                 120                 125


Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
```

Page 103

BO213WO seq list.ST25.txt

130   .   135   140

Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
145   150   155   160

Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
                    165   170   175

Gln Val Ile Glu Leu Ala Arg Gln Leu Asn Phe Ile Pro Ile Asp Leu
                180   185   190

Gly Ser Leu Ser Ser Ala Arg Glu Ile Asp Asn Leu Pro Leu Arg Leu
            195   200   205

Phe Thr Leu Trp Arg Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr
    210   215   220

Phe Phe Phe Leu Tyr Ser Phe Val Arg Asp Val Ile His Pro Tyr Ala
225   230   235   240

Arg Asn Gln Gln Ser Asp Phe Tyr Lys Ile Pro Ile Glu Ile Val Asn
                245   250   255

Lys Thr Leu Pro Ile Val Ala Ile Thr Leu Leu Ser Leu Val Tyr Leu
                260   265   270

Ala Gly Leu Leu Ala Ala Ala Tyr Gln Leu Tyr Tyr Gly Thr Lys Tyr
            275   280   285

Arg Arg Phe Pro Pro Trp Leu Glu Thr Trp Leu Gln Cys Arg Lys Gln
    290   295   300

Leu Gly Leu Leu Ser Phe Phe Phe Ala Met Val His Val Ala Tyr Ser
305   310   315   320

Leu Cys Leu Pro Met Arg Arg Ser Glu Arg Tyr Leu Phe Leu Asn Met
                325   330   335

Ala Tyr Gln Gln Val His Ala Asn Ile Glu Asn Ser Trp Asn Glu Glu
                340   345   350

Glu Val Trp Arg Ile Glu Met Tyr Ile Ser Phe Gly Ile Met Ser Leu
                355   360   365

Gly Leu Leu Ser Leu Leu Ala Val Thr Ser Ile Pro Ser Val Ser Asn
    370   375   380

Ala Leu Asn Trp Arg Glu Phe Ser Phe Ile Gln Ile Phe Cys Ser Phe
385   390   395   400

Ala Asp Thr Gln Thr Glu Leu Glu Leu Glu Phe Val Phe Leu Leu Thr
                            Page 104

        405   410   415

Leu Leu Leu

<210> 177

<211> 940

<212> DNA

<213> Homo sapiens

<400> 177

```
tggaagtgtc cgtatcatgg aatcaatctc tatgatggga agccctaaga gccttagtga        60
aacttgttta cctaatggca taaatggtat caaagatgca aggaaggtca ctgtaggtgt       120
gattggaagt ggagattttg ccaaatcctt gaccattcga cttattagat gcggctatca       180
tgtggtcata ggaagtagaa atcctaagtt tgcttctgaa ttttttcctc atgtggtaga       240
tgtcactcat catgaagatg ctctcacaaa aacaaatata atatttgttg ctatacacag       300
agaacattat acctccctgt gggacctgag acatctgctt gtgggtaaaa tcctgattga       360
tgtgagcaat aacatgagga taaaccagta cccagaatcc aatgctgaat atttggcttc       420
attattccca gattctttga ttgtcaaagg atttaatgtt gtctcagctt gggcacttca       480
gttaggacct aaggatgcca gccggcaggt ttatatatgc agcaacaata ttcaagcgcg       540
acaacaggtt catgcaaata ttgaaaactc ttggaatgag gaagaagttt ggagaattga       600
aatgtatatc tcctttggca taatgagcct tggcttactt tccctcctgg cagtcacttc       660
tatcccttca gtgagcaatg ctttaaactg gagagaattc agttttattc agtctacact       720
tggatatgtc gctctgctca taagtacttt ccatgtttta atttatggat ggaaacgagc       780
ttttgaggaa gagtactaca gattttatac accaccaaac tttgttcttg ctcttgtttt       840
gccctcaatt gtaattctgg tagagacgga gtttcaccgt gttagccagg atggtctcga       900
tctcctgacc tcgtgatccg cccgccttgg cctccaaagt                             940
```


<210> 178

<211> 299

<212> PRT

<213> Homo sapiens

<400> 178

Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
1   5   10   15

Cys Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr

BO213WO seq list.ST25.txt
```
                20                       25                    30
```

Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
        35   40   45

Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
    50   55   60

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
65   70   75   80

Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
                85   90   95

His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
            100   105   110

Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
        115   120   125

Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
    130   135   140

Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
145   150   155   160

Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
                165   170   175

Gln Val His Ala Asn Ile Glu Asn Ser Trp Asn Glu Glu Glu Val Trp
            180   185   190

Arg Ile Glu Met Tyr Ile Ser Phe Gly Ile Met Ser Leu Gly Leu Leu
        195   200   205

Ser Leu Leu Ala Val Thr Ser Ile Pro Ser Val Ser Asn Ala Leu Asn
    210   215   220

Trp Arg Glu Phe Ser Phe Ile Gln Ser Thr Leu Gly Tyr Val Ala Leu
225   230   235   240

Leu Ile Ser Thr Phe His Val Leu Ile Tyr Gly Trp Lys Arg Ala Phe
                245   250   255

Glu Glu Glu Tyr Tyr Arg Phe Tyr Thr Pro Pro Asn Phe Val Leu Ala
            260   265   270

Leu Val Leu Pro Ser Ile Val Ile Leu Val Glu Thr Glu Phe His Arg
        275   280   285

Val Ser Gln Asp Gly Leu Asp Leu Leu Thr Ser
                          Page 106

BO213WO seq list.ST25.txt
290   295

<210> 179

<211> 1388

<212> DNA

<213> Homo sapiens

<400> 179
tggaagtgtc cgtatcatgg aatcaatctc tatgatggga agccctaaga gccttagtga   60

aacttgttta cctaatggca taaatggtat caaagatgca aggaaggtca ctgtaggtgt   120

gattggaagt ggagattttg ccaaatcctt gaccattcga cttattagat gcggctatca   180

tgtggtcata ggaagtagaa atcctaagtt tgcttctgaa ttttttcctc atgtggtaga   240

tgtcactcat catgaagatg ctctcacaaa aacaaatata atatttgttg ctatacacag   300

agaacattat acctccctgt gggacctgag acatctgctt gtgggtaaaa tcctgattga   360

tgtgagcaat aacatgagga taaaccagta cccagaatcc aatgctgaat atttggcttc   420

attattccca gattctttga ttgtcaaagg atttaatgtt gtctcagctt gggcacttca   480

gttaggacct aaggatgcca gccggcaggt ttatatatgc agcaacaata ttcaagcgcg   540

acaacaggtt attgaacttg cccgccagtt gaatttcatt cccattgact tgggatcctt   600

atcatcagcc agagagattg aaaatttacc cctacgactc tttactctct ggagagggcc   660

agtggtggta gctataagct tggccacatt ttttttccttt attcctttgt cagagatgtg   720

attcatccat atgctagaaa ccaacagagt gacttttaca aaattcctat agagattgtg   780

aataaaacct acctatagt tgccattact ttgctctccc tagtatacct tgcaggtctt   840

ctggcagctg cttatcaact ttattacggc accaagtata ggagatttcc accttggttg   900

gaaacctggt tacagtgtag aaaacagctt ggattactaa gttttttctt cgctatggtc   960

catgttgcct acagcctctg cttaccgatg agaaggttca tgcaaatatt gaaaactctt 1020

ggaatgagga agaagtttgg agaattgaaa tgtatatctc ctttggcata atgagccttg 1080

gcttactttc cctcctggca gtcacttcta tcccgtcagt gagcaatgct ttaaactgga 1140

gagaattcag ttttattcag tctacacttg gatatgtcgc tctgctcata agtacttтcc 1200

atgtttttaat ttatggatgg aaacgagctt ttgaggaaga gtactacaga ttttatacac 1260

caccaaacтт tgttcttgct cttgtttтgc cctcaattgt aattctggta gagacggagt 1320

ttcaccgtgt tagccaggat ggtctcgatc tcctgacctc gtgatccgcc cgccttggcc 1380

tccaaagt   1388

<210> 180

<211> 234

<212> PRT

B0213WO seq list.ST25.txt

<213> Homo sapiens

<400> 180

Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
1   5   10   15

Cys Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr
                20   25   30

Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
            35   40   45

Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
        50   55   60 ;

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
65   70   75   80

Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
                85   90   95

His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
            100   105   110

Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
        115   120   125

Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
    130   135   140

Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
145   150   155   160

Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
                165   170   175

Gln Val Ile Glu Leu Ala Arg Gln Leu Asn Phe Ile Pro Ile Asp Leu
            180   185   190

Gly Ser Leu Ser Ser Ala Arg Glu Ile Glu Asn Leu Pro Leu Arg Leu
        195   200   205

Phe Thr Leu Trp Arg Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr
    210   215   220

Phe Phe Ser Phe Ile Pro Leu Ser Glu Met
225   230

<210> 181

B0213WO seq list.ST25.txt

<211> 1425

<212> DNA

<213> Homo sapiens

<400> 181
```
tggaagtgtc cgtatcatgg aatcaatctc tatgatggga agccctaaga gccttagtga      60
aacttgttta cctaatggca taaatggtat caaagatgca aggaaggtca ctgtaggtgt     120
gattggaagt ggagattttg ccaaatcctt gaccattcga cttattagat gcggctatca     180
tgtggtcata ggaagtagaa atcctaagtt tgcttctgaa ttttttcctc atgtggtaga     240
tgtcactcat catgaagatg ctctcacaaa aacaaatata atatttgttg ctatacacag     300
agaacattat acctccctgt gggacctgag acatctgctt gtgggtaaaa tcctgattga     360
tgtgagcaat aacatgagga taaaccagta cccagaatcc aatgctgaat atttggcttc     420
attattccca gattctttga ttgtcaaagg atttaatgtt gtctcagctt gggcacttca     480
gttaggacct aaggatgcca gccggcaggt ttatatatgc agcaacaata ttcaagcgcg     540
acaacaggtt attgaacttg cccgccagtt gaatttcatt cccattgact tgggatcctt     600
atcatcagcc agagagattg aaaatttacc cctacgactc tttactctct ggagagggcc     660
agtggtggta gctataagct tggccacatt ttttttcctt tattcctttg tcagagatgt     720
gattcatcca tatgctagaa accaacagag tgactttttac aaaattccta tagagattgt     780
gaataaaacc ttacctatag ttgccattac tttgctctcc ctagtatacc ttgcaggtct     840
tctggcagct gcttatcaac tttattatgg caccaagtat aggagatttc caccttggtt     900
ggaaacctgg ttacagtgta gaaaacagct tggattacta agttttttct cgctatggt     960
ccatgttgcc tacagcctct gcttaccgat gagaaggtca gagagatatt tgtttctcaa    1020
catggcttat cagcaggttc atgcaaatat tgaaaactct tggaatgagg aagaagtttg    1080
gagaattgaa atgtatatct cctttggcat aatgagcctt ggcttacttt ccctcctggc    1140
agtcacttct atcccttcag tgagcaatgc tttaaactgg agagaattca gtttattca    1200
gtctacactt ggatatgtcg ctctgctcat aagtactttc catgtttaa tttatggatg    1260
gaaacgagct tttgaggaag agtactacag attttataca ccaccaaact ttgttcttgc    1320
tcttgttttg ccctcaattg taattctgga gacggagttt caccgtgtta gccaggatgg    1380
tctcgatctc ctgacctcgt gatccgcccg ccttggcctc caaag               1425
```

<210> 182

<211> 461

<212> PRT

<213> Homo sapiens

BO213WO seq list.ST25.txt

<400> 182

Met Glu Ser Ile Ser Met Met Gly Ser Pro Lys Ser Leu Ser Glu Thr
1   5   10   15

Cys Leu Pro Asn Gly Ile Asn Gly Ile Lys Asp Ala Arg Lys Val Thr
            20   25   30

Val Gly Val Ile Gly Ser Gly Asp Phe Ala Lys Ser Leu Thr Ile Arg
        35   40   45

Leu Ile Arg Cys Gly Tyr His Val Val Ile Gly Ser Arg Asn Pro Lys
    50   55   60

Phe Ala Ser Glu Phe Phe Pro His Val Val Asp Val Thr His His Glu
65   70   75   80

Asp Ala Leu Thr Lys Thr Asn Ile Ile Phe Val Ala Ile His Arg Glu
                85   90   95

His Tyr Thr Ser Leu Trp Asp Leu Arg His Leu Leu Val Gly Lys Ile
            100   105   110

Leu Ile Asp Val Ser Asn Asn Met Arg Ile Asn Gln Tyr Pro Glu Ser
        115   120   125

Asn Ala Glu Tyr Leu Ala Ser Leu Phe Pro Asp Ser Leu Ile Val Lys
    130   135   140

Gly Phe Asn Val Val Ser Ala Trp Ala Leu Gln Leu Gly Pro Lys Asp
145   150   155   160

Ala Ser Arg Gln Val Tyr Ile Cys Ser Asn Asn Ile Gln Ala Arg Gln
                165   170   175

Gln Val Ile Glu Leu Ala Arg Gln Leu Asn Phe Ile Pro Ile Asp Leu
            180   185   190

Gly Ser Leu Ser Ser Ala Arg Glu Ile Glu Asn Leu Pro Leu Arg Leu
        195   200   205

Phe Thr Leu Trp Arg Gly Pro Val Val Val Ala Ile Ser Leu Ala Thr
    210   215   220

Phe Phe Phe Leu Tyr Ser Phe Val Arg Asp Val Ile His Pro Tyr Ala
225   230   235   240

Arg Asn Gln Gln Ser Asp Phe Tyr Lys Ile Pro Ile Glu Ile Val Asn
                245   250   255

Lys Thr Leu Pro Ile Val Ala Ile Thr Leu Leu Ser Leu Val Tyr Leu
                        Page 110

                        B0213WO seq list.ST25.txt
        260   265   ·   270

Ala Gly Leu Leu Ala Ala Ala Tyr Gln Leu Tyr Tyr Gly Thr Lys Tyr
        275   280   285

Arg Arg Phe Pro Pro Trp Leu Glu Thr Trp Leu Gln Cys Arg Lys Gln
    290   295   300

Leu Gly Leu Leu Ser Phe Phe Phe Ala Met Val His Val Ala Tyr Ser
305   310   315   320

Leu Cys Leu Pro Met Arg Arg Ser Glu Arg Tyr Leu Phe Leu Asn Met
                325   330   335

Ala Tyr Gln Gln Val His Ala Asn Ile Glu Asn Ser Trp Asn Glu Glu
            340   345   350

Glu Val Trp Arg Ile Glu Met Tyr Ile Ser Phe Gly Ile Met Ser Leu
        355   360   365

Gly Leu Leu Ser Leu Leu Ala Val Thr Ser Ile Pro Ser Val Ser Asn
    370   375   380

Ala Leu Asn Trp Arg Glu Phe Ser Phe Ile Gln Ser Thr Leu Gly Tyr
385   390   395   400

Val Ala Leu Leu Ile Ser Thr Phe His Val Leu Ile Tyr Gly Trp Lys
                405   410   415

Arg Ala Phe Glu Glu Glu Tyr Tyr Arg Phe Tyr Thr Pro Pro Asn Phe
            420   425   430

Val Leu Ala Leu Val Leu Pro Ser Ile Val Ile Leu Glu Thr Glu Phe
            435   440   445

His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu Thr Ser
    450   455   460

<210>   183

<211>   18

<212>   PRT

<213>   Homo sapiens

<400>   183

Val Glu Thr Glu Phe His Arg Val Ser Gln Asp Gly Leu Asp Leu Leu
1   5   10   15

Thr Ser
                                Page 111

B0213WO seq list.ST25.txt

<210> 184

<211> 24

<212> PRT

<213> Homo sapiens

<400> 184

Ile Phe Cys Ser Phe Ala Asp Thr Gln Thr Glu Leu Glu Leu Glu Phe
1   5   10   15

Val Phe Leu Leu Thr Leu Leu Leu
           20

<210> 185

<211> 8

<212> PRT

<213> Homo sapiens

<400> 185

Ser Phe Ile Pro Leu Ser Glu Met
1   5